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ABSTRACT OF THESIS 
The sleep apnoea/hypopnoea syndrome (SAHS) is characterised by obstruction of the 
airway during sleep, resulting in repetitive nocturnal breathing pauses, which provoke 
both oxygen desaturations and arousals from sleep. SAHS is associated with daytime 
deficits of excessive daytime sleepiness, cognitive impairment and psychological 
distress, probably as a result of these nocturnal events. The treatment of choice for 
SAHS is continuous positive airway pressure (CPAP) therapy, a mechanical treatment 
in which positive airstream pressure is administered to the upper airway through a 
nasal mask, splinting the airway open and preventing the nocturnal events of SAHS. 
A limited number of small clinical studies have indicated improvements in daytime 
function following CPAP therapy, but these have not been well-controlled, particularly 
in the area of cognitive performance. This thesis contributes controlled studies to the 
knowledge-base describing CPAP's effects on daytime function. A pilot study 
employing a parallel-group design in 37 patients showed improvements in objective 
daytime sleepiness and psychological distress with CPAP, but not cognitive function. 
This null finding however might have resulted from inter-individual variability. To 
rectify this, a randomised placebo-controlled crossover study of daytime function on 
CPAP and on an oral placebo was conducted in 64 patients with a wide range of 
severity of SAHS. This study showed CPAP-related improvement in symptoms, 
objective and subjective daytime sleepiness, cognitive performance and well-being. 
The use of balanced treatment order within a subgroup of 16 patients with mild SAHS 
(apnoea+hypopnoea index 5 to 14.9) allowed investigation of the minimum illness 
severity at which daytime benefits from CPAP are observed. Such mild patients 
demonstrated improvements in symptom score, cognitive performance and 
psychological distress on CPAP. Although the minimum illness severity meriting 
CPAP treatment has not been well defined, these data support the efficacy of CPAP at 
the lowest severity range of SAHS. A randomised study of auditory evoked potentials 
in 18 patients showed trends only towards improved neurophysiological function after 
CPAP, and a randomised crossover study of ambulatory blood pressure in 13 patients 
showed reduced blood pressure on CPAP only in a subgroup of patients who lacked 
significant dipping of nocturnal blood pressure. The nocturnal determinants of daytime 
dysfunction in SAHS were explored by correlating factors extracted from 
polysomnographic and daytime function variables. The principal component extracted 
from the polysomnographic variables was found to correlate significantly with 
daytime sleepiness and with intellectual function, corroborating weak or moderate 
associations between the severity of nocturnal events and daytime deficits. Patients' 
Ti' 
perceptions of benefit from CPAP, and their self-reported driving competence, were 
examined in a survey of 215 CPAP users. Patients reported wide-ranging 
improvements in nocturnal and daytime symptoms of SAHS, and showed a 
significant improvement in mileage adjusted rates of road traffic incidents following 
CPAP. Although side-effects of CPAP were common, these were minor in nature. 
Thus patients' reports corroborated the daytime benefits from CPAP documented in 
the project's controlled studies. The studies of this thesis demonstrated objective and 
subjective improvements in symptoms, daytime sleepiness, cognitive performance 
and well-being in SAHS patients treated with CPAP. 
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Chapter 1: Clinical background of SANS 
Chapter 1: 
CLINICAL BACKGROUND OF THE SLEEP APNOEAIHYPOPNOEA 
SYNDROME (SANS) 
The sleep apnoea/hypopnoea syndrome (SAHS) has been recognised as a clinical 
entity only in the last 30 years (Gastaut et al 1966), but evidence accumulating since 
this time has built up a picture of a relatively common illness with significant 
morbidity and mortality. SAHS may be loosely defined as consisting of restricted 
airflow during sleep, with resulting symptoms (Gould et al 1988). This introductory 
chapter provides background on the physiological and clinical features of SAHS. It 
begins with a description of the primary physiological events typical of SAHS, and the 
evolution of definitions and measures to describe the syndrome. Literature detailing 
patients' clinical presentation, physiological mechanisms, morbidity and mortality, 
epidemiology and treatments in SAHS will be briefly described in order to provide 
background information on the syndrome, before the specific daytime impairments of 
SAHS are reviewed in Chapter 2. 
1.1 Nocturnal events in SANS 
The central events of SAHS are recurrent episodes of restricted airflow, demonstrated 
as pauses in breathing known as apnoeas and hypopnoeas, and usually precipitated by 
obstruction of the upper airway during sleep. These primary events are associated with 
immediate physiological consequences in the form of oxygen desaturation and sleep 
fragmentation (Guilleminault et al 1978). Apnoeas and hypopnoeas frequently result 
in desaturations in arterial oxygen levels (Block et al 1979) and are usually terminated 
by short-lasting electroencephalographic arousals from sleep (Sullivan and Issa 1980) 
which allow the recommencement of normal respiration. 
Thus SAHS patients experience a triad of nocturnal events, with restricted respiration 
causing both transient hypoxaemia and sleep disruption. This cycle of events, 
illustrated in Figure 1.1, can be repeated as many as 100 times during each hour slept 
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Chapter 1: Clinical background of SANS 
Figure 1.1 shows one minute of typical polysomnography in a patient with severe 
SAHS. The first 3 channels labelled AIRFLOW, THOR RES and ABDO RES show 
breathing pattern, measured by oronasal airflow, thoracic and abdominal breathing 
movements respectively. The subsequent 7 channels of polysomnography (EOG, 
MIX EEG and EMG) represent neurophysiological recording and reflect sleep quality. 
The last channel, SaO2, represents arterial oxygen saturation. Three consecutive 
episodes of flattening of breathing movements are shown as hypopnoeas. The first 
two hypopnoeas result in dipping of oxygen saturation and are each terminated by a 
microarousal from sleep, represented in an increase in amplitude and frequency of 
neurophysiological parameters. These nocturnal events, as described in Chapter 2, 
may individually or collectively contribute to the daytime problems also associated 
with the syndrome. 
The hypoxaemia of SAHS, measured by ear oximetry, is of a transient but repetitive 
nature. Nocturnal studies on large groups of mixed severity SAHS patients have 
shown means of 282 3% oxygen desaturations per night (Roehrs et al 1989) and that 
an average 18% of the night is spent at less than 90% saturation (Poceta et al 1992, 
Guilleminault et al 1988). Desaturation events, though short lasting, can be quite 
severe, with mean nadirs in saturation from SAHS samples reported in the range 65 to 
76% (Greenberg et al 1987, Guilleminault et al 1988, Bedard et al 1991a, Poceta et al 
1992, Kribbs et al 1993b), but much lower levels being seen in severe patients, 
particularly during REM sleep (Sullivan and Issa 1980). 
In SAHS patients, discreet electroencephalographic arousals from sleep have been 
shown to correspond closely with apnoea (Roth et al 1980, Sullivan and Issa 1980) 
and apnoea+hypopnoea frequency (Cheshire et al 1992, Poceta et al 1992). These 
repetitive arousals impair both quantity and quality of sleep, scored according to the 
averaged, epoch-based system of Rechtschaffen and Kales (1968). Sleep efficiency 
index, the ratio of wakefulness to sleep, is low in SAHS and is consistently reported in 
the range 80%-86% (Roehrs et al 1989, Stepanski et al 1984, Greenberg et al 1987, 
Cheshire et al 1992, Kribbs et al 1993b). Normal sleep quality, as described by 
Rechtschaffen and Kales' (1968) sleep stage proportions, comprises approximately 
5% stage 1,50% stage 2,20% slow wave sleep (stages 3+4) and 20-25% stage REM 
(Erwin et al 1984). In SAHS the sleep stage distribution is shifted towards the light 
end of the non-REM spectrum, showing 13-69% of stage 1, but only 0-4% slow 
wave sleep and 9-14% stage REM (Roth et al 1980, Stepanski et al 1984, Roehrs et al 
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1989, Lamphere et al 1989, Bedard et al 1991a, Kribbs et al 1993b, Guilleminault et al 
1988). 
Many patients also show other immediate physiological consequences of increased 
airway resistance, such as elevations of pulmonary and systemic blood pressure 
(Schroeder et al 1978), increases in heart rate and cardiac arrhythmias (Schroeder et al 
1978, Shepard 1989, Hoffstein and Mateika 1994). 
1.2 Diagnosis of SAHS 
Disturbances in respiratory pattern in the form of apnoeas and hypopnoeas, as SAHS' 
name suggests, form the basis for definitions describing the syndrome. The technical 
definitions describing these nocturnal events, and in turn providing diagnostic criteria, 
are still evolving. 
The original observations of Guilleminault et al (1978) defined an apnoea in adults as 
10 seconds or longer of absent airflow signal, and offered as a diagnostic definition of 
the then ̀ sleep apnoea syndrome' an apnoea frequency (or apnoea index) of 5 or more 
apnoeas per hour slept While this technical definition for apnoea has been universally 
adopted, subsequent research has demonstrated that Guilleminault et al's early (1978) 
diagnostic definition may be insufficient. 
Apnoeas are conceptualised as the precipitant producing both oxygen desaturations 
and arousals from sleep within a triad of nocturnal events, so that an index of severity 
of apnoea should index the severity of desaturation and arousal. However, apnoea 
frequency has been shown to underrepresent 4% desaturation frequency by a factor of 
four (Block et al 1979) and to correlate poorly with electroencephalographic arousal 
from sleep (Gould et al 1988), leaving doubt that apnoea index is the most sensitive 
overall measure of the nocturnal events of SAHS. 
A second problem in early diagnostic descriptions of sleep apnoea syndrome is found 
in the high incidence within normal subjects of frequent apnoeas during sleep, 
particularly in the elderly and in men (Block et al 1979). Berry et al (1984) reviewed 
13 studies of nocturnal sleep in normals to show that by Guilleminaulf s definition, up 
to 72% of healthy subjects, as found in one study, could be diagnosed with sleep 
apnoea syndrome. These findings of apnoeas in the sleep of normals called into 
question the discriminability of the diagnostic criterion forwarded by Guilleminault et 
al (1978) in separating healthy normals from patients. They also emphasised the 
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importance of supporting symptoms, a prerequisite in any syndrome, in a diagnostic 
formulation for SAHS. 
Subsequent refinement of definitions relating nocturnal breathing abnormalities, their 
immediate physiological effects and clinical symptoms have been supplied in our 
group by Gould et al (1988), who has validated measures of nocturnal breathing 
disruption and formulated diagnostic definitions describing the sleep 
apnoea/hypopnoea syndrome (SAHS). 
The cessation of airflow during an apnoea reflects total occlusion of the airway, but 
episodes of restriction in the airway with persisting airflow may nevertheless 
precipitate arterial oxygen desaturations (Block et a11979, Gould et al 1988, Whyte et 
a! 1992) and arousals from sleep (Gould et al 1988). Such subtotal disturbances in 
respiration are known as hypopnoeas (Block et al 1979, Gould et al 1988) and have 
been variously defined as 50% reductions in airflow with (Berry et al 1986, 
Guilleminault et al 1988, Lamphere et al 1989, Kribbs et al 1993b) or without (Roehrs 
et al 1989) coincident desaturation, or as 50% reductions in respiratory movement 
(Gould et al 1988, Douglas 1993, Whyte et al 1992). 
In our own group, Gould et al (1988) proposed and validated a technical description of 
hypopnoeic activity, defined by a 50% or greater reduction in thoracoabdominal 
movement compared to the preceding stable baseline, measured by the semi- 
quantitative method of inductance plethysmography. This hypopnoea definition 
subsumes almost all apnoeas, shows good inter-rater reliability for both number 
(r=0.98) and duration (r=0.98) of hypopnoeic events (Whyte et a11992) and correlates 
better with both desaturation events and with arousals from sleep than 50% reduction 
in thermistor airflow, which underestimates both types of disruption. 
Gould et al (1988) compared the frequency of apnoeas+hypopnoeas by this validated 
definition in normals and patients with clinical features of SAHS, showing that 50 
patients had a minimum apnoea+hypopnoea index (AHI) of 16 and 33 normals had a 
maximum AHI of 14. Patients subdivided into groups experiencing predominantly 
apnoeic or hypopnoeic events could not be differentiated in terms of desaturation, 
arousal frequency or symptoms. In order to reflect the naturally occurring 
discontinuity between controls and patients, Gould et al (1988) suggested that an AHI 
of 15 should be used as a clinical diagnostic threshold. The addition to this definition 
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of SAHS of at least two coexistent clinical symptoms prevented the anomalous 
diagnosis of healthy normals as suffering from the syndrome. 
Recent research may extend the continuum of sleep apnoea syndromes to include a 
partial variant, ̀ upper airway resistance syndrome' (UARS: Guilleminault et al 1992, 
1993), similar to the 'heavy snorers' disease' first proposed by Lugaresi et al (1978). 
UARS contains no requirement for apnoeas or hypopnoeas or for desaturation during 
sleep. The central event in UARS is increased resistance in the upper airway, often 
(Guilleminault et al 1991, Hoffstein et al 1991) but not invariably (Guineminault et al 
1992,1993) associated with snoring, resulting in frequent arousal from sleep. UARS 
is diagnosed when episodes of high resistance in the upper airway, frequently seen 
with snoring (Liistro et al 1991, Stoohs and Guilleminault 1991), and arousal from 
sleep occur with the daytime symptom of excessive daytime sleepiness. 
While symptoms are vital in the diagnosis of SAHS, neither these nor physical 
examination alone are sufficiently reliable predictors of SAHS (Hoffstein and Szalai 
1993). The diagnosis of SAHS can be made only with the benefit of overnight 
monitoring to demonstrate disordered respiratory patterns in sleep. However, as 
indicated above, the techniques employed for nocturnal recordings and the outcome 
measures used to diagnose SAHS are not standardised, differing methods providing 
advantages and disadvantages. The codependence of the triad of nocturnal events 
allows clinicians to recognise abnormal activity during sleep through a variety of 
physiological systems. 
Diagnostic sleep studies can be accomplished through limited recordings consisting of 
overnight ear oximetry (Stradling and Crosby 1991) or of monitoring snoring sounds 
and heart rate (Penzel et a! 1990). Such studies offer the advantage of being relatively 
cheap, portable, and comfortable for subjects, thus facilitating large-scale home-based 
screening studies (Stradling and Crosby 1991). Many researchers have relied on 4% 
desalu ation frequency as their primary measure of respiratory abnormality (Telakivi 
et al 1988, Berry et a11986, Stradling and Crosby 1991). A certain degree of 
diagnostic accuracy is sacrificed in limited studies, as oximetry alone, scored by 
computer and thus free from inter- and intra-rater variation, results in false negative 
diagnosis of SAHS in 15% of patients when defined by >5 4% desaturations per hour 
in bed, and 28% when defined as >20 4% desaturations per hour in bed (Douglas et al 
1992). 
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Many laboratories use more detailed polysomnography incorporating thermistor 
measures of oronasal airflow and inductance plethysmography of respiratory 
movement, to differentiate and resolve apnoeic and hypopnoeic events. 
Neurophysiological recordings of EEG, EOG and EMG together facilitate the 
conventional Rechtschaffen and Kales (1968) scoring of sleep state and the monitoring 
of short arousals from sleep. Studies performed without the benefit of EEG 
monitoring may miss patients with mild SAHS or UARS, in whom frequent EEG 
arousals may occur without easily measurable respiratory abnormality. Ear oximetry, 
as in the limited sleep studies, provides a continuous and reliable evaluation of arterial 
oxygen saturation. Additional monitoring of ECG to detect arrhythmias associated 
with breathing restriction, tibialis EMG to detect leg movements typical of periodic leg 
movement syndrome, snoring-detection microphones and upper airway resistance 
monitoring are sometimes employed. These more elaborate studies are relatively 
uncomfortable for subjects, incur high running costs in terms both of equipment and 
staff labour, but offer greater diagnostic sensitivity and specificity (Douglas et al 1992) 
and may be particularly valuable for patients with borderline abnormality. 
1.3 Physiological mechanisms in SANS 
The breathing irregularities seen in SAHS are almost always a result of constriction or 
obstruction of the upper airway during sleep, this anatomical area being the final 
common site for a variety of abnormalities of structure and function causing irregular 
breathing in sleep (Hudgel 1992, Pepin et al 1992, Douglas and Polo 1994). Snoring 
sounds our in many healthy sleeping subjects as a result of high inspiratory 
pressures acting against narrowing of the pharynx, causing vibrations of the muscles 
of the upper airway. Many clinicians consider snoring to be precursor to SAHS, 
forming a link in the continuum from normal respiratory function in sleep to SAHS 
(Lugaresi et al 1978, Guilleminault et al 1991). 
The state of sleep establishes a physiological environment wherein other factors can 
interact to cause airway obstruction. Sleep causes hypotonia of the musculature 
supporting patency of the upper airway (Orem and Lydic 1978), the lowest tonic 
muscle activity occurring in REM sleep when partial paralysis of intercostal muscles 
may contribute to hypoventilation (Tabachnik et al 1981). The respiratory reflexes 
concerned with maintaining blood gas balance are also damped by sleep, particularly 
REM sleep (Douglas et al 1982). It has been noted that many SAHS patients' longest 
breathing pauses and lowest oxygen saturation dips occur in REM sleep 
(Guilleminault et al 1978). The supine posture adopted by sleeping humans also 
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contributes to airway obstruction, as it increases the uvular width and narrows the size 
of the post-palatal airway space, even in healthy non-snorers (Yildirim et al 1991). 
Studies of sleeping SAHS patients identify the site of obstruction during breathing 
pauses at the level of the pharynx (Chaban et al 1988). A number of anatomical 
abnormalities of the upper airway may contribute to this airway obstruction. 
Retrognathism (Riley et al 1983), prognathism (Lyberg et al 1989a), micrognathia 
(Coccagna et a1 1978) and tonsillar hypertrophy (Orr and Martin 1981) have been 
associated with SAHS. Patients with SAHS, studied while awake, have larger soft 
palates (Lyberg et al 1989b, Stauffer et al 1989), larger tongues (Lowe et al 1986) and 
overall smaller pharyngeal spaces (Riley et a11983, Haponik et at 1983, Rivlin et al 
1984, Martin et al 1995a) than normals. 
The dynamic function of the upper airway, in addition to its structure, is altered in 
SANS. The pharyngeal space is supported by muscle groups whose rigidity affects 
the collapsibility of the airway. The compliance of the pharyngeal soft tissues has been 
found to be lower in awake snoring controls than in SAHS patients (Brown et al 1985, 
Gleadhill et al 1991), predisposing SAHS patients to upper airway collapse in sleep. It 
has been found that the airways of SAHS patients show greatest compliance in REM 
sleep (Issa and Sullivan 1984). A recent study using acoustic reflection measurement 
of the oropharyngeal spaces in waking SAHS patients (Martin et al 1995a) suggested 
that, in addition to having a smaller cross-sectional area at the oropharyngeal junction 
than normals, SANS patients showed smaller reductions in airway area after lying 
down. This finding may reflect muscular `defending' of the upper airway, at least 
while awake, in SAHS patients. 
SAHS has long been associated with obesity, hence its early name of `Pickwickian 
syndrome'. Obesity is a clinical feature in around two-thirds of patients (Guilleminault 
et a! 1989a). Only 11 % of the Edinburgh case series were within 10% of their ideal 
body weight (Whyte et al 1989) and only 20% of the North American patient series 
were not overweight (Guilleminault et al 1978). 
It is thought that obesity mediates narrowing of the upper airway through mass 
loading of fat deposits on the pharynx (Davies and Stradling 1990, Hoffstein and 
Mateika 1992). Magnetic resonance imaging techniques have shown SAHS patients to 
have greater fat deposits in the pharynx than weight-matched controls (Homer et al 
1989). That SAHS patients have fatter necks than normals is corroborated by 
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Hoffstein and Mateika (1992) who showed that patients individually matched for 
body-mass index (BMI) and age to controls had an average 2 cm larger neck 
circumference. Stepwise multiple regression techniques to evaluate the value of factors 
in predicting sleeping oxygen saturation dip rates have isolated neck circumference as 
a more important factor than BMI alone (Davies and Stradling 1990), but desaturation 
rates may not directly equate with breathing or sleep abnormalities (Douglas et al 
1992). 
Aside from diet, other "lifestyle" factors exacerbating breathing irregularities in sleep 
include the ingestion of sedatives (Kales et al 1987) and alcohol (Remmers 1984), 
which may depress central ventilatory drive or decrease muscle tone and thus upper 
airway patency. 
In summary, the aetiology of SAHS is variable, but abnormalities of anatomy and of 
neuromuscular control, obesity and posture may all contribute to decreased upper 
airway calibre during sleep. It is likely that the causes of narrowed airway in any one 
individual are multifactorial. The wide range of causative mechanisms helps to explain 
the heterogeneity within SAHS patients, many of whom do not conform to the 
pickwickian archetype. Familial clustering of the symptoms of SAHS, independent of 
weight factors, has been noted (Mathur and Douglas 1995, Redline et al 1992). In 
familial SAHS, inherited morphological features of the upper airway may predispose 
towards airway obstruction during sleep (Mathur and Douglas 1995), whereas in other 
patients acquired characteristics such as excess weight or alcohol abuse might be more 
important. 
1.4 Clinical presentation 
Surveys of case series of patients diagnosed with SAHS have allowed a number of 
nocturnal and daytime symptoms to be associated with the syndrome. 
1.4.1 Nocturnal features 
Heavy snoring is an almost omnipresent feature in patients with SAHS, having been 
found in 100% of the 50 patients in one early case series (Guilleminault et al 1978) 
and in 97% of the 80 patients reviewed in another series (Whyte et al 1989). Restless 
sleep, as a result of excessive motor activity in sleep or frequent awakenings from 
sleep, is reported by 36% (Whyte et al 1989) to 100% (Guilleminault et al 1978) of 
SAHS patients. This high frequency of reported disturbed sleep in patients explains 
why some SAHS patients present to sleep clinics with an initial complaint of 
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insomnia, rather than excessive sleepiness. In the Edinburgh series, unsatisfying sleep 
was complained of by 35% of patients (Whyte et al 1989). High frequencies of 
nocturia or even enuresis are associated with SAHS, ranging from 10% (Whyte et al 
1989) to 30% (Guilleminault et al 1978) of patients. Complaints of heavy sweating in 
the night were found in 66% of a series of 200 patients (Guilleminault 1989). 
Awareness of nocturnal choking episodes, probably due to a return of consciousness 
at the termination of apnoeas or hypopnoeas, is a frightening symptom reported by 
26% of the Edinburgh series and 11 % of the Stanford series (Guilleminault 1989). It 
seems likely that the absence of a partner to report behaviour in sleep, when memory 
for events can be impaired, will have an effect on reported rates of snoring, nocturnal 
choking episodes and restlessness in sleep. 
1.4.2 Daytime features 
By far the most common daytime symptom of SAHS is excessive daytime 
sleepiness, found in 87% (Whyte et al 1989) and 78% (Guilleminault et a11978) of 
patients in two case series. Excessive daytime sleepiness can range in severity from 
evening naps in front of the television, a common behaviour with increasing age, to 
irresistible sleeping in such dangerous situations as driving, reported by at least 6% of 
one series (Whyte et a! 1989). It is likely that the sleep disruption of SAHS contributes 
to the findings of excessive daytime sleepiness. 
SAHS patients often report morning headaches, in frequencies from 24% (Whyte et al 
1989) to 36% (Guilleminault et al 1978), perhaps as a result of hypercapnia in sleep. 
Waking hypertension was found or was being treated in around 32% of two case 
series (Guilleminault et al 1978, Whyte et al 1989). Ankle oedema was reported by 
32% and polycythaemia found in 12% of one series (Whyte et al 1989). Sexual 
dysfunction has been associated with SAHS, with problems of impotence or loss of 
libido reported by 6% (Whyte et al 1989) and 42% (Guilleminault et al 1978) of 
patients in two case series. 
In addition to excessive daytime sleepiness, patients with SAHS often complain of 
less specific neuropsychological features during wakefulness: the nature of these 
features is the main concern of this thesis. The families of 11 % (Whyte et al 1989) to 
48% (Guilleminault et al 1978) of SAHS patients report personality changes, 
including increased irritability and emotional outbursts. A high proportion of patients, 
82% in one series (Guilleminault et al 1978), experience difficulties with concentration 
or memory. Indeed, intellectual deterioration can be the major presenting symptom of 
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SAHS in some individuals (Scheltens et al 1991). Moreover, SAHS patients have 
been found to experience high frequencies of minor psychiatric disorders such as 
depression and anxiety, found in 24% and 26% respectively of patients in one series 
(Guilleminault et al 1978). These affective problems may be a consequence of the 
chronic and significantly disabling symptoms of SAHS, as may be the high 
frequencies of employment problems reported by patients (Guilleminault et al 1978, 
Kales et al 1985). 
In summary, the clinical features of the SAHS are highly variable, often non-specific 
and common to many disorders, but most frequently include snoring and excessive 
daytime sleepiness. Diagnosis must thus be made through overnight monitoring to 
demonstrate disordered respiratory function in sleep (Hoffstein and Szalai 1993). 
1.5 Mortality and morbidity in SAIIS 
The respiratory abnormalities in sleep of SAHS may also produce elevations in 
systemic blood pressure (Schroeder et al 1978), perhaps contributing to higher-than- 
expected mortality rates in patients with SAHS (Partinen et al 1988). Untreated SAHS 
carries a risk of death, which appears to be related to the severity of breathing 
irregularity in sleep. He et al (1988) found in a retrospective case series that patients 
with more than 20 apnoeas per hour slept had a significantly lower 8-year survival rate 
than patients with fewer than 20 apnoeas per hour slept. The mortality risks in SAHS 
have been evaluated by comparing death rates in patients accepting effective 
treatments, such as tracheostomy or CPAP, to death rates in conservatively-treated 
patients. Aggressive therapeutic approaches have been found to significantly improve 
5-year mortality rates (He et al 1988). Despite the fact that conservatively-treated 
patients in another retrospective study (Partinen et al 1988) had fewer breathing 
abnormalities in sleep and were thinner than aggressively-treated patients, 14 out of 
127 died during a 5-year follow-up period, yielding a mortality rate of 11 per 100 per 
5 years. None of the 71 aggressively-treated patients died, although the two groups 
had had similar frequencies of vascular and pulmonary disease before treatment 
assignment. 
A further retrospective study found that untreated SAHS patients were more likely to 
die at night than their treated counterparts (Thorpy et al 1990), raising the possibility of 
an association between the nocturnal events of SAHS and sudden death. Sixty to 
eighty percent of SAHS patients may have daytime hypertension (Kales et a11984) 
and patients with SAHS can demonstrate intermittent elevations of arterial blood 
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pressure up to 200 mmHg (Schroeder et al 1978) as well as sinus arrhythmias 
(Guilleminault et al 1981) occurring in synchrony with breathing pauses during sleep, 
in contrast to the normal pattern of lowered blood pressure in sleep (Littler et al 1975). 
Polysomnographic examinations of identified hypertensives have shown excess 
frequencies of sleep apnoeic subjects in this group (Kales et al 1984). The causes of 
the cardiovascular problems associated with SAHS are not well understood, but 
nevertheless it seems possible that dramatic blood pressure swings may result in 
myocardial infarctions and strokes in patients with SAHS. 
Hung et al (1990), using multiple regression analyses, have shown that apnoea 
frequencies of greater than 5 per hour slept are an independent risk factor for heart 
attack. Using snoring as a less severe analogue for SAHS (see Section 1.3), 
epidemiological research has identified a 2.4 times greater risk of ischaemic heart 
disease and strokes in habitual snorers than in non-snorers (Koskenvuo et al 1987). 
The odds of vascular death have been calculated by comparing rates of death from 
cardiovascular accidents in conservatively- and aggressively-treated SAHS patients. 
Conservatively treated groups show a death rate from cardiovascular accidents at least 
4.7 times that of aggressively treated patients (Pantinen et al 1988). Studies comparing 
the rates of vascular problems in groups of SAHS patients suggest that aggressive 
treatments may protect against morbidity as well as mortality, as conservatively- 
treated patients have 2.3 times the odds of vascular problems of tracheostomised 
patients (Partinen and Guilleminault 1990). 
All studies on mortality and morbidity in SAHS have been retrospective, with 
associated methodological problems (Gonzalez-Rothi and Block 1988) including the 
absence of control patients or poor control matching, patient selection and response 
biases and difficulties with handling of missing data While careful interpretation of 
retrospective studies is mandatory, it does not seem ethical given the volume of 
research associating untreated SAHS with increased mortality and morbidity to 
conduct a prospective, controlled trial comparing treated and untreated mortality rates 
in SAHS (Schmidt-Nowara and Coultas 1988). 
Thus, the retrospective studies that are available for evaluating mortality and morbidity 
in SAHS suggest that the illness brings to its sufferers an increased risk of sudden 
death, particularly from cardiovascular causes, and a high incidence of raised blood 
pressure, myocardial infarctions and strokes. This makes it an illness to be taken 
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seriously, especially when information relating to its relatively common prevalence is 
considered. 
1.6 Epidemiology of SANS 
SAHS is the most common diagnosis for excessively-sleepy patients studied in sleep 
laboratories (Coleman et al 1982). Clinical case series show the majority of diagnosed 
patients with SAHS to be middle-aged, often overweight men. Eighty percent of a 
patient series studied in the Edinburgh laboratory were men, and the median age at 
diagnosis was 54 years (Whyte et al 1989). In an American series only 4% of SAHS 
diagnosed-patients were female and the average age of diagnosed patients was 45 
years (Guilleminault et al 1978). Probably for these reasons, many cross-sectional 
community-based studies estimating the prevalence of SAHS have concentrated on 
the male population. Such studies estimate the prevalence of SAHS in the community 
in the range of 0.3% to 4% of adult males, although the prevalence of some degree of 
disordered respiration in sleep is much higher (Lavie 1983, Franceschi et al 1982, 
Gislason 1987, Stradling and Crosby 1991, Peter et al 1987, Jennum and Sjel 1992, 
Bearpark et al 1993, Young et al 1993, Bearpark et al 1995). 
The variation in SAHS prevalence in these international studies may be partly 
explained by genetic factors in the studied populations, but may also result from local 
differences in diagnostic thresholds defining pathological frequency of breathing 
disruption in sleep and in nocturnal recording techniques. There is also variation in the 
emphasis on corroborating symptoms of SAHS in patients with breathing pauses in 
sleep. Some studies attempt to estimate the prevalence of SAHS, i. e. frequent apnoeas 
or hypopnoeas in sleep with coexistent symptoms, while other researchers may be 
investigating the prevalence of breathing irregularities in sleep per se. However, most 
researchers attempting to quantify the prevalence of sleep-related respiratory 
disturbance find a surprisingly high proportion of the population to be affected. 
About 1% of a sample of Israeli industrial workers were found to have SAHS, after a 
subsample reporting symptoms of excessive sleepiness underwent polysomnography 
(Lavie 1983). A prevalence of 1% for SAHS was also obtained in a study of 2518 
Italian hospital in-patients, who were screened with the Stanford Sleepiness Scale, a 
subjective rating for sleepiness, with subsequent polysomnography in excessively 
sleepy individuals (Franceschi et al 1982). Both of these studies used 10 apnoeas/hour 
as a diagnostic threshold for defining SANS. A similar prevalence estimate of 1.3% 
was made from a Swedish community-based survey, this time using a AHI threshold 
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of >30 per hour slept (Gislason 1987). In a sample of 1001 middle-aged British men, 
overnight oximetry identified 45 men (4.5% of the target population) with >5 4% dips 
in oxygen saturation per hour in bed who then underwent full polysomnography. 
Using criteria of >20 4% dips in arterial oxygen saturation per hour of sleep to define 
SAHS, 3 men (0.3%) were found to have definite SAHS (Stradling and Crosby 
1991). The authors of this study describe the identified SAHS cases as "severe", so it 
seems likely that this prevalence estimate represents a minimum rate. 
Higher prevalence rates have been obtained by German and Australian researchers. 
Almost 10% of a sample of 95 male German workers showed > 10 apnoeas per hour 
in bed (Peter et a! 1987), while 8.5% of a larger Australian community-based series of 
294 men had a similar level of respiratory disturbances during sleep (Bearpark et al 
1993). The prevalence rate of less severe sleep-disordered breathing is even higher. 
Nine percent of females and 24% of males (Young et al 1993), or 6% of females and 
11 % of males (Jennum and Sjel 1992) show respiratory disturbance indices > 5. 
The high obtained prevalence rates above reflect disordered respiration in sleep with or 
without accompanying symptoms, although some subjects showing disordered 
breathing in sleep might be asymptomatic. The more recent epidemiological studies 
(Jennum and Sjel 1992, Young et al 1993, Bestpark et al 1995) have incorporated 
symptom questionnaires to corroborate the presence of symptoms with disordered 
breathing patterns in sleep, to better estimate the true prevalence of SAHS. 
Both Danish (Jennum and Sjel 1992) and American (Young et al 1993) research 
groups have examined nocturnal breathing patterns and symptoms in large samples of 
more than 600 men and women, aged 30 to 60 years. Frequent sleepiness in addition 
to >5 respiratory pauses in sleep was reported by 1% of females and 2% of males in 
the Danish study and 2% of females and 4% of males in the American sample. A 
similar prevalence rate for suspected SAHS was found with the application of a 
symptom criterion to the large Australian cohort (Bearpark et al 1995). Three percent 
of the subjects in that study, all male, complained of frequent daytime sleepiness and 
showed a respiratory disturbance index > 5. 
The epidemiological studies performed yield a wide range of prevalence estimates for 
SANS, probably due to differences in sampling methods and diagnostic criteria, but 
all confirm that SAHS is a common condition. Those studies providing the best 
documentation of accompanying symptoms of SAHS, despite differences in nocturnal 
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measurements used, are consistent in indicating that 1-2% of middle-aged females and 
2-4% of middle-aged males may suffer from SAHS. 
1.7 Treatments for SAHS 
1.7.1 Tracheostomy 
The sites of upper airway obstructions during sleep can be bypassed by the surgical 
construction of a tracheostomy. This invasive surgical option was among the earlier 
treatments used in SAHS, and was offered to patients with severe obstructive SAHS, 
disabling symptoms of excessive daytime sleepiness, associated cardiac arrhythmias 
in sleep and extreme nocturnal oxygen desaturations (<40% Sa02) (Guilleminault et 
al 1981). There is no doubt that tracheostomy prevents respiratory pauses in sleep and 
associated abnormalities of sleep architecture, improves some nocturnal symptoms 
such as snoring and restless sleep, and alleviates daytime symptoms such as excessive 
daytime sleepiness and personality changes (Guilleminault et al 1981). This treatment 
may also prevent some of the cardiovascular sequelae of SAHS, as long-term vascular 
morbidity in SAHS patients treated with tracheostomy is lower than that of 
conservatively-treated patients (Partinen and Guilleminault 1990). 
However, tracheostomy carries with it its own substantial morbidity risk. Immediate 
post-operative complications include excessive wound bleeding and sepsis at the 
wound site or in the lower respiratory tract. These can lead to a requirement for 
total tracheostomy revision, which occurred in 16% of patients in one series 
(Guilleminault et al 1981). Longer-term problems such as chronic infection, 
granulomatous or position-dependent obstructions of the tracheostomy tube (these 
sometimes requiring a total tracheostomy revision) and problems with managing 
secretions, occurred in at least 60% of tracheostomised patients in two series 
(Guilleminault et al 1981, Conway et al 1981). Psychosocial problems in adjusting to 
the long-term management of a permanent stoma are common (Guilleminault et al 
198 1). Therefore, tracheostomy is now a superseded treatment and is reserved only 
for severe cases of SAHS refractory to other treatments (Guilleminault et a11989). 
1.7.2 Uvulopalatopharyngoplasty (UPPP) 
UPPP involves the surgical removal of excess tissue from the oropharynx (Fujita et al 
1981), a procedure which may be effective in preventing snoring (Gislason et al 1988) 
but which has a high failure rate for treating SAHS (Walker et al 1988, Gislason et al 
1988, Wetmore et al 1986, Fujita et a! 1985). The most common criterion used to 
assess the success of UPPP is a post-surgical reduction of 50% in apnoea and 
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hypopnoea frequency in sleep. Using this criterion, success rates for UPPP vary from 
9% to 65% (Walker et al 1988, Gislason et al 1988, Wetmore et al 1986, Fujita et al 
1985). It may be more pertinent to consider the effectiveness of UPPP in reducing the 
apnoea/hypopnoea index to below 15 per hour, and in the studies where data 
presentation allows this, close reading of papers yield success rates of 9% (Walker et 
a! 1988), 33% (Wetmore et al 1986) and 62% (Gislason et al 1988). The 
comparatively high success rate for the last study is in part due to a less severe patient 
group (mean AHI 27), 6% of whom had AHIs below 15 before surgery. There 
appears to be a marked inter-individual variation in the response to UPPP, which may 
be influenced by preoperative severity of breathing irregularities in sleep (Gislason et 
al 1988) or by the site of upper airway obstruction (Fujita et al 1985). In addition to 
inconsistent patient response to the surgery, UPPP involves considerable post-surgical 
discomfort and the risks of complications such as dysphagia, nasal regurgitation of 
food, nasal speech and infection (Guilleminault et al 1989). 
1.7.3 Drug treatments 
A number of drug treatments for SAHS are prescribed, although none has been 
markedly successful in reducing breathing irregularities in sleep. 
Protriptyline: 
Protriptyline, a tricyclic anti-depressant, reduces REM sleep duration (Hollister 1978) 
and increases airway muscle tone (Bonora et al 1985). Conway et al (1982) treated a 
small sample of 9 patients with protriptyline for 2 to 18 months and found improved 
measures of breathing irregularity in sleep in 4 of these patients. However, this study 
provided no control for the effects of weight loss, which may have been a significant 
factor in the clinical improvement of at least 2 of the 4 successfully-treated cases. A 
similar study assessing 14 SAHS patients also found improved duration of apnoeas 
after 1 to 15 months of protriptyline, but again employed no control for potential 
weight loss during the long follow-up period (Clark et al 1979). In another study, 12 
patients were given repeat sleep studies after an average 4 months on protriptyline 
(Smith et al 1983), during which time the patient group showed a significant loss in 
weight, but no significant difference in AHI after treatment. Two better-quality studies 
found no improvement in AHI when the effects of weight loss were limited by a 
shorter treatment duration of 2 weeks (Brownell et al 1982, Whyte et al 1988). 
Likewise, some researchers have documented subjective improvements in daytime 
symptoms of patients receiving protriptyline (Conway et al 1982), but this response 
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has not been documented in a patient-blind study, where the expectation of 
improvement was controlled by employing a placebo limb (Whyte et al 1988). The 
other study which provided a placebo limb reported in passing improvements in 
subjective daytime sleepiness, but provided no measurements to corroborate this 
impression (Brownell et al 1982). Smith et al (1983) assessed daytime sleepiness 
objectively with a modified multiple sleep latency test and found a significant 
lengthening of median sleep onset latency, but this patient group's significant weight 
loss over the treatment period remains a confounding factor when interpreting these 
results. 
Anti-cholinergic side-effects of protriptyline treatment, such as dry mouth, urinary 
hesitancy and impotence, are relatively common (Brownell et a! 1983), and 
confusional states (Conway et a11982) and cardiac complications (Clark et al 1979) 
have also been reported. It is notable that in Conway et al's study (1982), 3 of the 9 
patients treated with protriptyline suffered intolerable side-effects and that 6 of the 14 
patients in Clark et al's study (1979) experienced complications during protriptyline 
treatment 
Acetazolamide: 
Acetazolamide, a diuretic, may stimulate respiratory responses to hypoxia by inducing 
metabolic acidosis (Kales et al 1987). In a placebo-controlled, double-blind trial, 
acetazolamide halved apnoea+hypopnoea frequency in sleep, but daytime symptoms 
persisted and paraesthesiac side-effects occurred in 8 of 10 patients (Whyte et al 
1988). Though the improvement of polysomnographic features was statistically 
significant, a reduction in AHI from 50 to 26 per hour slept would not normally be 
considered a clinical success. Another study also found a significant reduction in 
apnoea, but not hypopnoea, index (Tojima et at 1988), but again the clinical benefit of 
a drop in mean apnoea index from 25 to 18 per hour slept is dubious. Although the 
authors of this study reported subjective improvements in daytime and nighttime 
symptoms of SAHS, the lack of a placebo control in their study weakens the force of 
this statement. 
Medroxyprogesterone: 
Drug treatment with medroxyprogesteerone, a progesterone derivative, has been 
advocated in SAHS cases where daytime hypoventilation is a feature (Kryger 1989, 
Sutton eta! 1975), but has not proven effective in other patients (Stroh! et a11981, 
Rajagopal et al 1986, Cook et a11989, Orr et al 1979). 
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Sutton et al (1975) found significant improvements in daytime blood gas values in an 
uncontrolled study of 10 `Pickwickian' patients, but sleep studies to evaluate the 
severity of nocturnal events before and after progesterone treatment were not 
performed. The 9 patients studied by Strohl et al (1981) underwent sleep studies 
before and after treatment which showed no significant improvement in mean apnoea 
frequency. However, the authors stated that a subgroup of patients exhibiting daytime 
hypercapnia had reduced levels of breathing irregularity in sleep during progesterone 
treatment. The study by Orr et al (1979) also included a subgroup of SAHS patients 
with pre-progesterone daytime hypercapnia, but technical failures prevented the re- 
evaluation of most of these patients' blood gases after treatment However, in contrast 
to Sutton et al (1975), Orr et al (1979) performed sleep studies before and after 
treatment, which showed no significant improvement in the frequency of obstructive 
apnoeas during progesterone treatment. The patients in the studies by Orr et al (1979) 
and Strohl et al (1975) reported improvements in daytime symptoms such as 
hypersomnolence, but in the absence of a placebo control the value of subjective 
impressions of improvement are doubtful. Neither the placebo-controlled crossover 
trial of Cook et al (1989) nor the withdrawal phase-controlled study of Rajagopal et al 
(1986), both of which employed short treatment durations which reduced the influence 
of weight changes, showed improved measures of breathing irregularity in sleep on 
progesterone. 
Steroid-type side-effects of medroxyprogesterone include weight gain, hair loss, 
gynaeomastia and impotence (Kales eta! 1987), with patients' testosterone levels 
reduced by 75% (Cook et al 1989). In an overwhelmingly male patient population, 
these feminising side-effects may be unacceptable. 
In summary, the available drug treatments for SAHS do not offer proven benefits in 
terms of improved respiration in sleep and all carry a high risk of unpleasant side- 
effects. 
1.7.4 Weight loss 
Weight reduction in obese patients, in whom excess fat on the upper airway may be an 
important factor in generating respiratory pauses, has been shown to be effective in 
reducing respiratory abnormalities in sleep (Browman et al 1984, Smith et al 1985). In 
a single case, a weight loss of 26 kg resulted in a reduction in apnoea index from 60 to 
3 per hour slept (Browman et al 1984). A larger sample of 15 overweight patients 
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losing an average of 10 kg over about 5 months showed a mean fall in apnoea 
frequency from 55 to 29 per hour (Smith et al 1985). There remains a question as to 
the sustainability of dietary weight loss in many patients. Some surgeons have 
recommended gastric bypass surgery in grossly overweight patients as a treatment for 
SANS, this method of weight reduction being perhaps more permanent than dietary 
weight loss. Apnoea indices in a group of 15 patients dropped from an average of 82 
to 15 after gastric bypass surgery (Peiser et al 1984), but long-term outcomes from 
this drastic surgery have yet to be assessed. l'hese studies of weight reduction in 
SAHS show that breathing irregularities may be reduced by weight loss, but that the 
magnitude of reduction in breathing irregularities may not be optimal. 
1.7.5 Continuous positive airway pressure (CPAP) 
Continuous positive airway pressure (CPAP) was developed by Sullivan in the early 
1980's (Sullivan et al 1981) and has become the treatment of choice for SAHS, due to 
its success in reversing respiratory irregularities in sleep and its non-invasive nature 
(Sullivan and Grunstein 1989, Polo et al 1994). The CPAP apparatus (for an 
illustration, see Figure 4.4) consists of an electrically-driven blower unit connected to a 
nasal mask via a flexible hose . The nasal mask is worn in sleep and delivers to the 
patient a gentle airstream that mechanically "splints" open the upper airway. The 
pharyngeal space is enlarged under CPAP (Abbey et al 1989) and pharyngeal 
compliance is reduced (Issa and Sullivan 1984), thereby preventing a collapse of the 
upper airway during sleep. 
CPAP has been demonstrated to be highly effective in abolishing respiratory pauses in 
sleep, reducing breathing irregularities in 5 patients from an average of 63 apnoeas per 
hour slept to zero (Sullivan et at 1981), and in 18 patients from an average of 53 
apnoeas per hour slept to 3 (Sanders 1984). Arterial oxygen saturation is also 
improved subsequent to the normalisation of breathing pattern (McEvoy and Thornton 
1984). In addition, sleep quality is enhanced by CPAP (Lamphere et al 1989), 
becoming less fragmented by multiple apnoea-related arousals and resulting in a 
lengthened total sleep time. Because sleep disruption is minimised, CPAP facilitates 
the return of normal sleep architecture, including percentages of slow wave sleep and 
REM. Effective nasal CPAP also eliminates snoring (Berry and Block 1984, 
Guilleminault et al 1992) and has been shown to significantly improve EEG-arousal 
index in snorers (Guilleminault et al 1992) and EEG-arousal index, objective daytime 
sleepiness and slow-wave sleep percentage in non-snorers (Guilleminault et at 1993) 
with suspected UARS. 
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Whereas CPAP is an effective treatment for SAHS, its short-term use does not effect 
a cure for breathing irregularity in sleep, so patients must use CPAP for the forseeable 
future. CPAP use has not been found to have carry-over effects after withdrawal on 
breathing patterns, sleep quality or pharyngeal volume (Collop et al 1991). 
As was implied earlier in this chapter, retrospective studies suggest that CPAP may 
significantly improve survival rates of SAHS patients, although the limited time that 
CPAP has been in use as a treatment for SAHS reduces the availability of information 
available on cumulative mortality rates. In a 5-year follow-up study, CPAP treated 
patients had a significantly better mortality rate that untreated patients (He et al 1988). 
Patient surveys provide anecdotal evidence of the beneficial effects of CPAP on 
daytime function. The majority of patients report subjective improvement in daytime 
sleepiness and other daytime symptoms of SAHS (Meurice et al 1994, Rauscher et al 
1991, Rauscher et al 1993b, Waldhorn et al 1990, Waldhorn et al 1993, Hoffstein et al 
1992, Pepin et a! 1995). Preliminary objective studies of daytime function, which are 
discussed in depth in Chapter 3, indicate that daytime sleepiness (Lamphere et al 
1989), cognitive performance (Bearpark et al 1987, Bard et al 1993, Kribbs et al 
1993b) and well-being (Derderian et al 1988) may improve with CPAP. 
Side-effects such as nasal obstruction, airstream-associated conjunctivitis and 
problems with mask comfort or airstream pressure tolerance are common in CPAP- 
treated SAHS patients (Nino-Murcia et al 1989) and have been found in around 40% 
of CPAP-treated patients in a follow-up study (McEvoy and Thornton 1984). 
However, the side-effects of CPAP are relatively trivial and can be managed 
effectively with adequate aftercare (Sullivan and Grunstein 1989). 
Recent international studies have found that SAHS patients' average CPAP use rates 
are lower than the 7 or 8 hours per night recommended by clinicians, and are 
frequently overestimated by patients (Rauscher et al 1993b, Kribbs et al 1993a). 
Studies in CPAP clinic populations, which include a cross-section of recent and 
established CPAP users, document average objective compliance rates of 
approximately 5 hours per night (Krieger 1992, Pepin et a! 1995). In other samples, 
objectively monitored CPAP use has ranged from 3.2 (Kribbs et al 1993a) to 6.7 
hours per night (Fleury et al 1994), with early CPAP use being associated with 
poorest use rates. The higher use rates in selected long-term users (Meurice et al 1994, 
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Fleury et al 1994) are likely to reflect self-selection on the part of patients, who 
frequently reject CPAP therapy (Waldhorn et al 1990, Rauscher et al 1991, Fleury et al 
1994). Because nightly CPAP treatment requires constant patient effort in 
remembering to use treatment, motivational factors such as the extent of daytime 
sleepiness may play a significant role in the take-up rates of CPAP treatment 
(Rauscher et al 1991). 
1.8 Summary 
In SAHS, respiratory pauses precipitated by obstructions of the upper airway result in 
frequent arterial oxygen desaturations and arousals from sleep. The syndrome may be 
as prevalent as 4% in middle-aged males and is associated with significant mortality 
and morbidity from cardiovascular causes. The most common symptoms of SAHS 
are heavy snoring and excessive daytime sleepiness, but positive diagnosis requires 
nighttime sleep studies with direct or indirect monitoring of respiratory patterns. 
Surgical treatments have limited usefulness due in the case of tracheostomy to a high 
independent risk of morbidity and in the case of UPPP to a restricted success in 
alleviating apnoeas and hypopnoeas. Pharmacological treatments are not of proven 
benefit and dietary weight loss may not be sustainable in those obese patients for 
whom it is effective. CPAP, a mechanical therapy that prevents airway obstructions in 
sleep, has become the treatment of choice for SAHS due to its efficacy in relieving 
daytime and nighttime features of the illness and due to the benign nature of its side- 
effects. CPAP's effects on daytime function will be dealt with in more depth in 
Chapter 3. 
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Chapter 2: 
DAYTIME NEUROPSYCHOLOGICAL FUNCTION IN SAHS 
Patients with SAHS, as outlined in Chapter 1, experience a constellation of daytime 
features in addition to nocturnal events. Three broad areas of neuropsychological 
function are known to be compromised in SAHS, with patients complaining 
frequently of excessive daytime sleepiness, cognitive deficit and degrees of 
psychological distress. These daytime problems can contribute to reduced functioning 
in a variety of domains, including work efficiency, road safety and psychosocial 
adjustment In this chapter I will seek to provide an overview of research studies 
documenting the daytime problems of SAHS patients, their possible causes and 
potential reversibility. 
The subjective complaint of excessive daytime sleepiness is second only to snoring in 
frequency as a presenting symptom of SAHS, occurring in 78% (Guilleminault et al 
1978) to 87% (Whyte et al 1989) of patients. Patients with SAHS very commonly fall 
asleep in situations of minimal stimulation, such as watching television or reading, but 
may also fall asleep under conditions when wakefulness is essential, such as whilst 
driving (Guilleminault et al 1989). Patients may also report intellectual deterioration. 
All of the patients reporting daytime sleepiness in one case series (78% of the total 
sample) complained also of inadequate concentration skills or memory (Guilleminault 
et al 1978). In one case report, a dementia-like cognitive deterioration was the major 
presenting symptom (Scheltens et al 1991). Mood problems are common in SAHS, 
with 48% of the American case series reporting personality changes and 11 % of the 
Scottish SAHS patients or their family members admitting to irritability. It is easy to 
imagine how these daytime problems can adversely affect a wide range of everyday 
activity, including social interaction and work achievement 
Patients state that the daytime symptoms of SAHS are more frequently the spur 
precipitating medical consultation than are nocturnal symptoms. Eighty percent of 
SAHS patients in one case series sought medical help primarily because of excessive 
daytime sleepiness or clouded mental states, while only 20% were seen as a result of 
their own or their spouses' complaints of nocturnal events such as snoring or choking 
(Guilleminault et a! 1978). SAHS patients' bias in reporting daytime problems to 
medical professionals may reflect individuals' lack of awareness of their breathing 
pauses during sleep, particularly when a partner is not present to witness these events, 
or a degree of ignorance of the long-term repercussions of disordered breathing in 
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sleep. But patients' emphasis on daytime symptoms may also reflect their importance 
in reducing overall quality-of-life. 
Research into the daytime problems of SAHS draws from historically divergent 
scientific fields, which have evolved distinctive batteries of assessment tools. The 
study of sleepiness has relied primarily on electrophysiological techniques of 
measurement, while cognitive function is typically assessed using paper and pen or 
computer-administered performance testing and psychological distress by self-rated 
questionnaire. For this reason it is expedient to deal with the three broad areas of 
daytime deficit in SAHS separately, but the distinction is at least partially artificial 
because the domains of sleepiness, cognitive performance and psychological 
wellbeing are interrelated. For instance, sleepiness produces measurable decrements in 
cognitive performance (Wilkinson et al 1966) and may provoke depression as a result 
of lowered quality-of-life (Isaac et al 1992), while mood and cognitive performance 
are highly interrelated (Matthews 1992). Detailed below are primarily case-control 
studies documenting daytime impairments in the form of sleepiness, cognitive 
dysfunction and psychological distress. 
2.1 Excessive daytime sleepiness 
While the great majority of SAHS patients complain of excessive daytime sleepiness, 
subjective accounts of degree of sleepiness are neither sufficiently specific nor 
sensitive for research purposes. Because of problems associated with some subjective 
assessments of sleepiness (Dement et al 1978, Roth et al 1980, Browman and Mitler 
1988), a variety of objective instruments for evaluating sleep tendency have been 
developed, all based on polysomnographic measurements of the latency to sleep 
during daytime nap opportunities. These instruments have shown that SAHS patients 
are significantly more sleepy than normals. 
The most commonly used objective tool for evaluating daytime sleepiness is the 
multiple sleep latency test (MSLT: Carskadon et al 1986; Thorpy 1992), which 
assesses leep tendency by measuring the actual ability to fall asleep. The test consists 
of five 20-minute daytime nap opportunities with concurrent polysomnography, 
spaced at 2 hour intervals starting at 10 am and with the final test at 6 pm. Patients are 
asked to try to fall asleep in a darkened, quiet room while the latency from lights-out to 
the first epoch of any sleep stage is measured. The nap duration is limited to a 
maximum of 20 minutes so that sleep debt will not be eradicated. 
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The wide use of the MSLT within sleep research has allowed a large database of 
measurements from individuals of different age-groups and health status to be built 
up, facilitating the establishment of norms for the primary measure obtained from the 
MSLT, the mean sleep onset latency of the five naps. A mean sleep onset latency of 5 
minutes or less corresponds to a level of sleepiness associated with decrements in 
performance and irresistible sleep episodes (Carskadon and Dement 1981), so this 
range is said to indicate pathological sleepiness (Carskadon et al 1986). While most 
normals have mean sleep latencies greater than 10 minutes (Richardson et al 1982), 
the range from 5 to 10 minutes represents a'diagnostic grey zone' of moderate 
sleepiness (Van den Hoed et al 1981). Case-control studies verify the validity of the 
MSLT in discriminating between hypersomnolent and normal subjects. In an early 
study, Dement et al (1978) matched six healthy control subjects for age, sex and 
weight to 10 SAHS patients, whose mean sleep latency was significantly lower at 3.4 
minutes than the controls' 10.8 minutes. In a similar study, 10 patients with a mean 
apnoea frequency of 57 per hour slept had a mean sleep onset latency of 2.6 minutes, 
while age-matched healthy controls averaged 12.9 minutes (Roth et a! 1980). 
Using the MSLT as an objective assessment of sleepiness, studies on SAHS patient 
samples have consistently documented mean sleep latencies either in the 'pathological' 
range of less than 5 minutes (Dement et al 1978, Roth et al 1980, Stepanski et al 1984, 
Browman and Winslow 1989, Lamphere et al 1989, Fry et al 1990, Kribbs et al 
1993b) or in the lower range of the 'grey zone' of excessive daytime sleepiness 
(Guilleminault et al 1988, Roehrs et al 1989, Bedard et al 1991a, Bedard et al 1991b, 
Mendelson 1992, Sangal et al 1992a), with latencies up to 7 minutes at longest (Sangal 
et al 1992a). 
An alternative, objective test of daytime sleepiness exists in the form of the 
maintenance of wakefulness test (MWT), wherein subjects are asked to try to stay 
awake in a sleep-conducive environment (Mitler et al 1982). Norms have yet to be 
established for the MWT, but this objective sleepiness test has also been shown to 
discriminate between normals and hypersomnolent patients. Early studies using the 
MWT paradigm in small samples of SAHS patients documented mean sleep onset 
latencies of approximately 11 minutes, significantly lower than the mean 19 minutes 
found in normals (Mitler et al 1982, Browman and Mitler 1988). Later studies on 
much larger numbers of SAHS patients (Sangaa et al 1992a, Poceta et al 1992) have 
found mean MWT latencies of 24 and 26 minutes respectively, but do not present 
control values for comparison. 
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Patients with SAHS also show elevated scores on a subjective rating of recent napping 
behaviour, the Epworth sleepiness scale (Johns 1991,1992,1993,1994), which has 
been reported as showing close correlation with the `gold-standard' MSLT (Johns 
1993,1994). SAHS patients' average Epworth score was 11 on a 24-point scale, and 
significantly higher than those of healthy controls, who averaged 6 points (Johns 
1991). Similarly elevated Epworth scores averaging 14 (Johns 1992) and 12 (Johns 
1993) have been reported in subsequent SAHS samples. 
Thus, both objective and subjective assessments of daytime sleepiness show that 
SAHS patients are excessively sleepy, and the objective polysomnographic 
instruments indicate that the sleepiness seen in SAHS is of a severe or moderate 
nature. 
2.2 Cognitive dysfunction 
As many patients in the American case series complained of mental deterioration as of 
excessive daytime sleepiness (Guilleminault et al 1978). Epidemiological studies have 
found that subjects with symptoms of SAHS, such as heavy snoring and tiredness, 
complain more of subjective problems with concentration and memory than do non- 
snorers (Jennum and Hein 1988). 
From the mid-1980s, case-control studies appeared which attempted to specify and 
quantify the cognitive deficits reported to clinicians by their patients (Kales et al 1985, 
Findley et al 1986, Greenberg et al 1987, Klonoff et a11987, Bedard et a! 1991a, 
199lb, 1993). In these studies (Table 2.1), descriptions of the cognitive dysfunction in 
SAHS were made by comparing neuropsychological test performance in SAHS 
patient samples to that of normals, sometimes individually matched for sex, age, 
education and socioeconomic level, as these variables are known to affect cognitive 
performance (Lezak 1983). Many studies have evident methodological problems as a 
result of control-matching problems, but nevertheless they hint at the nature and 
severity of cognitive dysfunction in SANS. 
In an early case series, Kales et al (1985) obtained Bender gestalt and Wechsler adult 
intelligence scale (WAIS) or Wechsler memory scale data from 50 patients with 
SAHS severe enough to warrant a recommendation of tracheostomy. Only 24% of the 
subjects showed no sign of organic impairment on reproduction of the Bender 
designs, and 24% scored sufficient errors to show mild to severe impairment. 
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Table 2.1: Case-control studies of cognitive function in SAHS 
Author Subjects Study design Measures Results 
Kales et al 50 severe Uncontrolled Bender, WAIS 40% of pts 
1985 SAHS pts case series- IQ, WMS, `impaired' in 
compared to intelligence 
norms and/or memo 
Greenberg et 14 SAHS pts, Controlled WAIS-R IQ, Pts < Controls 
at 1987 24 mixed PWA, Bender, in BD, Bender, 
sleepy/healthy PB, TM, LC, LC, PB 
controls W MS 
Klonoff et al 11 SAHS pts, Controlled WAIS-R, No differences 
1987 11 COrOTIarY BVRT, VF, 
bypass Pts TM, SP, SR, 
Category, FT 
Findley et at 26 SAHS pts; Hypoxaemic WAIS IQ, RT, Hypoxaemic < 
1986 17 hypoxaemic compared to TM, PASAT, non- 
and 9 non- non- W MS hypoxaemic in 





Pitson et at 87 snorers, 96 Controlled Median, simple Both snorers 
1993 SAHS pts and RT and SAHS pts 
39 healthy slower than 
controls controls 
B-dard et at 10 SAHS pts, Controlled RT, WAIS-R, Pts < Controls 
1993 10 controls WMS, LC, PB, in Perf IQ, LC, 
TM, PM, VF PB, TM, PM, 
VF, delayed 
WMS 
Naegel6 et al 17 SAHS Controlled TM, LC, Pts < Controls 
1995 patients, 17 Stroop, in Stroop, 
controls memory, memory, 
WISC, VF, perseverative 
Tower responses 
Key- 
WAIS- Wechsler Adult Intelligence Scale RT- Reaction time 
WMS- Wechsler Memory Scale PB- Pegboard 
TM- TrailMaking BD- Block design 
LC- Letter cancellation PM- Porteous mazes 
BVRT- Benton visual retention test FT- Finger tapping 
Tower- Tower of Toronto task SR- Seashore rhythm 
PASAT- Paced auditory serial addition test SP- Speech perception 
WISO- Wisconsin card sorting test VF- Verbal fluency 
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Cognitive impairment was judged to be present when the differential between obtained 
performance and verbal IQ scores exceeded 15 points, a condition met by 39% of the 
patients who underwent the WAIS battery. Forty-six percent of patients were judged 
to have impaired short-term memory and 32% deficits in long-term memory. This 
study included no control beyond the age-scaled norms obtained when standardising 
the tests, leaving the possibility that some other sampling bias besides age in the 
patient sample might have interacted in their apparently depressed performance. 
Loading towards lower educational level and socioeconomic status might then have 
contributed towards the high rates of impairment in the SAHS patients, but this study 
suggested a high incidence of cognitive impairment in SAHS. 
Findley et al (1986) assessed cognitive performance in 26 SAHS patients and 
compared age-scaled scores from 9 hypoxaemic SAHS patients to those of 17 non- 
hypoxaemic patients. A comprehensive psychometric battery included the WAIS-R 
subtests of block design and vocabulary, TrailMaking B, 4-choice reaction time, short- 
term and delayed elements from the Wechsler memory scale and the paced auditory 
serial addition task (PASAT), a test of sustained concentration. The hypoxaemic 
group's mean score lay in the impaired range for TrailMaking, PASAT and delayed 
recall, while the non-hypoxaemic group's average score was in the normal range for 
all tests. The hypoxaemic group's scores in TrailMaking, reaction time and recall, 
were significantly poorer than the non-hypoxaemic group's. The study was designed 
to evaluate the impact of hypoxaemia on psychometric function, rather than to 
discriminate particular deficits associated with SAHS. However, because the 
hypoxaemic patients also had significantly worse measures of severity of SAHS, a 
comparison of their scores to those of the less severely hypoxaemic patients provides 
valuable information. The study implies that frequency of nocturnal apnoeas may be 
related to degree of cognitive deficit, as the hypoxaemic group showed twice as many 
nocturnal desaturations as the less hypoxaemic group. A correspondingly more severe 
level of waking hypoxaemia in the more hypoxaemic group, whose Pa02 averaged 63 
mmHg, may have influenced the findings of more severe cognitive deficit in this 
group. 
Greenberg et al (1987) administered a psychometric battery to 14 SAHS patients with 
a mean frequency of 34 apnoeas per hour in bed, to 10 sleepy controls with other 
disorders of excessive sleepiness (narcolepsy [n=5], periodic leg movement syndrome 
[n=4] and idiopathic hypersomnia [n=1]) and to 14 healthy controls, whose mean age 
and education approximated that of the SAHS group. The battery administered 
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included performance and verbal subtests from the WAIS-R scale, a letter cancellation 
test, the Bender gestalt test, the TrailMaking B task, pegboard test, controlled word 
association test and the Wechsler memory scale, and thus covered a wide range of 
executive neuropsychological function. A clinical neuropsychologist produced a blind 
impression of the overall global impairment rating based on each subject's test scores. 
Oneway ANOVA showed that the SAHS group performed significantly worse than 
both control groups on the block design WAIS-R subtest, the letter cancellation test, 
the Bender design reproduction, pegboard test and the global impairment rating, 
leading authors to conclude that SAHS produces impairment in visuomotor skills, 
concentration ability, visuographic ability, motor efficiency and overall level of 
function respectively. The use of a sleepy control group allowed the authors to assess 
the influence of sleepiness per se on neuropsychological performance, when it was 
found that the sleepy controls scored nearer to the range of the healthy controls than to 
that of the SAHS patients. The level of cognitive impairment found was judged 
moderate in severity, as SAHS patients' scores lay half a standard deviation below that 
of the controls. 
This study provides useful evidence of the specific impairments of SAHS and in 
addition makes a methodological allowance for the impact of sleepiness itself on 
performance, but the control groups used were not ideal. Both control groups had a 
non-significant excess of years of education compared in the SAHS group, which 
could affect test performance (Lezak 1983), and in addition both control groups had 
non-significantly higher scores on the Vocabulary and Information subtests from the 
WAIS-R battery. These subtests were used by Greenberg et al (1987) to estimate pre- 
morbid performance as part of the control-matching procedure, yet both control 
groups' mean scores lay roughly half a standard deviation higher than those of the 
SAHS group. This decrement in SAHS patients' performance on pre-morbid 
estimates of function mirrors the half a standard deviation deficit in current 
performance found by Greenberg et al (1987), so it must be questioned whether the 
lower performance in SAHS patients is a function of lower pre-morbid ability. 
Klonoff et al (1987) compared the performance of a group of 11 SAHS patients 
(mean apnoea frequency 49 per hour slept) on the WAIS-R battery, the Benton visual 
retention test, verbal fluency test and several subtests from the Halstead-Reitan battery 
including the TrailMaking, speech perception, category, finger-tapping and seashore 
rhythm tests to that of a group of patients awaiting coronary bypass surgery. T-tests 
comparing the performance on these tests in the two untreated patient groups found no 
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differences, but the authors were careful to draw no concrete conclusions from this 
study concerning cognitive impairment in SAHS. Their discussion centred on the 
longitudinal changes in cognitive and psychological function after treatment in the two 
groups, rather than on the baseline characteristics of each patient group. The patient 
groups were not matched for education or occupational status, with the SAHS patients 
showing a generally less well-educated but higher socioeconomic profile. Further, 
poor cardiovascular function in the bypass group may have independently affected 
their neuropsychological performance, so a conclusion that this study showed no 
cognitive deficit in patients with SAHS cannot be drawn. 
Simple reaction time testing was employed by Pitson et al (1993) to compare the 
response speed of 37 controls, 96 patients complaining of snoring but with less than 5 
4% desaturations per hour in bed, and 87 symptomatic SAHS patients showing >5 
4% desaturations per hour in bed. Despite the fact that the controls were on average 
older than either patient groups (J Partlett, personal communication), their reaction 
times (mean 307 ms) were significantly shorter than both the snorers (350 ms) and 
the SAHS patients (358 ms). These results indicated that patients with permutations of 
SANS may suffer impaired vigilance. 
Two further case-control studies were published towards the end of the period covered 
in this thesis. Bedard et al (1993) matched 10 healthy control subjects for sex, age and 
education with 10 moderate and severe SAHS patients. His psychometric battery 
included Wilkinson-type four-choice reaction time, the WAIS-R tests, Wechsler 
memory scale, the complex figures test, a verbal fluency test, WISC-R mazes, a letter 
cancellation task, the pegboard test motor speed and dexterity and the TrailMaking 
tasks A and B. Although the patients scored only 4 IQ points lower on WAIS-R 
verbal tests, their performance IQ was significantly lower by 13 points. The patients 
performed significantly more poorly than the controls on the digit symbol substitution, 
object assembly and picture arrangement subtests of the WAIS-R, as well as on the 
letter cancellation test, delayed memory of the Wechsler scale, TrailMaking task B, 
WISC mazes, verbal fluency and pegboard proficiency. The data were obtained in a 
small sample where outlying scores can have profound effects, but suggest 
compromise of executive functions and decreased vigilance in SAHS patients. 
Naegele et al (1995) used a similar case-control design, this time with 17 patients 
(AHI > 10) and 17 age-matched controls, and administered a cognitive battery 
including the Stropp and TrailMaking tasks of mental flexibility; a digit-cancellation 
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test to assess attention; WAIS-R digit span, Corsi blocks, verbal and visual learning 
tests to test learning and memory; and tasks thought to index frontal lobe function, the 
Wisconsin card sorting test, verbal fluency test and the Tower of Toronto task of 
forward planning. Patients showed poorer performance on the Stroop test, in verbal 
and visual learning and retrieval, and in perseverative responses on the Tower and 
card-sorting tasks. Logistic regression analysis suggested that Stroop and Tower tests 
showed the best discrimination between patients and controls, suggesting that mental 
set shifting and planning abilities are most compromised in SAHS. 
These studies using neuropsychological testing yield an impression of mild and 
moderate deficits across a wide range of cognitive function in patients with SAHS. 
Impairment has been noted in attention skills, visuomotor co ordination, memory, 
abstract reasoning and planning ability. 
2.3 Evoked responses 
An alternative approach to the study of both cognitive function and sleepiness in 
SAHS is provided by electrophysiological studies of nervous system activity in the 
form of evoked responses (Walsieben et al 1989, Mosko et al 1981, Stockard 1982, 
Wetmore et al 1988, Snyderman et al 1982, Rumbach et al 1991). Neurophysiological 
activity is evoked during the response to stimuli, typically auditory tones, which can be 
presented under different paradigms in order to enhance the resolution of certain 
components of the waveform. The conformation of the waveform, the latency and 
amplitude to its peaks and troughs, indexes underlying neuronal activity (Callaway et 
al 1978). Typically, the longer the expected latency of a particular wave component, 
the higher and more specialised is its hypothesised function (Goodin et al 1978). 
Brainstem evoked responses (BSERs) are extremely short latency waveforms, 
recorded in the first 10 msecs after auditory stimuli, that appear to reflect sensory input 
processes (Walsleben et al 1989). Their conformation is unaffected by level of 
consciousness or attention (Amadeo and Shagass 1973), but is dependent on the 
function of the primary auditory pathway from cochlear nerve to brainstem (Mosko et 
al 1981). Case-control studies of BSERs in SAHS have yielded mixed results, most 
showing no differences between patients and normals (Mosko et al 1981, Stockard 
1982, Wetmore et al 1988) but others showing slower central conduction times 
(Walsleben et al 1989) or prolonged peak latencies (Snyderman et al 1982) in patients. 
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The longer latency auditory evoked potentials (AEPs) appear to reflect higher 
cognitive function (Blackwood et al 1987), indexing storage and retrieval of 
information and discrimination of stimuli (Figure 2.1). The P3 and N2 wave 
components of evoked auditory potentials appear to be delayed and often smaller in 
amplitude in brain dysfuntion (Blackwood et a! 1987). P3 latency is highly correlated 
with measures of cognitive function such as reaction time (McCarthy and Donchin 
198 1) and WALS IQ scores from both brain-damaged (Blackwood et al 1987) and 
healthy subjects (Pelosi et al 1992). P3 latency is a sensitive index not only of the 
cognitive deficit associated with dementia and organic brain damage (St Clair et al 









Figure 2.1: Auditory evoked potential waveform 
Deficits of SAHS apparent on cognitive testing and sleepiness assessments are also 
found by AEP measurements. 14 sleep apnoeics had significantly slower N2 and P3 
latencies than matched normals (Walsieben et al 1989), and P2, N2 and P3 
components were delayed in 47 SANS patients compared to age-matched controls 
(Rumbach et al 1991). 
Evoked cognitive potentials, like neuropsychological performance, may vary with 
level of attention and sleepiness, as well as with cognitive ability. Researchers have 
found decreasing amplitudes in the wave components with drowsiness, but then 
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increasing amplitudes and latencies with increasing depth of NREM sleep (Weitzman 
and Kremen 1965). Broughton et al (1982) found decreased amplitudes in Ni, P2 and 
N2 in awake narcoleptics compared to controls. The waking P3 amplitude was found 
to be significantly smaller in a group of narcoleptics, also shown to be sleepier on the 
MSLT, than that in controls (Aguirre and Broughton 1987). Thus, as in cognitive 
performance testing, evoked potentials may not discriminate between the effects of 
organic brain damage and sleep disruption in SAHS. This link between cognitive 
deficit and sleepiness is discussed in greater detail in a later section. The above 
evidence, however, from studies both of evoked responses and cognitive performance 
point to measurable cognitive deficits in SAHS patients. 
Thus research using nei rophysiological techniques indicates disturbances of higher 
cortical function and perhaps sensory activity in patients with SAHS, corroborating 
other evidence of both of impaired cognitive performance and alertness in SAHS. 
2.4 Psychological well-being 
Early characterisations of SAHS noted a high incidence of altered personality and poor 
mood in patients with the syndrome. Guilleminault et al (1978) reported that families 
had noted personality changes in almost half of SAHS patients, who were described 
as showing increased irritability and a greater propensity for emotional outbursts. Later 
studies employing quantitative methods to describe the personality profiles, mood and 
affect of SAHS patients document a higher frequency of minor psychiatric morbidity 
and psychopathology in SAHS patients than in normals. 
Psychological health in SAHS has been investigated using measures of personality, 
mood, psychiatric distress and quality-of-life. While these instruments contain 
differing biases towards trait, state or functional assessment, all contain information on 
psychological wellbeing. Most measures of well-being consist of self-rated 
questionnaires, which are vulnerable to manipulation by subjects who may feel that 
complaints of significant psychological distress might precipitate more rapid or 
effective treatment Additional methodological problems are posed by the lack of 
distinction (both in patients' perceptions and in the formulation of psychological 
instruments) between physical and mental symptoms of psychological distress. Many 
instruments cannot discriminate between a lack of vigour caused by excessive daytime 
sleepiness and the anergia of clinical depression (Lee 1990). 
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Trait assessment of personality in SAHS (Beutler et al 1981, Kales et al 1985, Klonoff 
et al 1987, Platon and Sierra 1992) has most commonly been conducted with the 
Minnesota Multiphasic Personality Inventory (MMPI: Dahlstrohm et al 1972,1975). 
The MMPI, which is considered a relatively stable measure of persistent personality 
and psychopathology (Beutler et al 1981), consists of a self-rated questionnaire 
comprising more than 500 questions, resolving into ten clinical subscales measuring 
hypochondriasis, depression, conversion hysteria, psychopathy, masculinity- 
femininity, paranoia, psychaesthenia, schizophrenia, hypomania and social 
introversion. It has been used with remarkably consistent results in samples of patients 
with SAHS. 
Beutler et al (1981) found that 20 SAHS patients scored significantly higher than 10 
age- and socioeconomic status-matched normals on the scales for hysteria and 
depression. High point pattern analysis characterised the apneics as having relatively 
high hysteria and hypochondriasis scores, reflecting a tendency to dependency on 
physical symptoms. In a larger sample of 48 patients with severe SAHS, Kales et al 
(1985) found significantly higher scores for hypochondriasis, depression, hysteria, 
schizophrenia and psychaesthenia than for 78 age- and sex-matched healthy controls. 
65 % of the patients had at least one scale score in the elevated range, versus 29% in the 
control group. The SAHS patients studied by Kales et al (1985) were severe enough to 
warrant treatment with tracheostomy, so the increased intensity and range of 
psychopathological MMPI scores in this sample compared to that of Beutler et al 
(1981) is likely to be related to differences in SAHS severity in the two patient groups. 
The personality profiles of 69% of Kales' patients were coded as somatic-neurotic in 
type, describing "a reactive type of psychopathology in response to a major medical 
illness" (Kales et a11985). Thus Kales et al (1985) suggest that the disturbances in 
psychological well-being in SAHS patients may be secondary to functional limitations 
imposed by SAHS. 
Because of impairment in daytime respiratory function, chronic obstructive pulmonary 
disease (COPD) produces severe physical limitations on behaviour and function, 
producing an objectively poor quality-of-life (McSweeny et al 1982). It is therefore 
notable that an even greater proportion of SAHS patients show MMPI characteristics 
of reactive depression than do COPD patients, suggesting that limitations to daytime 
function are at least as great in SAHS as in COPD (Kates et x11985). 
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A further, more recent study of MMPI scores in 23 SAHS patients and 17 healthy 
control subjects group-matched for age, sex and educational level has showed the 
familiar profile of significantly higher scores in the apnoeics than in controls on scales 
for depression, hypochondriasis, hysteria, schizophrenia and psychaesthenia (Platon 
and Sierra 1992). High point pattern analysis in this sample characterise the apnoeic 
group as showing relatively high scores for hypochondriasis, schizophrenia and 
depression. 
Thus MMPI-based studies of personality show a consistent, long-term somatic- 
neurotic coping strategy in SAHS patients. Longitudinal studies (discussed in Chapter 
3) have shown normalisation of MMPI-measured psychopathology after successful 
treatment of SAHS, implying that disordered respiration in sleep, or one of its 
sequelae in the form of daytime symptoms, are most likely the cause of the typical 
apnoeic MMPI pattern. 
Studies of more transient mood state in SAHS patients (Beutler et al 1981, Derderian 
et al 1988, Mosko et al 1989, Kribbs et al 1993b) have been performed almost 
exclusively with the Profile of Mood States (POMS: McNair et al 1981). Subjects are 
presented with 65 adjectives and are asked to rate the applicability of each of the 
adjectives to their state that day, using a five-point scale. The POMS yields scores for 
6 affective states: depression-dejection, anger-hostility, vigour-activity, fatigue-inertia, 
confusion-bewilderment and tension-anxiety, as well as a total mood disturbance 
score. As might be expected, SAHS patients show high POMS scores for fatigue and 
low DOMS scores for vigour. 
In Buetlei's study, which compared apnoeics' and control subjects' POMS scores, the 
patient group had significantly lower scores on the vigour and fatigue scales, reflecting 
lower energetic levels in the patient group. The studies by Derderian et al (1988), 
Mosko et al (1989) and Kribbs et al (1993b) were primarily concerned with 
monitoring change in mood after treatment for SAHS, and contained no direct 
comparison of POMS scores in SAHS cases and healthy controls. While there is a 
large variability in the mean POMS scores of SAHS patients reported by these 
researchers, rough comparisons show untreated patients' fatigue scores to be at least 2 
standard deviations outside of Beutler's healthy controls' scores, in the direction of 
greater inertia, in all three studies. Derderian's small sample of 7 patients were in 
Beutler's normal range on all other POMS scales, while Mosko's large group of 73 
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SAHS patients appeared to score outside the normal range on all scales except the 
confusion-bewilderment measure. 
Structured psychiatric interview techniques provide further evidence of psychiatric 
morbidity in SAHS. Reynolds et al (1984) found that 10 of 25 SAHS patients met 
research diagnostic criteria for a past or present psychiatric illness, most diagnosed 
with depressive or alcohol abuse disorders. Mosko et al (1989) employed a 
questionnaire based on standard psychiatric criteria (DSM-III) to catalogue the number 
of depressive symptoms suffered by patients in the preceding 5 years. 58% of the 
apnoeic patient sample had more than four symptoms of depression for 2 weeks or 
longer, fulfilling DSM-III criteria for a major depressive episode. The Zung self-rating 
depression scale classified 45% of 55 SANS patients as depressed, using a threshold 
score of 50 or more as diagnostic (Millman et al 1989), although reservations might 
be expressed concerning the inclusion of items in this scale that relate equally to 
symptoms of depression and sleep apnoea, such as sleep disruption, task performance 
deficits and decreased libido. Cheshire et al (1992) refined psychiatric screening in 
SANS by using the Hospital Anxiety and Depression (HAD) scale to assess 
symptoms of dysphoria The HAD scale (Zigmond and Snaith 1983) was designed 
for use in patients with physical illness and thus deliberately excludes questioning that 
may confound somatic symptoms of physical and mental illness instead concentrating 
on the anhedonic state specific to affective disorder. Cheshire et al (1992) found 12 of 
29 patients scored in the clinically suspicious range for anxiety and/or depression. 
A few preliminary and recent reports have directly attempted to measure the functional 
impact of SAHS on quality-of-life, although it can be assumed that many of the 
assessments described above indirectly measure satisfaction with and participation in 
daily activities. Isaac et al (1992) compared scores on the Sickness Impact Profile 
(Bergner et a! 1976) from patients with documented mild SAHS (AHI< 20) to a 
group of referred patients who had symptoms of SAHS (excessive daytime sleepiness 
and/or snoring) but too few respiratory events to permit diagnosis of SAHS. While 
the two groups could not be discriminated using the POMS scale, the diagnosed 
patients showed significantly poorer social, work, marital and family functioning than 
those with symptoms only. In a recent report, 44 sleep clinic patients completed the 
SF-36 rating of quality-of-life (Stewart et al 1988) before undergoing 
polysomnography and an MSLT (Briones et al 1995). The extent of daytime 
sleepiness in these subjects, many of whom had SAHS, was moderately correlated 
with the degree of impairment in mental health and social function, and both sleep 
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onset latency and respiratory disturbance index were associated with limitations due to 
emotional and physical problems and to tiredness. 
As these quality-of-life studies document, the daytime problems associated with 
SAHS have wide-ranging effects on everyday life for sleep apnoeics. Interpersonal 
relationships and work efficiency are further areas which appear to be compromised in 
SAHS. 
A questionnaire administered to a consecutive series of SAHS patients with illness 
severe enough to warrant tracheostomy found a high incidence of psychosocial 
problems (Kales et al 1985). 66% of this series believed their relationships to be 
adversely affected by their illness, and 64% attributed marital and family problems to 
SAHS. 
In a study evaluating the psychosocial function of married male apnoeics and their 
partners, Carter and Knight (1987) used the Social Adjustment Scale to show 
disturbed function for both patients and spouses in marital and social/leisure areas. In 
the Marital Satisfaction Inventory, the SAHS patients' wives rated themselves higher 
for global distress and conflict over child-rearing than normals. 
In Kales et al's series (1985), 89% of severe SAHS patients reported experiencing 
problems in the workplace as a result of their illness. Within this adversely affected 
subgroup, 79% found that their work capacity was limited, 62% had fallen asleep at 
work on several occasions and 13% reported leaving employment as a direct 
consequence of their symptoms. These self-reports remain the only source of 
information on productivity and safety in the workplace in SAHS. 
Thus, the various state, trait and functional measures of psychological health so far 
used in the assessment of patients SAHS have provided evidence showing significant 
psychological dysfunction. Sleep apnoeics show higher mean scores for personality- 
based trait assessments of psychopathology than do normals, have typically tired and 
anergic mood state profiles compared to normals, show a high incidence of suspected 
psychiatric illness and a poorer quality-of-life than controls. 
2.5 Road safety 
Much effort has been channelled into study of the road safety risks associated with 
impaired daytime functioning in SAHS (Guilleminault et al 1978, Parsons 1986, 
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George et al 1987, Findley et al 1988, Findley and Bonnie 1988, Gonzalez-Rothi et al 
1988, Aldrich 1989, Findley et al 1989a, Findley et al 1989b, Stradling 1989, Cassell 
et a11990, Zomer and Lavie 1990, Haraldsson et al 1990a, Haraldsson et al 1990b, 
Haraldsson et a11991, Findley et al 1992, Home 1992, Home and Reyner 1995). 
Most of these studies investigating the incidence of car accidents use self-reports from 
SAHS patients, who may fear the loss of their driving licenses, and thus are likely to 
under-report the scale of their problem. Nevertheless, the available evidence points 
clearly to a greatly increased rate of automobile accidents in patients with SAHS. 
Many of these accidents occur due to frank falling asleep while driving (Aldrich 
1987), but impairment of more subtle perceptuo-motor ability may also contribute to 
the high accident rates in SAHS patients (Home 1992). Findley et al (1989a) 
demonstrated that SAHS patients perform worse than controls on a 30-minute 
driving-based vigilance task, but was unable to document electroencephalographic 
episodes of sleep during performance (Findley et al 1993). 
Probably one half of SAHS patients fall asleep at the wheel of their car. Uncontrolled 
studies have found that 54% (Guilleminault et al 1978) and 56% (Cassell et al 1990) 
of SAHS patients fall asleep whilst driving, while controlled studies show that the 
incidence of sleeping whilst driving is far higher in sleep apnoeics than in the normal 
population (Findley et al 1988, Haraldsson 1990b). Twenty-four percent of Findley's 
(1988a) sample of polysomnographically-diagnosed SAHS patients fell asleep at the 
wheel at least once per week, against 3% of a control group who demonstrated a 
clinically insignificant frequency of apnoeas during sleep. Haraldsson et al (1990b) 
compared responses on a questionnaire of driving experiences from 73 patients with 
symptoms highly suggestive of SAHS and 142 controls, recruited from a pool of 
ENT patients with no symptoms of SAHS. Fifty-two percent of the probable SAHS 
sufferers reported habitual sleeping whilst driving, against less than 1% of the control 
group. These figures on sleeping at the wheel correlate well with other studies of near- 
miss car accidents, which find frequencies in SAHS patients of 32% (Gonzalez-Rothi 
et al 1988) and 66% (Aldrich 1989). 
Driving skills of SAHS patients have been evaluated in the laboratory using long, 
monotonous driving simulators. Findley et al (1989a) administered several types of 
driving simulator to a small number of severe SAHS patients and to age- and sex- 
matched normals, and found significantly poorer performance in the patients on all of 
the three simulators employed. The SAHS patients scored a modestly lower number 
of correct responses during film-projection simulations of both highway and urban 
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roads, each simulation lasting 22 minutes, than the controls. But more dramatic 
differences in performance were found with the SteerClear computer driving 
simulation, when patients averaged 44 errors versus the controls' score of 9. 
SteerClear is a 30-minute vigilance task presenting subjects with a view of a two-lane 
road on which cows periodically appear. Because the only response required from the 
subject is to change lanes and avoid cows by pressing a computer key, it cannot be 
termed a true driving simulation: but it nevertheless contains elements of response 
speed and visuomotor co-ordination that contribute to driving skill. A slightly larger 
group of 15 patients with the symptoms of SAHS showed significantly poorer 
performance during a more sophisticated driving simulation than 10 matched controls 
(Haraldsson et al 1990a). After 10 minutes practice at the task, subjects drove at 55 
mph for between 30 and 90 minutes in a realistic interactive simulation, during which 
braking speed, steering precision and off-road incidents were monitored. The SAHS 
patients' mean and 90th centile scores for both braking speed and steering deviation 
were significantly poorer than the controls', and patients had a significantly greater 
number of off-road incidents, corresponding to a car crash scenario. 
Empirical evidence of truly poorer driving performance is gained from retrospective 
studies comparing car accident rates in SAHS patients and the larger population. 
Findley et al (1988a) found that the 5-year accident rate of 29 diagnosed sleep apnoeics 
was 7 times greater than that of 32 patients who showed no significant abnormality on 
sleep study. The SAHS patients' accident rate was more than twice that of all 3.7 
million Virginian drivers. The patients' high accident rate was not attributable to a few 
highly dangerous drivers in the patient group, as the frequency of drivers reporting 
accidents was also significantly higher in the patient group. Seven of the 29 SAHS 
patients reported at least one accident, while only 1 of the 35 the non-SAHS patients 
had had an accident in the last 5 years. The odds of SAHS patients being the driver at 
fault in their reported accidents was 8 times higher than in the non-SAHS patients. In 
another study, George et al (1987) used centralised governmental computer records to 
match 10 control subjects to each of 27 sleep apnoeics, and found a lifetime accident 
rate more than twice as high in patients than in controls. Around half of the randomly 
selected controls had had an accident, against 93 % of the patients. These retrospective 
studies provide convincing evidence that SAHS patients represent a risk on the road. 
Sleep-related accidents, which are appear to be frequent in SAHS patients, may pose 
an even greater safety risk than accidents caused by other driving errors. Sleep-related 
accidents may be difficult to identify, particularly in fatal crashes, but three studies 
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have attempted to assess the relative safety risks imposed by accidents caused by 
sleeping. In an analysis of casualty and mortality rates in accidents thought to be 
caused by falling asleep, by fits or by heart attacks, sleep-related accidents accounted 
for 27% of accidents but 83% of deaths (Parsons 1986). Zomer and Lavie (1990) 
employed centralised records of accidents and coroners' verdicts to identify sleep- 
related accidents and found that such accidents claimed 50% more casualties and 
almost 3 times more fatalities than expected. Home and Reyner (1995), in a recent 
British survey of road traffic accidents, have also indicated that sleep-related accidents 
more often resulted in death or serious injury than those with another cause. 
If, as these studies suggest, sleep-related accidents are more serious than crashes from 
other causes, untreated drivers with SAHS present an additional risk to the public. 
Part of this additional risk from sleep-related accidents may relate to the conditions 
under which these particular accidents occur. Zorn er and Lavie (1990) found that the 
great majority of their sleep-related accidents, 75%, occurred outside of an urban 
setting. Seventeen of the 38 press reports (45%) collated by Parsons (1986) described 
accidents occurring on a motorway, and in Home and Reyner's study (1995), 75% of 
suspected sleep-related accidents occurred on motorways or major roads. It is notable 
too that the driving simulation task that best discriminated SAHS patients from 
normals was the highly monotonous SteerClear (Findley et al 1989a). The stimulation 
provided by traffic lights, road junctions, pedestrians and stop-go traffic in a town 
environment thus may aid vigilance in sleepy drivers. With a paucity of alerting 
stimuli against which to measure one's performance, the dangerous monotony of the 
motorway environment may provoke a loss of awareness of conscious state (Home 
1992), with potentially high costs. Despite the high accident risks documented in the 
above research studies, even sleepy SAHS patients do not appear to alter their driving 
behaviour to reduce hazards to themselves and others (Cassel et al 1990). 
2.6 Severity of SANS and daytime function 
Many authors have documented significant correlations between the severity of 
nocturnal events in SAHS and their daytime sequelae, suggesting that the severity of 
SANS determines the extent of daytime impairment. 
Studies in SAHS patients show significant correlations between objective daytime 
sleepiness measured by the MSLT and MWT and nocturnal events in the form of 
apnoeic (r-0.5, Roth et al 1980) and apnoeic+hypopnoeic frequency (r--0.3; Roehrs et 
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al 1989, Poceta et al 1992), as well as hypoxaemic variables (r=0.3-0.5; Roehrs et al 
1989, Bedard et al 1991a, Poceta et al 1992) and sleep quality measured by the 
averaged procedure of Rechtschaffen and Kales (1968) (r=0.3-0.8; Stepanski et al 
1984, Guilleminault et al 1988, Roehrs et al 1989) or by more sensitive event scored 
arousals (r--0.4-0.7; Roehrs et al 1989, Poceta et al 1992, Roth et al 1980). Post hoc 
splitting of a large sample of apnoeic patients by Guilleminault et al (1988) showed 
significantly higher indices of respiratory abnormality and sleep disruption in patients 
with greater objective excessive daytime sleepiness, measured by the MSLT. 
Subjective sleepiness evaluated by the Epworth sleepiness scale correlates with both 
AHI and nocturnal hypoxaemia (r=0.4, Johns 1993). However, others have found no 
nocturnal correlate of MSLT score from a large array of variables indexing breathing 
disruption, sleep fragmentation and hypoxaemia (Cheshire et a! 1992). 
Cognitive performance correlates significantly with Al (r0.5, Bedard et al 1991a) and 
AHI (r=0.4-0.6, Cheshire et al 1992) in SAHS patients, in heavy snorers (r=0.3, 
Berry et al 1986) and in an elderly subject sample, some of whom had significant 
AHIs and sleepiness (r0.3-0.5, Yesavage et a! 1985). Hypoxaemia has also been 
significantly correlated with cognitive impairment in SAHS patients (r=0.4-0.8; 
Cheshire et al 1992; Bedard et al 1991a, Greenberg et al 1987, Findley et al 1986) and 
in heavy snorers (r=0.3-0.5; Beny et al 1986, Telakivi et al 1988), as has event-scored 
arousal frequency (r-0.5-0.6, Cheshire et a11992) and Rechtschaffen and Kales' 
(1968) sleep quality (r=0.5, Bedard et a1 1991a). Findley et al's (1986) split-sample 
study of hypoxaemic vs. non-hypoxaemic SAHS patients implies that the frequency 
and severity of oxygen desaturation during sleep is related to the degree of cognitive 
impairment. 
An unexpected positive correlation between AHI and Beck depression self-rating 
(Watson et al 1985), reflecting less distress with more severe SAHS, is the only 
evidence linking severity of SAHS with psychological distress, but studies are few in 
this area. 
The severity of SAHS is also associated with the degree of impairment of driving 
performance in correlational and split-group studies (Haraldsson et al 1990a, Aldrich 
1989, Cassel eta! 1990, Findley et al 1989b). Haraldsson et al (1990a) found the 
relative risk of having had an accident in the preceding 5 years grew with the intensity 
of symptoms of SAHS. Heavy snorers who did report subjective excessive daytime 
sleepiness had an accident rate 1.4 times that of normals, while patients with 
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symptoms more suggestive of SAHS, but with no subjective sleepiness whilst 
driving, had accident rates 2.3 times that of controls. Sleepy drivers in a 
symptomatically-defined SAHS group were 3 times as likely to have had an accident 
than the controls. Aldrich (1989) demonstrated a higher frequency of SAHS patients 
admitting sleep-related accidents when AHI was greater than 60 (30%) than in less 
severe patients with indices less than 60,15 % of whom reported sleep-related crashes. 
Cassell et al (1990) published a dose-response relationship between apnoea index and 
the incidence of once-weekly sleeping at the wheel in patients assessed for sleep 
apnoea. While less than 10% of patients with fewer than 5 apnoeas per hour slept 
reported this behaviour, around half of patients with apnoea indices from 5 to 20 per 
hour dozed at the wheel and almost 70% of those with indices greater than 20 dozed 
weekly while driving. A similar dose-response relationship was seen in mild, 
moderate and severe SAHS patients' self-reported accident rates, which were 82%, 
150% and 290% respectively of that expected from the Virginian population (Findley 
et a! 1989b). 
These studies document associations between the nocturnal features of SAHS and 
consequent daytime function, and provide evidence that the degree of nocturnal 
disruption experienced by patients is reflected in their waking slate. 
2.7 Aetiology of daytime impairment in SANS 
The correlational findings presented above suggest that overall severity of breathing 
disruption in SAHS is related to subsequent magnitude of daytime impairment But 
these studies do not provide a detailed information on the separate contributions of 
individual nocturnal events to individual daytime deficits of SAHS. Repetitive airway 
restriction in sleep has immediate physiological consequences in both hypoxaemia and 
sleep disruption. These two secondary events are the putative causative agents for the 
daytime neuropsychological impairment of SAHS. 
The issue of the aetiology of daytime impairment in SAHS is pertinent, and impinges 
on the primary investigation of this thesis, the reversibility of daytime deficits of 
SAHS by CPAP therapy. The determinants of daytime deficit in SAHS can be 
investigated by examining models of the effects on daytime function of hypoxaemia 
and sleep disruption, and by assessing clinical studies conducted to explore this issue. 
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2.7.1 Models of sleep fragmentation and hypoxaemia 
Studies examining the daytime effects of sleep loss and chronic obstructive pulmonary 
disease (COPD) provide approximate models for the impairments associated with 
sleep fragmentation and hypoxaemia respectively. 
The types of daytime deficits documented by these two models show overlap in 
effects, particularly for cognitive impairment, but the literature attaches rather different 
prognoses to daytime deficits mediated primarily through sleep fragmentation and 
hypoxaemia, the former being temporary and remediable by the restoration of quality 
and quantity of sleep, while the latter's effects are associated with only partial reversal 
of deficits with treatment. 
2.7.1.1 Experimental sleep loss 
Experimentally-produced sleep loss models the sleep disruption of SAHS, where 
repetitive arousals from sleep at the termination of apnoeic and hypopnoeic events 
(Guilleminault et al 1978, Sullivan and Issa 1980) result in characteristic alterations in 
sleep architecture (Roth et al 1980, Roehrs et al 1989, Lamphere et al 1989, Kribbs et 
al 1993b, Poceta et al 1992, Stepanski et al 1984). 
Human studies show that experimental partial and total sleep loss provoke measurable 
deficits in daytime alertness, cognitive performance and mood very similar to those 
observed in SAHS. 
The most noticeable effect of sleep loss is to induce sleepiness (Home 1988). A clear 
association between prior sleep quality and both objective (Carskadon and Dement 
1979, Bonnet 1987, Philip et al 1992) and subjective (Bonnet 1985) daytime 
sleepiness has been demonstrated. Both sleep fragmentation (Bonnet 1985, Bonnet 
1987, Philip et al 1992) and sleep deprivation (Carskadon and Dement 1979) in 
healthy normals produce measurable decreases in sleep onset latency during daytime 
naps. Sleep reduction studies show correlations of 0.5 to 0.6 between prior night's total 
sleep time and objective daytime sleepiness evaluated by the multiple sleep latency test 
(Carskadon and Dement 1979). 
Impaired alertness may be reflected in altered daytime waking EEG activity. Brunner 
et al (1993) found altered EEG spectra, with power increases in the high delta 
frequency range and decreases in the alpha range, after 4 nights' partial sleep 
deprivation of normals. Such slowing of EEG is typical of the lapse into drowsiness 
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(Rechtschaffen and Kales 1968), and has been also been found, coinciding with 
behavioural wakefulness, during total sleep deprivation (Home 1978). 
An association between sleep loss and daytime sleepiness is documented in the above 
studies, some of which closely mimic the sleep fragmentation seen in SAHS. These 
findings provide circumstantial evidence that the chronic and continuous sleep 
disruption seen in SAHS may provoke excessive daytime sleepiness. 
Experimental sleep loss, whether produced through deprivation (Williams et al 1959, 
Wilkinson 1961, Donnell 1969), reduction (Wilkinson et al 1966) or fragmentation 
(Bonnet 1985, Bonnet 1987, Downey and Bonnet 1987), provokes a fall-off in 
cognitive performance, particularly on long and boring tasks (Wilkinson 1964, 
Donnell 1969). 
Experimentally-produced sleep fragmentation in normals, more closely simulating 
that of SAHS, results in impairment of cognitive performance. The elegant series of 
studies performed by Bonnet and colleagues (Bonnet 1985, Bonnet 1987, Downey 
and Bonnet 1987) documented objective decrements in performance on arithmetical 
vigilance tasks (Bonnet 1985), oddball auditory tone detection tasks (Bonnet 1987), 
reaction times (Bonnet 1985, Downey and Bonnet 1987) and digit symbol coding 
efficiency (Bonnet 1985) after 2 nights of sleep fragmentation at 1 (Bonnet 1985) and 
2 (Bonnett 1987) minute frequencies. 
Bonnet (1985) compared his findings of cognitive impairment under conditions of 
sleep fragmentation against those obtained under the same duration of total sleep 
deprivation, commenting that the decrease in addition efficiency after 2 nights of sleep 
fragmentation approximated that seen after 1 night of total sleep deprivation, thus 
showing a surprisingly large impact of sleep fragmentation on performance. His 1987 
study explored the effects of different intensities of arousal from sleep, showing that 
short, EEG-only arousals were not less damaging to performance than fuller 
awakenings from sleep. Downey and Bonnet (1987) showed that performance is 
worse affected by fragmentation than restriction of sleep. Reaction time to an 
arithmetic problem was slower during fragmentation at 10 minute intervals than after 
2.5 hours of continuous sleep, and worst when sleep was disrupted at 1 minute 
frequencies. These data suggest that sleep continuity, rather than quality of sleep 
architecture or total quantity of sleep, may be extremely important in maintaining 
43 
Chapter 2: Daytime function in SANS 
cognitive function. This then implies that SAHS-mediated sleep fragmentation may be 
even worse for daytime cognitive performance than restricted but continuous sleep. 
It has been hypothesised that cognitive deficits after sleep loss may be due to changes 
in the state of consciousness, representing drifts into sleep (Williams et al 1959, Home 
1988, Home 1992). Such a "lapse" hypothesis, proposing that performance fall-off 
occurs during microsleep episodes, is supported by the subanalysis of mean and 
median reaction times obtained during sleep deprivation, presented by Williams et al 
(1959). While median reaction time increased approximately 20% after 78 hours of 
sleep deprivation, mean reaction time doubled, suggesting that a few outlying, long 
latency responses skewed the mean score. However, Williams et al (1959) later 
discarded the lapse hypothesis of cognitive impairment when they showed that lapses 
in memory with a word-learning list task were worst in the delayed recall of the word 
list, rather than on immediate recall. The lapse hypothesis proposed that microsleeps 
during the word list presentation would impair information acquisition such that 
immediate recall should have been as poor as delayed recall. However, word learning 
is a relatively short and stimulating task, and the loss of word recall might be 
attributable to motivational deficits after sleep deprivation. Certainly the lapse 
hypothesis fits with Williams et al's (1959) reaction time data. 
Studies showing altered neurophysiological state during wakefulness after sleep loss 
(Bjerner 1949, Naitoh et al 1969, Williams et al 1959, Brunner et al 1993), like those 
documenting altered evoked potential conformation in hypersomnia (Weizman and 
Kremen 1965, Aguirre and Broughton 1987, Broughton et al 1982) may support the 
lapse hypothesis of cognitive dysfunction in SAHS. 
The EEG correlates of sleep deprivation were investigated as far back as 1949, when 
Bjerner observed that delayed responses on serial RT tasks after sleep deprivation 
were associated with depressed alpha EEG amplitudes (Bjerner 1949). A reduction in 
alpha EEG frequencies is recognised as the cardinal feature of stage I sleep 
(Rechtschaffen and Kales 1968), usually perceived by subjects as a state of 
drowsiness (Hauri 1982). In a study following 205 hours of sleep deprivation, Naitoh 
et al (1969) also noted that alpha frequencies progressively disappeared through the 
increasing duration of sleep loss. Williams et al (1959) scored the percentage of alpha 
frequencies occurring during the second before and the second after stimuli during a 
auditory vigilance task, performed before and during the course of total sleep 
deprivation. EEG signals during errors of omission had lower percentages of alpha 
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frequency that correct omissions or commissions and errors of commission. Brunner 
et al (1993), showed increased delta EEG frequency powers during behavioural 
'wakefulness' after sleep restriction, also supporting the lapse hypothesis. It may be 
that functional and neurophysiological sleep states, not necessarily measurable through 
conventional, averaged, Rechtschaffen and Kales (1968) sleep scoring, can occur 
during behavioural wakefulness. 
The impact of sleep loss on internal psychological state is familiar to most individuals 
as a result of personal experience. Typically, short-duration compromise of sleep 
quality or quantity provokes a loss of energy and motivation, while episodes of 
irritability, aggression and suspiciousness may be produced by extended sleep 
deprivation (Home 1988). Experimental sleep fragmentation for 2 nights resulted in 
significant increases in morning 'unhappiness' (Bonnet 1987) and in both increased 
'unhappiness' and decreased 'clear-thinking' on Clyde mood subscale (Bonnet 1985). 
These behavioural, personality and mood state changes may parallel those documented 
in case series of SAHS patients (Guilleminault et al 1978). 
These studies show that experimental sleep loss results in increased sleepiness, 
impaired cognitive performance, most noticeably on attention-based tasks, and 
decreased psychological wellbeing. Thus sleep disruption appears to provoke daytime 
impairments overlapping closely with those associated with SAHS. These effects are 
however completely reversible following the recovery of sleep debt (Home 1988). 
Following 1 or 2 nights of recovery sleep following sleep disruption, objective and 
subjective daytime sleepiness are normalised (Carskadon and Dement 1979, Naitoh et 
al 1969), as are cognitive performance deficits (Williams et al 1959, Home and Pettitt 
1985). 
2.7.1.2 Chronic obstructive pulmonary disease (COPD) 
COPD is limited as a model for evaluating the isolated effects of hypoxaemia on 
daytime function, as COPD is associated with significantly disrupted objective 
(Calverley et al 1982, Flee ham et a11982) and subjective (McSweeny et al 1982) 
sleep quality, and with subjective daytime sleepiness (McSweeny et al 1982). Such 
sleepiness may act as a covariate in the daytime cognitive impairment associated with 
COPD. 
Nevertheless, the continuous hypoxaemia of COPD may provide useful information 
about the effects hypoxaemia on cognitive function. COPD is associated with 
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generalised cognitive impairment, including deficits in perceptuomotor skill, motor 
speed, memory, verbal facility, abstract reasoning, problem-solving and executive 
functions (Krop et al 1973, Prigitano et al 1983, Grant et al 1982, Huppert et al 1982). 
The severity of hypoxaemia in COPD is associated with the degree of cognitive 
impairment in split group (Krop et al 1973) and correlational (Huppert et al 1982) 
studies. Because studies find that sleep is less disrupted in more hypoxaemic COPD 
patients (Douglas et a11979, Calverley et al 1982), this suggests that hypoxaemia may 
be more influential in determining cognitive deficit in COPD than sleep disruption. 
Krop et aFs (1973) split group study of more and less hypoxaemic COPD patients 
demonstrated greater impairment on the Bender gestalt, the background interference 
procedure, finger-tapping and facial recognition task in the more hypoxaemic group, 
this pattern of neuropsychological dysfunction suggesting diffuse organic damage. 
Similar, wide-ranging impairments were also shown in large case-control studies 
(Prigitano et a11983, Grant et al 1982) employing carefully-matched healthy controls. 
Prigitano et al (1983) found that 100 mildly hypoxaemic COPD patients showed 
impairments in abstract reasoning, perceptuomotor skill, mental set flexibility, 
memory and language facility compared to well-matched controls. Grant et al (1982) 
employed the Halstead-Reitan Battery, the Wechsler Memory Scale and pegboard 
tests to evaluate attention, verbal skills, perceptual-motor performance, sensory 
function, abstracting facility, motor ability and memory and to provide three summary 
indices. 'Ilse COPD patient group were rated as significantly more impaired by all 
summary indices and in all functional domains examined by the battery. While 14% 
of the control subjects' scores were clinically judged to indicate moderate or severe 
cerebral dysfunction, 42% of the COPD patients were rated as moderately or severely 
impaired. 
Cognitive deficits in COPD may be only partially ameliorated by the restoration of 
normoxia (Krop et al 1973, Heaton et al 1983, Wilson et al 1985). Following 
continuous oxygen therapy, severely hypoxaemic COPD patients' performance on 
tests of organicity, motor speed and stamina was no longer worse than that of retested 
untreated COPD patients with initially less severe hypoxaemia (Krop et al 1973). 
The NOTT study group also assessed the effects of oxygen treatment, both continuous 
and nocturnal, of 6 months and 12 months duration (Heaton et al 1983). On retesting 
after 6 months of oxygen therapy, COPD patients were found to have made 
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significantly greater improvements in score than retested controls on the TrailMaking 
B task, hand dynamometer and the tapping test. When the assessment test scores were 
grouped into functional areas, such as memory or attention skill, and rated blindly by a 
clinician, a significantly greater percentage of the patient group showed "slight 
improvements" in verbal facility, abstraction skill, simple sensory perception and 
motor speed than in the control group. The authors emphasised that the statistically 
significant increases in patients' test scores over controls' scores represented only 
subtle improvements in cognitive function. 
A carefully-controlled, crossover-type study by Wilson et al (1985) attempted to 
examine the effects of shorter administrations of oxygen on COPD patients' mental 
function. This study compared performance on 20 minutes and 6 hours of room air 
and enriched oxygen, with the order of treatment type and treatment duration 
randomised to control for practice effects. The psychophysiological tests used, the 
repetition test and the critical flicker fusion test, were selected to assess information- 
processing ability and had the advantage of being less prone to learning-related 
increases in score than other cognitive tests. No improvements in information- 
processing ability were found. This may be due to the small sample size of 10 
patients, or to the relatively short durations of oxygen treatments used. Patients 
recruited for this study continued to use nocturnal oxygen therapy on the nights before 
their assessments and it is possible that nocturnal oxygen treatment already optimises 
performance. Alternatively, this study could be employed to support the hypothesis 
that cognitive impairment secondary to hypoxaemia is permanent 
The findings of these studies of cognitive deficits in COPD, like those examining the 
cognitive impairments of SAHS, showing wide-ranging neuropsychological deficits. 
The mixed findings from COPD treatment studies do not amount to conclusive proof 
of improved functioning after the correction of hypoxaemia, but do give some cause 
for optimism that deficits associated with mild to moderate cerebral hypoxia can be at 
least attenuated by the restoration of normoxia. Thus if daytime function in SAHS, 
and most specifically cognitive function, is most closely linked to hypoxaemia, CPAP 
might be expected to produce minimal or partial reversal of cognitive deficit. 
Thus experimental and pathological conditions analogous with the physiological 
environment of SAHS produce daytime impairments overlapping with those of 
SAHS. Hypoxaemic processes can cause wide-spectrum cognitive impairments very 
similar to those documented in SANS patients. Research on the effects of sleep loss 
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supports the hypothesis that sleep loss produces measurable deficits in subjective and 
objective daytime sleepiness and cognitive performance. However, while the 
restoration of sleep quality following CPAP therapy might be expected to reverse 
deficits induced by sleep fragmentation, cognitive impairment linked to hypoxaemia 
might be more resistant to treatment. 
2.7.2 Nocturnal predictors of daytime impairment in SANS 
Correlational studies in SAHS patient do not unambiguously select either 
hypoxaemia-related or sleep fragmentation-related measures as more closely related to 
daytime dysfunction. A simple comparison of r-values obtained from different studies 
reflects considerable disagreement While some find that objective daytime sleepiness 
is most closely associated with measures of hypoxaemia (Bedard et al 1991a), others 
document stronger correlations with measures of sleep quality and quantity (Roehrs et 
a11989, Poceta et al 1992, Roth et al 1980, Guilleminault et al 1988, Stepanski et al 
1984). Cognitive performance has been most closely correlated with hypoxaemic 
indices by some (Telakivi et al 1988, Findley et al 1986, Berry et al 1986, Bedard et al 
1991a) and with measures of sleep quality by others (Cheshire et al 1992). 
This ambiguous situation is influenced by problems involving intercorrelations within 
measures of nocturnal and daytime function, and by variation in the selection and 
sensitivity of measures in different studies. 
Strong intercorrelations between individual polysomnographic variables (rM0.7; 
Roehrs et al 1989) and between sleepiness and cognitive function (r=0.3-0.6: 
Carskadon and Dement 1979, Telakivi et al 1988, Cheshire et al 1992) have been 
documented, reflecting either internal causative relationships or shared antecedents 
within both nocturnal events and areas of daytime function. Such intercorrelation 
confounds the use of simple correlational techniques in assessing the contribution of 
individual nocturnal events to daytime impairments. 
All correlational studies of the aetiology of daytime deficits will in addition be limited 
by the selection, sensitivity and specificity of background nocturnal measures. 
Hypoxaemia is universally measured using continuous and responsive ear oximetry, 
providing an abundance of sensitive parameters reflecting duration, severity, frequency 
and cumulative distributions of hypoxaemia for statistical analysis. But the variability 
in measures of breathing disorder and sleep fragmentation employed by researchers 
may have a profound impact on studies' results. The introductory chapter alluded to 
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shortcomings in the apnoea index as a measure of breathing abnormality during sleep. 
In addition, the conventional practice within sleep research of using averaged, epoch- 
based Rechtschaffen and Kales (1968) sleep staging, thus evaluating 30-second blocks 
of recording for overall sleep quality, underestimates sleep disruption more accurately 
measured by event based arousal scoring (Stepanski et al 1984). Reliance in many 
studies on apnoea index (Roth et al 1980, Greenberg et al 1987, B&lazd et al 1991a) 
and/or averaged sleep staging (Guilleminault et al 1988, B6dard et al 1991a, 
Mendelson 1992) may result in insensitive variables within correlation matrices. At a 
more basic level, some studies include no correlations of breathing disturbance 
separate from oxygenation variables (Findley et a11986, Telaldvi et al 1988) or no 
evaluation of sleep quality (Yesavage et al 1985, Berry et al 1986, Greenberg et al 
1987, Telakivi et a11988, Johns 1993), thus further limiting these studies' usefulness 
in discriminating the aetiology of specific daytime impairments in SAHS. 
The problem of intercorrelation of polysomnographic measures, pre-defined by the 
causative relationships between nocturnal events, may be partially solved through the 
use of statistical techniques, such as multiple and logistic regression, to disentangle the 
independent contributions of hypoxaemia-related and sleep disruption-related 
variables. These can only be compared in studies using measures of both hypoxaemia 
and sleep disruption. 
The studies using such an approach to examine daytime sleepiness (Roehrs et al 1989, 
Guilleminault et al 1988, Bedard et al 1991a, Mendelson 1992, Cheshire et al 1992) 
yield mixed results. Neither Guilleminault et al (1988) nor Cheshire et al (1992) were 
able to build a multiple regression model explaining MSLT scores. Bedard et al 
(1991a) found no significant contribution from epoch-scored sleep quality to mean 
sleep onset latency, but found that MSLT score was independently determined by 
minimum oxygen saturation. The use of relatively insensitive measures of sleep 
disruption perhaps compromises the robustness of this comparison of the effects of 
hypoxaemia and sleep fragmentation. 
Mendelson (1992) built models showing independent contributions from mean 
minimum oxygen saturation in REM sleep and AHI to mean sleep onset latency, 
explaining 67% of variance. Subjective sleepiness, self-rated on a5 point Liken scale, 
was explained with a 2-factor equation containing first sleep efficiency and second 
AHI, together explaining 63% of subjective sleepiness variance. The measures of 
sleep disruption included only epoch-based scores of nocturnal sleep latency, sleep 
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efficiency and wakefulness after sleep onset. The insensitivity of measures of sleep 
disruption in this study might have biased its findings relating hypoxaemia and 
objective daytime sleepiness, although the independent association between subjective 
sleepiness and sleep efficiency fits with the hypothesis linking excessive daytime 
sleepiness most strongly with sleep disruption. 
Roehrs et al (1989) used a good-quality array of nocturnal measures to assess arousal 
from sleep and hypoxaemia, and performed a multiple regression analysis of the 
effects of polysomnographic variables from nocturnal studies on MSLT scores in 466 
SAHS patients. The single best predictor of objective daytime sleepiness was the 
respiratory arousal index, here defined as an increase in EEG frequencies or EMG 
activity of 3 seconds' duration at the termination of an apnoeic or hypopnoeic event. 
The best two-variable predictor of MSLT score was a combination of the percentage 
of stage 1 sleep and the total sleep time from the nocturnal study. 
Only two studies allow multiple regressions of daytime cognitive performance, 
through their inclusion of both oxygenation and sleep fragmentation measures (Bedard 
et al 1991a, Cheshire et al 1992). 
B6dard et al (1991a) performed stepwise multiple regression with the correlates of 
four-choice reaction time, which included epoch-scored sleep quality and oximetry 
variables. Response time was independently predicted firstly by minimum oxygen 
saturation and secondly by stage shifts to wakefulness. 
Cheshire et al's (1992) study included a sensitive range of nocturnal background 
variables measuring sleep disruption and hypoxaemia and proceeded to a construction 
of individual multiple regression models to explain the determinants of performance 
on block design, IQ decrement and reaction time, using background variables of 
arousals, hypoxaemia and AHI. Block design was best explained by a model 
containing AHI alone, neither minimum saturation nor arousal frequency contributing 
independently to performance. Reaction time showed equal independent determinants 
in microarousal index and AHI, with no additional contribution from hypoxaemia. IQ 
decrement was explained with a model containing first AHI with a minor secondary 
contribution from minimum saturation. This study, the best available to investigate the 
aetiology of cognitive impairment in SAHS, thus suggests that sleep disruption and 
hypoxaemia independently and differentially contribute to specific performance 
deficits. 
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The only multiple regression analysis of the contribution of nocturnal variables to 
daytime mood is that performed on data from 25 patients by Reynolds et al (1984), 
who constructed a predictive model containing age, use of anti-hypertensive drugs, 
REM latency and REM density to explain depression self-ratings, selection of these 
independent factors based on variables shown to influence depression in a median- 
split analysis. No raw polysomnographic data is presented and while the methods 
section describes sleep stage scoring it contains no reference to oximetry or to event 
scored arousals. It is thus difficult to evaluate whether sensitive measures of 
hypoxaemia and sleep loss might have been predictors of psychological distress. 
Recent studies have attempted further to disentangle the contributions of hypoxaemia 
and sleep fragmentation to daytime impairments of SAHS through other experimental 
approaches. 
Colt et al (1991) administered two nights of CPAP to 7 SAHS patients under two 
randomised conditions. In the first condition, CPAP was administered to reduce 
apnoeas, hypopnoeas, microarousals and desaturations, while in the second, CPAP 
was administered with the addition of experimental intermittent hypoxia. Mean sleep 
onset latency was improved by both types of CPAP, and improvements were similar 
in both conditions, suggesting that the addition of hypoxaemia has lesser influence on 
objective daytime sleepiness than sleep fragmentation. 
riadgelb et al (1995) investigated the aetiology of cognitive deficit in SAHS by 
performing logistic regression analyses to examine which cognitive scores 
discriminated between moderate and severe apnoeic patients, and which between 
patients with moderate and severe hypoxaemia. Coding efficiency, memory and 
planning ability appeared to best contrast high and low levels of breathing disruption, 
while coding ability and abstract reasoning were most different in the contrasted 
hypoxaemia groups. The study did not include specific measures of sleep quality, and 
showed overlap in those performance tests related to breathing abnormality and 
hypoxia, probably as a result of correlation in the two nocturnal measures. 
Another recent study has attempted to delineate the respective contribution of 
hypoxaemia and sleep fragmentation to daytime performance impairment by 
comparing neuropsychological performance in patients with SAHS and COPD. 
Roehrs et al (1995) found greater objective and subjective sleepiness in SAHS 
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patients, and greater sleep disruption on averaged Rechtschaffen and Kales (1968) 
sleep scores, supporting a role for sleep fragmentation in inducing excessive daytime 
sleepiness. COPD patients had greater impairment in motor speed and SAHS patients 
greater deficit on a visual vigilance task. Within the SAHS patients, the best 
independent predictor of overall cognitive performance, adjusted for age and 
education, was objective daytime sleepiness, with a minor contribution from duration 
of hypoxaemia. This study lacked age-matching in the two patient groups, but its 
results suggest that sleepiness is more closely related to sleep fragmentation, and that 
cognitive function may have determinants in both hypoxaemia and sleep disruption. 
Thus, only a limited number of clinical studies offer a comparison of the contribution 
of hypoxaemia and sleep disruption to the domains of daytime impairment associated 
with SAHS. The balance of evidence may lean towards a role for sleep disruption in 
determining the excessive daytime sleepiness typical of SAHS. The picture is less 
clear for the aetiology of cognitive dysfunction in SAHS, although studies containing 
sensitive nocturnal and daytime variables implicate determining roles for both 
hypoxaemia and sleep fragmentation. 
2.8 Summary 
SAHS patients' complaints of excessive daytime sleepiness, cognitive impairment and 
psychological dysfunction are corroborated by objective case-control studies. 
Polysomnographically-determined sleep tendency is largely within the pathological 
range in samples of SAHS patients. Neuropsychological performance drawing on 
attention, memory and co-ordination is moderately impaired and neurophysiological 
function may be disturbed. A high incidence of psychological and psychosocial 
distress is seen in SAHS. Patients with SAHS have an elevated road traffic accident 
rate, and their sleep-related accidents may claim greater casualties. The severity of 
nocturnal events in SAHS has been widely associated through correlational and split 
sample studies with the patients' degree of sleepiness and cognitive impairment. 
Psychological distress in SAHS has been associated with the intensity of physical 
symptoms and role limitations imposed by illness. Evidence both from clinical 
samples of SAHS patients and from experimental and disease models suggests that 
excessive daytime sleepiness and attention deficits may be related to sleep 
fragmentation, while other intellectual deficits may arise as a result both of sleep 
disruption and intermittent nocturnal hypoxaemia. While daytime symptoms arising 
from sleep disruption are potentially completely reversible following restoration of 
sleep quality, the hypothetical reversibility of hypoxia-mediated intellectual deficits 
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may be more limited. The next chapter reviews the limited number of clinically-based 
studies examining the efficacy of CPAP treatment in ameliorating daytime 
impairments in SAHS. 
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Chapter 3: 
DAYTIME FUNCTION FOLLOWING CONTINUOUS POSITIVE 
AIRWAY PRESSURE (CPAP) TREATMENT IN SAHS 
Themes developed in the preceding chapter included the hypothetical bases of 
reversibility of daytime problems associated with SAHS. I now hope to summarise 
the findings of empirical studies, though limited in number and quality, of daytime 
neuropsychological function after continuous positive airway pressure (CPAP) 
therapy in samples of SAHS patients. 
The success of CPAP in reversing the nighttime features of SAHS, including apnoeas 
and hypopnoeas, arterial oxygen desaturations and disruption of sleep architecture, 
was described in Chapter 1. CPAP can abolish respiratory abnormalities in sleep 
(Sullivan et a11981, Sanders 1984) by mechanically maintaining upper airway patency 
(Issa and Sullivan 1984, Abbey et al 1989). CPAP thus removes the causal agent, 
airway obstruction, in the triad of nocturnal events characteristic of SAHS, 
normalising both arterial oxygenation profiles (McEvoy and Thornton 1984) and sleep 
architecture (Lamphere et a11989, Guilleminault et al 1992). Because these nocturnal 
events are the putative aetiological forbears of daytime impairment in SAHS, CPAP 
may also be effective in reversing patients' daytime deficits. 
Studies of change in daytime function after CPAP (Bearpark et a11987, Lamphere et 
a11989, Wittig et a11986, Derderian et al 1988, Millman et a11989, Findley et al 
1989a, Walsieben et a11989, Fry et al 1990, Mayleben et al 1990, Gaddy and 
Doghramji 1991, Platon and Sierra 1992, Charbonneau et a11992, Johns 1992, Sangal 
eta! 1992a, Sangal eta! 1992b, Poceta et al 1992, Bedard et al 1993, Kribbs et al 
1993b, Partlett et a11994) assume that the patient sample has complied effectively 
with CPAP treatment, which has only been objectively verified in a few studies 
(Kribbs et al 1993b, Partlett et a! 1994). This assumption may compromise the 
reliability of some studies. 
In many North American centres, research practice involves daytime studies of 
sleepiness, mood and cognitive performance following a night of polysomnography 
with CPAP (Lamphere et al 1989, Fry et al 1990, B6dard et al 1993, Knobs et al 
1993b). Such studies have advantages, in that proper CPAP use can be verified during 
the night before daytime testing, but produce concurrent disadvantages as a result of 
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the untoward effects of recording procedures on sleep quality, which may have knock 
on effects on the subsequent day's function. 
Sleep continuity in the laboratory is known to be compromised, partly because of the 
subject's lack of familiarity with the environment, causing the so-called "first night 
effect" (Cooper and Bradbury 1994) of reduced sleep efficiency. Consequently, many 
research protocols schedule a night's acclimitisation to sleep in the lab before 
conducting measurements. Naturalistic sleep in a laboratory is also compromised by 
the presence of equipment such as ear oximeters, oronasal thermistors and EEG wires 
on the patient's body. This equipment reduces subjects' comfort, easily falls off and 
becomes tangled during sleep. While an acclimitisation night's sleep may familiarise 
subjects with the experience of sleeping "wired up", it is likely (although untestable) 
that the polysomnographic measurement itself reduces sleep continuity. Thus pre- 
assessment polysomnography, while ensuring CPAP compliance, may skew the 
results of daytime measures of function. 
Despite these reservations applying to almost all of the studies reviewed here, the 
available evidence suggests that CPAP therapy may be effective in reducing daytime 
sleepiness, improving cognitive impairment and ameliorating psychological 
dysfunction. 
3.1 Excessive daytime sleepiness after CPAP 
As was hinted at in Chapter 2, objective measurements of sleepiness in SAHS 
represent a'gold-standard assessment of excessive daytime sleepiness, as patients' 
subjective ratings using the Stanford sleepiness scale have been shown to be unreliable 
in hypersomnolent patients (Dement et al 1978, Roth et al 1980, Browman and Miller 
1988). Objective studies of sleepiness using polysomnographic techniques after 
CPAP (Wittig et al 1986, Lamphere et al 1989, Walsleben et al 1989, Fry et al 1990, 
Gaddy and Doghramji 1991, Sangal et al 1992b, Poceta et al 1992, Charbonneau et al 
1992, Bedard et al 1993, Kribbs et al 1993b) have shown varying degrees of 
resolution of daytime sleepiness, perhaps, as explained here, as a function of the 
precise instructions administered to subjects. 
Lamphere et al (1989) showed dramatic improvements in objective daytime sleepiness 
following CPAP therapy. A single night of CPAP significantly extended daytime 
sleep latencies during an MSLT from a pre-treatment mean of 3 minutes to 6 minutes 
(within the 'grey zone' of daytime sleepiness), and following 14 nights of CPAP the 
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mean sleep latency reached almost 10 minutes. This normalisation in sleep onset 
latency on the MSLT after CPAP commencement has been corroborated by Wittig et 
al (1986), who found that daytime mean sleep latencies averaged more than 10 
minutes after 6 weeks of CPAP. Thus in these two studies, CPAP precipitated a rise 
in MSLT score to a level outwith the 'pathological' range and into the normal range of 
greater than 10 minutes (Carskadon et al 1986). 
However, these findings of clinically-significant reversibility in daytime sleepiness 
have not been replicated by others employing the MSLT to measure changes in 
sleepiness after CPAP in sleep apnoea. In a preliminary report, Fry et al (1990) 
reported a change in MSLT scores from 4.1 minutes before the institution of CPAP to 
7.8 minutes after at least 2 months of CPAP in 21 patients with SAHS. Similar small 
improvements, with latencies remaining within the 'grey zone', have also been reported 
by Gaddy and Doghramji (1991), Bedard et al (1993) and Kribbs et al (1993b). A pre- 
treatment mean sleep latency of 6 minutes rose to 9 minutes after CPAP in 63 patients 
(Gaddy and Doghramji 1991), and in a small sample of 20 moderate and severe 
apnoeic patients, 6 months of CPAP resulted in an increase in sleep onset latency from 
a baseline average of 4.6 minutes to 8.9 minutes (Bedard et al 1993). These findings 
are paralleled by those of Kribbs et al (1993b) who reported daytime mean sleep 
latencies before CPAP of around 3 minutes in 15 patients, rising to approximately 6 
minutes after at least one month of CPAP. 
It remains a possibility that the conflicting evidence for normalisation of MSLT scores 
after CPAP from these studies reflects differences in CPAP compliance rates or in 
effectiveness of CPAP in these samples of SAHS patients. However, the studies of 
Lamphere et al (1989), Bbdard et al (1993), Fry et al (1990) and Kribbs et al (1993b) 
made specific mention that the study subjects attended for polysomnography on the 
night preceding both the baseline and the post-treatment MSLT, ensuring that CPAP 
was complied with on at least that one night prior to assessment. In Kribbs et al's 
(1993b) patient group, a subsample had CPAP compliance rates objectively 
monitored, but for the majority diaries were the only measure of compliance. If these 
data are to be trusted, in itself a controversial assumption (Rauschen et al 1993b), 
CPAP compliance averaged 5.7 hours per night, which compares well to the objective 
CPAP compliance findings from cross-national studies (Kribbs et al 1993a, Rauscher 
et al 1993b, Krieger and Kurtz 1988). Thus Kribbs' findings of relatively small 
improvements in MSLT score cannot be necessarily be attributed to poor CPAP 
compliance in that sample. 
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Nor can the relative effectiveness of CPAP in reversing apnoeas and hypopnoeas be 
blamed for the inter-study variability in patients' MSLT scores after CPAP. Bedard et 
al (1993) and Lamphere et al (1989) both reported an objectively-demonstrated 
reduction of respiratory event indices during the CPA P-treated night of 
polysomnography to around 10 per hour slept. In these two studies then, the 
effectiveness of CPAP preceding the assessment MSLT were comparable and cannot 
explain the discrepancies concerning normalisation of objective daytime sleepiness. In 
the study by Kribbs et al (1993b), respiratory events in sleep on the night preceding 
the post-CPAP MSLT fell to 3 per hour slept, yet MSLT latencies averaged only 6 
minutes. 
Some researchers believe that the disappointingly small improvements in MSLT 
found by some studies after the institution of CPAP may be due to the effect of 
instruction in the test. The instructions at the commencement of each MSLT nap 
specifically encourage subjects to "try to fall asleep" (Carskadon et a! 1986), relying on 
an assumption that an increase in alertness (or the ability to remain awake) will 
provoke a parallel decrease in sleepiness (or the ability to fall asleep). This 
unidimensional model of a sleepiness/alertness drive has been challenged by recent 
studies comparing the sleep onset latencies during daytime nap tests when 
hypersomnolent patients are given paradoxical instructions to remain awake (in the 
MWT) or to fall asleep (in the MSLT) on succeeding nap opportunities (Sangal et al 
1992a, 1992b). 
Sangal et al (1992a) performed a factor analysis of the sleep onset latencies obtained 
from an MSLT and an MWT, performed concurrently, in a heterogeneous sample of 
258 hypersomnolent patients. The analysis revealed two major factors corresponding 
to 'sleepiness' and 'alertness' loaded on MSLT and MWT latencies respectively. One 
third of a subsample of SAHS patients were shown to have discordant results in the 
two tests. Sangal et al (1992b) found no significant change in MSLT score, but a 
significant lengthening of MWT score after treatment in his mixed sample of sleepy 
patients, suggesting that the ability to stay awake, but not the ability to sleep, was 
altered with treatment. 
The MWT has no established norms, limiting its use in quantifying clinically- 
significant improvements in excessive daytime sleepiness, but recent studies 
(Walsieben et al 1989, Poceta et al 1992, Sangal et al 1992b) suggest that it may be 
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sensitive to treatment-related improvements in excessive daytime sleepiness. Poceta et 
al (1992) administered the MWT before and after CPAP to a group of 24 SAHS 
patients with an AHI greater than 5 per hour slept and found significant lengthening of 
MWT sleep onset latencies from 18 minutes to 32 minutes. Sangal et al (1992b) 
compared post-CPAP MWT score of 15 SAHS patients to baseline MWT score, 
showing a significantly increased mean sleep onset latency from 24 minutes to 32 
minutes. Walsieben et al (1989) administered the MWT before and then after 2 nights 
of CPAP, reporting a statistically significant lengthening of sleep onset after CPAP, 
but included no raw or group data. 
Objective studies of daytime sleep tendency using polysomnographic techniques have 
thus shown improvements in sleepiness in SAHS patients treated with CPAP, as 
might be predicted from theoretical research linking excessive daytime sleepiness to 
sleep fragmentation. The only studies reporting no statistically significant 
improvements in MSLT score after CPAP have been confounded by the inclusion of 
non-SAHS patients or the inclusion of ineffectively treated SAHS patients. 
Charbonneau et al (1992) studied a mixed group of 26 snorers and SAHS patients, 
and found a non-significant drop in MSLT sleep onset latency from 12.3 minutes pro- 
CPAP to 11.4 minutes after one month of CPAP. The incorporation of non-SAHS 
patients in this study is reflected in the normal pre-treatment sleep onset latency. 
Sangal et al (1992b) found no statistical lengthening of MSLT score after treatment in 
a sample of 26 SAHS patients, but 11 of these subjects were treated with 
unsuccessfully UPPP, as demonstrated by polysomnography showing a reduction of 
AHI from 56 to only 45 per hour slept in these 11. Thus the negative findings of these 
two studies, showing no improvement after CPAP, are potentially unreliable. 
A recently developed self-rated scale quantifying daytime sleepiness, the Epworth 
sleepiness scale (ESS: Johns 1991,1992 and 1993), may show promise as a more 
reliable and sensitive measure of daytime sleepiness than the Stanford sleepiness scale 
(Hoddes et al 1973), whose subjective-perception based items have been shown to be 
unreliable in hypersomnolent patients (Dement et al 1978, Roth et al 1980, Browman 
and Mitler 1988). The ESS asks subjects to reflect on their likelihood of experiencing 
specific sleep-related behaviours under different conditions such as "sitting and 
reading" or "watching TV", and may thus provide greater reliability in patients who 
have become inured to the sensations of impending sleep, but can still reliably assess 
their recent napping behaviour retrospectively. 
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Factor analysis of the ESS item scores from both healthy and apnoeic samples reveals 
only one main factor, reflecting internal consistency within the scale (Johns 1992). The 
total ESS score has been found to discriminate snorers from SAHS patients, to relate 
to the severity of breathing disruption in sleep (Johns 1991 and 1993) and, unlike the 
SSS, to correlate significantly with objective measures of sleepiness obtained from the 
MSLT in hypersomnolent patients (Johns 1991). 
Scores from the ESS were significantly reduced from a pre-CPAP average of 14 to 
post-CPAP mean of 7 in 54 SAHS patients treated with CPAP for 3 months (Johns 
1992). While no measure of compliance was obtained in the SAHS patients to 
corroborate that ESS score changes were attributable to CPAP, this significant 
improvement in scores cannot be attributed to an order effect, as in normals test retest 
scores are remarkably stable (Johns 1992). Thus a potentially valid subjective 
sleepiness scale supports objective studies documenting statistical and at least partial 
clinical improvements in excessive daytime sleepiness following CPAP therapy. 
Researchers continue to debate which instrument provides the best measure of sleep 
tendency and whether the improvement in sleepiness after CPAP is large or small in 
magnitude, but no researcher has so far found an absence of improvement after CPAP 
treatment. These empirical findings support the hypothesis that excessive daytime 
sleepiness in SAHS may arise from reversible nocturnal sleep disruption. 
3.2 Cognitive function after CPAP 
Both empirical and hypothetical evidence suggested that cognitive impairment in 
SAHS might result from a combination of hypoxaemia and sleep disruption. Thus the 
reversibility of cognitive impairment in SAHS, based on models of hypoxic disease, 
remains ambiguous, and the existing empirical studies in SAHS patients do not 
conclusively resolve this important question. 
Clinical studies of CPAP's effects in SAHS patient samples are limited in both 
number and quality, at least partially because of the problems of learning curves with 
repeated testing, which confound the evaluation of true improvements in performance. 
In fact, research in this important area has been confined to a very few, often 
preliminary, studies (Bea park et al 1987, Charbonneau et a11992, Walsleben et al 
1989, Bedard et al 1993, Kribbs eta! 1993b, Pardett et al 1994). 
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Table 3.1: Changes in cognitive function with CPAP 
Author Subjects Study design Measures Results 
Bearpark et al 12 `impaired' Uncontrolled, WMS, BVRT, Improvements 
1987 SANS pts before and after TM, S troop, in WMS, 
>4 months on VF, NART BVRT, VF, 
CPAP Stroop 
Charbonneau 26 mixed Uncontrolled, DS, memory Improved 
et at 1992 snorers/ before and after memory 
SAHS is 1 month CPAP 
Kribbs et at 15 SAHS pts CPAP RT, DS, DSp, RT improved 
1993b withdrawal Stroop with CPAP but 
study did not fall off 
after CPAP- 
withdrawal 
Walsieben et 7 SAHS pts AEP controls WMS, TM, No change in 
at 1989 tested once. Pts VF, BD, PB, cognitive 
assessed before DS, AEPs performance, 
and after 2 but improved 
nights CPAP. P3 latency after 
CPAP. 
Rumbach et 47 SANS pts Partially AEPs Improved 
at 1992 controlled latency and 
(controls tested amplitude of 
once). Pts N2 and P3, but 
assessed before decrease in 
and after 6 amplitude of P2 
weeks CPAP. amplitude with 
CPAP. 
Bidard et at 10 SAHS Partially RT, WAIS-R, Pts improved in 
1993 pts, 10 controlled WMS, LC, PB, RT, Perf IQ, 
controls (controls tested TM, VF LC, immediate 
once). Pts and delayed 
retested after 6 WMS, PM, PB 
months CPAP 
Oveson et at 5 SAHS pts Withdrawal trial RT Improvement 
1992 of CPAP in RT with 
CPAP and fall- 
off on CPAP 
withdrawal 
Partlett et at 18 SAHS pts Uncontrolled RT No change in 
1994 median RT 
Key to Table 3.1 
WAIS- Wechsler Adult Intelligence Scale 
WMS- Wechsler Memory Scale 
TM- TrailMaking 
LC- Letter cancellation 
BVRT- Benton visual retention test 
VF- Verbal fluency 
PASAT-Paced auditory serial addition test 
NART- National adult reading test 
AEPs- Auditory evoked potentials 
RT- Reaction time 
PB- Pegboard 
BD- Block design 
PM- Porteous mazes 
FT- Finger tapping 
SR- Seashore rhythm 
SP- Speech perception 
DS- Digit symbol substitution 
DSp- Digit span 
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Bearpark et al (1987) was the first to report improvements in cognitive function after 
CPAP after studying 12 moderate and severe SAHS patients before and at least 4 
months after the commencement of CPAP. The authors administered a cognitive 
battery that included the Wechsler memory scale and the Benton visual retention test 
as measures of memory, the TrailMaking B task from the Halstead-Reitan battery and 
the Stroop test as assessors of mental set flexibility, a test of word production and the 
National Adult Reading Test (NART). The use of the NART allowed Bea park to 
identify those 9 patients who were "impaired", by comparing obtained performance 
IQ measures to the pre-morbid estimates of performance IQ derived by the NART 
scores. In the 9 impaired patients, Bearpark reported statistically significant 
improvements in performance scores obtained after CPAP for Wechsler subjective 
memory, Benton visual memory, verbal fluency and the Stroop test. 
Charbonneau et al (1992), in a study already referred tu in the review of sleepiness 
after CPAP, also reported significant improvements in memory on an unspecified test, 
but no improvement in coding efficiency as assessed by the digit symbol substitution 
test from the WAIS-R battery, in 26 subjects treated with one month of CPAP. 
Both of these studies can be criticised for their lack of control for the effects of 
learning on measures of performance. Neither a familiarisation session to obtain 
plateauing of performance, nor a balanced, placebo-controlled crossover design, nor a 
parallel group design (following untreated as well as treated patients) were employed 
in these studies, making the assessment of the relative contribution of improved 
functional ability and learning-related improvement impossible to disentangle. Neither 
author reported the use of alternative forms of tests, where available, which might 
mitigate against such learning effects, although since both publications were short 
reports, pressure of space might have prevented this. In addition, the study by 
Charbonneau et al (1992) combined snorers with SAHS patients, although even a 
subsample of 11 severe sleep apnoeics showed no improvement in digit symbol 
performance after CPAP. 
The study by Kribbs et al (1993b) reported the effects of at least one month of CPAP 
followed by the withdrawal of CPAP for a single night in 15 patients. Performance 
was evaluated before CPAP, after 2 weeks on CPAP and upon withdrawal of CPAP 
for one night. The psychometric battery included a Wilkinson-type 4-choice reaction 
time task, the digit symbol substitution and digit span subtests from the WAIS battery 
and the Stropp test of mental processing speed under conditions of interference. 
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Simple reaction time improved significantly from baseline levels after CPAP but did 
not return to pre-treatment levels after withdrawal of CPAP for a single night. This 
finding of improvement after CPAP and lack of fall-off after CPAP withdrawal may 
have been due to practice effects and/or to a carry-over effect of CPAP treatment 
Performance on the digit symbol, digit span and Stroop tests all showed time-course 
improvement from baseline to on-CPAP to off-CPAP conditions, which the authors 
attributed to the effects of a learning curve. 
Walsieben et al (1989) evaluated cognitive performance before and after 2 nights of 
CPAP in 7 SAHS patients. Her cognitive assessments included the Wechsler memory 
scale, a verbal learning test, TrailMaking tasks A and B, a verbal fluency test, the 
information and block design subtests of the WAIS-R battery, pegboard test of 
manual dexterity and the symbol digit modalities test. Alternative forms of these tests 
were reportedly used on the second testing session, although no validated alternative 
versions of the block design, information or TrailMaking tasks are published. In any 
case, the results of paired comparisons of pre- and post-CPAP assessments found no 
significant improvements in any of the tests in this battery. With such a small patient 
sample, a lack of statistical power may be responsible for the lack of positive finding. 
in addition, Walsleben etas (1989) recorded auditory evoked potentials (AEPs) before 
and after CPAP, finding a post- CPAP trend towards normalisation of P3 latency. The 
authors conducted a subtrial within the larger study to assess order effects on wave 
component latencies during repeated testing and found no effect, providing 
reassurance that the shortened latency of P3 after treatment was not due to a 
familiarisation effect. These results are supported in a study of 47 SAHS patients, who 
showed a significant decrease in latency and increase in amplitude of both N2 and P3 
wave components after 6 weeks of CPAP (Rumbach et al 1992), although P2, N2 and 
P3 latencies remained slower than those of a control group, tested once only. P2 
amplitude was significantly higher in patients before treatment than in controls, and 
was significantly decreased after CPAP. This finding is of uncertain significance and 
was not discussed by the authors. Learning may be less of a problem in these 
neurophysiological studies than in neuropsychological research, and the shared 
association between measures of both sleepiness and cognitive processing and AEP 
waveforms mean that AEPs may prove effective markers for overall treatment 
response in therapeutic studies. 
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In B6dard et al's study (1993), a matched control group was tested only once while a 
patient group of 10 SAHS patients underwent comprehensive neuropsychological 
testing both before and after 6 months' treatment with CPAP. In this study design no 
control was provided for the effects of repeated test administration in the patient group. 
Paired t -tests of pre- and post-CPAP scores in the patient group showed significantly 
higher scores in the overall performance IQ after CPAP, with individual statistical 
improvements in performance on the digit symbol, block design, object assembly and 
picture arrangement subtests. Patients also performed significantly better on repeated 
testing in the letter cancellation test, four-choice reaction time, immediate and delayed 
memory from the Wechsler memory scale, WISC mazes and pegboard skills. Some 
post-CPAP test scores, specifically those for Porteous mazes, TrailMaking B, picture 
arrangement, verbal fluency and pegboard skills, remained significantly lower than 
those of the controls. While some post-CPAP increases in test score may have been 
influenced by learning, the persisting deficits in others on retesting provide support for 
an argument that SAHS patients are cognitively compromised, even after treatment 
BMazd et at (1993) hypothesised that CPAP treatment reverses some cognitive 
deficits, specifically those affecting attention, memory and constructional abilities, but 
not others, such as verbal fluency, manual dexterity and planning ability. This 
conclusion may not be strictly correct, as learning effects might be responsible for 
some increased scores on second testing. Despite extensive efforts to closely match 
the 10 cases and controls for background factors, the small number of subjects in this 
study compromises its reliability. However, the study may support a hypothesis, 
derived from hypoxic disease models, that some cognitive deficits are irreversible after 
CPAP, as despite the benefit of extra exposure, the patients' performance remained 
significantly lower than that of the controls. 
A further small-scale study (Oveson et a11992) examined median reaction time in 5 
patients before treatment, after 2 weeks on CPAP and after withdrawal of CPAP for 2 
days. Patients' reaction time shortened with CPAP and extended again after 
withdrawal, all the magnitude of improvement is difficult to assess against a probable 
background learning curve. 
In contrast to the findings of Oveson et al (1992), Bedard et al (1993) and Kribbs et al 
(1993b), Partlett et al (1994) found no change in reaction time, this time in a simple 
unprepared paradigm, in 18 SAHS patients treated with CPAP. Only the second 10 
minutes of a 20-minute reaction time task were analysed, when attention deficits 
provoked by sleep loss are most evident (Donnell 1969, Wilkinson et al 1966). 
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Although simple unprepared reaction time is relatively free of a learning curve 
(Wilkinson and Houghton 1975), the use of the latter half of the task provided an extra 
control for this effect. Compliance with CPAP, assessed by time counters logging 
time that units were switched on, averaged 4.3 hours, in line with other recent studies 
of SAHS patient series (Kribbs et a] 1993a, Reeves-Hoche et al 1994, Rauscher et al 
1993b). All patients reported a subjective improvement in daytime sleepiness, but this 
was not reflected in improved reaction time. This study, conducted in a larger sample 
of verifiably compliant patients, raises the possibility that improved subjective 
sleepiness is not accompanied by improved objective vigilance, or that reaction time 
tests are not a useful probe for daytime alertness in SAHS. 
While the short reports of Bearpark et al (1987) and Charbonneau et al (1992) contain 
no data on CPAP compliance, polysomnography performed on the night prior to post- 
CPAP cognitive testing in some studies (Kribbs et a! 1993b, Walsleben et a11989, 
Bedard et al 1993) provides some assurance that compliance with and pressures of 
CPAP were acceptable, at least on that single monitored night. Pardett et al (1994) 
reported average CPAP runtimes. 
The empirical evidence on the reversibility of SAHS' cognitive impairment with 
CPAP remains cloudy, like the hypothetical reversibility based on experimental and 
disease analogues for SAHS. No large scale, adequately controlled trial has yet been 
conducted to tip the balance either in favour or against the restoration of cognitive 
ability after CPAP. This nebulous area thus provides rich research opportunities, to be 
explored further in the practical work within this thesis. 
3.3 Psychological wellbeing after CPAP 
Longitudinal measurements of changes in mood, personality and psychological 
distress pose their own particular methodological problems. The effects of repeated 
administration of a scale may have an independent effect on responses, as the subject 
may answer the questions in a comparative rather than absolute manner. Thus controls 
for repeated administration are desirable. A second methodological problem concerns 
the anticipation of recovery after clinical intervention, the'placebo effect'. The 
expectation of improvement after treatment may confound the measurement of 
improvement, necessitating in ideal studies the use of a placebo control. In addition, 
the previously mentioned criticisms of the assumption of acceptable CPAP 
compliance, common to most CPAP-based studies, apply to psychosocial studies. 
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The MMPI has been extensively used in studies of personality in SAHS and has been 
used, perhaps controversially, to show change after successful treatment of the 
syndrome (Platon and Sierra 1992, Mayleben et al 1990). The MMPI theoretically 
measures stable and enduring traits, so may not be the most suitable instrument for 
assessing short-teen therapeutic changes in personality. Platon and Sierra (1992) 
retested a small sample of apnoeic patients after approximately 3,9 and 12 months of 
"successful" CPAP treatment, and found that mean MMPI scores that were elevated 
before therapy were reduced to the normal range after 9 months. Only 4 SAHS 
patients were re-tested with the MMPI after 12 months of CPAP, but scores for this 
group were significantly lower than those found at 9 months. The study by Mayleben 
et al (1990) used paired pre- to post-CPAP treatment comparisons to show that 
MMPI hysteria, hypochondriasis and depression scores were all significantly reduced 
following CPAP. Neither author used controls for the effects of repeated 
administration or for the expectation of improvement after commencement of CPAP. 
However, both studies suggest that trait evaluations show improved psychological 
function after CPAP. 
Mood state assessment using the POMS adjective checklist featured in a small 
parallel-group study that controlled for the effects of repeated administration of mood 
measures by examining the changes in scores in 7 untreated and 7 CPAP-treated 
patients with SAHS (Derderian et a! 1988). ANOVA found that depression-dejection 
and fatigue-inertia scores were significantly improved by CPAP, as was the total 
mood disturbance score. Kribbs et al (1993b) examined the change in POMS scores 
with the withdrawal of CPAP treatment for one night and found a return to pre-CPAP 
scores in the energetic arousal-loaded subscales of vigour-activity and fatigue-inertia 
scales. While these results suggested that mood effects may be perceptible after as 
little as one night off CPAP, the study did not control for the patients' own anticipation 
of a return of symptoms of SAHS with the withdrawal of CPAP. However, this study 
was the only one which objectively monitored some patients' compliance with CPAP 
treatment, via the use of microprocessors concealed within the CPAP units. 
Measures of psychiatric morbidity also appear to be sensitive to CPAP-mediated 
improvements in wellbeing. Millman et al (1989) repeated the administration of the 
Zung self-rating depression scale in 19 patients after at least 3 weeks of CPAP use and 
found that the group's mean score, which was above the pathological threshold before 
treatment, then fell within normal limits. The fall in scores was particularly dramatic in 
those patients with elevated scores before CPAP, perhaps reflecting a resolution of the 
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somatic symptoms of SAHS that are embedded within the questionnaire. However, if 
the limitations of these studies are accepted, they provide evidence for improved 
psychological well-being after CPAP. 
The above studies suggesting, with methodological reservations, improved 
psychosocial function following CPAP and fit well with Kales et al's (1985) 
hypothesis that the psychological distress of SAHS is secondary to physical 
symptoms and limitations. Such studies support CPAP's effectiveness in breaking the 
mechanistic cycle producing nocturnal events and thereby daytime sequelae. 
3.4 Driving performance after CPAP 
The observed reductions in excessive daytime sleepiness and the possible 
improvements in cognitive function implied by the existing studies in clinical SAHS 
patient samples would be expected to directly effect improvements in road safety for 
patients. However, objective evidence of such improvement is thin, at least partially 
because of the relatively recent availability of CPA P. Neither retrospective nor 
prospective studies examining driving accident rates after CPAP have yet been 
performed. However, laboratory evaluations of performance on driving simulators 
suggest that some of the demonstrable deficits driving skills associated with SAHS 
are reversible (Findley eta! 1989a, Haraldsson et al 1991). 
Findley et al (1989a) retested 6 SAHS patients after at least 3 months of CPAP on the 
SteerClear driving-based vigilance task and found that the pre-treatment error score of 
29 during the 30-minute task was reduced to 13. This post-CPAP performance was 
no longer significantly different from that of 7 normals, who were tested only once. 
The influence of CPAP compliance rates and of repeated testing on this simulation's 
scores is not known, nor controlled for in the study. 
Although the focus of this chapter is the daytime effects of CPAP, a valuable study 
evaluating post-UPPP driving skills on a realistic driving simulator suggests that 
treatment with CPAP might provoke significant improvements in road safety in 
SAHS. Haraldsson et al (1991) matched 10 controls to 15 patients complaining of 
significant sleepiness whilst driving, and tested both groups twice for 90-minutes in a 
realistic driving simulator, which measured braking reaction time, swerving and off- 
road incidents. The patient group's first drive occurred before treatment with UPPP 
and the second after surgery. Patients' performance, significantly depressed compared 
to that of controls at baseline, was not significantly different from the controls' second 
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performance. The study, along with the others above, suggests that driving 
competence may improve with effective treatment. 
3.5 Summary 
In keeping with the hypotheses formed in Chapter 2, empirical evidence from limited 
controlled studies suggest that daytime function may improve, at least partially, after 
CPAP. Large and small improvements in sleepiness have been shown by objective 
polysomnogiaphic techniques. Evidence for the reversibility of cognitive deficits after 
CPAP for SAHS is inconclusive, but studies of psychological health suggest overall 
improved wellbeing after CPAP. Preliminary laboratory-based studies imply that 
reductions in sleepiness and, possibly, cognitive deficit indirectly produce improved 
driving performance. The inconclusiveness of many of the studies reviewed in this 
chapter, particularly those relating to cognitive performance, preserves the daytime 
effects of CPAP therapy as an incompletely explored and potentially fruitful research 
area. Practical studies performed to elucidate the effects of CPAP therapy on daytime 
neuropsychological function, beginning with a description of the assessment tools 
used in this project, will now occupy the remainder of this thesis. 
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Chapter 4: 
METHODS OF MEASUREMENT 
The aims of this project, to examine changes across a broad range of daytime function 
in SAHS patients treated with CPAP, required the use of diverse measurement 
techniques. Polysomnographic methods developed within the field of respiratory sleep 
research were used to diagnose and characterise patients, and to assess objective 
daytime sleepiness. Cognitive performance and psychological well-being were 
assessed using psychometric instruments from the fields of clinical, experimental and 
health psychology. Mechanical techniques were used to measure objective CPAP 
compliance. 
4.1 Polysomnography 
Overnight polysomnographic sleep studies, performed according to the laboratory's 
standard procedure (Gould et al 1988), were conducted to diagnose and characterise 
the severity of SAHS in patients. An example of such polysomnography is shown in 
Figure 1.1. Physiological measures reflecting patients' sleep quality, breathing pattern 
and oxygenation were recorded on a 16 channel chart recorder (SLE, Croydon). 
4.1.1 Sleep quality 
Electroencephalography (EEG), electo-oculography (EOG) and electromyography 
(EMG) were recorded from bipolar montages of signals obtained from surface 
electrodes of chlorided silver placed on the face and scalp. Submental EMG was 
recorded from two electrodes placed below the ramus of the jaw, the signal from the 
left chin referred to that from the right chin. EOG was recorded from 4 electrodes, 
placed at the outer canthus of each eye and on the frontal bone above each eye at sites 
FP1 and FP2 of the 1020 electrode placement system. The outer canthus signal from 
each eye was referred to the frontal bone signal of the contralateral eye to optimise 
recorded changes in electrical potential created by eye movements. EEG activity was 
recorded from two scalp electrodes, referred to each other and placed at 1020 sites Cz 
and Pz. A `mixed' montage consisting of an EEG-EOG signal was also employed, as 
this resolves frontally-detected sleep spindles. EEG, EOG and EMG recordings were 
scored for sleep stage by the conventional criteria of Rechtschaffen and Kales (1968). 
In Rechtschaffen and Kales' (1968) system, information on brain activity from EEG, 
eye movements from EOG and muscle tone from EMG is synthesised to produce an 
overall score for sleep stage within a time-window of 20 or 30 seconds. Thus 
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Rechtschaffen and Kales' (1968) system provides an `averaging' method for 
examining shifts in sleep stage over the time course of the night. 
Awakenings lasting less than half an epoch (10 or 15 seconds) are missed by the 
macroscopic approach of Rechtschaffen and Kales' (1968), so EEG, EOG and EMG 
recordings were also scored for microarousals, short awakenings from sleep of 1.5 
seconds or more. Microarousals were defined by a return of alpha or theta EEG 
activity for 1.5 seconds or longer, with a coincident rise in EMG activity of any 
duration (Cheshire et al 1992). This definition was developed in-house, as no 
consensus was available at the time of inception of this project. A consensus definition 
subsequently published by the American Sleep Disorders Association (Atlas Task 
Force 1992) has yet to be validated. A microarousal index was calculated by dividing 
the total number of arousals by total time slept. 
4.1.2 Breathing pattern 
A thermocouple placed on the upper lip sensed both nasal and oral airflow. This signal 
was scored for apnoeas, which were defined by the cessation of oronasal flow for 10 
seconds or more (Guilleminault et al 1978). Abdominal and thoracic breathing 
movements were recorded using inductance plethysmography (Respitrace) from 
stretchable bands placed around the trunk. These signals were scored for hypopnoeas, 
defined by a reduction in thoracoabdominal effort of 50% or more for 10 seconds or 
longer (Gould et al 1988). Apnoea+hypopnoea index (AHI) was calculated as the 
frequency of apnoeas+hypopnoeas per hour slept. 
4.1.3 Oxygenation 
Oxygen saturation was recorded continuously by pulse oximetry (Biox) from a probe 
placed on the earlobe. This allowed the frequency of desaturation events and the 
waking and the minimum oxygen saturation during the night to be measured. 
4.2 Multiple sleep latency test (MSLT) 
Objective daytime sleepiness was measured using the multiple sleep latency test 
(MSLT), an polysomnographically-based procedure for assessing daytime sleep 
tendency (Carskadon et al 1986, Thorpy 1992). The test consists of 5 daytime nap 
opportunities, during which the latency to electrophysiological sleep is measured. The 
MSLT is considered a gold-standard measure of sleepiness against which subjective 
scales are measured (Dement et al 1978, Roth et al 1980, Browman and Mitler 1988, 
Johns 1991,1992,1994) and has been widely used for over 10 years in clinical and 
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experimental sleep research (Dement et al 1978, Carskadon and Dement 1979, Roth et 
al 1980, Carskadon and Dement 1981, Van den Hoed et al 1981, Richardson et al 
1982, Carskadon and Dement 1982, Carskadon et al 1986, Browman and Winslow 
1989), allowing norms for the principal outcome measure, mean sleep onset latency, 
to be established. A mean sleep onset latency of 5 minutes or less is thought to 
correspond to `pathological' sleepiness, while a mean latency between 5 and 10 
minutes represents moderate sleepiness (Carskadon et al 1986, Thorpy 1992). Mean 
latencies greater than 10 minutes are considered normal. 
The MSLT was conducted according to the research protocol recommended by 
Carskadon et al (1986), with five daytime nap opportunities during which EEG, EOG 
and EMG, as described above, were recorded. The nap opportunities were regularly 
spaced at 2 hour intervals commencing at 10 am and with the last nap at 6 pm, so that 
circadian variations in sleep tendency were monitored. Each nap opportunity is 
terminated 15 minutes after the first appearance of sleep or after a maximum 20 
minutes (Carskadon et al 1986), thus minimising reductions in sleep drive on 
subsequent nap opportunities that day. For each nap opportunity, subjects are asked to 
lie on a bed in a darkened room, and given standardised instructions to `lie 
comfortably with your eyes closed and try to sleep'. 
Sleep onset latency is usually defined as the time from `lights out' to the first of three 
consecutive epochs of stage 1 sleep, or to the first epoch of any other sleep stage 
(Carskadon et al 1986). However we used a modified criterion for defining sleep onset 
latency in this study, comprising the latency to the first 20 second epoch of any sleep 
stage, including stage 1, because in SAHS frequent arousals associated with breathing 
irregularities interrupt periods of stage 1 sleep and prevent the scoring of three 
continuous epochs of stage 1 sleep. This criterion was subsequently independently 
adopted in a consensus paper from the American Sleep Disorders Association 
(Thorpy 1992). All MSLT traces, including those recorded by Katherine Cheshire, 
were restored using the modified criterion, eliminating inter-rater differences in this 
outcome measure. The MSLT yielded two measures for subsequent analysis; a mean 
sleep onset latency (the average of the sleep onset latency for the five nap 
opportunities), and the minimum sleep onset latency seen on the five nap 
opportunities. 
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4.2.1 Reproducibility of MSLT scoring 
An intra-rater reliability exercise to assess the reproducibility of MSLT scoring was 
performed on 21 MSLT records. The values for the first and second scoring of the 
records, and correlations between the two values, are shown in Table 4.1. Test-retest 
correlations for individual sleep onset latencies on the 5 nap opportunities and for 
mean sleep latency were high (r>0.93, p<0.001), indicating highly acceptable 
reproducibility (Table 4.1). 
Table 4.1: Reproducibility of sleep onset latency scoring 
First scoring 
Mean ± SEM 
Second scoring 
Mean ± SEM r-value 
10 am nap (rains) 9.3 ± 1.5 9.4 ± 1.6 0.99 
12 am nap (mies) 7.2 ± 1.3 6.9 ± 1.2 0.99 
2 Pm n(mins) 6.5±1.2 6.7±1.1 0.93 
4 pm nap (rains) 7.0 ± 1.1 7.1 ± 1.1 >0.99 
6m nap (mies) 11.0 ± 1.6 10.8 ± 1.6 >0.99 
Mean sleep onset 
latency (mies) 
8.2 ±1.1 8.2 ±1.1 0.99 
4.3 Psychometric instruments 
A wide variety of neuropsychological tests were used within the project to examine a 
broad range of daytime function. The chief psychological domains investigated were 
cognitive performance and well-being. 
4.3.1 Cognitive performance tests 
Wechsler adult intelligence scale (WAIS" Wechsler 1955) and Wechsler adult 
intelligence scale-revised (WAIS-R" Wechsler 1981) 
General level of intellectual function was assessed using four selected subtests from 
the Wechsler adult intelligence scale (WAIS: Wechsler 1955) and the revised WAIS 
(WAIS-R: Wechsler 1981) battery, which consist in their entirety of 11 subtests. The 
four subtests used in the project, information, arithmetic, block design and digit 
symbol substitution, have the highest correlations with general intelligence (Lezak 
1983) and are the most resistant to learning effects. Performance on WAIS subtests 
have been found to be impaired in SAHS patients (Bedard et al 1991b) and to correlate 
with the extent of nocturnal breathing disruption (Greenberg et al 1987). The WAIS 
and WAIS-R versions of subtests were used in the pilot parallel-group study and the 
principal crossover study respectively. 
71 
Chapter 4: Methods of measurement 
Information subtest (British adaptation: Wechsler 1955) comprises a series of general- 
knowledge questions of progressively increasing difficulty, with points awarded for 
correct answers. At the easier end of the test, the subject is asked to name four Prime 
Ministers of Great Britain since 1900; at the most difficult level, the subject is asked to 
demonstrate more esoteric knowledge such as the name of the writer of Faust. 
Educational level influences score on this test (Lezak 1983), but the executive function 
of recall is also called into play in its performance. 
Arithmetic subtest (British adaptation: Wechsler 1955) is a task of increasing 
complexity involving mental arithmetic skills. All questions are presented in practical 
and concrete, not abstract or mathematical, terms (e. g. if one peach costs 6 pence, how 
many peaches can you buy for 36 pence? ). As the test progresses, the number of 
arithmetical operations required to produce a correct answer increases, while at the 
same time a premium in terms of points scored is gained for quick answers. Although 
this subtest contributes towards the calculation of the Verbal IQ outcome measure, it 
incorporates non-verbal faculties such as concentration, particularly in the more 
difficult questions at the end of the test. 
Digit symbol substitution subtest (Wechsler 1955.1981 is a paper-and-pen coding 
exercise, in which the subject is required to write appropriate abstract symbols 
underneath one-digit numbers, according to a code key printed at the top of the page. 
Task duration is limited to 90 seconds and is scored by the total number of correct 
codings. The task brings into play visuomotor co-ordination, attention and learning. 
Block design subtest (Wechsler 1955.1981) is a construction task in which the subject 
is requested to replicate 2 dimensional geometric patterns using the top surfaces of 
coloured ̀ playing bricks'. The task progresses from simple 4-brick designs to 
complex and rotated 9-brick designs, with bonus points awarded for quick completion 
of designs. The test requires attention to detail, gaining zero points in the event of any 
mistake, however small, and calls into play visuospatial conceptualisation and motor 
dexterity. 
Raw, unscaled scores from the individual WAIS subtests were used in statistical 
analyses. Scaled scores from block design and digit symbol subtests were used to 
prorate a performance IQ score and from information and arithmetic subtests to 
prorate a verbal IQ score (Wechsler 1955,1981). Full IQ score was estimated from all 
subtests' scaled scores. 
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The additional WAIS-R performance subtests of object assembly, picture completion 
and picture arrangement, were administered once only, at the familiarisation session of 
the principal crossover study, and used with block design and digit symbol 
substitution to rate performance IQ. 
National adult reading test (NART) (Nelson 1982) is a brief reading task which is 
used to estimate pre-morbid intellectual ability on the basis that word knowledge is 
highly correlated with general intelligence, and that the ability to pronounce familiar 
words is preserved even in organic brain damage (Nelson and McKenna 1975). It has 
been extensively validated in normal (Crawford et al 1988a, Crawford et al 1989a) and 
patient samples (Nelson and McKenna 1975, Hart et al 1986, O'Carroll et al 1987, 
Crawford et al 1988b). The NART comprises a list of fifty English words of 
increasing obscurity, all of whose pronunciation is irregular with regard to standard 
phonetic rules (e. g. from the easier level ̀ psalm' to the more difficult `demesne'). The 
subject is asked to read slowly down the list while pronunciation is monitored. The 
number of correctly pronounced words provides an estimate of pre-morbid IQ. 
IQ decrement score (Ingan et al 1991) 
Performance IQ score obtained from the WAIS and WAIS-R performance subtests 
was subtracted from the NART-estimated pre-morbid performance IQ to calculate an 
estimated `IQ decrement' score for each patient While the performance IQ estimate 
may be the least reliable of the IQ estimates obtained from the NART (Crawford et al 
1989a), the performance IQ subtests call on the executive functions disrupted by 
organic disease (Lezak 1983) and might be expected to prove more sensitive to 
SAHS-induced deficit. 
TrailMaking tasks A and B (Reitan 1958 Boll 1981), paper-and-pen tests from the 
Halstead-Reitan battery, assess visuomotor tracking using a `join-the-dot' procedure 
(Figure 4.1). The A task consists of digits 1 to 25 scattered on a page, while the B task 
uses letters 1 to 13 and letters A to L. The subject is asked to join consecutive numbers 
in the case of task A, or alternate numbers and letters in task B, as quickly as possible 
but without making mistakes. The score obtained is the time taken to completion. Any 
mistakes in connection order are pointed out and the subject is asked to rectify them, 
thus adding time to the score. These tests are commonly used to assess general 
cognitive function (Lezak 1983) and TrailMaking B is thought to be particularly 
sensitive to organic brain damage (Reitan 1958). Performance on the B task has been 
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Figure 4.1: TrailMaking B task 
74f- 
Chapter 4: Methods of measurement 
found to be impaired in SAHS patient samples compared to normals (Bedard et al 
1991b) or less hypoxaemic patients (Findley et al 1986). 
Paced audiM serial addition test (PASAT1(Gronwall 1977) is an arithmetic-based 
task requiring sustained concentration. The subject is required to listen to a sequence of 
61 one-digit numbers, which are presented at a regular pace on an audio tape, and is 
instructed to add the first number to the second and give the answer, the second to the 
third and give the answer, and so on, until 60 sums have been given from the 
consecutive pairs in the 61-number list. Explanation followed by a practise sequence is 
administered until the nature of the task is grasped by the subject, who then goes on to 
attempt the test first at a 4-second per number presentation rate, then at a 2-second per 
number presentation rate. The PASAT provides information on information- 
processing speed, attention and concentration ability, and has been shown to reflect 
cognitive deficit in hypoxaemic SAHS patients (Findley et al 1986). 
i Radion time test (IT: Brand and Dewy 19821 is a computer-administered task 
which assesses perceptual intake speed with visual stimuli of short duration. Pairs of 
vertical bars of markedly different lengths are presented briefly on a computer screen. 
The subject is required to consider which of the pair was the longer, and indicate, by 
pressing a computer key their perception. While some presentations will be 
sufficiently long in duration to allow correct discrimination of the longer bar, short- 
lasting presentations below a subject's individual information-processing threshold 
will require a guess on the part of the subject. The task is of variable duration, from 2 
to 25 minutes, depending on response consistency s assessed by an adaptive staircase 
psychophysiological procedure. The measures obtained from the task are the stimulus 
duration for which 80% of responses are correct (the inspection time) and the total 
number of trial stimuli administered (indicating consistency of response). The 
reliability of the test is dependant upon reasonable visual acuity in the subject, and test 
retest reproducibility requires identical lighting conditions. Thus, the test was 
administered in a darkened room on a dedicated monochrome monitor whose 
brightness was controlled. 
Ra" visual information processing test (RVIP' Wesnes and Warburton 1983) 
This 10-minute, computer-administered test based on signal detection theory was 
included in the cognitive battery as a measure of sustained concentration and 
information-processing ability and response caution. RVIP performance may be 
sensitive to cortical arousal mediated by cholinergic activity in the reticular activating 
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system (Wesnes and Warburton 1983, Petrie and Deary 1989), likely to be altered in 
SAHS, and correlates well with measures of general intellectual function in patient 
samples (Deary et al 1992). Single, one-digit numbers are presented at a rate of 100 
numbers per minute on a computer screen. The subject is required to press the 
spacebar when a sequence of 3 consecutive odd or 3 consecutive even numbers 
occurs: such target sequences are embedded within the digit presentation array at a 
frequency of 8 per minute. The `hit score' (number of correct target identifications) 
estimates subjects' ability to classify, memorise and respond at speed to incoming 
information, while the `miss score' (number of incorrect target identifications, i. e. 
pressing the spacebar when no target triplet has occurred) estimates the subjects' level 
of response caution. 
Simple unprepared reaction time (RIE) tests (Wilkinson and Houghton 1982) 
Reaction time tests, one of the few tasks validated as sensitive to the effects of sleep 
loss (Williams et al 1959, Wilkinson et al 1966), were administered according to the 
procedure of Wilkinson and Houghton (1982) using in-house software run on a 
Commodore computer. Each 4 minute test run comprised 30 visual stimuli, 
consisting of blocks appearing on a computer screen, to which subjects were requested 
to react by pressing a button ̀ as quickly as possible'. The inter-stimulus interval varied 
pseudorandomly from 1 to 4 seconds, increasing subject unpreparedness. Five 
reaction time runs were administered during the testing session, yielding a principal 
outcome measure of average mean reaction time. Mean, rather than the more standard 
median, RT was selected for analysis because of evidence linking vigilance loss with 
the appearance of occasional ̀lapses' in response (Williams et al 1959, Dinges et al 
1987) which skew the mean RT toward slow responses. 
Hick reaction time (Hick 1952, Jensen 1987) 
Reaction time (RT) tests used in the crossover study were based on the Hick paradigm 
(Hick 1952). This RT testing procedure yields not only mean and median RT values 
under varying degrees of choice (response uncertainty), but also provides information 
about the rate of gain of information with increasing complexity of stimulus choice. 
RT variables, particularly those relating to decision time, give a measure of 
information-processing ability and are correlated with IQ in healthy (Eysenck 1967, 
Jensen 1987) and diabetic (Langan et al 1991, Deary 1992, Deary et al 1992) subjects. 
Decision time variables have proved sensitive to the cognitive effects of organic 
disease in diabetic patients with repeated severe hypoglycaemia (Langan et al 1991). 
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Hick RT tests were conducted on apparatus consisting of a Jensen-type reaction box 
(Figure 4.2) interfaced with a BBC computer. The reaction box (Electronic 
Developments Ltd, Hampton, Middlesex) contains 8 yellow stimulus/response 
buttons in a semi-circular array around a central blue `home' button. 
Stimulus/response buttons can be covered by shields, to allow RT testing under 
different conditions of stimulus choice. Initial depression of the blue `home' button 
activates the lighting of a single yellow stimulus/response button after an unpredictable 
interval. Subjects are instructed to react by pressing the yellow stimulus/response 
button as quickly as possible' after it lights. Software (Mike Holmes, University of 
Edinburgh) allows a variable number of RT responses to be recorded under varying 
choice conditions and discriminates decision time (the time from stimulus onset to 
lifting of the `home' button) from movement time (the time from lifting of `home' 
button to pressing of the stimulus/response button). Decision times are typically 
longer than movement times. 
Subjects were given a total of 80 RT trials, with 20 tests at each of 1-, 2-, 4- and 8-light 
choice conditions, the session lasting about 20 minutes. RT tests were administered in 
batches of 10, first in ascending order and then in descending order of choice 
complexity, in order to prevent within-session learning effects being confounded with 
response uncertainty. Inter-stimulus interval varied between 150 and 250 ms from re- 
depression of the ̀ home' button. The mean, median and standard deviation of decision 
and movement times were determined for each choice condition, and the slope of the 
regression of decision time against response uncertainty condition was calculated to 
estimate the rate of gain of information. 
EPIC IV driving simulator (HJ Wildgus was administered using a BBC computer 
equipped with a set of pedals and a steering apparatus. The simulator was developed 
as a divided attention task requiring both steering skills (tracking a randomly moving 
triangle at the top of the screen) and reaction to stimuli (responding to traffic lights 
changing colour at a junction). The test was administered as five 3-minute runs after 
several practises to establish a performance plateau. It could not be said to simulate 
true driving conditions, as the task was neither as complex nor as boring as real 
driving, but elements of vigilance skills and mental flexibility were called into play in 
its performance. The scores obtained from the test were accuracy in steering tracking 
(with a low score indicating more accurate tracking), average response-time in braking 
(a low score indicating better performance) and the number of missed reactions to 
traffic light changes. 
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SteerClear (Finft et al 1989a) 
SteerClear (Healthdyne, Brussels) is a monotonous, 30-minute, computer- 
administered vigilance task which assesses attention and reaction speed. Subjects view 
a schematic representation of a two-lane road with a car travelling up the computer 
screen. When obstacles in the form of cows appear in the car's lane, the subject must 
switch lanes by pressing the spacebar to avoid a collision. Over a thousand cows are 
presented, but none during three 2-minute periods in the task, when subjects may be 
lulled into a state of unreadiness for the resumption of cows' appearances. The score 
obtained is the number of cows hit, i. e. an error score. Previous research has found 
that SteerClear performance is impaired in SAHS patients compared to normals, and 
is improved on retesting after CPAP (Findley et al 1986). 
Borkowski verbal fluency test (Borkowski et al 1967) 
This test of verbal fluency and putatively of frontal lobe function requires subjects to 
say as many words as possible beginning with a nominated letter within a minute. 
Subjects were asked to avoid using people's or place names, to avoid giving words 
with the same root (such as go and going) and to try not to repeat themselves. Three 
letters are nominated during the test. The letter triplets FAS, CFL and PRW were 
administered at the familiarisation session and first and second treatment assessments, 
respectively, to minimise learning effects in the experimental sessions. These latter 
two triplets have been validated as alternatives (Lezak 1983). The number of correctly 
produced words gives a measure of fluency, while perseverative word naming on the 
task, represented by repetitions and words with the same root, reflects frontal lobe 
damage (Lezak 1983). In a previous study, verbal fluency was compromised in 
SAHS patients compared to normals (Bedard et al 1991b). 
Auditory-verbal learning test (AVLT) (=k 1983) assesses memory and learning of 
a list of 15 common words. The subject is asked to repeat as many words as possible 
after each of five readings of the list by the experimenter. A second word list is then 
administered as a distracter before the subject is asked to recall the original word list 
for a sixth time without the benefit of its further repetition. Longer-term memory 
retention is tested by leaving a 45-minute gap before a final recall, again without the 
benefit of a further repetition of the list. The sum of words remembered from the first 
five administrations yields a measure of learning, while the delayed 45-minute recall 
tests memory retention. Because performance on the AVLT is improved by repeated 
testing using the same list, even after a4 week gap, a standardised and validated 
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alternative word list (Crawford et al 1989b) was used to reduce learning-related 
improvements in score at the second session. 
Benton visual retention test (revised) (BVRT: Benton 1974) 
The BVRT is a test of immediate memory and putatively of organic brain damage 
which requires subjects to reproduce designs involving geometric figures using paper 
and pencil Each of 10 designs are presented for 10 seconds, then hidden. Immediately 
after each design presentation, the subject is required to `draw what they saw'. Strict 
scoring rules classify errors of commission and omission in design reproduction. 
Subjects gain a score for the number of designs correctly reproduced and for their total 
number of errors. Three alternative versions of the designs are available, two (C and E 
versions) more similar than the third (Benton 1974). The D version was employed in 
the familiarisation session, and C and E in the first and second treatment assessments, 
respectively. 
4.3.2 Well-being scales 
The tests used to assess well-being may be subdivided into those examining 
psychological distress (HAD scale, GHQ-28), quality-of-life (NHP part 2, SF-36), 
mood (UMACL), sleepiness (Epworth scale) and symptoms (in-house 
questionnaire). 
Hospital anxiety and depression (HAD) scale (Zigmond and Snaith 1983) is a 14 
item, multiple choice, self-rated scale assessing the extent of anxiety and depressive 
symptoms, independent of somatic illness. Thus question items relating to somatic 
symptoms common to physical and psychiatric illness, such as headache or insomnia, 
are eliminated. The depression questions focus on symptoms related to the anhedonic 
state (e. g. `I can laugh and see the funny side of things'), while the anxiety questions 
probe the psychological symptoms of anxiety disorder (e. g. `I get a sort of frightened 
feeling as if something awful is about to happen'). The subject is asked to choose 
from four answers representing the frequency of the feeling or the intensity of the 
concordance with the statement, scored form 0 (for no symptom) to 3 (high level of 
symptom). Its use as a screening instrument for non-psychotic psychiatric illness has 
been validated in out-patient samples (Zigmond and Snaith 1983, Moorey et al 1991, 
Janson et al 1994a). A score on either subscale of 11 or more is considered indicative 
of significant mood disorder (Zigmond and Snaith 1983, Moorey et al 1991), and this 
threshold was used to identify `cases' of anxiety and depression before and after 
treatment 
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General health questionnaire-28 (GHQ-28: Goldberg and Hillier 1979) 
The 28-item GHQ is a widely used multiple-choice, self-rated questionnaire assessing 
non-psychotic distress. Patients are asked to rate their concordance with statements on 
health and well-being on a 4-point Likert scale, with responses scored 0-0-1-1. Factor 
analyses of responses from an out-patient setting indicate that the instrument contains 
4 components relating to somatic symptoms, anxiety, social dysfunction and severe 
depressive symptoms (Goldberg and Hillier 1979). Sample questionnaire items 
include `been feeling run down and out of sorts' (somatic symptoms), `been edgy and 
bad-tempered' (anxiety), `been satisfied with the way you have carried out your task' 
(social dysfunction) and `felt that life isn't worth living' (severe depression). The 
scoring method allows the total GHQ-28 score (the sum of all 28 responses) to be 
used to screen for minor psychiatric morbidity, with a threshold at 5 or more points 
used to identify `cases'. 
Nottingham health f part 2 (NHP Part 2: Hunt et al 1980.1984) 
Quality of life was measured using the 20-item second part of the NHP, a scale 
developed to measure the impact of health problems on daily living. Patients are asked 
to state whether questions concerning the functional areas of paid work, housework, 
social life, family relationships, sex life and interests and hobbies are true or false. 
Items include `I have difficulty in concentrating at work', `I am talking less at home' 
and `I find it difficult to get sexually aroused'. The NHP Part 2 has been shown 
responsive to treatment-induced change in a previous study of surgical hip 
replacement (Wiklund and Romanus 1991). This scale was selected for its brevity and 
for its avoidance of items on sleep quality, which might have merely documented 
symptoms of SAHS. It includes a subscale on sex life, which was considered useful 
given the high incidence of sexual dysfunction in SAHS (Guilleminault et al 1978, 
Whyte et al 1989). The total number of positive item responses formed the NHP part 
2 score. 
! JWIST mood adjective checklist (UMACL" Matthews et al 1990) 
Transient mood state was rated using the UMACL, consisting of 24 adjectives 
describing internal states, each with a 4-point scale. Subjects were asked to use the 4- 
point scale to rate how closely each adjective described their current mood. Factor 
analyses of mood items reveal a three-factor structure, with dimensions of energetic 
arousal, tense arousal and hedonic tone reflecting major mood states ('Thayer 1989, 
Matthews et al 1990, Matthews 1992). The 24 adjectives of the UMACL were 
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selected for their high and specific loadings on the three mood dimensions and 
including ̀ alert' and ̀ sluggish' (energetic arousal), ̀ jittery' and ̀ relaxed' (tense 
arousal), and ̀ cheerful' and ̀ depressed' (hedonic tone). The energetic arousal factor is 
thought to relate to reticular activation, and thus may offer a useful index of 
physiological activity (Thayer 1989). The energetic arousal subscale score is well- 
correlated with cognitive performance and is reduced in sleep deprivation (Matthews et 
al 1990, Matthews 1992), malting it particularly relevant to the study of SAHS. 
Epworth sleepiness scale (Johns 1991,1992.1993.1994). 
This self-completed subjective sleepiness questionnaire asks subjects to rate their 
likelihood of dozing on a4 point scale in each of 8 situations (e. g. sitting and reading, 
in a car while stopped for a few minutes in traffic, etc. ) `in the recent past'. Whereas 
state assessments of sleepiness such as the Stanford sleepiness scale (Hoddes et al 
1973) rely on subjects' recognition of internal feelings associated with impending 
sleep, the trait-oriented Epworth scale, by assessing remembered behaviours, may 
represent a more robust measure of sleepiness (Johns 1991). Its internal consistency 
and test-retest reliability have been investigated in normals, students and sleep disorder 
patients (Johns 1991,1992). Epworth scores in small samples of untreated SAHS 
patients correlate significantly with AHI (Johns 1991,1993) and with MSLT scores 
(Johns 1991) and are significantly reduced by CPAP (Johns 1992). 
Symptoms were assessed using an in-house questionnaire on which patients rated the 
presence or absence of symptoms comprising snoring, choking in sleep, morning 
headaches, morning confusion, wakening during the night, daytime napping, evening 
napping, and sleepiness whilst driving. 
4.4 CPAP compliance 
4.4.1 Runtime 
The average time in hours per night that CPAP units were switched on over the study 
period was termed the CPAP `runtime'. The method of measurement of this variable 
differed in the pilot parallel-group and the principal crossover studies. 
SleepEasy II and III CPAP units (Respironics Inc) issued for home use in the pilot 
parallel-group study were equipped at manufacture with external meters logging the 
total number of hours that units were switched on. These runtime timeclocks were 
read at issue and again at the end of the study period. The difference between 
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timeclock readings was divided by duration of CPAP treatment to provide an average 
CPAP runtime in hours per night. 
The Sullivan APD-1 CPAP units (Rescare, Abingdon) used in the crossover study 
were not equipped with timeclocks at purchase, and were modified in-house to 
facilitate compliance monitoring. The compliance monitoring system was largely 
hidden within the CPAP unit casing, allowing more discreet assessment of 
compliance. Runtime measurement in the crossover study was accomplished with a 
small hour meter (RS part no. RS260-072), glued to the interior of the screwed-down 
unit casing. This timeclock was connected directly to the on-off power switch of 
CPAP units so that the switch's 240V signal triggered logging of time that the unit 
was switched on (see Figure 4.3). As in the parallel-group study, the runtime 
timeclock was read at the time the CPAP unit was issued and again on return at the 
end of the CPAP treatment period, so that average runtime could be calculated for the 
CPAP treatment duration. 
4.4.2 Masktime 
Patients' average effective use of CPAP was termed `masktime'. Masktime reflects 
the time that the CPAP mask is properly applied to the face, rather than the time that 
the blower unit is switched on and was used in addition to runtime in the crossover 
study as a measure of CPAP compliance, The mechanical method of detecting 
effective CPAP delivery was developed by Reeves-Hocke et al (1992,1994) and 
adapted for use in the modified APD-1 units issued in the crossover study. 
A second hour meter (RS part no. RS260-072) glued inside the APD-1 unit casing 
monitored masktime. The masktime timeclock was triggered by a pressure-sensitive 
switch (Europart no 48-BN-02), also hidden inside the unit casing, which detected 
whether pressure at the mask was within approximately 2 cmH2O of that prescribed. 
Mask pressure detection was accomplished with blue narrow-bore tubing which ran 
inside the CPAP hose from the nasal mask to the pressure switch (see Figure 4.4). 
The pressure switch operated on the principle of hysteresis, so that the pressure 
required to activate the switch was greater than that required to switch it off. This 
meant that the switch was not de-activated during each inspiration, when pressure 
within the mask falls by around 2 cmH2O. 
The thresholds of the switches could be adjusted so that, if the mask was removed 
from the face, pressure loss would de-activate the switches. Testing of pressure 
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Figure 4.3: Interior of modified CPAP unit 
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Figure 4.4: CPAP apparatus 
85 
" -- 
Chapter 4: Methods of measurement 
thresholds for the monitoring system was conducted in modified CPAP units set 
across the operating range from 5 to 20 cmH2O. CPAP units were switched on and 
left to run for at least 3 hours under two conditions: firstly, with the mask lying loose 
on a counter and secondly, with the mask firmly taped to a counter to simulate the 
obscuring of the mask by the face. Readings of both runtime and masktime 
timeclocks were taken before and after the running of CPAP machines under each 
condition. Separately adjusted pressure switches were found to be required for CPAP 
units set to deliver 5 cmH2O and those set at higher pressures, as low-set pressure 
switches in high-pressure CPAP units continued to activate the masktime timeclock 
when unobscured, because pressure at the mask exceeded 5 cmH2O. Trials were re- 
run to evaluate the precision of both timecounters in separately modified CPAP units 
set at 5 cmH2O and higher pressures, and both types were found to log CPAP 
masktime accurately. 
In the crossover study, each unit was unscrewed to be serviced, sterilised and 
pressure-set before being issued, allowing the runtime and masktime timeclocks to be 
inspected and shown to be in working order. 
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Chapter 5: 
PARALLEL-GROUP CONTROLLED STUDY OF DAYTIME FUNCTION 
AFTER CPAP THERAPY: A PILOT STUDY 
The literature review presented in Chapter 3 detailed the few, and often preliminary, 
studies of daytime function after CPAP treatment which were available at the inception 
of this project The existing studies using objective daytime sleepiness tests (Wittig et 
al 1986, Walsleben et at 1989, Lamphere et at 1989, Fry et at 1990, Gaddy and 
Doghramji 1991) yielded conflicting results on improvements in sleep onset latency 
after CPAP and lacked objective information on compliance with CPAP on any but 
those nights preceding the laboratory MSLT or MWT (Lamphere et at 1989, 
Walsieben et at 1989, Fry et at 1990). The effects of CPAP on cognitive function had 
been explored only through small-scale, uncontrolled studies (Bearpark et al 1987, 
Walsieben et al 1989). Finally, the selection of instruments to assess psychological 
well-being after CPAP were, in some published studies, controversial. Researchers 
had employed personality inventories, which index relatively stable traits, to assess 
changes in changeable psychological distress states (Mayleben et at 1990), or had used 
psychiatric screening instruments which incorporated somatic symptom items thus 
aggregating symptoms of SAHS and their impact on wellbeing (Millman et at 1989). 
The pilot study of daytime function after CPAP in SAHS patients described in this 
chapter was an attempt to improve on existing studies through two means. Firstly, the 
study design incorporated a conservatively-treated patient group, acting as a control for 
the repeated administration of cognitive, psychological wellbeing and objective 
daytime sleepiness tests. Secondly, the objective measurement of average CPAP 
compliance rates through the use of CPAP timeclocks allowed the relationship 
between CPAP usage and benefits in daytime function to be evaluated. 
5.1 Subjects and methods 
The study was prospective and employed a parallel-group design to compare the 
change in outcome measures of daytime function following at least 3 months of 
treatment with either CPAP or conservative therapy only. The conservative treatment 
regime acted as a control for the effects of learning in this longitudinal study and 
consisted of advice on weight loss and the avoidance of evening alcohol. Similar 
advice was given to CPAP-receiving patients. 
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Patients were recruited from referrals to an out-patient Respiratory Sleep Clinic, who 
subsequently underwent a clinical sleep study, conducted according to the method 
described in Chapter 4, to confirm the diagnosis of SAHS (Gould et al 1988). All 
patients recruited into the study had 15 or more apnoeas+hypopnoeas per hour of 
sleep and at least two symptoms of SAHS from a list including snoring, excessive 
daytime sleepiness, nocturnal choking, unrefreshing sleep, ankle oedema and 
polycythaemia (Whyte et al 1989). 
Six of the 43 patients who underwent baseline assessment were lost to post-treatment 
follow-up. One patient died suddenly soon after starting CPAP therapy, while a 
further 5 patients were unavailable for follow-up due to residence abroad, or family 
and work commitments. Twenty-one patients were followed up after CPAP treatment 
and 16 after conservative treatment. 
Allocation to treatment type was not randomised, but was based partially on patient 
preference. Half of the control group patients chose conservative treatment over 
CPAP, while the other half were directly assigned to conservative therapy. The clinical 
features of the patient groups before treatment was commenced are summarised 
below. The clinical features of the two groups were not significantly different on 
Student's unpaired t-testing (Table 5.1), but showed more severe mean values for all 
variables in the CPAP group. 








Mean ± SEM -value 
Age (years) 53±3 53±3 1.00 
Body mass index (k Im) 34 ±2 32 ±2 0.31 
A noeas+h noeasl hr slept 57 ±6 49 ±6 0.38 
Microarousalsl hr slept 54 ±5 45 ±6 0.26 
Minimum02 saturation (96) 61± 5 69± 4 0.27 
The CPAP-receiving group underwent a second night of polysomnography in the 
laboratory with CPAP to titrate the required pressure to minimise both respiratory 
abnormalities and arousals from sleep. Patients in the CPAP treatment group were 
educated in the use of CPAP, advised that all-night use was necessary to improve 
sleep quality and health, and were issued with SleepEasy II or SleepEasy III 
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(Respironics Inc) units for home use after the pre-treatment assessment of daytime 
function. 
5.1.1 Assessments 
Repeated testing was performed in both treatment groups, first before the 
commencement of treatment and then on a second occasion at least 3 months after 
treatment started, in order to allow time for the effects of CPAP or weight loss to 
become apparent. Although the latency of benefit from CPAP is not well-defined, 
patients' own reports suggest that subjective improvements in function occur after as 
little as a single night's CPAP use (Whyte et al 1989), an observation supported by 
improvements of objective daytime sleepiness after 2 nights of CPAP (Lamphere et al 
1989). 
At each time of testing, patients underwent a multiple sleep latency test (MSLT) in 
order to assess objective daytime sleepiness (Carskadon et al 1986) and, on a non- 
consecutive day, a comprehensive 3-hour psychometric battery, detailed in Table 5.2. 
The neuropsychological tests used are described in detail in Chapter 4. These tests 
were administered according to a standardised schedule to control for circadian effects 
on cognitive performance and well-being. The battery was assembled to test general 
level of intellectual ability (Wechsler adult intelligence scale [WAIS] subtests, 
TmilMaking tasks), intellectual deficit (IQ decrement), memory (auditory verbal 
learning test [AVLT)) and information processing speed (Inspection time [IT] test), 
and included task-specific tests of concentration ability (paced auditory serial addition 
test [PASATI), vigilance (simple reaction time [RT]) and driving-based skills (Epic 
IV driving simulator) which might be relevant to sleep-loss induced deficit. The 
impact of illness on psychological well-being was assessed using the hospital anxiety 
and depression (HAD) scale. 
Because of the considerable time input from patients required by the study, only 20 
CPAP-receiving patients and 9 conservatively-treated patients attended for a second 
multiple sleep latency test, although all had repeated psychometric testing. Breakdown 
of computer equipment resulted in the loss of full datasets for IT test and simple RT. 
Paired IT datasets were available for 15 CPAP patients and 14 conservative patients, 
and for simple RT in 13 conservative patients. The late addition of the EPIC IV 
driving equipment meant that full data were only available for 12 CPAP patients and 7 
controls. 
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Table 5.2: Parallel-study psychometric battery 
Psychometric Battery 
" Tests of general cognitive 
function and memory 
" Pre-morbid level of 
cognitive function 





Digit Symbol Substitution 
TrailMaking Tasks A and B 
Auditory-Verbal Learning Test (AVLT) 
National Adult Reading Test (NART) 
Inspection time (IT) test 
Simple unprepared reaction time (RT) 
Concentration and attention Paced Auditory Serial Addition Test 
(PASAT: 2 and 4 sec presentation rates) 
Epic IV Driving Simulator 
" Psychological wellbeing Hospital Anxiety and Depression (HAD) 
Scale 
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All daytime testing sessions were performed after patients had slept in their own bed, 
so that poor sleep quality resulting from polysomnography did not independently 
affect daytime function measures. Patients were asked to avoid caffeine-containing 
beverages on the days of testing and were offered only non-caffeinated beverages 
during the day. 
Compliance with CPAP therapy was objectively monitored with an external timeclock 
which logged time that units were switched on (see Chapter 4). These runtime 
timeclocks were read on issue of CPAP units and at follow-up assessments, in order 
to calculate an average nightly CPAP runtime for each patient 
The baseline assessments of daytime function of 5 of the CPAP-treated patients and 7 
of the conservatively-treated patients were performed by a colleague, as part of a 
previous study (Cheshire et al 1992). However, standardisation of instruction and 
scoring on psychometric tests, as well as the inclusion of the colleagues' baseline 
assessments in both treatment groups, minimised any problems with inter-rater 
differences in the study. 
5.1.2 Statistics 
Daytime function outcome variables were analysed using the BMDP package (Dixon 
1988). Students unpaired t-tests were employed to compare differences between the 
treatment groups at baseline. Two-way analysis of variance (A NOVA) was used to 
assess the effects of treatment, with treatment as a between subjects factor with two 
levels (CPAP or conservative therapy) and time as a repeated measure (baseline and 
follow-up). Mann-Whitney tests were used to assess changes from baseline for non- 
normally distributed variables (number of inspection time trials, number of missed 
driving-test responses, and both anxiety and depression scores). Chi-square tests were 
used to examine the distribution of HAD scale ̀cases' between groups. 
5.2 Results 
5.2.1 Timing of follow-up 
The CPAP group underwent their second assessment an average 3.3 months after the 
start of treatment (range 2.6-4.5 months) while the control group's second assessment 
occurred on average 9.5 months after treatment commenced (range 2.9-16.8 months). 
This difference in the timing of the second assessment was significant on unpaired t- 
testing (p<0.01). The longer treatment duration in the control group was due to the late 
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recruitment of previously tested, conservatively treated patients from a previous study 
(Cheshire et al 1992). 
5.2.2 Weight changes during treatment 
Both treatment groups showed non-significant rises in BMI at follow-up, which were 
not significantly different between the two groups (CPAP group's mean change +0.4 
± SEM 0.2, conservative group +0.6 ± 0.5 kg/m2; p=0.08). In the CPAP-receiving 
group, 12 patients at baseline and 13 patients at follow-up were obese (BMI >30 
kg/m2: Bray 1979). Of the conservatively-treated patients, 9 at baseline and 10 at 
follow-up were obese. Only one patient in each group was not overweight (BMI >25 
kg/m2: Bray 1979) at follow-up. 
5.2.3 Comparison between daytime function tests of treatment groups at 
baseline 
The scores on the cognitive and distress-related tests were not significantly different in 
the two treatment groups at their first testing (Table 5.3). However the mean sleep 
latency on the MSLT was significantly longer in the control group (p=0.01), who had 
a mean sleep onset latency of 5.7 minutes compared to the CPAP group's mean sleep 
onset latency of 3.4 minutes. 
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Table 5.3: Daytime function of treabnent groups at baseline 
CPAP 
group 
Mean ± SEM 
Conservative 
group 
Mean ± SEM p-value 
Mean sleep onset latency (mins) 3.4 ± 0.5 5.7 ± 0.8 0.01** 
Minimum sleep onset latency (mins) 1.3 ± 0.3 2.1±0.5 0.16 
WAIS information 17.5 ± 1.0 18.6 ± 1.1 0.49 
WAIS arithmetic 13.9 ± 0.7 12.8 ± 0.8 0.31 
WAIS block design 33.5±1.5 29.9±1.5 0.11 
WAIS digit symbol 43.9 ± 2.2 46.4 ± 3.7 0.55 
Verbal IQ 114.9 ± 3.0 113.4 ± 3.6 0.75 
Performance IQ 108.3 ± 2.6 106.8 ± 3.7 0.74 
Full IQ 113.0 ± 2.5 111.3 ± 3.5 0.68 
Pre-morbid rformance IQ 109.5 ± 1.2 108.9 ± 1.2 0.74 
IQ decrement 1.2 ± 2.2 2.1 ± 3.2 0.82 
TrailMaking A (secs) 32.6 ± 2.6 35.6± 2.6 0.42 
TrailMaking B (secs) 87.3 ± 8.3 102.5 ± 10.5 0.26 
AVLT short-term recall 45.5 ±1.7 50.0 ± 2.0 0.12 
AVLTdelayed recall 10.0 ± 0.5 10.4±0.7 0.43 
Inspection Time Duration (msecs) 106.3 ± 10.5 81.9 ± 10.1 0.10 
Inspection Time Trialst 150 ± 12 185 ± 26 0.56 
Sim le RT (msecs) 310 ± 15 291 ± 20 0.45 
PASAT 4sec presentation 48.4 ± 2.1 51.4 ± 2.2 0.33 
-PA-SAT 2sec presentation 30.0 ± 1.6 33.1 ± 2.7 0.18 
Driving accuracy 40.2 ± 5.0 36.6 ± 5.7 0.65 
Driving response-time 61.0 ± 3.3 52.8 ± 3.2 0.11 
Driving missed responsest 1.4 ± 0.3 1.110.4 0.60 
_ Cognitive Z-score -0.8± 1.8 1.5 ± 1.9 0.40 
HAD anxiety scoret 7.0 ± 1.1 6.5 ± 0.8 0.83 
HAD depression scoret 6.0 ± 1.0 4.5 ± 0.9 0.30 
HAD anxiety ̀cases! n=5 n=2 0.66 
HAD depression ̀ cases'l n=5 n=0 0.11 
t Mann-Whitney test 
I Chi-square test 
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5.2.4 Within-group changes in daytime function scores from first to second 
assessment 
The paired data showing baseline and follow-up scores within each of the two 
treatment groups is shown in Table 5.4. 
The CPAP-receiving group showed a significant increase in both mean (p=0.01) and 
minimum (p=0.02) sleep onset latency measured during the follow-up MSLT, 
indicating a lessening of daytime sleepiness. This group also showed improvements 
on second testing in performance on the information (p<0.001) and digit symbol 
substitution (p<0.001) subtests, and in calculated full-scale IQ (p=0.05). Follow-up 
scores was also significantly improved for both administered speeds of the PASAT 
(p50.01) and for accuracy in the driving task (p=0.03). All mean values for cognitive 
performance and well-being were improved on retesting after CPAP, except for the 
arithmetic subtest and inspection time trials. 
The conservatively-treated group had no increase in sleep onset latency following 
treatment, and in contrast to the CPAP-receiving subjects, showed a non-significant 
decrease in mean and minimum sleep onset latency. However, this group 
demonstrated a similar improvement in cognitive performance with retesting to that 
seen in the CPAP group. The conservatively treated patients demonstrated significant 
increases in information subtest score (p=0.05) and in calculated scores for verbal 
(p=0.04), performance (pß. 02) and full-scale IQ (p<0.01). Performance on 
TrailMaldng B (p<0.01) and on the 2-second presentation rate PASAT improved on 
retesting (p=0.01). All mean cognitive scores, except those for IT duration and simple 
RT, had improved on second testing. However, in contrast to the CPAP group, the 
conservatively treated patients had mean HAD scale scores reflecting non-significantly 
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5.2.5 Comparison of change in daytime function scores between the two 
treatment groups 
The comparison between the two treatment groups' changes in scores are shown in 
the last column of Table 5.4. 
Mean sleep onset latency from the MSLT was significantly more improved in the 
CPAP-treated group than in the control group (Figure 5.1). The CPAP group's mean 
sleep onset latency increased by 2.1 ± 0.8 minutes at the second testing, while the 
conservative-therapy group showed a decrease in mean sleep onset latency of 1.2 t 
1.0 minutes (F=6.22, pß. 02). The minimum sleep onset latency from the five nap 
opportunities showed a trend (F=3.96, p=0.06) towards greater improvement after 
CPAP: the CPAP group's minimum sleep latency increased by 1.3 minutes on 












Figure 5.1: Change in mean sleep onset latency in CPAP and conservative patients 
No significant differences were found between changes in cognitive performance in 
the two groups (F<1.39, p>0.2). 
The change in raw depression scores between the two groups showed a trend for 
better improvement in CPAP-receiving subjects than in the conservatively treated 
group (pß. 07). The frequency of depression ̀cases' was better improved in the 
CPAP-treated group than in the controls (p-0.03), with one depression ̀case' 
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resolving in the CPAP-receiving group while 2 `cases' developed in the 
conservatively-treated group. 
5.2.6 CPAP compliance 
The average CPAP usage for the whole group was 5.9 ± SEM 1.4 hours per night, 
although a wide range of compliance rates was observed (0.3-16.8 hours/night). The 







Figure 5.2: CPAP compliance in the CPAP-treated SAHS patients 
Good CPAP Compliers 
To further investigate the relationship between change in daytime function and CPAP 
compliance, the CPAP group was divided post-hoc into those who complied well with 
treatment by using their units for an average 4.5 hours per night or more (n=14), and 
those who were less assiduous. A further statistical comparison of the change in 
daytime function in these good CPAP compliers to the change in the control group 
yielded findings similar to those obtained when comparing all CPAP users to controls. 
Objective daytime sleepiness was better improved in good CPAP users than in 
controls, with mean sleep onset latency rising by 2.1 ± 0.9 minutes in good CPAP 
compliers, but falling by 1.2 ± 1.0 minutes on retesting of the conservatively-treated 
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Chapter 5: Parallel-group pilot study 
Good CPAP compliers showed a significantly better improvement in raw depression 
score on the HAD scale than controls (CPAP, -1.5 ± 0.9, conservative +1.2 ± 1.0; 
p=0.05) (Figure 5.3). The difference in changes in depression `cases' remained 















Figure 5.3: Change in HAD scale depression score in good CPAP compliers and 
conservative patients 
5.3 Discussion 
The results of the parallel-group pilot study supported the proposition that CPAP 
improves objective daytime sleepiness and psychological wellbeing, but provided no 
evidence of improved cognitive performance after CPAP. 
The positive improvements in objective daytime sleepiness within the CPAP-receiving 
group and, when the two treatment groups were compared, daytime sleepiness and 
psychological wellbeing, are evidence to support the effectiveness of CPAP treatment. 
The lack of weight loss among either treatment group suggested that conservative 
therapy is an unreliable treatment. 
The MSLT results of this study, showing an increase in sleep onset latency following 
CPAP, corroborated other authors' findings of improved daytime sleepiness after 
CPAP (Wittig et al 1986, Lamphere et al 1989, Walsleben et al 1989, Fry et al 1990, 
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Gaddy and Doghramji 1991). The scale of improvement in the CPAP-treated sample 
was less dramatic than that reported by Lamphere et al (1989) and Wittig et al (1986), 
and bore a closer resemblance to that reported by Fry et al (1990) and Gaddy and 
Doghramji (1991), who both showed a statistically significant lengthening of sleep 
onset latency, remaining below the "normal" range, after CPAP. Ihre findings of 
improved, but not normalised, sleepiness after CPAP may have in part been due to 
our modification of sleep onset scoring criteria, which has subsequently been 
independently adopted and recommended by the American Sleep Disorders 
Association (ASDA: lborpy 1992). But other recent studies published after this 
study's completion have shown similar results, with sleep onset latencies rising 
following CPAP, but remaining below the normal range (Bedard et al 1993, Kribbs et 
al 1993b). 
The parallel-group pilot study confirmed the results of Derderian et al (1988), which 
showed significant improvements in self-rated depression after 2 months of CPAP. 
Derderian's depression inventory had a high concentration of somatic-symptom 
items, raising the possibility that subjective improvement in symptoms of SAHS, 
rather than mood disorder, was being measured. The pilot study avoided this by using 
a screening instrument specifically designed for use in somatic illness, the HAD scale. 
The proportion of patients reporting clinically significant depressive symptoms was 
better improved by CPAP than by conservative treatment, and raw depression score 
was significantly lessened in the better CPAP compliers compared to `controls'. 
However, the parallel-group pilot study provided no evidence for improved cognitive 
performance after CPAP. This null finding on changed cognitive performance after 
CPAP was compatible with that of the uncontrolled study of Walsleben et al (1989), 
who also found no change in 7 patients retested after 2 nights on CPAP therapy. 
However, in this study one or both of the factors of short CPAP treatment and small 
patient sample (n=7) might have contributed to the lack of apparently improved 
cognitive performance. 
The null findings on cognitive performance after CPAP were contrary to patients' 
reports, raising the possibility that it was a Type 2, or `false negative', statistical error 
(Bryman and Cramer 1990). This might be influenced by features of the study design, 
which introduced concern of sampling bias. The two treatment groups were not 
explicitly matched for any background variable. Treatment allocation was not 
randomised, nor were groups matched for social class or education in this pilot study. 
100 
Chapter 5: Parallel-group pilot study 
An impression of worse clinical status in the CPAP-treated group at baseline is gained 
by examining the mean polysomnography values in Table 5.1, although these were 
not statistically different in the two treatment groups. This perception is supported by 
the significantly greater objective daytime sleepiness and non-significantly lower mean 
cognitive z-score of the CPAP group when tested before treatment (Table 5.3). Such 
observations may imply that the treatment groups were not ideally matched, allowing 
the potential for sampling differences to obscure treatment effects. These selection 
factors might influence the magnitude of learning effects in the two treatment groups 
and contribute to uncertainties in interpretation of results. 
A related contributant to a Type 2 error might have been the extensive learning effects 
on repeated testing. The conservative group showed wide-ranging improvement in 
cognitive score, despite a lack of weight loss. This observation demonstrates the 
pervasiveness of learning effects, which occurred even in those tests whose specific 
detailed format could not feasibly be remembered (for example the PASAI), 
illustrating the importance of familiarity as well as memory in promoting better 
performance on repeated testing. The observation of learning effects on repeated 
testing in the parallel-group trial compromised the reliability of previous and 
subsequent reports of improved cognitive function after CPAP from uncontrolled, 
longitudinal studies (Bearpark et al 1987, B6dard et a! 1993). 
The coexistence of these two potential methodological flaws could together have a 
deleterious effect on the study's sensitivity to cognitive change. Differences in learning 
curve in the two non-randomised treatment groups could potentially obscure subtle 
treatment related change in cognitive performance. 
Another concern presented by the lack of between-group difference in cognitive 
improvement was that some tests selected for the psychometric battery might be 
insufficiently sensitive or relevant to the specific deficits of SAHS. In contrast to 
others, findings in case-control studies (Bedard et al 1993, Greenberg et al 1987), 
baseline IQ decrement score in the parallel-group pilot study was only marginal in 
both treatment groups (52 IQ points), perhaps indicating a role for monotonous, 
vigilance-type tasks such as those validated in sleep-deprivation experiments 
(Wilkinson et al 1966). 
Despite potential shortcomings, the parallel-group pilot study provided valuable 
information which guided the development of the subsequent larger project (Chapter 
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6). Experience with the pilot parallel-group trial aided the refinement, both in structure 
and of measures of the subsequent full-scale study of daytime function after CPAP 
treatment for SAHS. 
The parallel-group structure, and the lack of random isation, in the pilot trial allowed 
inter-individual variability in differing treatment groups to potentially obscure the 
subtle improvements predicted. Thus the subsequent fullscale study was designed as a 
randomised-entry, placebo-controlled crossover trial, where each patient acted as their 
own control, and where the effects of learning could be measured and controlled for 
by a balanced order of treatments. To attempt to reduce learning-related improvements 
in cognitive scores, a familiarisation session was built into the protocol. 
Experience in the parallel-group pilot study gave some indication of which types of 
daytime function measures might be useful in the later trial. The utility of objective 
daytime sleepiness tests and measures of psychological distress were verified in the 
parallel-group study, as these instruments appeared sensitive to the improvements in 
daytime function subjectively reported by patients. The test of objective sleepiness, the 
MSLT was retained in the revised daytime function battery. However, given the small 
magnitude of observed change in sleep onset latency, the MSLT was supplemented 
with recently developed subjective scales, in an effort to measure the subjective 
improvements in daytime sleepiness perceived by patients. The Epworth sleepiness 
scale asks patients to rate recent napping behaviour, while the energetic arousal 
subscale of the UWIST mood adjective checklist (UMACL) is thought to index 
physiological arousal (Thayer 1989). These scales might yield information on CPAP- 
related changes in trait and state sleepiness, respectively. The HAD scale of 
psychological distress was supplemented with the similar 28-item General Health 
Questionnaire (GHQ-28), and well-being measures were extended with the inclusion 
of the Nottingham Health Profile (NHP), part 2. This questionnaire sought to assess 
the impact of illness on quality-of-life, through investigating limitations in 
psychosocial functioning, and additionally contained a subscale on sexual function, 
which was considered particularly relevant to the study of SAHS. Two subscales from 
the UMACL, hedonic tone and tense arousal, would also provide information on 
mood state. 
The selection of cognitive tests for the subsequent study was more difficult Tests 
which showed no significant within-group improvement in the CPAP group were 
removed from the battery, on the basis that these could not be sensitive to CPAP- 
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related improvement in intellectual function. The classical simple, unprepared RT test 
used in the pilot-study showed no improvement with CPAP, despite others' findings 
in uncontrolled studies, emerging over the course of this project, that RT might be 
improved with CPAP (Oveson et al 1992, Bedard et al 1993, Kribbs et al 1993b). The 
parallel-group pilot study's findings of unchanged RT found agreement in another 
(Partlett et al 1994), which showed no significant improvement after CPAP. Because 
of the lack of significant improvement in the simple RT task, it was replaced by RT 
tests administered under the Hick paradigm in the full-scale study, in order to gain 
extra information on information-processing ability. Information processing was also 
assessed by the addition of the rapid visual information processing (RVIP) test, based 
on signal processing theory. The verbally-based AVLT memory task was replaced 
with a visual memory test, the Benton visual retention test (BVRT), which has been 
used in other organic syndromes. The EPIC IV driving simulator, which also showed 
no within-group improvement in the CPAP treated group, was considered stimulating 
to perform and, being a divided attention task, allowed a ̀ trade-off between 
performance on tracking accuracy and braking response-time, which might reduce 
sensitivity in either one measure. It was replaced with the long and monotonous 
SteerClear vigilance task, which yields a single outcome score. Because of evidence 
linking reduced verbal fluency and hypoxaemia (Nelson 1982), the Borkowski test of 
verbal fluency was added to the psychometric battery. With these modifications, it was 
hoped, the effects of CPAP on cognitive function could be better resolved. 
The usefulness of objective CPAP timeclock readings in the parallel-group pilot study 
was corroborated by the fact that better improvement in raw depression score was 
determined by better CPAP compliance. However, the standard manufacturer- 
supplied timeclock logged only time that units were switched on, not time that the 
CPAP mask was worn. The unusually high average use times of three of the subjects 
(Figure 5.2), exceeding the accepted normal time in bed by some hours, hints that 
some patients were leaving their CPAP units switched on when not in use. The 
`masktime' method for monitoring average CPAP effective use (Chapter 4) was 
subsequently implemented. With this and the other amendments discussed above, the 
full-scale crossover study of daytime function was commenced. 
103 
Chapter 6: Randomised crossover study 
Chapter 6: 
RANDOMISED, PLACEBO-CONTROLLED CROSSOVER STUDY OF 
DAYTIME FUNCTION ON CPAP THERAPY 
Continuous positive airway pressure (CPAP) is the treatment of choice for the sleep 
apnoea/hypopnoca syndrome (SAHS), and is frequently prescribed to ameliorate the 
daytime impairments of the syndrome, in which excessive daytime sleepiness 
(Dement et al 1978, Roth et al 1980), increased road traffic accidents (George et al 
1987, Findley et al 1988), deficits in cognitive performance (Greenberg et a! 1987, 
Bedard et al 1993, Cheshire et al 1992) and dysphoric mood (Reynolds et a! 1984, 
Derderian et al 1988) feature prominently. However, few controlled trials exist to 
show objective improvements in daytime function after CPAP therapy, particularly in 
the domain of cognitive performance, where learning effects during repeated testing 
(see previous chapter) produce particular methodological problems. A protocol was 
adopted which would minimise and control for learning effects, inter-individual 
variability and expectation of benefit. 
6.1 Study protocol 
The study was constructed as a prospective placebo-controlled randomised crossover 
trial of daytime function (Hills and Arm itage 1979). Patients spent 4 weeks on CPAP 
therapy (Sullivan APD-1 units, ResCare, Abingdon, UK), which patients were asked 
to use all night, and 4 weeks on oral placebo (Ranitidine 300 mg homologue, Glaxo, 
Greenford, UK) in a dose of two tablets at bedtime, with no intervening washout 
period between treatments. Study patients were informed of the mechanisms of action 
of CPAP therapy and were told that the placebo tablets might improve upper airway 
muscle function in sleep. The study was approved by the local medical ethics 
subcommittee. 
A treatment order schedule consisting of balanced blocks within each of 4 SAHS 
severity groups was prospectively filled by patient recruits. The severity groups were 
each formed of 16 patients, with AHI in the ranges 5-14.9 (group 1), 15-24.9 (group 
2), 25-39.9 (group 3) and > 49.9 (group 4) per hour slept, respectively. Eight patients 
commenced treatment with placebo and 8 with CPAP treatment in each group. The 
randomisation slots of patients withdrawing after treatment commencement were 
filled by the next available subject with appropriate severity criteria. 
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6.2 Patients 
Subjects were recruited from a consecutive series of outpatients referred for 
investigation of SAHS, who had at least 2 symptoms of SAHS (Whyte et al 1989). 
All patients in the consecutive series underwent a clinical sleep study conducted and 
scored by a standard procedure (Gould et al 1988) with monitoring of EEG, EOG, 
EMG, thoracic and abdominal respiratory effort, oronasal flow and oximetiy to 
establish a minimum apnoea+hypopnoea index (AHI) of 5 or more per hour slept. 
Consecutive patients with appropriate AHI, who had no coexisting neurological or 
sleep disorder causing excessive sleepiness and who lived within 50 miles of the 
laboratory were approached. Ninety patients were asked to take part in the study, of 
whom 68 accepted. Of the patients who did not participate, 7 could not afford the 
required time off work, 7 gave no reason, 2 did not want to use CPAP, 2 did not want 
to take tablets, 2 were intolerant of a nasal mask due to facial angio-oedema and 
claustrophobia respectively, and one each had transport or family problems. 
Subjects underwent a subsequent night of CPAP titration with polysomnography to 
establish the therapeutic CPAP pressure at which breathing irregularities and arousals 
from sleep were minimised. Subjects were instructed to use their CPAP units all night 
and every night and were specifically asked to use their CPAP units the nights before 
assessments. All patients were encouraged to report any problems with CPAP use 
immediately by telephone so that these could be effectively managed and CPAP 
compliance could be optimised. 
Four patients withdrew after treatment was commenced, one each for reasons of work 
pressure, suspected myocardial infarction, intolerance of CPAP unit noise and 
relocation. All patients withdrew whilst on the CPAP limb, two having previously 
completed the placebo limb. The relocating patient continues to use the study CPAP 
unit (personal communication, M King, Papworth Hospital). The assessment results 
were excluded from analysis. 
The full study group of 64 SAHS patients comprised 57 males and 7 females, who 
averaged 49 ± SEM 1 years of age, with a mean body mass index of 31 ±1 kg/m2. 
These patients demonstrated a mean AHI of 35 ±4 per hour slept on 
polysomnography, with an average 43 ±4 microarousals per hour slept (Cheshire et al 
1992), mean minimum oxygen saturation of 79 ± 2% and an average 4% desaturation 
rate of 17 ±3 per hour slept 
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6.3 Assessments 
The last day of each treatment limb was spent in the laboratory, when assessments of 
objective and subjective daytime sleepiness, symptoms, cognitive function and well- 
being were obtained (see Table 6.1). Each test and questionnaire was administered at 
the same time of day on each limb in order to avoid the influence of circadian factors 
on cognitive performance or mood. Questionnaires rating sleepiness, symptoms and 
well-being were administered in the early part of the day, when endogenous mood 
symptoms tend tobe most severe, while the cognitive tests were administered later in 
the day. Weight and height were measured at each assessment. At the final 
assessment, subjects were asked to rate which treatment they preferred. 
Objective daytime sleepiness was assessed with the multiple sleep latency test (MSLT: 
Carskadon et al 1986, Thorpy 1992), consisting of 5 20-minute daytime nap 
opportunities, during which the latency to the first 20-second period of 
electroencephalographic sleep is measured. The modified sleep onset criteria of a 
single 20-second epoch of any sleep stage, subsequently recommended by the 
American Sleep Disorders Association (ASDA: 'Ihorpy 1992), was employed. 
Subjective sleepiness was scored using the Epworth sleepiness scale (Johns 1991, 
1992,1993,1994), a questionnaire asking patients to rate their chance of dozing in 
each of 8 situations ̀in recent times', and the energetic arousal subscale of the 
UMACL, a self-rating of alertness state. 
An 8-item symptom questionnaire was formulated in-house, on which patients rated 
symptoms as present or absent at each assessment The selected items were com mon 
daytime and nocturnal symptoms reported by SAHS patients (Whyte et al 1989), and 
comprised snoring, choking, morning headaches, morning confusion, frequent 
wakenings during the night, daytime napping, evening napping and sleepiness whilst 
driving. 
The cognitive tests covered a broad range of function thought to be affected in SAHS 
(Findley et al 1986, Greenberg et al 1987, B6dard et al 1991a, Cheshire et al 1992), 
including general intellectual ability (block design and digit symbol subtests from the 
Wechsler adult intelligence scale-revised [WAIS-R] battery), information processing 
speed (Hick reaction time [RT], rapid visual information processing [RVIP] test, 
paced auditory serial addition test [PASAT]), vigilance (SteerClear), visuomotor 
tracking (TrailMaking), verbal fluency (Borkowski test) and memory (Benton visual 
retention test [BVRTI). The national adult reading test (NART), administered at the 
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Table 6.1: Crossover study daytime function assessments 
Symptoms 
" In-house questionnaire 
Sleepiness 
" Multiple sleep latency test (MSLT) 
" Epworth sleepiness scale 
Cognitive function 
" WAIS-R block design and digit symbol substitution subtests 
" TrailMaking 
" National adult reading test (NART) 
" Hick reaction time (Hick RT) 
" Rapid visual information processing (RVIP) test 
" Paced auditory serial addition test (PASAT) 
" SteerClear 
" Borkowski verbal fluency test 
" Benton visual retention test (revised: BVRT) 
Well-Being and Mood 
" Hospital anxiety and depression (HAD) scale 
" General health questionnaire-28 (GHQ-28) 
" Nottingham health profile (NHP) part 2 
" UWIST mood adjective checklist (UMACL) 
107 
Chapter 6: Randomised crossover study 
familiarisation session only, provided an estimate of pre-morbid level of intellectual 
function, while the WAIS-R subtests conducted on each treatment were scaled and 
prorated to provide a current performance IQ score of intellectual function. 
Performance IQ score on each treatment was subtracted from the NART estimate of 
pre-morbid IQ to yield an `IQ decrement score'. 
Well-being questionnaires were selected to evaluate the impact of illness in terms of 
psychological distress (hospital anxiety and depression [HAD] scale and general 
health questionnaire [GHQ-28]), quality-of-life, excluding perceived sleep function 
(Nottingham health profile [NHP] part 2), and the mood dimensions of energetic 
arousal, tense arousal and hedonic tone (UWIST mood adjective checklist 
[UMACL]). 
Only 51 patients were drivers, and thus able to complete the symptom questionnaire 
item on sleepiness whilst driving. Computer breakdowns reduced the number of 
complete data pairs for SteerClear to 61, and for the Hick RT task to 59. Two patients 
suffered from stammering, and thus did not perform the PASAT task requiring rapid 
verbal answers under conditions of stress. One patient did not have English as his first 
language, compromising the accuracy of the NART in predicting pre-morbid IQ. This 
patient also failed to complete TrailMaking B, stating that his native Polish alphabet 
contained a different letter order. The late addition of the Epworth sleepiness scale into 
the assessment battery meant that paired ratings both on CPAP and placebo were 
available for 31 patients only. One patient had no sexual partner and declined to 
complete the NHP items relating to sexual function. However, full data were obtained 
for all other measures. 
Before the start of the study, subjects attended for a 5-hour session of familiarisation 
with the psychometric battery, in order to introduce questionnaires and to minimise 
subsequent test retest improvements in cognitive test scores. At this session patients 
were educated in CPAP use and an accurate mask-fitting was performed. Subjects 
were asked to avoid caffeine-containing beverages before attending for assessments, 
and were offered decaffeinated beverages only during the assessment day. 
Compliance with CPAP therapy was monitored by reading timeclocks hidden within 
the unit casing which measured total duration that units were switched on ('runtime') 
and that CPAP was delivered effectively ('masktime': Reeves-Hochb eta! 1994). 
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6.4 Statistical analysis 
Effects of treatment were examined by comparing outcome measures from placebo 
and CPAP assessments. The distributions of non-dichotomous variables were 
examined and non-normal distributions noted. Floor effects were seen in minimum 
sleep onset latency and scores for TrailMaking B, misses on the RVIP task, Hick RT 
movement time, Borkowski verbal fluency perseveration, BVRT errors, UMACL 
tense arousal, and total scores for HAD anxiety and depression, GHQ-28 and NHP 
part 2. Ceiling effects were observed in scores for the 4 second presentation rate 
PASAT, correct BVRT reproductions and UMACL hedonic tone. These non-normal 
measures, along with those of an interval nature (subscale scores on the GHQ-28 and 
NHP part 2 questionnaires), were examined using paired Wilcoxon tests. All other 
dependent variables were continuous and normally distributed, and were analysed 
using 2-way analysis-of-variance (ANOVA: Hills and Armitage 1979), with 
treatment order as a between-subjects factor and treatment type as a within-subject 
factor. McNemar tests were used to examine changes in frequency of individual 
symptom items and psychiatric `cases' identified by HAD scale and GHQ-28. The 
binomial test was used to examine the distribution of treatment preference. The 
influence of illness severity and CPAP compliance on treatment response were 
investigated by entering these as putative covariates in the ANOVA. All statistical 
analyses were performed using SPSS-PC+ (Norusis/SPSS Inc. 1988, Bryman and 
Cramer 1990). 
6.5 Results 
6.5.1 CPAP compliance 
CPAP units were switched on for an average 3.3 ± SEM 0.3 hours/night, and used 
effectively for 3.0 ± 0.3 hours/night. One-way ANOVA showed no significant 
variation in effective CPAP compliance across severity groups (F< 1.09, p>0.3; Figure 
6.1), which averaged 2.8 ± 0.6 (group 1), 2.3 ± 0.6 (group 2), 3.7 ± 0.5 (group 3) and 
3.0 ± 0.5 (group 4) hours per night. 
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SAHS Severity group 
Figure 6.1: CPAP compliance in SAHS severity groups 
6.5.2 Weight changes 
Body mass index (BMI) was slightly but significantly higher on CPAP (30.6 ± 0.9 
kg/m2) than on placebo treatment (30.8 ± 0.9; F=4.34, p=0.04). 
6.5.3 Daytime function 
Mean daytime function scores for assessments at familiarisation and on placebo and 
CPAP are shown in Tables 6.2 and 6.3. The p-values in both tables are from the 
comparison of treatment type, i. e. CPAP versus placebo. Outcome measures from the 
domains of sleepiness, symptoms and cognitive performance are collated in Table 6.2, 
and those for well-being in Table 6.3. 
Better function is indicated by a lower score in Table 6.2 on the Epworth sleepiness 
scale, symptom total and items, SteerClear, TrailMaking tasks, RVIP misses, 
movement and decision time variables, Borkowski test perseverations, BVRT errors, 
and in Table 6.3 by lower score on all GHQ-28, HAD scale, NHP part 2 variables and 
UMACL tense arousal. Better function is indicated by a higher score in Table 6.2 on 
MSLT variables, RVIP hits, WAIS-R measures, including IQ decrement, Borkowski 
test total, PASAT measures and BVRT correct, and in Table 6.3 on hedonic tone. 
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While of the results of all daytime function outcome analyses are shown in Tables 6.2 
and 6.3, significant results are highlighted and illustrated in the succeeding sections. 
Table 6.2: Sleepiness, symptoms and cognitive performance at familiarisation and 













Mean sleep onset latency 
(mins) 
- 7.1 ± 0.6 8.4 ± 0.5 12.11 <0.01 
Minimum sleep onset latency 
(mins) t 
- 3.7 ± 0.4 4.5 ± 0.4 - 0.01 
Epworth sleepiness score 12.3 ± 0.7 10.0 ± 0.7 8.1 ± 0.7 10.44 <0.01 
UMACL Energetic arousal 20.5 ± 0.7 20.8 ± 0.7 23.4 ± 0.7 11.83 <0.01 
Symptom total 5.0 ± 0.2 4.0 ± 0.2 2.2 ± 0.2 59.53 <0.001 
Symptom items- Snoring t n=64 n=60 n=6 - <0.001 
Choking t n=35 n=11 n=11 - 1.00 
Morning headache t n=25 n=21 n=16 - 0.33 
Morning confusion t n=14 n=12 n=5 - 0.09 
Frequent awakening f n=38 n=41 n=37 - 0.56 
Daytime napping f n=53 n=46 n=26 - <0.001 
Evening napping f n=55 n=46 n=36 - 0.06 
Sleepiness while driving t n=34 n=13 n=6 - 0.07 
SteerClear (obstacles hit) 102.2 ± 5.8 74.0 ± 4.3 69.0 ± 3.4 5.33 0.02 
TrailMaking A (secs) 36.6 ± 1.8 29.5 ± 1.2 30.7 ± 1.2 1.34 0.25 
TrailMaking B (sees) t 79.6 ± 4.2 72.1 ± 3.9 66.3 ± 3.4 - 0.01 
RVIP Hit 27.8 ± 1.5 36.5 ± 1.7 36.4 ± 1.8 0.02 0.90 
RVIP Misst 11.4 ± 1.9 10.8 ± 2.0 10.3 ± 1.9 - 0.33 
WAIS -R digit symbol 48.5 ± 1.4 52.6 ± 1.5 532 ± 1.5 1.11 0.30 
WAIS-R block design 28.5 ± 1.2 312 ± 1.1 32.2 ± 1.1 2.21 0.14 
WAIS-R performance IQ 101.2 ± 1.4 106.2 ± 1.7 107.7 ± 1.6 2.74 0.10 
IQ decrement 9.7 t 1.3 5.0 t 1.5 3.3 t 1A 3.44 0.07 
Median decision time (ms) 359 t7 346 t6 350 t6 1.47 0.23 
Decision time slope (mslbit) 23.8 t 2.0 22.1 f 1.7 22.6 f 1.9 0.10 0.75 
Median movement time (ms) t 224 ± 10 216 t9 214 t9 - 0.37 
Borkowski total 37.5 ± 1.5 40.4 t 1.4 39.7 t 1.6 0.83 0.30 
Borkowski perseverations t 1.4 ± 0.2 1.6 ± 0.2 1.7 ± 0.2 - 0.88 
PASAT 4 see presentation t 51.6 f 1.3 53.5 ± 1.3 54.0 ± 1.2 - 0.37 
PASAT 2 sec presentation 32.0 f 1.1 36.5 ± 1.3 38.9 ± 1.4 13.90 <0.001 
BVRT correct t 7.2±0.3 7.5 ±0.2 7.6±01 - 0.67 
BVRT errors t 3.7 ± 0.4 3.4 ± 0.3 3.1 ± 0.3 - 0.29 
i Non-parametric test 
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GHQ-28 total 6.9 ± 0.8 4.1 ± 0.7 3.0 ± 0.6 0.15 
GHQ-28 `cases' n=31 n=17 n=16 1.00 
GHQ-28 subscales 
A (somatic symptoms) 1.9 ± 0.3 1.4 ± 0.2 1.0 ± 0.2 0.18 
B (anxiety) 2.0±03 1.0 ± 2.0 0.8 ± 0.2 0.31 
C (social dysfunction) 2.3 ± 0.3 1.4 ± 03 0.9 ± 0.2 0.08 
D (severe depression) 0.7 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 0.49 
HAD anxiety score 7.5±0.5 6.0 ± 0.6 5.6±0.5 0.32 
HAD depression score 6.1 ± 0.5 4.9 ± 0.5 3.7 ± 0.4 <0.01 
HAD anxiety `cases' n=14 n=11 n=7 0.29 
HAD depression `cases' n=12 n=6 n=3 0.45 
NHP Pt 2 total 8.7 ± 0.7 6.8 ± 0.7 5.3 ± 0.6 0.02 
NHP Pt 2 subscales 
Work efficiency 1.7 ± 0.2 1.3 ± 0.1 0.9 ± 0.1 0.03 
Household jobs 1.5 ± 0.1 1.2 ± 0.1 0.7 ± 0.1 <0.01 
Home relationships 1.4 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 0.54 
Social life 1.5 ± 0.1 1.3 ± 0.1 1.1 ± 0.1 0.12 
Sexual function 1.0 ± 0.1 0.9 ± 0.1 0.7 ± 0.1 0.06 
Hobbies and interests 1.6 ± 0.2 1.1 ± 0.2 0.9 ± 0.2 0.30 
UMACL Tense arousal 14.9 ± 0.6 13.5 ± 0.7 13.0 ± 0.7 0.45 
UMACL Hedonic tone 26.3 ± 0.7 27.1 ± 0.6 27.7 ± 0.7 0.26 
Preferred treatment - n=28 n=36 0.38 
All non-parametric tests 
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Sleepiness (Table 6.2): 
Both mean and minimum sleep onset latency on the MSLT were significantly 
lengthened on CPAP compared to placebo (p<0.001: Figure 6.2), reflecting improved 
objective daytime sleepiness on CPAP. Both measures of subjective sleepiness were 
also significantly improved on CPAP. Epworth sleepiness scores were significantly 
lowered on CPAP, reflecting lesser recent sleepiness, (p<0.01). The energetic arousal 
of the UMACL showed higher scores, reflecting increased state of alertness, at the 








Figure 6.2: Mean (±SEM) sleep onset latency on placebo and CPAP 
Symptoms (Table 6.2): 
Total symptom score was significantly lower on CPAP than placebo (p<0.001), with 
snoring (p<0.001) and daytime napping (p<0.001) showing significant individual item 
improvement (Figure 6.3). Trends towards a lowered frequency of patients reporting 
evening napping (p=0.06), sleepiness while driving (p=0.07) and morning confusion 
(p=0.09) were seen with CPAP. 
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Cognitive function (Table 6.2): 
Patients hit significantly fewer obstacles during the SteerClear vigilance task on CPAP 
than on placebo (p=0.02: Figure 6.4), and completed the TrailMaking B task of mental 
flexibility significantly more quickly (pß. 01: Figure 6.5). The number of correct 
mental additions during the 2 second presentation rate PASAT increased significantly 
on CPAP compared to placebo (p<0.001: Figure 6.5). Trends towards improvements 









Figure 6 . 4., SteerClear performance (± SEM) on placebo and CPAP 
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Figure 6.6: PASAT performance (t SEM) on placebo and CPAP 
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Well-being (Table 6.3): 
Psychological distress assessed by the raw depression score on the HAD scale was 
significantly lessened on CPAP compared to placebo (p<0.01: Figure 6.7). Quality of 
life score on the NHP part 2 was improved on CPAP compared to placebo (p=0.02: 
Figure 6.8), with individual score reductions, indicating better function, in the work 
efficiency and household tasks subscales (p50.03). Trends towards improvement in 
the NHP part 2 sexual function subscale (p=0.06) and in the social dysfunction scale 





Figure 6.7: HAD scale depression rating (± SEM) on placebo and CPAP 
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Figure 6.8: NHP part 2 score (± SEM) on placebo and CPAP 
6.5.4 Preferred treatment 
Thirty-six of the 64 patients (56%) preferred CPAP when the factors of ease of use 
and treatment benefit were weighed, but this was not significant (p>0.4). Within each 
severity subgroup, the frequency of patients preferring CPAP over tablets varied from 
7 of 16 patients (44%; group 2) to 10 of 16 (63%; groups 1 and 3). 
6.5.5 Order, learning and placebo effects 
No significant order effects in variables were found (p>0.06), indicating that the 
randomised allocation to treatment order was successful. Learning effects during 
treatment assessments (excluding familiarisation scores) were statistically examined 
through ANOVA in normally-distributed cognitive and sleepiness scores. Significant 
treatment x treatment order interactions were observed for SteerClear performance 
(p<0.001), RVIP hit score (p<0.001), digit symbol substitution (p=0.01), median 
decision time (p=0.03) and 2 second presentation rate PASAT (p<0.001), all 
representing better performance on retesting. A significant interaction was also 
observed for mean sleep onset latency on the MSLT (pß. 03), reflecting lesser 
sleepiness on first testing. No learning effects were found on subjective symptom, 
Epworth or energetic arousal variables. The study design, by randomising treatment 
order, controlled for those learning effects that existed. 
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Visual inspection of the mean scores at familiarisation and at treatment assessments 
shows the combined impact of learning and expectation of benefit on sleepiness, 
symptoms, cognitive performance and well-being. All scores, whether subjective or 
objective, reflected worse function before treatment, and mean values or frequencies 
representing better status on both CPAP and placebo compared to familiarisation. 
6.5.6 Analysis-of-covariance 
The investigation of relationships between compliance or polysomnographic severity 
and changes in daytime function was complicated by the crossover study design, 
containing two patient groups represented by differing treatment orders. Learning 
effects in the separate treatment-order groups would act to scatter the differences 
between CPAP and placebo assessments. Those receiving CPAP first would show 
smaller improvements in score from CPAP to placebo to those receiving placebo first, 
in whom the difference with CPAP on second testing would be boosted by learning. 
Such learning effects, indicated by treatment x treatment order interactions, were 
demonstrated for cognitive and sleepiness variables (see Section 6.5.5). Because of 
these, a univariate correlational analysis was not attempted. 
Two variables, AHI and CPAP masktime, were selected as putative covariates of the 
changes of daytime function by treatment type, and were entered into the ANOVA of 
continuous, normally-distributed variables. AHI showed no significant correlation 
with treatment changes. Masktime was a significant covariate in the analysis of 
UMACL energetic arousal (p=0.03) and symptom total (p=0.004), indicating that 
response to CPAP varied with compliance. In the case of energetic arousal, the 
addition of masktime as a covariate rendered the analysis of treatment type non- 
significant (F=0.00, p>0.9), indicating that treatment response in state of alertness was 
strongly associated with compliance. 
6.6 Discussion 
The crossover study showed, for the first time in a controlled investigation, objective 
and subjective improvements in daytime function after CPAP therapy. All of the areas 
of function examined, including sleepiness, symptoms, cognitive performance and 
well-being, showed benefits from CPAP. 
In contrast to the studies of others (Kribbs et al 1993b, BMdard et al 1993), the use of a 
familiarisation session, placebo control and balanced treatment order within this study 
minimised and controlled for the longitudinal learning effects documented in the 
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previous parallel-group study and observed in the ANOVA analysis in this sample. 
The observed improvements on CPAP compared to placebo are small in magnitude, 
but this margin of difference is attenuated by expectation of benefit from placebo, 
which can have substantial impact on performance and mood (Griffiths 1981). The 
reductions in all psychological distress scores on placebo compared to familiarisation 
(Table 6.2) and the high proportion of patients who preferred placebo over CPAP 
(44%) substantiates the perceived benefit from placebo in this patient sample. Patients 
were minimally heavier on CPAP over the course of the study, providing assurance 
that the documented improvements were due to active effects of CPAP, and not to 
weight loss. 
Multiple comparisons of inter-related measures were employed in this study, raising 
the possibility that the significant improvements shown with CPAP were Type 1, false 
positive statistical errors, and represented spurious significant findings, occurring at a 
rate of 1 in 20 comparisons by chance alone (Bryman and Cramer 1990). Thus of the 
50 endpoints measured and compared within the study, 2 or 3 might show false 
positive findings. Although this criticism may be warranted, the use of multiple 
outcome measures was designed into the study to allow evaluation and comparison of 
instruments which might prove useful in the discrimination of treatment sensitive 
function. 
Statistical techniques such as the Bonferroni method have been developed for 
improving the likelihood of avoiding `false positive' findings (Smith et al 1987, Bland 
and Altman 1995), although these are more commonly applied to the multiple 
comparisons of treatment type (Smith et al 1987) than to multiple comparisons of 
related outcome measures (Bland and Altman 1995), as contained in the crossover 
study. Bonferroni corrections require the use of more conservative p-value thresholds, 
which in turn limit statistical power. Thus the application of these more stringent 
techniques concomitantly reduces the possibility of demonstrating true positive 
differences, and may result in a requirement for unfeasibly large subject samples in 
order to produce the very small p-values (which would approximate 0.001 if applied 
to this study) set as thresholds for significance. 
The application of a Bonferroni correction to the crossover study data, with a stringent 
alpha significance value at p<0.001, would restrict statistical significance to the total 
symptom score, its individual items of snoring and daytime sleepiness, and the 2- 
second presentation rate PASAT. This more conservative interpretation still suggests 
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objective improvement in cognitive function, but would limit CPAP-related 
improvement to subjective, but not objective, sleepiness, and would exclude 
improvement in well-being with CPAP. 
Although the possibility of Type 1 statistical errors in the more liberal analysis without 
Bonferroni corrections cannot be discounted, the coherence of the observations of the 
crossover study support the effectiveness of CPAP therapy for daytime function. It is 
notable that although 2 or 3 false positives might be expected, 14 significant 
improvements, all occurring with CPAP and not placebo, were observed. 
All measures of sleepiness, whether objective or subjective, were improved on CPAP. 
Both the Epworth sleepiness score, a measure of recent sleepiness behaviour, and 
UMACL energetic arousal score, rating state of alertness at assessment, were 
improved on CPAP. The average Epworth score on placebo lay in the range 
associated with severe SAHS (Johns 1993), while that on CPAP fell to a level similar 
to that observed by Johns (1992) in his study of CPAP-treated SAHS patients. The 
mood dimension of energetic arousal is thought to index excitement in the reticular 
activating system of the brainstem (Thayer 1989), suggesting that CPAP resulted in a 
higher level of physiological alertness. The concurrence of all measures of sleepiness 
in showing improvement on CPAP provides cross-validation and may suggest that 
these measures share a common biological substrate. 
Objective daytime sleepiness was significantly improved, but not normalised, on 
CPAP, with both placebo and CPAP mean sleep onset latencies falling within the 
`grey zone' of 5 to 10 minutes (Van den Hoed et al 1981), which is clinically 
associated with moderate sleepiness (Thorpy 1992). Mean sleep onset latency rose by 
only 1.3 minutes, from 7.1 minutes on placebo to 8.4 minutes with CPAP. The small 
magnitude of improvement is surprising, and may indicate persistent sleepiness 
following therapy, but may also relate to the choice of the MSLT instrument, to 
placebo effects dictated by the study design, to patient selection factors with the 
inclusion of a subsample of patients with mild SANS, and to the low level of CPAP 
compliance. 
This lack of normalisation in MSLT scores after CPAP is in conflict with the findings 
of Lamphere et al (1989) and Wittig et a! (1986), who showed sleep onset latencies of 
exceeding the ̀ normal' threshold of 10 minutes following 14 days or 6 weeks 
respectively of CPAP treatment, However, the small improvement in objective 
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daytime sleepiness seen in the crossover study concurs with the findings of others 
(Fry et al 1990, Gaddy and Doghramji 1991, Bßdard et a! 1993, Kribbs et a! 1993b) 
showing lengthened, but still moderately `sleepy' onset latencies below 10 minutes, 
following CPAP treatment. Thus the majority of studies, like this one, tend to indicate 
that objective daytime sleepiness as measured by the MSLT may not be normalised by 
therapy. 
It has been argued that the lack of normalisation of MSLT scores in treatment studies 
demonstrates a lack of sensitivity in the MSLT to treatment-related changes (Miner et 
al 1982). The relatively small improvements seen in treated excessively sleepy patients 
shows a persistence of the ability to fall asleep at will, but may not measure the more 
clinically relevant ability to stay awake when required. The MSLT and the maintenance 
of wakefulness test (MWT), a polysomnographic test in which patients are instructed 
to remain in awake in sleep-conducive environment, appear on factor analyses to 
measure separate abilities, and the MWT may show greater sensitivity to treatment 
effects (Sangal et a! 1992a, 1992b). Thus the small improvement in sleep latency may 
in part result from the choice of the MSLT as the measure of objective daytime 
sleepiness. 
The magnitude of change in sleep onset latency is also likely to be attenuated by 
placebo effects within this study, which would act to prolong sleep onset latencies off 
CPAP, and reduce the size of effect with CPAP. Mean sleep onset latencies on 
placebo were in the moderate, and not the severe, range for daytime sleepiness, in 
contrast to pre-treatment latencies in many other samples of SAHS patients (eg. 
Lamphere et al 1989, Kribbs et al 1993b), including those in the pilot parallel-group 
study. MSLT scores have recently been shown to be alterable with incentive (Page et 
a! 1993), raising the likelihood that placebo effects in this study contributed to these 
relatively extended sleep onset latencies. 
The small magnitude of improvement in MSLT score may also be related to the 
inclusion of patients with very mild SAHS, who showed normal objective daytime 
sleepiness on placebo (see Chapter 7). Those studies showing the most dramatic 
improvements in sleep latency with CPAP (Wittig et al 1986, Lamphere et al 1989) 
were conducted on patients with severe SAHS (mean AHI 70 per hour slept), in 
whom treatment benefits might be expected to be greater. The stable MSLT score 
across treatments in the patients with mild SAHS, described in Chapter 7, would tend 
to equalise sleep onset latencies within the full patient sample examined in this study. 
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Total symptom score was significantly reduced on CPAP, with individual item 
improvements in the frequency of patients reporting snoring and daytime napping. 
Since these symptoms are the most frequent reasons for seeking medical intervention 
(Guilleminault et al 1978, Whyte et al 1989), the study corroborates the usefulness of 
CPAP in ameliorating major symptoms. The trend towards improvement in 
sleepiness while driving is particularly relevant given the evidence for increased 
driving accident rates in SAHS patients (Findley et al 1988). Statistical power was 
reduced on this item because only a subset of patients were drivers, and the short 
treatment limbs meant that many patients had not undergone sufficient long drives to 
assess their sleep propensity under duress. Thus the finding of this trend is notable. 
Significant improvements were seen in cognitive tests of vigilance, mental flexibility 
and concentration ability. Performance of all these tests required rapid and complex 
responses. Patients with SAHS have previously been shown to have impaired 
performance on the SteerClear test of vigilance (Findley et a! 1989a) on TrailMaking B 
(Findley et al 1986, Bedard et al 1993), and on the PASAT (Findley et al 1986). Thus 
improvements in scores on these tests are appropriate and suggest reversibility of at 
least some of the cognitive deficits induced by SAHS. The tasks improving with 
CPAP imply that vigilance and psychomotor speed may improve with therapy. The 
IQ decrement score at familiarisation (before learning effects improved obtained IQ 
scores) showed, in contrast to the pilot parallel-group study, an average shortfall of 10 
IQ points between expected and observed performance in the sample of patients. 39 of 
63 patients (62%) demonstrated a positive performance IQ decrement score, 
suggesting some degree of cognitive deficit. This observation corroborates existing 
evidence of deficits in executive skills and attention in SAHS (Greenberg et al 1987, 
Bedard et al 1993), while the statistical trend towards improvement of performance IQ 
score implies that such skills might benefit from CPAP. 
None of the other cognitive scores assessed were significantly different on CPAP and 
placebo, although most mean scores showed better function on CPAP (Table 6.2). 
There was no evidence for improvement in information processing speed with CPAP, 
as neither RVIP test nor Hick RT scores changed with treatment type. This result 
confirmed the null finding using simple RT in the parallel-group study, despite the use 
of sophisticated paradigms to examine processing speed. Neither verbal fluency nor 
the BVRT memory test were influenced by treatment 
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The lack of improvement in many cognitive measures may be due to absence of 
deficit, persistent impairment after CPAP, or insensitivity of the tests employed, most 
of which were developed to detect brain damage. Such tests might prove insensitive to 
the subtle and variable deficits induced by sleepiness. The design of the study does not 
address this question, and conflict in the literature concerning the specific types of 
daytime deficits in SANS (Greenberg et a11987, Findley et al 1986, Bedard et at 
1993, Naegel6 et a11995) and their best nocturnal correlates (Berry et al 1986, B6dard 
et al 1991a, Roehrs et a11989, Cheshire et al 1992, Poceta et a11992) does not help to 
clarify this subsidiary question. 
All mean values for well-being scores reflected better function on CPAP, and 
significant improvements were found in self-rated depression from the HAD scale 
and quality-of-life, assessed by the NHP part 2. The finding of improved depression 
rating corroborates previous studies showing lessened depression following treatment 
(Derderian et al 1988, Millman et al 1989). The subscales of the NHP part 2 showing 
improvement with CPAP, those for work efficiency and household jobs, imply that 
CPAP may improve the productivity in the workplace and in the home. The 
improvement in quality-of-life (NHP part 2) is supported in the trend towards 
improvement in the social dysfunction subscale of the GHQ-28, which investigates 
patients' satisfaction with their participation in work and family life. The trend towards 
improvement in the sexual function subscale of the NHP may imply that CPAP, far 
from discouraging sexual activity, as many patients fear, may facilitate a more 
fulfilling sexual life. 
Objective CPAP compliance was, on average, much lower than the all-night use 
recommended to patients before treatment commencement However, recent 
prospective studies of early CPAP use (Kribbs et al 1993a, Reeves-Hoch6 et al 1994) 
have shown similar, low objective compliance rates. As has been noted (Reeves- 
Hoch6 et al 1995), no standard method for calculating compliance exists, but the stated 
CPAP `runtimes' from these two studies (4.9 and 4.7 hours per night respectively) 
were skewed towards higher values by their method of calculation. Kribbs et al 
(1993a) reported the hours of CPAP use on the nights when CPAP was turned on: a 
recalculation including a component from nights when CPAP was not used reduces 
this figure to 3.2 hours per night Reeves-Hoch6 et al (1994) excluded values from 
patients who discontinued CPAP use during the 6 month study: if the CPAP use-rates 
for 9 CPAP rejecters are incorporated, average CPAP `runtime' is 3.9 hours per night 
Thus, with adjustments to standardise the CPAP compliance calculation, the average 
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CPAP `runtime' in the crossover study of 3.3 hours per night is closely in agreement 
with that of other studies, all showing that objective CPAP compliance is unexpectedly 
low. 
The minimum therapeutic use-rate for CPAP is as yet unknown, but it seems likely 
that patients may adjust their CPAP use to a level that produces subjective benefits in 
daytime function. Our findings of significant improvement in all examined areas of 
daytime function suggest that full-night CPAP use may not be necessary to reduce 
daytime deficits. 
Effective CPAP compliance was a poor covariate in the analysis of treatment effects, 
showing strong association only with the treatment effects of UWIST energetic 
arousal score. The paucity of associations between compliance and other endpoints 
may relate to inter-individual differences in thresholds for benefit from CPAP, or may 
result from insufficient sensitivity to fluctuating CPAP use in the objective monitoring 
system employed. AHI lacked significance as a covariate in the analysis of treatment 
effect, and thus provided no evidence that patients' response to CPAP varies with their 
severity of SAHS. 
The randomised crossover study demonstrated objective and subjective improvements 
in daytime function following CPAP therapy. Despite the lack of clear finding from 
correlations between measures of severity of SAHS and improvement in daytime 
function, the relationship between SANS severity and benefit from CPAP remains of 
great clinical interest. As is described in the introduction to the next chapter, the level 
of SANS severity at which CPAP treatment is indicated is not known. However, to 
attempt to define the lower limit of severity at which daytime benefits from CPAP are 
produced, a separate analysis of the mildest severity group studied within the 
crossover protocol was conducted. 
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Chapter 7: 
THE EFFECTS OF CPAP ON DAYTIME FUNCTION IN PATIENTS 
WITH MILD SAHS 
Sleepiness and impaired daytime function are major clinical features of the sleep 
apnoea/hypopnoea syndrome (Whyte et al 1989, Cheshire et al 1992), and the primary 
indication for CPAP therapy is to try to improve these features. Evidence from 
previous studies had suggested that CPAP has beneficial effects on daytime 
sleepiness, cognitive performance and psychological well-being (Bedard et al 1993, 
Kribbs et a! 1993b, Derderian et al 1988), and these were confirmed in the randomised 
crossover study (Chapter 6). However, the level of severity of the sleep 
apnoea/hypopnoea syndrome (SAHS) at which treatment is indicated is not well- 
defined. Patients with mild SAHS (apnoea+hypopnoea index 5 to 15 per hour slept) 
have, by definition, symptoms of the syndrome, but there is a dearth of data indicating 
whether their objective daytime sleepiness and performance is abnormal. 
Earlier work carried out on a small sample of SAHS patients and controls showed a 
discontinuity in the symptomatology reported by those with an apnoea+hypopnoea 
index (AHI) greater than and less than 15 per hour slept (Gould et al 1988). Fewer 
subjects with the lower level of breathing pauses in this study complained of 
symptoms of SAHS, leading to the empirical use of this threshold as a cutoff for 
diagnosis and treatment However, symptoms and deficits in daytime function have 
since been observed in patients with low levels of breathing pauses in sleep. Evidence 
for daytime problems in patients with low AHI is complicated by variation in 
nocturnal measures used to diagnose SAHS, and thresholds for defining pathology, 
but it is apparent that patients may experience distressing symptoms at low levels of 
breathing abnormality in sleep. 
Studies in sleep clinic populations have shown considerable congruence in 
symptomatology of patients above and below AHI thresholds of 5 (Hillerdal et al 
1991) or 10 (Hoffstein and Szalai 1993). This lack of specificity in the symptoms of 
SAHS has also been demonstrated by a large community-based study, in which 
excessive daytime sleepiness was reported by 41 % of subjects with an AHI greater 
than 15, but by 37% of subjects with AHI less than 15 (Olson et al 1995). Patients 
with the upper airway resistance syndrome (UARS) have, by definition, low AHIs 
(mean values < 5) and daytime symptoms in the form of excessive daytime sleepiness 
(Guilleminault et al 1992,1993, Downey et al 1993), which are thought to result from 
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elevated frequencies of EEG arousals during sleep. Thus symptoms, a prerequisite in 
diagnosing SAHS (Gould et al 1988), do not appear to be necessarily linked to a 
`diagnostic' AHI. 
Few studies have attempted to tie the chief measure of breathing disruption in sleep, 
AHI, to daytime deficits at the lower SAHS severity range, although nocturnal 
correlates of daytime deficits have previously been found in more severe samples of 
SAHS patients (Roehrs et al 1989, Bedard et al 1991a, Poceta et al 1992, Cheshire et 
al 1992). One report showed that symptomatic patients with AHIs < 20 have impaired 
quality-of-life, specifically in the areas of social and emotional function and vitality, 
compared to others with no daytime symptoms (Gall et al 1993). This fording 
suggests that daytime deficits may occur even at the lower severity range in SAHS. 
Symptoms of SAHS, such as snoring, may help identify a patient group without 
`significant' polysomnography according to local conventions, but suffering daytime 
impairment. Evidence in the literature links snoring with significant daytime deficits 
(Telakivi et al 1988, Jennum and Sjel 1994, Janson et al 1994b). Snorers with 4% 
desaturation rates <5 per hour slept show high incidences of daytime fatigue and 
sleepiness, including while driving (Janson et al 1994b). Epidemiological (Jennum 
and Sjel 1994) and case-control (Telakivi et al 1988) studies have shown associations 
between snoring, daytime sleepiness and cognitive and memory problems. Snorers 
without diagnostic AHIs show a significant correlation between snoring frequency and 
epoch-scored awakenings from sleep (Hoffstein et al 1991), and in a mixed group of 
snorers both with and without diagnostic AHIs, microarousal frequency correlated 
with clinical assessment of excessive daytime sleepiness (Zucconi et al 1995). These 
data suggest that snoring without `significant' levels of breathing disruption may 
fragment sleep and produce daytime impairment. 
CPAP has been recommended as a treatment both for `heavy snorers disease' 
(Lugaresi et a11989) and UARS (Guilleminault et a11993, Strollo and Sanders 1993). 
CPAP treatment in UARS patients results in decreased microarousal frequency in 
sleep and improvement in objective daytime sleepiness (Guilleminault et al 1993). 
However, the effects of CPAP treatment in mild SAHS have yet to be assessed. The 
inclusion within the crossover protocol of a randomised subgroup of patients with 
mild SAHS (AHI 5-15) allowed the individual daytime functions induced by CPAP 
in such patients to be assessed. 
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7.1 Study protocol 
A subgroup of mild subjects, participating in the larger crossover study (Chapter 6), 
were analysed separately. The protocol and methods were thus the same as the larger 
crossover study. 
7.2 Patients 
Subjects were prospectively recruited from consecutive sleep clinic outpatients referred 
for investigation of SAHS. Entry criteria required two or more symptoms of SAHS 
(Whyte et al 1989) and an AHI in the range 5.0 to 14.9 per hour slept during clinical 
polysomnography, conducted and scored according to our usual method (Gould et al 
1988). Patients with coexisting neurological or sleep disorder, or residence outwith a 
50 mile radius of the laboratory, were excluded. 
Twenty-eight subjects were invited to participate in the study, of whom 18 accepted. 
Of the 10 non-acceptors, 4 declined to participate because work pressure meant they 
could not spend the required 3 full days in the sleep laboratory. Four non-acceptors 
gave no reason and 2 were intolerant of nasal CPAP during the pre-treatment CPAP 
titration trial. Two patients withdrew after study treatment was commenced, both 
during the CPAP limb, and were excluded from analysis. One of these moved away 
unexpectedly, and remains on CPAP therapy, while the other was intolerant of noise 
from his CPAP unit and declined to complete the treatment limb. The treatment order 
slots of patients withdrawing after treatment commencement were filled with the next 
available subject. 
The 16 studied patients, 12 of whom were male, averaged 52 ± SEM 2 years of age, 
with a mean body mass index of 29.8 ± 1.8 kg/m2. The subjects demonstrated a mean 
AHI of 11 ±1 per hour slept, with an average 24 ±3 microarousals per hour slept 
(Cheshire et a! 1992), mean minimum oxygen saturation of 86 ±1% and average 4% 
desaturation rate of 4±1 per hour slept. 
7.3 Statistical analysis 
Outcome measures of daytime function from placebo and CPAP assessments were 
compared. Continuous, normally-distributed data were examined with 2-way 
ANOVA, with treatment order as a between-subjects factor and treatment type as a 
within-subject factor. Paired Wilcoxon tests were conducted in interval and non- 
normal data. The binomial test was used to examine the distribution of treatment 
preference, and McNemar tests to assess changes in frequency of individual 
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symptoms. Patients were split into better and poorer compliers, using median effective 
CPAP use as a cutpoint. A subanalysis comparing CPAP and placebo outcome 
measures was conducted within the better-complying group. Mann-Whitney tests 
were conducted to compare background variables in better and poorer CPAP 
compliers. All statistical analyses were performed using SPSS-PC+ (Norusis/SPSS 
Inc. 1988). 
7.4 Results 
7.4.1 Full group 
CPAP units were run for an average 3.2 ± SEM 0.7 hours per night, and used 







Figure 7.1: CPAP compliance in patients with mild SAHS 
Mean values and treatment effects for daytime function scores are shown in their 
entirety in Table 7.1, with selected results highlighted in Figures 7.2 to 7.5. 
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Body mass index (kglm2) 29.8 ± 1.8 30.0 ± 1.9 30.1 ± 1.9 2.06 0.17 
Mean sleep onset latency 
(mins) 
- 9.9 ± 1.5 10.0 ± 1.2 0.05 0.83 
Minimum sleep onset latency 
(mins) t 
- 5.4 ± 13 5.6 ± 1.0 - 0.73 
Epworth sleepiness score 14.2 ± 0.9 10.0 ± 1.2 10.1 ± 1.4 0.00 1.00 
Symptom total 4.9 ± 0.4 3.7 ± 0.4 2.0 ± 0.3 10.65 <0.01 
SteerClear (obstacles hit) 119.9 ± 9.3 75.3 ± 8.9 74.8 ± 7.3 0.59 0.45 
TrailMaking A (secs) 35.6 ± 3.0 30.2 ± 2.9 30.8 ± 2.7 0.05 0.83 
TrailMaking B (secs) t 81.3 ± 7.0 77.7 ± 9.2 64.1 ± 5.5 - 0.02 
RVIP Hit 23.7 ± 3.2 34.8 ± 3.2 36.9 ± 3.2 0.58 0.46 
RVIP Misst 16.5 ± 5.2 18.0 ± 6.0 20.0 ± 5.3 - 0.98 
WAIS -R digit symbol 50.4 ± 2.9 56.0 ± 3.2 55.1 ± 3.3 0.86 0.37 
WAIS-R block design 25.7 ± 2.3 29.3 ± 2.5 28.6 ± 2.1 0.43 0.52 
WAIS-R performance IQ 102.8 ± 2.9 108.5 ± 3.9 106.2 ± 3.5 2.53 0.13 
IQ decrement 9.3 t 2.5 5.3 t 3.5 7.0 f 3.1 1.62 0.23 
Median decision time (ms) 372 t 19 356 t 14 365 t 16 1.52 0.24 
Decision time slope (mslbit) f 30.7 t 5.1 25.2 t 4.3 27.9 t 4.7 - 0.71 
Median movement time (ms) t 220 t 25 209 t 20 212 t 19 - 0.88 
Borkowski total words 343 t 3.1 39.2 t 3.1 38.5 t 3.5 0.44 0.52 
Borkowski perseverationst 1.5 ± 0.5 1.6 ± 0.4 1.2 ± 03 - 0.38 
PASAT 4sec presentationt 47.8 ± 3.4 49.8 ± 3.3 51.1 ± 3.1 - 0.29 
PASAT 2sec presentation 29.9 ± 2.4 35.3 ± 2.8 37.8 ± 3.3 2.59 0.13 
BVRT correct t 7.2 ± 0.5 73 ± 0.6 7.3 ± 0.6 - 0.96 
BVRT errors t 3.6 ± 0.8 3.8 ± 0.8 3.6 ± 0.8 - 0.76 
GHQ-28 total t 5.7 ± 1.7 3.2 ± 1.3 1.4 ± 0.6 - 0.22 
GHQ-28 `cases't n=6 n=3 n=3 - 1.00 
HAD anxiety score t 6.4 ± 1.2 5.1 ± 1.1 4.5 ± 1.2 - 0.48 
HAD depression score t 5.6 ± 0.9 5.0 ± 1.0 3.4 ± 0.9 - 0.03 
HAD anxiety `cases' t n=3 n=3 n=2 - 1.00 
HAD depression 'cases' t n=1 n=2 n=1 - 1.00 
NHPPt2total t 6.9 ± 1.4 5.8 ± 1.4 3.8 ± 1.1 - 0.17 
UMACL Energetic arousal 21.9 ± 1.6 22.7 ± 1.7 25.4 ± 1.4 3.14 0.10 
UMACL Tense arousal t 13.9 ± 1.2 13.3 ± 1.5 12.1 ± 1.1 - 0.55 
UMACL Hedonic tone t 27.0 ± 1.3 28.3 ± 1.1 28.4 ± 1.1 - 0.95 
t Non-parametric test 
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Average objective daytime sleepiness measured by the MSLT approached the normal 
range on placebo and was not significantly improved by CPAP (p>0.8; Figure 7.2). 
The subjective Epworth sleepiness score remained in the severe range on both 
treatments (p>0.9), but energetic arousal score from the UMACL showed a trend 
towards increase in state of alertness on CPAP (p=0.10). Total symptom score 
(Figure 7.3) was significantly lower on CPAP than placebo (p<0.001), reflecting an 
improvement in status. Performance on the TrailMaking B task of mental flexibility 
was significantly improved on CPAP (p=0.02; Figure 7.4), but no other treatment 
effects on cognitive performance were found. Self-rated depression score on the HAD 
scale was significantly reduced by CPAP (p=0.03, see Figure 7.5), corresponding to 
lower distress. Ten of 16 patients (p>0.4) preferred CPAP when the factors of ease of 
use and treatment benefit were weighed. 
Treatment order effects in variables examined in the above analysis were non- 
significant (p>0.12), with the exception of mean sleep onset latency, which was 
significantly longer in patients treated first with CPAP than in those commencing 
treatment with placebo (p=0.05). Since mean sleep onset latency showed no 
significant effect for treatment, this was not considered crucial. The lack of treatment 
order effects provided assurance that the balancing of treatment order could control for 
learning effects. Such learning effects, represented by a significant treatment x 
treatment order interaction, were demonstrated for SteerClear performance (p<0.001), 
WAIS-R performance IQ score (p=0.05), RVIP hit score (p<0.01) and verbal fluency 
total score (p<0.01). 
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Figure 7.3: Symptom total score on placebo and CPAP 
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7.4.2 Better CPAP compliers 
The patient group was split by median effective CPAP use into better and poorer 
compliers (n=8 in each group). Mean effective CPAP compliance averaged 5.0 ± 0.6 
hours per night in the better users, and 1.1 ± 0.2 in the poorer users. Four patients 
commenced treatment with tablets in each group. 
As in the full group, the better compliers (Table 7.2) showed significant CPAP-related 
improvement in symptom total score (pß. 02), TrailMaking B performance (p=0.04) 
and HAD scale depression rating (p-0.04). In addition, NHP part 2 score was 
significantly reduced on CPAP (p=0.03; Figure 7.6), indicating improved quality-of- 
life. The only individual subscale of the NHP showing improvement within the group 
was that for social life (p=0.04). The somatic symptom subscale of the GHQ-28 
showed an individual reduction in score (p=0.04), reflecting lesser distress from 
physical symptoms, but total GHQ-28 score was not significantly reduced on CPAP 







Figure 7.6: Quality-of-life on placebo and CPAP in better CPAP compliers 
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Body mass index (kglm2) 31.3+3.1 30.7 ± 2.5 30.8 ± 2.6 0.64 0.46 
Mean sleep onset latency 
(mins) 
- 10.8 ± 2.3 11.0 ± 2.1 0.74 0.42 
Minimum sleep onset latency 
(mins) 
- 6.4 ± 2.3 6.0 ± 1.5 - 0.87 
Epworth sleepiness score t 17.0 ± 0.0 6.7 ± 1.5 7.3 ± 3.5 - 1.00 
Symptom total 4.9 ± 0.9 3.6 ± 0.8 1.5 ± 0.3 9.53 0.02 
SteerClear (obstacles hit) 122.1 ± 16.6 83.7 ± 11.8 81.7 ± 12.1 2.16 0.20 
TrailMaking A (secs) 39.9 ± 5.6 30.4 ± 4.2 29.5 ± 3.6 0.10 0.76 
TrailMaking B (secs) t 82.1 ± 14.2 76.1 ± 14.1 61.9 ± 9.1 - 0.04 
RVIP Hit 20.4 ± 5.0 36.6 ± 4.0 34.4 ± 3.5 0.63 0.46 
RVIP Misst 17.4 ± 6.3 20.6 ± 9.6 14.6 ± 6.3 - 0.31 
WAIS -R digit symbol 46.1 ± 5.2 53.6 ± 5.6 52.6 ± 5.6 0.78 0.41 
WAIS-R block design 23.9 ± 3.2 27.4 ± 2.8 26.3 ± 2.6 0.25 0.63 
WAIS-R performance IQ 100.4 ± 3.5 106.6 ± 5.6 103.6 ± 5.4 0.74 0.42 
IQ decrement 9.2 t 3.8 5.9 t 5.4 7.0 t 4.4 0.19 0.68 
Median decision time (ms) 368 t 24 365 t 18 386 t 25 0.51 0.51 
Decision time slope (mslbit) t 37.5 t 10.3 27.9 t 7.2 27.5 t 6.0 - 0.87 
Median movement time (ms) t 221 t 30 198 t 21 204 t 25 - 0.31 
Borkowski total words 32.7 t 6.3 36.7 t 5.4 35.0 t 5.8 3.53 0.11 
Borkowski perseverationst 2.1 ± 1.0 1.4 ± 0.6 1.1 ± 0.4 - 0.74 
PASAT 4sec presentationt 43.0 ± 7.0 48.4 ± 5.4 48.3 ± 5.3 - 1.00 
PASAT 2sec presentation 28.4 ± 4.8 33.3 ± 4.1 37.4 ± 5.7 2.49 0.17 
BVRT correct t 6.9 ± 1.0 7.1 ± 0.7 7.1 ± 0.9 - 1.00 
BVRT errors t 3.7 ± 1.3 3.8 ± 1.0 3.5 ± 1.0 - 0.86 
GHQ-28 total t 7.0 ± 3.0 3.3 ± 1.9 0.3 ± 0.3 - 0.12 
GHQ-28 `rasest n=3 n=1 n=0 - 1.00 
HAD anxiety score t 5.6 ± 2.1 4.5 ± 1.7 3.9 ± 1.8 - 0.75 
HAD depression score t 5.7 ± 1.5 4.8 ± 1.5 2.5 ± 1.0 - 0.04 
HAD anxiety `cases' t n=1 n=1 n=1 - 1.00 
HAD depression 'cases' t n=1 n=1 n=0 - 1.00 
NHP Pt 2 total t 8.0±2.3 6.8±2.5 2.4±1.5 - 0.03 
UMACL Energetic arousal 20.0 ± 2.2 23.0 ± 2.8 27.8 ± 1.6 3.48 0.11 
UMACL Tense arousal T 14.0 ± 1.8 12.9 ± 1.9 13.3 ± 1.9 - 0.68 
UMACL Hedonic tonet 26.0 ± 2.3 29.6 ± 1.1 30.4 ± 1.0 - 0.68 
f Non-parametric test 
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Background features of better and poorer CPAP compliers were compared to identify 
predictors of greater CPAP use. The variables that were compared included 
polysomnographic measures, symptoms and sleepiness reported at familiarisation and 
sleep onset latency off CPAP (Table 7.3). Both microarousal index (p<0.01) and AHI 
(p=0.02) were significantly higher in better compliers. However, ranges for 
microarousal index (Figure 7.7) and AHI (Figure 7.8) overlapped in good and poor 
compliers. There was no difference between pre-treatment symptom score in poor and 
good compliers, and no difference in sleepiness measures off CPAP between the two 
groups. 
Table 7.3: Differences in background features of poor and better CPAP compliers 
Poor compliers 
Mean ± SEM 
Better compliers 
Mean ± SEM D-value 
AHI (per hour slept) 9.6 ± 0.7 12.5±0.5 0.02 
Microarousal index (per hour slept) 16.6 ± 3.4 32.2 ± 3.2 <0.01 
Minimum 02 saturation (%) 87 ±1 85 f2 >0.2 
4% desaturations (per hour slept) 2.3 ± 1.1 5.3 f 1.7 >0.1 
Symptom score 5.1± 0.2 4.8 ± 0.8 >0.4 
Epworth sleepiness score 13.8 ± 1.1 15.0 ± 2.0 >0.5 
UMACL energetic arousal score 22.6 ± 2.4 21.1 ± 2.2 >0.5 
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Figure 7.8: Apnoea+hypopnoea index in poorer and better CPAP compliers 
7.5 Discussion 
This study suggests that patients with mild SAHS may improve symptoms, cognitive 
performance and psychological distress on CPAP, as was documented in the wider- 
severity sample examined in Chapter 6. Thus, the study extends the previous findings 
of the therapeutic value of CPAP to apply to symptomatic patients with 5 to 15 
apnoeas+hypopnoeas per hour of sleep, and indicates that such patients should be 
given a trial of CPAP therapy. 
Those daytime function tests showing improvement in patients with mild SAHS- 
symptoms, cognitive performance and depression ratings- were also improved by 
CPAP in the wider-severity study of daytime function in SAHS, corroborating the 
sensitivity of these measures to CPAP effects. In patients with mild SAHS and higher 
levels of CPAP compliance, additional benefits for quality-of-life, which was also 
improved in the wider-severity study, were found with CPAP. 
The inclusion of multiple measures of outcome in daytime function, as in the 
crossover study of the full group of SAHS patients (Chapter 6), increases the 
137 
Poor Good 
Chapter 7. " Mild SANS study 
possibility that the improvements seen are Type 1, `false positive' statistical errors 
(Smith et al 1987, Bland and Altman 1995). A comparatively large number of 
endpoints was measured in order to identify CPAP-sensitive instruments for future 
studies. Although the criticism of multiple comparisons cannot be discounted, it is 
mitigated by the observation that all improvements related to CPAP administration 
and none to placebo treatment. 
Neither objective (MSLT) nor subjective (Epworth scale) sleepiness was improved by 
CPAP in mild SAHS patients. Mean sleep onset latency approached the normal range 
on both placebo and CPAP (Thorpy 1992), while subjective sleepiness was elevated 
on both placebo and MSLT (Johns 1993). The study's findings using the MSLT 
contrast with those from studies of `upper airway resistance syndrome' (UARS) 
patients (Guilleminault et al 1992,1993), whose short sleep onset latencies, indicative 
of moderate or severe sleepiness before treatment, were extended into the normal 
range (Thorpy 1992) by CPAP. Recent CPAP-treatment studies in more severe 
samples of SAHS patients have shown statistical improvement, but a lack of 
normalisation in objective daytime sleepiness with CPAP (B&dard et al 1993, Kribbs 
et al 1993b). Thus the utility of the MSLT in treatment-related studies may be 
questioned. 
The cognitive task showing improvement with CPAP (TrailMaking B) required rapid 
and complex responses. Performance on this particular test is impaired in patients with 
severe SAHS (Findley et al 1986, Bedard et al 1993). However, only a small 
proportion of the cognitive tests administered showed improvement on CPAP. This 
may reflect marginal cognitive impairment in mild SAHS, may relate to the 
difficulties in detecting sleepiness-induced eficit with cognitive tests (Wilkinson 
1964), or may show insensitivity in the tests employed. 
The HAD scale depression self-rating has previously been shown to be responsive to 
CPAP's effects on well-being, both in the pilot parallel-group study (Chapter 5) and 
the full-scale crossover study (Chapter 6). Quality-of-life, most notably in social 
function, was also improved in better CPAP compliers. Impaired social function is 
associated with greater sleepiness (Briones et a11995) and has been identified as 
impaired in mild SAHS subjects (Gall et al 1993 ). Thus this finding suggests that 
CPAP may reverse some of the functional and behavioural limitations seen in mild 
SAHS. 
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The study was carried out in patients with mild SAHS who had 5 to 15 
apnoeas+hypopnoeas per hour slept, using standard definitions for apnoeas 
(Guilleminault et al 1978) and hypopnoeas (Gould et a! 1988). These data cannot be 
directly extrapolated to the UARS (Guilleminault et al 1993), although it is likely that 
an overlap between patients diagnosed with mild SAHS in this study would be 
classified as having UARS elsewhere. 
An earlier study of CPAP administration in 15 snorers with AHI less than 5 found 
that no subjects opted for long-term therapy (Guilleminault et al 1991). In this study, 
10 of the 16 patients (and 6 of 8 better CPAP compliers) preferred CPAP and opted 
for home CPAP therapy. The discrepancy between CPAP treatment acceptance in 
these two studies is likely to relate to the symptomatology of the patient samples. All 
subjects in the current study complained of two or more symptoms of SAHS, while 
the level of daytime problems in the previous study were low. 
The low objectively monitored CPAP compliance rates might be considered 
disappointing, but are similar to those observed in other prospective studies of early 
CPAP compliance rates in new users (Kribbs et a! 1993a, Reeves-Hoch6 et al 1994) 
and in both parallel-group (Chapter 5) and crossover studies (Chapter 6) of this thesis. 
Although clinicians recommend all-night CPAP use, there is little research defining 
the relationship between use-rate and benefit. Patients with mild SAHS are likely, like 
patients with the UARS (Downey et al 1993) or snorers with AHI < 10 (Zucconi et al 
1995), to show proportionately less disturbed sleep than those with more severe 
SAHS. It is possible that such patients may thus require shorter CPAP administration 
each night to acquire the `core sleep' required for normal daytime function (Home 
1988). 
It is suspected that many of the poorer CPAP users heeded requests to use CPAP on 
the nights immediately preceding assessments, despite low averaged effective 
compliance rates in this group. Providing that the latency to benefit from CPAP is as 
short as one or two nights, as has previously been suggested (Lamphere et al 1989), 
pre-assessment CPAP use would tend to equalise performance on state assessments 
of sleepiness and cognition in better and poorer compliers. 
The examination of background differences between good and poorer CPAP 
compliers found evidence of greater microarousal frequency and higher AHI in better 
compliers. This empirical finding may support the role of sleep fragmentation in 
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inducing daytime deficits (Cheshire et al 1992, Guilleminault et al 1993, Zucconi et al 
1995), particularly in patients at the milder end of the spectrum. However, no 
predictors of future CPAP compliance rate were found in patients' symptoms or 
sleepiness. 
It is concluded that CPAP therapy improves symptoms and daytime function in 
patients with mild SAHS. Thus a therapeutic trial of CPAP therapy may be clinically- 
indicated for symptomatic patients with 5 to 15 apnoeas+hypopnoeas per hour of 
sleep. However, further controlled studies in this patient group are required to help 
identify whether the improvements in daytime function are sustained, to identify 
whether other features of SAHS are improved by CPAP, and to help predict patients' 
CPAP use. 
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Chapter 8: 
AUDITORY EVOKED POTENTIALS AFTER CPAP IN PATIENTS WITH 
SAIIS 
Auditory evoked potentials (AEPs) are electroencephalographic waveform complexes 
elicited during the cerebral processing of auditory information (see Section 2.3 for 
explanation, and Figure 2.1 for illustration). While the shorter latency Ni and P2 
peaks are thought to index cerebral sensation of information, the later N2 and P3 
components appear to reflect higher cognitive information processing (Blackwood et 
a! 1987). All wave components may show smaller amplitudes and delayed latency 
with cognitive deficit (Blackwood et a11987) and with sleepiness (Weitzman and 
Kremen 1965), both of which are common complaints amongst patients with SAHS 
(Cheshire et a! 1992). Because of the convergence of symptoms of SAHS and 
correlates of AEP conformation, AEP testing may offer a useful probe for clinical 
evaluation of SAHS patients and for assessment of treatment response. 
Case-control studies have suggested that AEP conformation is altered in SAHS, 
showing extended latency and diminished amplitude of N2 and P3 components 
(Walsieben et al 1989) or slowed latency of P2, N2 and P3 and smaller amplitude of 
P3 peak (Rumbach et al 1991). These same studies assessed the effects of 2 nights 
(Walsleben et al 1989) or 6 weeks (Rumbach et al 1991) of CPAP therapy on AEP 
variables. The 14 patients studied by Walsieben showed improved, but not 
normalised, P3 latency after therapy, while the 47 subjects in Rumbach's trial showed 
improvements in latency and amplitude of N2 and P3 components, and normalisation 
of P3 amplitude. These data are compatible with studies of daytime function, which 
suggest improvements in cognitive function and daytime sleepiness with CPAP, but a 
lack of normalisation in objective daytime sleepiness after CPAP (B6dard et al 1993). 
However, like many of studies of daytime function after CPAP, neither AEP study 
conducted in SAHS patients offered a control for repeated testing or for expectation of 
benefit. The use of a crossover design in the study below allowed these factors to be 
controlled by the study procedures. 
8.1 Methods 
8.1.1 Study protocol 
SAHS patients were prospectively recruited for a placebo-controlled crossover study 
of AEPs after CPAP. Most of the patients undergoing AEP testing were participating 
simultaneously in the crossover study of daytime function (Chapter 6), with the AEP 
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testing session inserted into the larger protocol. Patients spent 4 to 5 weeks on CPAP 
and on an oral placebo, with assessments of weight and AEPs conducted after a 
minimum of 21 and maximum 35 days on each treatment, with no washout period 
between the two treatment limbs. Fifteen patients underwent the daytime function tests 
of the crossover study (Chapter 6) in addition to AEP assessment, and in these 
treatment order was randomised by the daytime function study schedule. Three 
patients underwent assessments of AEPs and ambulatory blood pressure (Chapter 9) 
only, and with these an attempt to balance treatment order was made. All patients 
underwent education in the mechanisms of CPAP before treatment commencement, 
and attended for a night of CPAP titration. For the CPAP treatment limb, patients 
were issued APD-1 CPAP units equipped with hidden timeclocks (see Chapter 4) 
logging total time that units were switched on and that CPAP was effectively 
delivered. 
8.1.2 Patients 
Eighteen patients (14 male) complaining of least two symptoms of SAHS (Whyte et 
al 1989) were prospectively remelted from a sleep clinic series. All demonstrated an 
apnea+hypopnea index (AHI) of 5 or more per hour slept during clinical 
polysomnography, conducted and scored according to our usual method (Gould. et al 
1988). Microaiousals were scored according to the method of Cheshire et al (1992), 
consisting of a return of faster EEG frequencies lasting 1.5 seconds or more, and 
coinciding with any duration of elevated EMG activity. The background features of 
participants are shown in Table 8.1. Seven patients commenced treatment with placebo 
and 11 with CPAP. 
Table 8.1: Background features of AEP study subjects 
Mean ± SEM Ran 
Age (years) 48 ±2 32-66 
Body mass index (kghm2) 35.4 ± 2.3 22.5-49.8 
AHI (per hour slept) 38 ±6 7-88 
Microarousal index (per hour slept) 45 ±6 12-115 
Minimum 02 saturation (%) 77 ±4 22-94 
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8.1.3 Auditory evoked potentials (AEPs) assessment 
AEPs were recorded with the subject seated comfortably in an armchair. The AEP 
paradigm consisted of an `oddball' task, in which patients were asked to listen to tones 
through headphones, and were required to ignore frequent low-pitched tones, but to 
count rare high-pitched tones. Rare tones occurred at pseudo-random intervals, at a 
frequency of 1 in 10 tones. Four hundred tones of 100 ms duration were played at a 
stimulus rate of 1 tone per 1.25 seconds, frequent tones at a frequency of 1 kHz and 
rare tones at 1.5 kHz. The AEP response at Cz (vertex) was recorded for 750 ms at 
each tone on Nicolet equipment with a low frequency pass at 30 Hz. AEP responses 
to rare and frequent tones were separated and averaged on-line. Latency and baseline- 
to-peak amplitude of `sensory' Ni and P2 components were measured on the 
averaged response to ignored frequent tones, while those of `cognitive' N2 and P3 
components were assessed in the averaged response to counted infrequent tones. 
8.1.4 Data analysis 
Outcome measures obtained on placebo and CPAP were examined using 2-way 
repeated measures ANOVA, with treatment order as a between-subjects factor and 
treatment type as a within-subject factor. This analysis assessed the effects of 
treatment type (CPAP versus placebo), treatment order (placebo first or CPAP first) 
and their interaction, representing learning. A separate subanalysis was conducted in 
better CPAP compliers using their units effectively for 3 hours or more per night 
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8.2 Results 
CPAP units were switched on for an average 4.4 ± SEM 0.7 hours per night, with 
mean effective CPAP use of 4.2 ± 0.6 hours per night. The comparison of AEP wave 
component variables obtained on placebo and CPAP is shown in Table 8.2 and Figure 
8.1. There were no significant treatment effects found, although a trend for improved 
N2 amplitude on CPAP emerged (p=0.08). Patients' BMI was significantly increased 









Figure 8.1: AEPs on placebo and CPAP in full group 
Table 8.2: AEPs on placebo and CPAP 
Placebo 
Mean ± SEM 
CPAP 
Mean ± SEM 
Treatment effect 
F-value -value 
N1 latency (msecs) 97 ±2 98 ±2 0.26 0.61 
N1 amplitude ( V) 5.1 ± 0.7 4.9 ± 0.6 0.51 0.49 
P2 latency (msecs) 179 ±6 180 ±6 0.38 0.54 
P2 amplitude ( V) 5.8 ± 1.0 5.6 ± 0.8 0.00 0.96 
N2 latency (msecs) 238 ±7 227 ±7 1.16 0.30 
N2 amplitude ( V) 3.0 ± 0.7 3.8 ± 0.7 3.50 0.08 
P3 latency (msecs) 345 ±9 333 ±9 2.37 0.14 
P3 amplitude ( V) 7.3 ± 0.9 7.7 ±2 0.36 0.56 
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8.2.1 Good CPAP compliers 
Ten patients used CPAP effectively for 3 hours per night or more. Four of these 
commenced treatment with placebo and 6 with CPAP. A second ANOVA was 
performed on the data for these 10 subjects (Table 8.3 and Figure 8.2). Again, no 
significant differences were found between AEP variables on CPAP and placebo, 









Figure 8.2: AEPs on placebo and CPAP in the good compliers 
Table 8.3: AEPs on placebo and CPAP in good compliers 
Placebo 
Mean ± SEM 
CPAP 
Mean ± SEM 
Treatment effect 
F-value -value 
Ni latency (msecs) 99 ±3 99 ±3 0.12 0.73 
N1 amplitude ( V) 4.9 ± 0.6 4.4 ± 0.5 0.97 0.35 
P2 latency (msecs) 180 ±9 183 ± 10 0.72 0.42 
P2 amplitude ( V) 4.5 ± 0.6 4.8 ± 0.8 3.35 0.11 
N2 latency (cosecs) 237 ± 10 222 ±9 0.84 0.39 
N2 amplitude ( V) 3.7 ± 1.2 4.7 ± 1.0 1.81 0.22 
P3 latency (msecs) 347 + 3 1 318 9 4.90 0.06 
P3 amplitude ( V) 0 . 8 
7.1 ± 7.7 ± 2.5 0.24 0.64 
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8.2.2 Learning effects 
A significant treatment x treatment order interaction was seen for P2 amplitude in the 
full group (p<0.01), representing a learning effect of improved amplitude on second 
testing, irrespective of treatment type (Table 8.4). 
Table 8.4: Learning effects in fug group 
Visit 1 
Mean ± SEM 
Visit 2 
Mean ± SEM 
Treatment order x 
treatment interaction 
F-value -value 
Ni later (msecs) 98 ±2 97 t2 0.62 0.44 
Ni amplitude (pV) 5.0 t 0.6 4.9 t 0.7 0.11 0.75 
P2 latency (msecs) 176 t5 183 f5 2.75 0.12 
P2 amplitude V) 5.2 t 0.8 6.1 t 0.9 10.70 0.005 
N2 later (msecs) 230 t7 235 t7 1.16 0.30 
N2 amplitude (V) 3.2 t 0.6 3.5 f 0.6 0.90 0.36 
P3 latency (msecs) 339± 9 338 t 13 0.20 0.66 
P3 amplitude V) 6.9 ± 0.9 8.0 f 1.3 1.09 0.31 
8.3 Discussion 
This randomised study does not provide conclusive evidence of improvements in 
AEP conformation after CPAP therapy for SAHS, in contrast to previous 
uncontrolled studies (Walsieben et al 1987, Rumbach et al 1991). Improvements in 
N2 amplitude with CPAP remained statistically non-significant in the full group, as 
did the shortening of P3 latency in better CPAP compliers. Thus, although N2 and P3 
components appeared on average to be improved by CPAP (see Figures 8.1 and 8.2), 
inter-subject variability in AEP treatment response resulted in trends only towards 
shortened latency or increased amplitude of `cognitive' N2 and P3 components with 
CPAP. Although a statistically significant increase in BMI on CPAP compared to 
placebo was observed, the trivial magnitude of the increase would not be thought 
likely to have a substantial impact on response to CPAP. 
The lack of statistical improvement in AEPs with CPAP may reflect insensitivity of 
AEPs as a measure of higher cortical function in SAHS, particularly in the light of the 
observed improvement in cognitive and sleepiness measures from the daytime 
crossover study (Chapter 6). Alternatively this negative finding may relate to persistent 
deficit after treatment for SAHS, which has been previously suggested in a small-scale 
study of cognitive function (Bedard et al 1993) and in studies showing lack of 
normalisation of objective daytime sleepiness (e. g. Kribbs et al 1993b, Bedard et al 
1993). The limited sample size may also contribute to a Type 2 statistical error, a 
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significant possibility in such a small-scale study as this, which indicated substantial, 
hypothesised trends towards improvement after CPAP. The presence of a learning 
effect representing improved P2 amplitude with repeated testing is a cause for 
methodological concern which may have contributed to the positive findings of 
previous, uncontrolled and longitudinal studies (Walsieben et al 1989, Rumbach et al 
1991). 
AEPs have been considered potentially useful tools to assess impairment at diagnosis, 
and to assess treatment response. The data from this study gave encouragement to the 
idea that AEPs might improve with treatment, a finding that might well emerge with a 
larger patient sample. Significant improvements in AEP markers would be cross- 
validated by the demonstrated improvements in cognitive performance and alertness 
following CPAP (Chapter 6). But this study may also have added methodological 
complexity to the usefulness of this technique in a clinical setting, due to the learning 
effects demonstrated. However, it may be that further validation will establish 
consistent age-based norms for cognitive potentials, which may supplement other 
investigations in judging overall daytime impairment in SAHS patients. 
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Chapter 9: 
AMBULATORY BLOOD PRESSURE ON AND OFF CPAP THERAPY IN 
PATIENTS WITH SANS 
A strong association between SAHS and hypertension exists, linking SAHS both to 
nocturnal swings in blood pressure (BP) (Schroeder et a11978, Jennum et a11989, 
Mayer et al 1991) and to daytime BP elevation (Kales et at 1984, Lavie et a11984, 
Millman et al 1991, Rauscher et at 1992), with the prevalence of daytime hypertension 
approximating 50% in SAHS patient series (Millman et a11991, Rauscher et al 1992). 
This association may relate to systemic hypertension and SAHS having in common 
the epidemiological risk factors of obesity and age. This view is supported by studies 
showing that the best, and often sole, correlate of casual daytime (Stradling and 
Crosby 1990, Rauscher et a11992, Millman et al 1991) and nocturnal BP (Wilcox et al 
1992, Wilcox et a11994) in the community (Stradling and Crosby 1990) and in 
SAHS patient populations (Rauscher et a11992, Rauscher eta! 1993a, Wilcox et al 
1992, Wilcox et a11994) is body mass index (BMI), and not breathing disruption in 
sleep. 
However, other recent evidence from large samples in the community (Hla et al 1994) 
and in sleep patient series (Carlson et al 1994) suggests that disrupted breathing in 
sleep, obesity and age are independent and additive risk factors for both daytime 
(Carlson et al 1994, Hla et a! 1994) and nocturnal (Hla et al 1994) BP elevation. 
Nocturnal BP elevation may represent an added risk to sleep apnoea patients, as 
inadequate overnight dropping of BP ('non-dipping') is associated with cardiovascular 
events (Verdeochia et al 1990). The high prevalence of hypertension in SAHS 
populations, of whatever cause, is likely to contribute to the excess mortality (Partinen 
et a! 1988, He et al 1988) and morbidity (Hung et al 1990) from cardiovascular 
disease reported in SAHS. 
CPAP, by blocking nocturnal events in SAHS (Sullivan and Issa 1980), may reduce 
one sequels in the form of nocturnal and/or daytime hypertension (Working Group on 
OSA and Hypertension 1993). Previous studies of the effects of CPAP (see Table 
9.1) on nocturnal, casual daytime or ambulatory BP (ABP) have yielded mixed 
results. Some researchers have documented improvements in nocturnal, but not 
daytime BP with CPAP (Davies et al 1994a), or have found no changes in sleeping 
(Ali et al 1992) or casual daytime (Rauscher et al 1993a) BP after therapy. Others have 
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Table 9.1: Studies of blood pressure with CPAP in SALIS 
Author Subjects Methods Outcome 
measures Effect of CPAP 
Jennum et at 14 SAHS pts, Continuous Nocturnal Decrease in 
1989 some nocturnal BP BP nocturnal BP 
hypertensives off 
Rx 
Mayer et at 12 SAHS, all Continuous Nocturnal Decrease in both 
1991 hypertensives off nocturnal BP, and daytime nocturnal and 
Rx, after 6 casual BP daytime systolic 
months on CPAP daytime BP and diastolic BP 
Ali et at 1992 8 SAHS pts Beat to-beat Waking and Decrease in 
on and off CPAP nocturnal BP sleeping BP variability only of 
within the same sleeping systolic 
night and diastolic BP 
Worsnop et al 18 SAHS pts, 7 Casual BP Daytime BP In hypertensives 
1993 hypertensives on only, a decrease 
Rx, after 10 in systolic and 
nights CPAP diastolic BP 
Rausches et at 33h SAHS pts, Casual BP Daytime BP No effect on BP 
1993a all hypertensives and independent of 
on Rx, after 2 hypertensive weight loss 
years on CPAP status 
Suzuki et al 9 SAHS pts, 5 ABP Daytime and In hypertensives 
1993 hypertensives on nocturnal BP only, a decrease 
Rx, after 5 weeks in daytime heart 
CPAP rate and nocturnal 
systolic BP and 
heartrate 
Wilcox et al 14 SAHS pts, ABP Nocturnal Decrease in 24- 
1993 some and daytime hour and daytime 
hypertensives off BP systolic and 
Rx, after 8 weeks diastolic BP, and 
CPAP nocturnal systolic 
Davies et at 11 SAHS pts, ABP Nocturnal Decrease in 
1994a some and daytime nocturnal systolic 
hypertensives on BP BP 
Rx 
Hedner et al 12 SAHS pts, ABP Nocturnal No change in 
1995 some and daytime mean 24-hour BP 
hypertensives off BP 
Rx, after 1-2 
years on CPAP 
ABP- ambulatory blood pressure 
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shown decreased daytime (Mayer et al 1991, Wilcox et al 1993, Worsnop et al 1993) 
and nocturnal (Jennum et al 1989, Mayer et al 1991, Wilcox et al 1993, Suzuki et al 
1993) BP. A recent study employing ABP monitoring before and after long-term 
CPAP found no change in BP after CPAP (Hedner et al 1995). 
Patient selection procedures in these studies vary greatly (see Table 9.1), some 
conducted in hypertensive SAHS patients alone (Mayer et a11991, Rauscher et al 
1993a, Worsnop et a11993) and some in mixed normo- and hypertensive patients 
(Jennum et al 1989, Wilcox et al 1993, Davies et al 1994a, Hedner et al 1995). Study 
procedures also vary as to whether patients are studied on (Rauscher et al 1993a, 
Worsnop et al 1993, Suzuki et al 1993) or off (Jennum et al 1989, Mayer et a11991, 
Wilcox et a11993, Hedner et al 1995) anti-hypertensive medication. 
Blood pressure might be expected to show a `white coat effect' of higher BP on first 
recording, which would predispose to findings of lower BP after treatment in 
longitudinal intervention studies. However, only one of the studies of BP after CPAP 
in SAHS (Table 9.1) employed a control for repeated BP measurement (Davies et al 
1994a). Aside from those studies conducted during CPAP administration (Jennum et 
al 1989, Mayer et al 1991, Ali et ah 1992), there is little objective corroboration of 
patients' self-reports of acceptable CPAP compliance (Wilcox et al, Suzuki et al 1993, 
Worsnop et al 1993, Davies et al 1994a, Hedner et al 1995). The only study 
objectively monitoring average CPAP use times (Rauscher et al 1993a) attributed BP 
reductions to weight loss. 
The study reported here investigated the influence of CPAP therapy on nocturnal and 
daytime BP during normal activities within a controlled crossover trial. 
9.1 Study protocol 
Thirteen SAHS patients were prospectively recruited for the placebo-controlled 
crossover study of ABP on CPAP. Most of the patients undergoing ABP testing were 
participating simultaneously in the crossover study of daytime function (Chapter 6), 
with the ABP testing session inserted into the larger protocol Patients spent 4 to 5 
weeks on CPAP and on oral placebo, as previously described (Chapter 6), with 
assessments of weight and ABP conducted after a minimum of 21 and maximum 35 
days on each treatment. 
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A CPAP titration study, performed before the commencement of treatment, 
established the therapeutic pressure at which hypopnoeas and electroencephalographic 
arousals from sleep were minimised. CPAP units (ResCare, Abingdon, UK) issued 
for home use contained hidden timeclocks (Reeves-Hoch6 et al 1994; see Chapter 4), 
read at the beginning and end of the treatment limb, which logged hours of effective 
CPAP use over the treatment limb. Patients were contacted during the second week of 
treatment to check progress with treatment and encouraged to report any problems 
with CPAP use. 
9.2 Subjects 
A total of 16 patients were recruited from a sleep clinic series complaining of least two 
symptoms of SAHS and demonstrating an AHI of 5 or more/hour slept during 
clinical polysomnnography conducted according to our usual method (Gould et al 
1988). Complete assessment datasets were obtained in 13 subjects, one case each 
being lost due to equipment unavailability, poor ABP quality and patient non- 
attendance. 
Ten of the 13 patients participating in the BP trial were also taking part in the crossover 
trial of daytime function, so that treatment order in these patients was effectively 
randomised by the schedule of that trial. An attempt to balance treatment order was 
made with the last 3 patients recruited for ABP and auditory evoked potential 
assessments only. Seven patients commenced treatments with CPAP and 6 with 
placebo tablets. 
These 13 patients (11 male) averaged 51 ± SEM 3 years of age with a mean BMI of 
36.0 (f 2.6) kg/m2. Clinical sleep study yielded an average AHI (Gould et al 1988) of 
48.7 (t 8.6) per hour slept, ranging from 13.5 to 118.2 per hour slept, an average 
microarousal index (Cheshire et al 1992) of 49 ± 11 per hour slept and average 
minimum oxygen saturation of 71 ±6 percent. Four were taking hypertensive 
medication, which remained stable throughout the study period. 
9.3 Ambulatory blood pressure assessment 
ABP was recorded using an oscillometric method (SpaceLabs 90207), the equipment 
consisting of an inflatable brachial cuff connecting via a hose to a pump/solid-state 
memory unit, the size of a Walkman, worn belted to the waist. The cuff was 
automatically inflated and measurement of systolic, diastolic and mean arterial BP 
made at half-hourly intervals throughout the day and night of a 24-hour period. 
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Patients were encouraged to conduct their normal day-to-day activities during the 
recording periods. Subjects underwent three cuff inflations before leaving the lab, to 
familiarise them with the measurement procedure and to reduce any `white coat 
effect'. Systolic, diastolic and mean arterial BP was calculated for 24-hour, daytime 
(08.00-00.00) BP and nocturnal (00.00-08.00) period and percentage nocturnal dip 
(nocturnal BP dip/daytime BP: Verdecchia et al 1990) in systolic, diastolic and mean 
arterial BP determined. 
9.4 Data analysis 
Ambulatory BP data obtained on CPAP and placebo were compared using 2-way 
analysis-of-variance, with treatment order as a between-subjects factor and treatment 
type as a within-subject factor. The change in frequency of `non-dipping' and 
hypertensive ̀cases' was examined with McNemar tests. Because of the large number 
of outcome variables, an alpha value at pS0.01 was adopted to denote significance. 
Subgroups of patients classed as ̀ non-dippers' (placebo-limb nocturnal BP 
dip/daytime BP < 10%: Verdecchia et al 1990), hypertension ̀cases' (placebo-limb 24- 
hour systolic BP > 134 mmHg and diastolic BP > 84 mmHg: Consensus document 
1990) and good CPAP compliers (effective average CPAP use >_ 3 hours/night) were 
selected for further exploratory analysis. Comparisons between ̀dippers' and ̀ non- 
dippers' were made using unpaired t -tests and chi-square tests. 
9.5 Results 
9.5.1 Full group 
Effective CPAP use averaged 4.3 ± 0.6 hours/night over the treatment limb, although 
all patients reported using their CPAP on the night of their assessment The patient 
group showed a non-significantly higher BMI on CPAP (35.8 ± 2.5 kg/m2) compared 
to placebo (see Table 9.2). 
No significant differences between BP variables on placebo and on CPAP were found 
(p>0.05; see Table 9.2), and mean values for ABP variables showed similar profiles 
on the two treatments. No significant changes in the frequency of hypertensive ̀cases' 
(placebo 5 versus CPAP 5; p=1.00) or `non-dippers' (placebo 5 versus CPAP 6; 
p=1.00) were found. No significant order effects on ABP were found (p>O. 12). 
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Table 9.2: CPAP and placebo BP assessment in all patients 
Placebo CPAP 
(Mean ± SEM) (Mean ± SEM) p-value 
24-hour SBP 135±4 134±5 0.63 
(mmHg) 
24-hour DBP 83± 3 81± 3 0.33 
(mmHg) 
24-hour MAP 100 ±3 99 ±3 0.46 
(mmHg) 
Daytime SBP 139 ±3 138 ±4 0.68 
(mmHg) 
Daytime DBP 86± 3 84 ±3 0.13 
(mmHg) 
Daytime MAP 103 ±3 102 ±3 0.26 
(mmH 
Nighttime SBP 129 ±7 124± 5 0.28 
(mmHg) 
Nighttime DBP 76± 4 74 ±4 0.40 
(mmHg) 
Nighttime MAP 94 t5 91± 4 0.31 
(mmf ) 
Nocturnal SBP 7.3 t 3.2 10.2 ± 2.2 0.36 
dip (%) 
Nocturnal DBP 11.7 ± 3.7 12.6 ± 2.9 0.83 
di (%) 
Nocturnal MAP 9.0 ± 3.5 11.1 ± 2.5 0.55 
dip (%) 
BMI (k Im) 35.8 ± 2.5 36.3 ± 2.6 0.08 
ABP- ambulatory BP 
SBP- systolic BP 
DBP- diastolic BP 
MAP- mean arterial pressure 
bpm- beats/minute 
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9.5.2 `Non-dippers' 
Five `non-dippers' were identified, 3 commencing treatment with placebo. 
Examination of background features showed that these patients were not significantly 
older or more overweight than `dippers' (p>0.22). Frequency of 
apnoeas+hypopnoeas, microarousals and 4% desaturations, documented during 
nocturnal polysomnography, were not significantly different in `dippers' and 'non- 
dippers'(p > 0.05). 
The comparison of BP variables obtained on placebo and on CPAP in `non-dippers' is 
shown in Table 9.3. Daytime mean arterial pressure fell significantly from 102 ±4 
mmHg on placebo to 98 ±4 mmHg with CPAP (p=0.01; see Figure 9.1). Two of the 
5 `non-dippers' became ̀dippers' with CPAP, increasing their nocturnal dipping 
percentage from 1% and 7% on placebo to 27% and 13% on CPAP, respectively, but 
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Figure 9.1: Mean arterial blood pressure in `non-dippers' and `dippers' on 
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Table 9.3: CPAP and placebo ABP assessment in `non-dippers' 
Placebo CPAP 
(Mean ± SEM) (Mean ± SEM) p-value 
24-hour SBP 139 ±7 133 ±7 0.03 
(mmHg) 
24-hour DBP 83±4 79±4 0.05 
(mmHg) 
24-hour MAP 102+5 97±5 0.06 
(mmHg) 
Daytime SBP 140±6 136±7 0.14 
(mmHg) 
Daytime DBP 84 ±4 81± 4 0.06 
(mmHg) 
Daytime MAP 102±4 98±3 0.01 
(mmHg) 
Nighttime SBP 144 ± 15 125 ± 11 0.09 
(mmll ) 
Nighttime DBP 85 ±7 74 ±7 0.17 
(mmHg) 
Nighttime MAP 105 ± 10 91 ±8 0.11 
(mmHg) 
Nocturnal SBP 2±6 9±5 0.17 
dip (%) 
Nocturnal DBP 0±5 10± 6 0.33 
dip (%) 
Nocturnal MAP 2 ±5 9±6 0.22 
dip (%) 
ABP- ambulatory BP 
SBP- systolic BP 
DBP- diastolic BP 
MAP- mean arterial pressure 
bpm- beats/minute 
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9.5.3 Hypertensive `cases' and good CPAP compliers 
Five patients were classified as hypertensive (24-hour systolic BP > 134 and diastolic 
BP > 84 mmHg) and 9 patients used CPAP effectively for more than an average 3 
hours/night CPAP did not alter BP significantly in either the hypertensive `cases' or 
the good CPAP compliers. 
9.6 Discussion 
Although based on a limited patient sample, as are all other studies examining ABP 
with CPAP (Davies eta! 1994a, Wilcox et al 1993, Suzuki et al 1993, Hedner et al 
1995), the study shows no generalised improvement in BP profile with CPAP. These 
findings are compatible with those of Suzuki et al (1993) and Hedner et al (1995). The 
study protocol contained the additional control of treatment randomisation to remove 
order effects during repeated testing, the only investigation to provide this. Body mass 
index remained stable both in the full group and in `non-dippers', providing assurance 
that weight changes were not interacting in outcomes. 
Because of the limited sample size, a post hoc power analysis was conducted to assess 
the ability of the study to show differences in BP. Assuming a5 mmHg change in BP 
as the effect size, the power of the study to show differences at the 0.01 significance 
level in diastolic BP and mean arterial pressure is 95ßö and 75% respectively. Because 
of the larger standard deviation in changes in systolic BP with treatment, the power to 
detect a5 mmHg difference in BP at the 0.05 level was reduced to 65 %. 
The findings within the subgroup of `non-dippers' suggest that some patients with 
SANS may benefit from reduction in daytime mean arterial BP with the use of CPAP 
therapy. These findings within a subgroup are compatible with those of others 
showing improved daytime BP with CPAP, measured either casually (Mayer et al 
1991) or with ABP (Wilcox et al 1994). 
In some studies, improvements in daytime (Mayer et a11991, Worsnop et al 1993) 
and nocturnal (Jennum et a11989, Mayer et al 1991, Suzuki et a11993) BP were 
found in hypertensive patients only. Such results were not replicated within the 
subgroup of hypertensive SAHS patients, who showed no changes in BP with CPAP. 
However, selective improvement in daytime BP with CPAP therapy was observed 
within a subgroup of `non-dippers'. 
156 
Chapter 9: Blood pressure study 
The only other study which attempted to examine the role of `dipping' status in BP 
response to CPAP was thwarted by the low frequency of `non-dippers' (1 of 9 
subjects) in the patient group (Suzuki et at 1993). The incidence of `non-dipping' in 
the studied sample (5 of 13 patients) was similar to that in a larger but non- 
interventional study of ABP in SAHS patients, 29% of whom were `non-dippers' 
when withdrawn from hypertensive medication (Wilcox et at 1992). `Dipping' effects 
were found to be independently determined only by BMI in Wilcox et al's study 
(1992), although no significant differences were found between BMI in `dippers' 
compared to the CPAP-responsive group of `non-dippers'. However, the study's 
findings suggest that patients most at risk for cardiovascular disease (Verdecchia et al 
1990) may obtain the greatest benefit from CPAP. 
The study's attempt to relate changes in BP profiles to objectively monitored CPAP 
compliance was unsuccessful. A differential response to CPAP could not be identified 
in good CPAP compliers, but this lack of finding may be due to the limited specificity 
of compliance averaged over a month's treatment, as well as other potential 
confounders, such as ̀ dipping' status. 
The lack of improvement in nocturnal BP and in extent of nocturnal dipping with 
CPAP may conflict with the demonstrated improvement in daytime BP in 'non- 
dippers', as any improvement in daytime BP status is hypothesised to arise as a 
consequence of attenuation of nocturnal cardiac load (Working Group on OSA and 
Hypertension 1993). However, the lack of fording may result from methodological 
limitations in using ABP, which provokes both autonomic and 
electmencephalographic arousal from sleep (Davies et al 1993, Davies et al 1994b). 
Nevertheless, use of a cuff-inflating device is the only method available to record 24- 
hour BP in mobile patients, and may well have a lesser effect on sleep quality than the 
invasive methods used by others (Jennum et al 1989, Mayer et a! 1991). Individuals 
may differ in their degree of autonomic response during arousals, whether caused by 
breathing pauses or by cuff inflation, thus explaining the selective daytime benefits of 
CPAP for BP in `non-dippers' with SAHS. 
157 
Chapter 10: Nocturnal correlates of daytime function 
Chapter 10: 
NOCTURNAL CORRELATES OF DAYTIME FUNCTION IN PATIENTS 
WITH SAiS 
The cause of the daytime problems of SAHS is not well understood, although putative 
determinants in either the sleep fragmentation or hypoxaemia experienced by SAHS 
patients during sleep, or a combination of the two factors, are thought to be involved. 
The literature is equivocal on the best nocturnal correlates of both objective daytime 
sleepiness and cognitive dysfunction. 
As described in Section 2.7.2, evidence can be found to support hypotheses that any 
one of the nocturnal physiological events of SAHS is most closely related to each 
aspect of daytime impairment. In previous correlative studies, there is little agreement 
on the strongest nocturnal correlate of the daytime impairments of SAHS. Objective 
daytime sleepiness has been correlated most highly, or independently in multiple 
regression models, with AHI in some studies (Yesavage et al 1985, Poceta et al 1992, 
Johns 1993), but with minimal oxygen saturation (Mendelson 1992, Bbdard et al 
1991a) or arousal frequency (Roehrs et al 1989, Stepansid et al 1984) in others. 
Cognitive performance has been significantly correlated with AHI (Yesavage et al 
1985, Naegele et al 1995), measures of hypoxaemia (Findley et al 1986, Bedard et al 
1991a, Naegel6 et a! 1995) and nocturnal indices of sleep fragmentation (Cheshire et al 
1992). 
This conflict in the literature is likely to relate to differences in both the sensitivity and 
selection of nocturnal measurements, as well as to the intercorrelation within the 
nocturnal and daytime measures being assessed. Some studies did not include a 
representative sample of measures of individual nocturnal events, while in those that 
did, the contrasts in the strongest correlates of daytime impairments might suggest that 
nocturnal events are so tightly bound as to be inconsistently separable. 
Even studies designed to elucidate this question (Colt et al 1991, Nagele et al 1995) 
have not provided clear-cut descriptions of the specific daytime impairments 
attributable to oxygen desaturation or to sleep disruption. Nevertheless, the question of 
the nocturnal determinants of daytime impairment in SANS has considerable clinical 
salience. As outlined in Chapter 2, the reversibility of daytime consequences of 
hypoxaemia may be different from that of deficits related to sleep fragmentation. Thus 
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the focus of this thesis, the reversibility of daytime impairments in SAHS patients by 
CPAP, may be conditional to the source of these deficits. 
Although the crossover study (Chapter 6) was designed as a treatment intervention 
study, the protocol design yielded data that could be used to examine the relationships 
between nocturnal events and daytime function. Patients participating in the crossover 
study of daytime function underwent full polysomnography and also attended for a 
psychometric familiarisation session before proceeding to treatment These 
assessments provide a baseline dataset of nocturnal and daytime function, free from 
learning, placebo or active treatment effects, allowing an correlative analysis of 
putative determinant variables and dependent daytime function variables to be 
undertaken. 
A large number of variables were obtained from the assessments of 
polysomnography, cognitive performance and well-being. To reduce their number, but 
still retain the information underlying the variables, principal components analysis was 
conducted. This exploratory factor analysis simplifies the complex structure of 
intercorrelations between variables by `pulling out' underlying patterns common to 
variables, which can then be expressed as variables in themselves. Principal 
components analysis is also useful in describing the tightness of the relationships 
between variables, by providing a quantitative measure of the proportion of total 
variance in variable scores explained by individual components. 
Thus principal components analyses of measures within nocturnal 
(polysomnography) and daytime (cognitive performance and well-being) domains 
were conducted, in order to investigate the underlying structure among these measures 
and to provide a rational basis for reducing the number of these variables. Such 
`simplified' factor scores, along with an objective measure of sleepiness, were then 
inserted in a correlation matrix, to examine relationships between putative determinant 
nocturnal variables and dependent daytime variables. 
10.1 Patients 
Sixty-six patients, including two who withdrew during the subsequent treatment 
protocol, had baseline polysomnography, psychometric familiarisation and objective 
daytime sleepiness tests off active (CPAP) treatment These formed the sample for the 
exploratory factor and correlative analyses. The patient sample comprised 59 men and 
7 women, with an average of age of 49 ± SEM 1 years and mean body mass index of 
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31.2 ± 1.0 kg/m2. Polysomnography (see below) showed that patients had an average 
AHI of 35 ± 4, microarousal index of 43 ±4 and 17 ±3 4% desaturations per hour 
slept Mean minimum oxygen saturation was 79 ±2%. Mean sleep onset latency on 
the placebo limb, reflecting objective daytime sleepiness off active treatment, averaged 
7.0 ± 0.6 minutes. 
10.2 Assessments 
10.2.1 Polysomnography 
Full polysomnography was conducted in all patients and included monitoring of EEG, 
EOG, EMG, respiratory movement by inductance plethysmography, oronasal airflow 
by thermistor and oxygen saturation by pulse oximetry. Summary indices of 
frequency of apnoeas and hypopnoeas (Gould et al 1988), microarousals from sleep 
(Cheshire et al 1992) and 4% oxygen desaturations were calculated. Minimum 
oxygenation level was noted. These variables were considered putative predictors of 
daytime function. 
10.2.2 Daytime function tests 
Assessments at the familiarisation battery included tests of symptoms, subjective 
sleepiness, cognitive performance and well-being. Scores from these tests formed the 
dependent variables. Symptoms were assessed using the in-house symptom 
questionnaire and sleepiness with the subjective Epworth sleepiness scale. The mean 
sleep onset latency from the placebo assessment MSLT was used as a measure of 
objective daytime sleepiness off active treatment. Performance tests administered at 
the familiarisation session comprised the National Adult Reading Test (NART), the 
object assembly, picture completion, picture arrangement, block design and digit 
symbol substitution performance subtests from the WAIS-R battery, TrailMaking 
tasks A and B, Hick reaction time (RT) test, rapid visual information processing 
(RVIP) test, SteerClear, PASAT at 4 and 2 second presentation rates, the Borkowski 
verbal fluency test and the Benton visual retention test (BVRT). Psychological distress 
was assessed with the hospital anxiety and depression (HAD) and general health 
questionnaire-28 (GHQ-28) scales. Quality-of-life was rated using the Nottingham 
health profile (NHP) part 2 and mood state with the UWIST mood adjective checklist 
(UMACL). 
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10.3 Data analysis 
10.3.1 Principal components analysis of measures 
Principal components analysis can be used to examine the framework of association 
between measures. Using algebra or geometry, principal components analysis can 
construct mathematical representations of the relationships between the multiple 
measures of large datasets. In a geometric representation, vectors representing the size 
and direction of correlations between 3 or more variables can be plotted in 
multidimensional space. Reference vectors, set orthogonally (at 90 degrees) to each 
other, can then be applied to a grouping of plotted variable vectors, to quantify the 
associations between the variable correlations and the reference vectors. The reference 
vectors represent putative `factors', patterns of common structure, to which some 
variable vectors may have a significant relationship. The relative position of a variable 
vector to a reference vector can be mathematically transformed into a test statistic 
known as a `loading', a quantitation of the degree of association between the variable 
and the factor. The variable loadings on the first reference vector, or factor, applied to 
the plot will subsume the largest proportion of variance within variable scores, 
subsequently extracted factors accounting for smaller and smaller proportions of total 
variance. The strength of a principal component factor in explaining total variance is 
expressed in a test statistic known as an eigenvalue, comprising the sum of the squares 
of the loadings on a factor, divided by the number of variables. In principal 
components analyses which extract more than one significant factor, the contrasts 
between the individual factor loadings of a single variable are not always maximised, 
with many variables showing significant but low loadings on multiple factors. The 
differences between factor loadings of different variables can be enhanced 
subsequently by spatially rotating the reference vectors. This has the effect of 
providing greater interpretability to the matrices of variables' factor loadings, by 
maximising disparities between the loadings on different factors of different variables. 
Variables within each of the domains of polysomnography, cognitive function and 
well-being were subjected to exploratory factor analysis (Child 1990) in order to 
simplify the structure, and rationally reduce the number of variables for subsequent 
correlation. 
The principal components analysis of the domain of polysomnography was conducted 
on the variables AHI, microarousal index, minimum oxygen saturation and 4% 
desaturation rate. 
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Within the cognitive domain, variables that were transformations of other raw scores 
(performance IQ, IQ decrement), or inverses of other raw scores (BVRT errors) and 
those which were excessively truncated (Borkowski perseverations) were excluded, as 
recommended (Child 1990). Cognitive scores considered to be primarily for task 
practice (4 second presentation rate PA SAT, TrailMaking A) were also excluded, to 
reduce the number of variables so that an acceptable ratio between sample size and 
variable number was achieved (Child 1990). Remaining variables for the exploratory 
factor analysis of cognitive function comprised the scores for NART pre-morbid 
performance IQ estimate, all WAIS-R performance subtests, TrailMaking B, RVIP 
hits and misses, BVRT correct, 2 second presentation rate PASAT, SteerClear, verbal 
fluency word naming total, and median decision and movement times and decision 
time slope from the Hick RT. 
The factor structure of the domain of well-being was examined using principal 
components analysis of the total scores of the GHQ-28 and NHP part 2, and subscale 
scores for anxiety and depression (HAD scale) and energetic arousal, hedonic tone and 
tense arousal (UMACL). 
In each of these separate principal components analyses, factors with eigenvalues 
greater than 1.00 were extracted, and, when multiple factors were identified, subjected 
to oblique rotation. Oblique rotation was selected in preference to orthogonal rotation 
due to the intercorrelation of the extracted factors (r approximating 0.30). Variable 
factor loadings greater than 0.30 were considered significant. Following oblique 
rotation, the structure factor matrix was selected in preference to the pattern matrix 
because of the exploratory nature of the analysis (Child 1990). 
Factor regression scores, derived from equations modelling the loadings of test scores 
on factors, were calculated to reflect each subjects' scores for principal components 
and rotated factors. These factor regression scores were saved and used in the 
subsequent correlational analysis. 
10.3.2 Correlation analysis 
Putative determinant variables in the form of polysomnographic measures were 
entered into a correlation matrix with the factor scores created as a result of the factor 
analyses above. Daytime sleepiness and mood were considered potential predictors of 
cognitive function, so mean sleep onset latency and the ̀ well-being' factor score were 
tested both as putative determinants of daytime function and as dependent variables. 
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Non-normal data, comprising all the polysomnographic variables, were normalised 
with log transformation. Partial Pearson correlations, controlling for age, were 
conducted between the dependent daytime variables and putative determinants. 
Dependent variables showing multiple significant correlations with individual 
polysomnographic variables were subjected to multiple regression to seek independent 
correlates of daytime function. Multiple regression was conducted by a mixed direct 
and stepwise method, first entering age directly, then proceeding to stepwise addition 
of significant correlates. In this technique, successive predictive variables which 
explain a significant proportion of variance in test scores are entered into a equation. 
This technique takes account of the intercorrelations between putative determinant 
variables, as the first entered of two nearly-identical determinants will subsume nearly 
all the variance explained by the second. Because the determinants are entered in a 
stepwise fashion, i. e. starting with the best correlate of the dependent variable, the 
strongest correlates of dependent variables will gain a larger role in the equation, at the 
expense of weaker but related correlates. 
10.4 Results 
10.4.1 Principal components analysis of polysomnography 
principal components analysis of AHI, microarousal index, minimum oxygen 
saturation and 4% desaturation rate extracted a single component with eigenvalue 3.30, 
explaining 83% of the total variance in polysomnographic measures (Table 10.1). This 
component was called `SANS severity'. 
Table 10.1: Polysomnographic principal components matrix 
First principal component 
AHI 0.94 
4% desaturation rate 0.93 
Microarousal index 0.89 
Minimum 02 -0.86 
10.4.2 Principal components analysis of cognitive performance 
Principal components analysis extracted four factors. The first unrotated principal 
component and the four rotated factors are shown in Table 10.2, with significant 
loadings highlighted with bold typeface. 
The first unrotated principal component had an eigenvalue of 6.44, accounting for 40% 
of the total variance in scores. This principal component corresponded with 
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Spearman's ̀g', or general ability factor, which determines the largest proportion of 
individuals' variance in cognitive skill (Spearman 1927). This first principal 
component showed significant loadings on all variables except decision time slope and 
RVIP hit score, the highest of these on tests of general performance ability, including 
the digit symbol and block design subtests from the WAIS-R battery, and 
TrailMaking B. This component was called ̀ general ability' for the subsequent 
correlational analysis. 
Table 10.2: Cognitive domain: first unrotated principal component and rotated 
















WAIS-R Block design 0.77 0.81 0.50 0.28 -0.33 
RVIP misses -0.45 -0.77 -0.12 0.14 0.20 
BVRT correct 0.67 0.76 0.19 0.38 -0.37 
TrailMaking B -0.83 -0.74 -0.47 -0.41 -0.38 
WAIS-R Digit symbol 0.80 0.73 0.37 0.43 0.55 
W AIS-R Picture arrangement 0.74 0.55 0.78 0.29 -0.28 WAIS-R Picture completion 0.59 0.34 0.74 0.04 -0.37 
NART estimated IQ 0.64 0.30 0.72 0.54 -0.21 W AIS-R Object assembly 0.57 0.47 0.59 0.20 -0.17 Decision time slope -0.22 -0.30 0.41 -0.40 0.40 
RVIP Hit -0.30 0.07 0.02 0.81 -0.13 SteerClear -0.74 -0.55 -0.39 -0.59 0.51 
PASAT 2 second rate 0.70 0.51 0.37 0.54 -0.50 
Median decision time -0.50 -0.28 -0.01 -0.27 0.88 Median movement time -0.50 -0.31 -0.16 -0.09 0.78 
V e" fluency total 0.73 0.38 0.58 0.49 -0.59 
The extracted components were then rotated, and factor loadings examined to interpret 
the loadings' mapping of areas of cognitive skill (Table 10.2). The first oblique rotated 
factor had significant loadings on many of the scores in the performance battery, but 
the highest of these were on block design, Benton visual retention and RVIP miss 
scores. The WAIS-R subtests showing high loadings on this factor, block design and 
digit symbol, are those relying most on abstract skills and least on culturally and 
educationally derived knowledge. This pattern of loading, in contrast to that of the 
second oblique rotated factor described below, appeared to be biased towards tests of 
reasoning and conceptual ability. In examinations of the higher-order factors extracted 
during analyses of intellectual performance, these types of skills have been linked to 
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the factor called `fluid ability' (Horn and Cattell 1966). This factor is thought to relate 
to inherited, or otherwise biologically-determined, intellectual ability. Because of this 
speculative resemblance between the first oblique rotated factor and Horn and Cattell's 
(1966) fluid intelligence, this factor was called `fluid ability'. 
The second oblique rotated factor showed highest loadings on the picture arrangement, 
object assembly and picture completion subtests of the WAIS-R battery, the most 
culture-dependent subtests of the WAIS-R performance battery. Performance on these 
subtests requires culturally-obtained knowledge, such as familiarity with stylised 
graphic images (object assembly), the existence of a rowlock on a rowing boat (picture 
completion), or the humorous sequence of events in cartoons (picture arrangement). 
This factor also had a high loading for the NART score, dependent on educationally- 
obtained knowledge of esoteric vocabulary. The suggestion from this segregation was 
that the second factor might reflect `crystallised ability' in intellectual function (Horn 
and Cattell 1966), another higher-order factor indexing the accretion of cultural and 
educational influences. Thus this factor was named `crystallised ability'. 
The third oblique rotated factor showed high loadings on RVIP hit score, SteerClear 
and 2 second presentation rate PASAT. All of these are challenging tasks in which 
subjects are under pressure to process information rapidly. The SteerClear task 
resembles a prolonged reaction time test with frequent stimuli, while the PASAT 
requires shorter periods of intense information processing. The RVIP hit score is a 
measure of `signal detection' ability and is both extended and cognitively challenging. 
These three tests are rapid, complex and require the maintenance of concentration; all 
might be thought likely to index physiological activation. This third factor appeared to 
load most heavily on tests requiring vigilance and attention, and bore similarities to, 
and was thus named after, the primary-order factor described as `perceptual speed' by 
Horn and Cattell (1966). 
The fourth oblique rotated factor showed its largest loadings on reaction times (both 
movement and decision) and on verbal fluency total. It also showed significant 
loadings on digit symbol, PASAT and SteerClear. All of these test scores are strongly 
determined by cognitive and motor speed. The fourth oblique rotated factor had high 
loadings for decision and movement times from the Hick RT task and verbal fluency 
total, all dependent on subject pacing, and was thus named ̀response speed'. 
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10.4.3 Principal components analysis of well-being 
Principal components analysis of scores for HAD scale anxiety and depression, 
GHQ-28, NHP part 2 and the UMACL scores for energetic arousal, tense arousal and 
hedonic tone extracted a single component, with eigenvalue 4.68 (Table 10.3). This 
component accounted for 67% of total variance in well-being scores. 
Table 10.3: Well-being principal components matrix 
HAD Depression 
NHP part 2 total 
HAD Anxiety 
GHQ-28 total 
UMACL tense arousal 
UMACL hedonic tone 
UMACL energetic arousal 








The principal components analyses described above provided a rational structure for 
reducing the number of variables in each of the examined domains of function. Only 
one significant factor could be resolved within the respective domains of 
polysomnography and well-being, suggesting that the variables within each of these 
domains were largely determined by single underlying attributes. The analysis of 
cognitive function suggested that four significant factors could be identified to explain 
the patterns of scores. 
The factor regression scores derived from factors resolved by the above principal 
components analyses were used pragmatically as variables in themselves, and entered 
into a subsequent correlational analysis. 
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10.4.4 Correlations between nocturnal variables and domains of daytime 
function 
The constructed correlation matrix (Table 10.4), controlled for age, was used to 
examine associations between putative determinants (`SANS severity' component 
score, individual polysomnographic scores, placebo mean sleep onset latency, ̀well- 
being' factor score) and dependent daytime function variables ('general ability', `fluid 
ability', `crystallised ability', `perceptual speed ̀response speed' and ̀ well-being' 
factor scores, placebo mean sleep onset latency and symptom total). 
Better status in the correlation matrix was reflected by lower scores for the `SANS 
severity' factor, AHI, microarousal index, 4% desahuation rate, `well-being' and 
`response speed' factors, and for symptom total. Better status was reflected by higher 
score for minimum oxygen saturation, mean sleep onset latency, and for `general 
ability', `fluid ability', `crystallised ability' and `perceptual speed' factors. 
Six significant correlations were observed in the correlation matrix, all of these weak 
in magnitude. ̀SANS severity' score correlated significantly with the ̀ general ability' 
and ̀ crystallised ability' cognitive factors, linking greater illness severity with poorer 
cognitive performance. ̀SAHS severity' score, AHI and minimum oxygen saturation 
each correlated significantly, and in the expected direction, with mean sleep onset 
latency. These correlations associated greater SAHS illness severity with-greater 
objective daytime sleepiness. Minimum oxygen saturation showed a significant, 
positive relationship with symptom total, linking worse illness status with lesser 
symptom complaints. 
Mean sleep onset latency showed plural suggestive relationships with putative 
determinants, by correlating significantly with the individual polysomnographic 
variables of AHI and minimum oxygen saturation. A multiple regression analysis was 
thus conducted, to investigate which of these individual polysomnographic variables 
independently showed the closest relationship with the daytime function variables. 
After the variance attributable to age had been subtracted, by forcing age into the 
regression model, the only independent correlate of placebo sleep onset latency was 


















es . 4.6 




C. i W) 
3 ö ý? ö V Ö Ö ý ö 
















N N - N O 




O N E 9 99 4 9 9 9 




d Q Ö Q Ö Q Q Q Q 
cO 
CPS ON 









Chapter 10: Nocturnal correlates of daytime function 
10.5 Discussion 
This exploratory analysis of baseline data used principal components analysis to 
rationally reduce the large number of nocturnal and daytime function variables 
obtained in the SAHS patient sample. The reduced variables were then examined 
using univariate and multiple correlation techniques, to investigate possible 
determinant relationships. The age-controlled correlation analysis showed significant 
but modest relationships between AHI and sleepiness and between the overall severity 
of SAHS and cognitive impairment. These findings indicate that overall severity of 
SAHS contributes to the scale of daytime impairments. One of the aims of this study, 
to examine the relative strength of hypoxaemic and sleep-disruptive processes in 
determining daytime impairments, was thwarted by the paucity of significant 
relationships between individual nocturnal events, biased towards measuring sleep 
fragmentation or hypoxaemia, and daytime function. Nevertheless, the principal 
components analysis of the domains of polysomnography, cognitive performance and 
well-being provided useful information on the structure underpinning the scores in the 
domains. 
The principal components analyses of daytime function variables in the domains of 
polysomnography, cognitive function and well-being produced coherent factor 
explanations. Tight linkage between the variables within the respective domains of 
polysomnography and well-being was observed. Within each of these domains, only a 
single factor was demonstrated, explaining in each case a substantial majority of the 
total variance in scores. These principal component analyses suggested that a high 
degree of intercorrelation existed within the psychological distress variables and the 
polysomnographic variables respectively. Thus high scorers for quality-of-life, for 
example, were also likely to score highly for depression, and patients with a minimal 
AHI also demonstrated few microarousals. 
The principal components analysis of the cognitive domain extracted a first, unrotated 
principal component and four oblique rotated factors. These rotated factors showed 
segregation in item loadings consistent with some of the first and second order factors 
in intellectual ability identified by Horn and Cattell (1966), towards which the 
cognitive battery was biased. The cognitive factor scores thus appeared to demonstrate 
internal coherence. 
In the univariate correlational analysis (Table 10.4), three significant nocturnal 
correlates of objective daytime sleepiness were found, comprising the ̀ SAHS 
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severity' component, AHI and minimum oxygen saturation. The multiple regression 
of objective daytime sleepiness showed AHI as the only independent correlate 
amongst the individual polysomnographic measures. This finding corroborated 
others' reports of AHI as the best nocturnal predictor of sleep onset latency (Yesavage 
et al 1985, Poceta et al 1992, Johns 1993), and may help cross-validate AHI as the 
best currently available measure of severity of SAHS, as suggested in other studies of 
polysomnographic techniques in diagnosing SAHS (Gould et al 1988). Nevertheless, 
the correlation between AHI and mean sleep onset latency was moderate in size 
(multiple r=0.36), explaining only 13% of the variance in scores. 
`SAHS severity' score related significantly, and in the hypothesised direction, with the 
`general ability' and `crystallised ability' cognitive factor scores. The correlation with 
'general ability' is coherent, suggesting that overall cognitive performance is related to 
overall severity of SAHS. It was perhaps surprising that `SAHS severity' score was 
also significantly related to the `crystallised ability', but not the `fluid ability', cognitive 
factor. These cognitive factor names are speculative and tentative, but may 
nevertheless suggest the `flavour' of the factors. It is `fluid intellect' (Horn and Cattell 
1966) which is considered most related to biological determinants of CNS function, 
such as inheritance or organic insults, while `crystallised intellect' may index the 
cognitive performance attributes relating to acquired knowledge and environmental 
influence. It may be that the severity of SAHS causes selective impairment to 
educationally-obtained knowledge and learned skills, rather than to biological 
information-processing ability, but wide-ranging conclusions should not be drawn 
from this result. Although the correlation with `crystallised ability' (r--0.27) is larger 
in magnitude than that demonstrated for the `fluid ability' score (r=-0.07), these 
correlation coefficients are unlikely to be significantly different. 
In the correlation analysis, minimum oxygen level was positively related to larger 
symptom score. This finding indicates that more severe hypoxaemia was associated 
with a fewer number of symptom complaints. This may reflect the loss of awareness 
of impairment with greater hypoxaemia, or possible over-rating of symptom severity 
in the milder patients of this study, but may also reflect the poor value of symptoms in 
predicting severity of SAH S. The lack of specificity of symptom complaints for 
predicting illness severity has previously been reported by others (Hillerdal et al 1991, 
Hoffstein and Szalai 1993, Olson et al 1995). 
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The correlation between minimum oxygen saturation and symptom complaints may 
also represent a Type 1 statistical error, two or three of which might be expected by 
chance alone in a correlation matrix containing 56 cells. However, the potential for 
spurious findings in the correlational analysis was reduced by the use of two-tailed 
probabilities and principal components analysis, which consolidated factors 
underpinning test scores and minimised the number of correlations conducted. 
The well-being factor score showed no significant correlations with either nocturnal 
determinants or daytime impairments, suggesting that simple, positive and linear 
relationships between severity of SAHS and distress were not observed. However, a 
preliminary report has previously documented a counter-intuitive negative correlation 
between depression ratings and AHI (Watson et al 1985), linking greater distress with 
milder SAHS. This report is also consistent with the finding associating greater 
symptom complaints with milder hypoxaemia, discussed above. 
The findings from the crossover study of CPAP (Chapter 6) indicated that the daytime 
impairment of SAHS were to some degree reversible, although the scale of these 
CPAP-mediated improvements was not clarified due to the study design. 
Nevertheless, the breadth of the improvements across the range of daytime function 
might support the hypothesis that sleep fragmentation was the more potent 
determinant of impairment. This suggestion is supported by similarities in type and 
scale of impairment in sleep-fragmented normals (Martin et al 1995c) and 
improvements with CPAP in the crossover study (Chapter 6). However, in the current 
study, hypoxaemic-weighted and sleep disruption-weighted variables did not show 
selective or independent associations with specific daytime impairments. This may 
relate to the peculiarities of the patient sample, biased towards milder patients, but may 
also be due to the tight intercorrelations between nocturnal events. 
This latter view is supported by the findings of the principal components analysis of 
the polysomnographic variables, which showed only one factor underlying the 
variance in these measures, and determining the substantial majority of total variance. 
This study's lack of success in extracting individual polysomnographic determinants 
of most daytime deficits, has been encountered by others (Guilleminault et al 1988, 
Cheshire et al 1992) using multiple regression. Their lack of success in building 
multiple regression models, and ours in demonstrating individual polysomnographic 
predictors of sleepiness and cognitive impairment, may be related to the tightly-bound 
structure of the nocturnal measures, which are so closely linked as to defy 
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disentanglement The demonstration of this strong principal component may help 
explain the disparity in previous studies regarding the best correlates of daytime 
function, as findings will be heavily influenced by the loading of particular 
measurement sensors or scoring techniques on this primary severity factor. 
In this study, objective daytime sleepiness was found to be independently determined 
only by AHI, with no additional significant contribution from microarousal index, 
minimum oxygen saturation or 4% desaturation rate. None of the cognitive 
performance factor scores correlated significantly with individual polysomnographic 
variables that were hypoxaemia-weighted or sleep disruption-weighted. 
These finding conflict with the work of others, showing significant relationships 
between cognitive performance and both hypoxaemia (Findley et al 1986, Cheshire et 
al 1992, Bedard et al 1991x, Naegele et al 1995) and microarousal frequency (Cheshire 
et al 1992), and between daytime sleepiness and hypoxaemia (Mendelson 1992, 
Bedard et al 1991a) or microarousal frequency (Roehrs et a11989, Martin et al 1995b). 
This may result in part from a bias towards milder patients in this current sample. 
Alternatively, it may reflect that, with the exception of Cheshire et al (1992) and 
Martin et al (1995b), no adjustment for age, in the form of a partial correlation, was 
made. Greater age might be expected to be associated with both worse SAHS severity 
and lesser cognitive performance, and might thus contribute to the correlations 
between nocturnal events and daytime deficits. 
In contrast to the studies of others, performed in the same laboratory (Cheshire et al 
1992, Martin et al 1995b) and elsewhere (Roehrs et al 1989), this study showed no 
significant correlations between microarousal index and daytime function. In other 
Scottish National Sleep Lab (SNSL) studies, microarousals formed coherent and 
significant (if weak) associations with cognitive function (Cheshire et al 1992) and 
objective daytime sleepiness (Martin et al 1995b). In these, worse sleep fragmentation 
was associated with greater daytime impairment Part of this discrepancy may arise 
from the bias towards patients with mild illness in the present study. A further 
potential explanation for the surprising lack of microarousal correlates in this study is 
the fact that it alone of the SNSL microarousal studies used several scorers of 
microarousals. It may be that inter-rater variability compromised the reliability of the 
microarousal variable. 
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Recent interest has been generated in `sub-cortical' arousals, changes in autonomic 
markers such as blood pressure, that precede full-blown `cortical' arousals measured 
by scalp EEG techniques (Davies et al 1993,1994b, Rees et al 1993, Rees and 
Calverley 1995, Calverley and Rees 1995, Rees et at 1995, Sahloul et al 1995). Part of 
this interest has been generated by the observations of relatively weak associations 
between EEG measures of sleep fragmentation and daytime function. It may be that 
future research may validate novel, autonomic markers of sleep disturbance as more 
sensitive to daytime deficits. 
In summary, significant but modest relationships were observed between 
polysomnographic illness severity and both cognitive performance and objective 
daytime sleepiness. The factor score for `SAHS severity' correlated significantly with 
cognitive impairment, while AHI was identified as the only independent correlate of 
daytime sleepiness. Principal components analysis identified tight linkage between the 
polysomnographic variables examined. This close association between 
polysomnographic measures may explain our own inability to describe hypoxaemic- 
or sleep fragmentation-related determinants of daytime impairment, and others' 
difficulties in building multiple regression models of daytime function by 
hypoxaemia-weighted versus sleep fragmentation-weighted variables. Greater 
hypoxaemia was linked to lesser symptom complaints by patients. Impairments in 
well-being were not associated with the severity of SAHS. The relative paucity of 
significant correlations, and their small magnitude, may be due in part to peculiarities 
of the patient sample, or to possible technical deficiencies in scoring reproducibility. 
However, these findings may demonstrate that few simple dose-response 
relationships between nocturnal events and daytime function exist, and that the impact 
of illness is not mechanistically linked to individual nocturnal events. 
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Chapter 11: 
SELF-REPORTED USE OF CPAP AND BENEFITS OF CPAP THERAPY: 
A PATIENT SURVEY 
CPAP is effective in reducing nocturnal events of SAHS (Sullivan and Issa 1980), 
and it has been suggested both in the crossover study (Engleman et al 1994b; Chapter 
6) and by others to improve objective daytime sleepiness, cognitive function and 
wellbeing (Kribbs et al 1993b, Bedard et al 1993, Derderian et al 1988). Yet CPAP is 
frequently rejected by patients (Waldhorn et al 1990, Rauscher et al 1991), at least 
partly because of the unwieldy and inconvenient nature of the treatment. Patients' use 
of CPAP is likely to be determined by perceived benefits and drawbacks of treatment, 
but the determinants of these factors are not well understood. 
Studies of CPAP use, its determinants and effects are highly variable in terms of 
patient selection and outcome measures employed, and thus in results reported (Nino- 
Murcia et al 1989, Findley et al 1989a, Lamphere et al 1989, Waldhorn et al 1990, 
Fletcher and Lockett 1991, Rauscher et al 1991, Krieger 1992, Hoffstein et al 1992, 
Waldhorn and Wood 1993, Bedard et al 1993, Kribbs et al 1993a, Kribbs et al 1993b, 
Rauscher et al 1993b, Reeves-Hoche et al 1994, Fleury et al 1994, Meurice et al 1994, 
Pepin et al 1995). Studies based primarily on objective measures of function may 
neglect patient assessment of benefit (Kribbs et al 1993b, Bedard et al 1993, Pepin et 
al 1995). Those studies using self-reported measures (Meurice et al 1994, Rauscher et 
al 1991, Rauscher et al 1993b, Waldhorn et al 1990, Waldhorn and Wood 1993) 
usually examine limited areas of function, often sleepiness alone, while open-ended 
questionnaire formats (Hoffstein et al 1992) restrict comparability between studies. 
With two exceptions (Krieger 1992, Pepin et al 1995), one synchronous with the 
current study, studies of CPAP's effects have been performed in small patient 
samples of less than 100 patients. 
CPAP use rate varies between 3.2 to 6.7 hours/night, depending on whether new 
CPAP users (Kribbs et al 1993a, Reeves-Hoche et al 1994, Engleman et al 1993, 
Engleman et al 1994a, Engleman et al 1994b), cross-sectional CPAP clinic 
populations (Krieger 1992, Rauscher et al 1993b, Pepin et al 1995) or selected long- 
term acceptors of CPAP (Fleury et al 1994, Meurice et a11994, Fletcher and Luckett 
1991) are studied. The literature on the determinants of CPAP compliance and 
acceptance is contradictory, with CPAP use predicted by polysomnographic severity 
in some (Rauscher et al 1991, Rauscher et al 1993b, Meurice et al 1994) and not other 
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studies (Waldhorn et a1 1990, Fletcher and Luckett 1991, Hoffstein et al 1992, Kribbs 
et al 1993a, Reeves-Hocke et a11994, Engleman et al 1994a), by prior sleepiness in 
some (Waldhorn et a11990, Rauscher et al 1991) but not others (Hoffstein et a11992, 
Rauscher et al 1993b, Kribbs et al 1993a, Engleman et al 1994a), and compliance 
adversely affected by side-effects in some (Rauscher et al 1993b, Hoffstein et al 1992, 
Engleman et al 1994a) but not other studies (Waldhorn et a11990, Fletcher and 
Luckett 1991, Kribbs et al 1993a, Nino-Murcia et a11989, Pepin et a11995). 
A particular area of interest is the effect of CPAP on driving competence. The road 
traffic accident rate in SAHS is increased by a factor of 2 to 7 times that of the normal 
population (Findley et al 1988, George et al 1987), either as a result of sleep intrusion 
(Home 1992) or generalised performance deficits (Cheshire et al 1992). Sleep-related 
accidents cause more fatalities than other accidents (Parsons 1986, Zomer and Lavie 
1990, Home and Reyner 1995). A short report has suggested a relationship between 
driving accident rate and sleep apnoea severity (Findley et al 1989b). Lab-based 
studies, whether using monotonous driving-based vigilance tasks (Findley 1989a) or 
more realistic simulators (Haraldsson et al 1991), suggest improved driving 
performance after CPAP (Findley et al 1989a) and uvulopalatopharyngoplasty 
(Haraldsson et al 1991), but actual driving competence after CPAP has not been 
evaluated. 
This questionnaire-based study therefore assessed reported use of CPAP and 
perceived benefits and drawbacks of CPAP therapy in a clinic population, so that these 
factors could be described and relationships between them could be examined. 
11.1 Methods 
11.1.1 Study design 
A questionnaire (Appendix A) was sent in June 1994 to all patients issued with 
CPAP units by the Scottish National Sleep Laboratory (SNSL) for 2 weeks or longer. 
Questionnaire data were supplemented with information, obtained from SNSL 
records, on age, sex, polysomnographic SAHS severity, objective CPAP use from 
runtime clock readings and objective daytime sleepiness on the multiple sleep latency 
test (MSLT) (Carskadon et al 1986, Thorpy 1992). Information from the 
questionnaire and SNSL sources were grouped into domains of illness severity, 
CPAP compliance, road traffic incidents and sleepiness before and after CPAP, 
perceived change in function and symptoms, problems with CPAP use and weight 
change. 
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11.1.2 Questionnaire 
All 253 patients issued with CPAP unit by the SNSL, and their partners, were sent a 
four-page questionnaire (Appendix A) enquiring about use of CPAP, sleepiness and 
road traffic incidents before and after CPAP, changes in nocturnal and daytime 
function, problems with CPAP therapy and weight change. 
Self-reported CPAP use 
Patients were asked how many nights per week and for how long each night CPAP 
was used. This data allowed an average self-reported use-rate to be calculated. 
Epworth Sleepiness Score 
Patients' subjective sleepiness after and, retrospectively, before CPAP was rated by 
patients and their partners using the Epworth sleepiness scale (Johns 1991,1992, 
1993,1995), a self-rating of sleepiness behaviour in the recent past. 
Road traffic incidents 
Drivers were asked their yearly mileage and the frequency of road traffic incidents in 
the 5 years before starting CPAP and in the time since CPAP was commenced. Self- 
reported incidents were divided into near-misses, casualty-free collisions ('minor' 
collisions) and accidents causing injury ('major' collisions) and further subdivided for 
those felt to be sleep-related or not. The rates of road traffic incidents per 10,000 miles 
were calculated for each class of event. 
Function and symptoms 
Patients were asked to rate changes in function and symptoms on a bipolar 5-point 
scale with options of much worse, worse, no change, better and much better, coded 
-2, -2,0, + 1, +2 respectively. Items rated by patients were snoring, breathing pauses, 
daytime sleepiness, sleep quality, tiredness, concentration ability, ability to drive long 
distances safely, work of ciency, time taken off work, sex drive and general health. 
Partners were asked to rate change in patients' snoring, breathing pauses, daytime 
sleepiness and temper. 
Problems with CPAP use 
Patients were presented with a 12-item list of frequently reported side-effects and 
problems with CPAP use, and asked to indicate on a4 point-scale whether each 
problem was absent, a minor problem, a significant problem but not interfering with 
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CPAP use or a significant problem interfering with CPAP use. The items comprised 
nasal stuiness, dry throat, red/sore eyes, leaking mask, cold airstream, nosebleeds, 
mask rubbing, difficulty exhaling, more frequent awakenings, excessive noise fr' om 
CPAP unit, stomach bloating' latulence and chest wheeze. 
Change in weight 
Patients were asked to report any weight gain or loss since the commencement of 
CPAP treatment 
Items not completed by or inapplicable to individuals were excluded from relevant 
item analyses. 
11.1.3 Statistics 
The significance of reported changes with CPAP were assessed using Wilcoxon tests. 
Principal components analysis (Child 1990) was conducted within the two domains of 
change in function and symptoms and CPAP-related problems, to reduce the number 
of variables for subsequent rank correlation (see Section 10.3.1 for explanation). 
Variables with excessively skewed distributions (nosebleeds, wheezing, sore eyes, 
difficulty exhaling) or with reduced sample sizes (sex drive, bloating, work efficiency, 
days taken off work, ability to drive long distances safely) were excluded. 
Components with eigenvalues greater than 1 were extracted and rotated using the 
varimax method. Significance for variable factor loadings was set at 0.30. Rank 
correlation of putative determinant and dependent variables was performed, to 
examine relationships between pre-treatment status, CPAP compliance, benefits and 
problems with CPAP. All analyses were performed using SPSS-PC+ (Norusis/ 
SPSS 1988). 
11.2 Results 
11.2.1 Questionnaire response 
Of 253 patients issued with CPAP units, 215 (85%) returned questionnaires. Non- 
responders were significantly younger (mean age 46 ± SEM 1 years) than responders 
(53 ±1 years; p<0.0001), but were otherwise no different from the responders, who 
had a mean apnoea+hypopnoea index of 47 ±3 per hour slept, 47 ±3 microarousals 
per hour slept, average minimum oxygen saturation of 74 ±1 percent and mean 
duration of CPAP treatment of 632 ± 43 days. 
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Eleven patients (5% of responders) stated that they no longer used CPAP. Three 
patients cited mask discomfort as a factor, three lack of benefit and one each frequent 
awakenings, excessive CPAP pressure and throat dryness. One patient's nasal 
stuffiness, following nasal surgery, precluded CPAP use. Three patients gave no 
reason for discontinuing treatment. Of CPAP users, 21 patients (10%) had an AHI 
<15. The responses of the 204 patients who indicated that they were continuing with 
CPAP therapy were analysed. 
11.2.2 Self-reported and objective CPAP use 
Self-reported compliance in 204 CPAP users averaged 5.8 ± 0.1 hours per night, 
ranging from 0.1 to 9.5 hours per night. Synchronous CPAP runtime clock readings, 
available in 62 patients, yielded an average objective CPAP use of 5.1 ± 0.3 hours per 
night, significantly lower than that reported by the same patients (6.0 ± 0.2 hours per 
night; p=0.0003). Subjective and objective compliance data were significantly 
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Figure 11.1: Scatiergram of objective and subjective CPAP use 
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11.23 Change in subjective and objective sleepiness with CPAP 
Patients' sleepiness, whether subjectively rated by patient or partner, was significantly 
improved with CPAP, as was objective daytime sleepiness assessed by MSLT (Table 
11.1). Pre-CPAP MSLT data were available in 52 patients and post-MSLT data in 41 
patients. Pre-CPAP scores on Epworth scale and MSLT correlated significantly 
(r=-0.38, p=0.01), but post-CPAP scores for the two measures of sleepiness did not 
(r=0.06, p>0.36). 
Table 11.1: Sleepiness before and after CPAP 
Pre-CPAP 




Epworth sleepiness score (patient) 15 ±0 7±0 <0.0001 
Epworth sleepiness score (partner) 14 ±1 8 ±1 <0.0001 
Mean sleep latency (MSLT" mies) 4.6 ± 0.5 6.6 ± 0.5 <0.001 
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11.2.4 Changes in road traffic incidents with CPAP 
Information on road traffic incidents were obtained from 147 driving patients. The 
prevalence of road traffic incidents, divided into sleep-related and non sleep-related 
incidents, is shown in Figure 11.2. and detailed in Table 11.2. These data were 
unadjusted for time on CPAP therapy. Sleep-related driving impairment in the form of 
near-misses were reported by 39% of patients, and sleep-related collisions admitted by 
8%. These frequencies were reduced to 5% and 2% respectively following CPAP 
therapy. No sleep-related major collisions were reported after CPAP commencement. 
M 
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Figure 11.2: Prevalence of road-traffic incidents before and after CPAP 
Table 11.2: Prevalence of road traffic incidents before and after CPAP 
Before CPAP After CPAP 
All incidents 
Near-Misses 67 (46%) 22(15%) 
Minor 29 (20%) 11(7%) 
Major 5(3%) 1 (<1%) 
Sleep-related incidents 






Major 3(2%) 0(0%) 
Mileage- and time-adjusted road traffic incident rates showed a significant reduction in 
the rate of near-miss incidents after CPAP therapy (Table 11.3), which fell to a third of 
the pre-CPAP rate. No significant difference in major or minor accidents rates were 
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seen following CPAP, although the mileage-adjusted major collision rate fell to a fifth 
of its former level after therapy. However, the number of patients reporting actual 
collisions was low both before and after CPAP (Table 11.2), limiting statistical power 
to detect change. 
Table 11.3: Mileage-adjusted road traffic incident rates before and after CPAP 
Pre-CPAP 
Mean ± SEM 
Post-CPAP 
Mean ± SEM -value 
Incident rate (per 10,000 miles 
Near-Miss 0.92 ± 0.25 0.32 ± 0.13 <0.0001 
Minor 0.09 ± 0.04 0.09 ± 0.04 >0.3 
Major 0.005 ± 0.002 0.001 ± 0.001 >0.2 
Total incidents 1.02 ± 0.26 10.41±0.13 0.0001 
Sleep-Related incident rate r 10,000 miles) 
Near-Miss 0.86 ± 0.24 0.11 ± 0.05 <0.0001 
Minor 0.07 ± 0.04 0.03 ± 0.02 >0.2 
Major 0.003 ± 0.002 0 >0.1 
Total incidents 0.93 ± 0.26 0.14 ± 0.06 <0.0001 
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11.2.5 Change in function and symptoms with CPAP 
All items relating to function and symptoms, rated by patients and partners (Table 
11.4), showed highly significant improvements with CPAP, except sex drive. These 
items were scaled from -2 to +2 points, a score of 0 representing no change. Thus 
average ratings for all items represented improvement following CPAP. 




Mean ± SEM 
change in score 
Patient ratin 
Breathing pauses 94 1.6 ± 0.0*** 
Snoring 92 1.6 ± 0.1*** 
Daytime, sleepiness 84 1.3 ± 0.1*** 
Sleep quality 81 1.2 ± 0.1*** 
Tiredness 79 1.0 ± 0.1*** 
Ability to drive bn distances safely 77 1.3 ± 0.1*** 
Concentration 68 0.9 t 0.1*** 
Work efficient 66 0.9 t 0.1*** 
General health 61 0.8 t 0.1*** 
Time taken off work 32 0.5 t 0.1*** 
Sex drive 22 0.1 t 0.1 
Partner rann 
Snoring 95 1.6 t 0.1*** 
Breathing pauses 90 1.4 t 0.1*** 
Daytime sleepiness 79 1.1 t 0.1*** 
Temper 49 0.6 t 0.1*** 
***p<U. 0001 
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11.2.6 Problems with CPAP 
Patients' reports of problems with CPAP use are shown in Table 11.5. The frequency 
of patients reporting some degree of problem was high, but the proportion reporting 
problems severe enough to limit CPAP use were less than 5% for all items. 





Nasal stuffiness 64 4 
Mask leak 63 <1 
Dry throat 62 1 
Cold airstream 45 2 
Noise from CPAP unit 41 2 
Mask rubbing 41 1 
Bloatin (flatulence 37 <1 
More frequent awakenings 32 2 
Red /sore eyes 31 1 
Chest wheeze 21 <1 
Ditiicult exhaling 18 1 
Nosebleeds 10 0 
11.2.7 Change in weight 
Weight gain was significant (mean 1±1 kg; p=0.005), although the majority of 
patients (55%) reported no change in weight. 
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11.2.8 Principal components analysis 
Principal components analysis was conducted within the individual domains of 
perceived benefits and problems with CPAP. 
The items relating to change in function and symptoms with CPAP reduced to two 
components (Table 11.6), the first having loadings on tired/ sleep quality/ general 
health/ concentration ability/ excessive daytime sleepiness (called `daytime function') 
and the second on snoring/ breathing pauses (called `nocturnal symptoms'). It was 
notable that all seven items in this analysis had high loadings on the first unrotated 
principal component. This indicates that, apart from the two clearly separable 
components `daytime function' and `nocturnal symptoms', the total score from the 
seven items may be used as a `general function' measure. 





Component 1 Component 2 
Tired 0.86 0.86 0.23 
Sleep quality 0.81 0.79 0.16 
General health 0.77 0.77 0.08 
Concentration ability 0.71 0.73 0.37 
Daytime sleepiness 0.68 0.72 0.12 
Snoring 0.54 0.12 0.89 
Breathing pauses 0.61 0.23 0.85 
Component name `General 'Daytime `Nocturnal 
Function' Function' Symptoms' 
Principal components analysis revealed that problems with CPAP use formed three 
components, with loadings on frequent awakenings/ noise/ sore eyes (called 
`nuisance'), leaking mask/ mask rubbing/ cold airstream (called ̀mask problems') and 
dry throat/ nasal stuffiness (called ̀ side effects') respectively (Table 11.7). The item 
describing cold airstream problem loaded at > 0.3 on all three factors, suggesting that 
it had lower specificity than other variables in this analysis, which loaded at a high and 
significant level only on one factor each. For this reason the cold airstream item was 
excluded. 
Scores for created variables named ̀ daytime function', `nocturnal symptoms', 
`general function', `nuisance', ̀mask problems' and ̀ side effects', were constructed 
by summing item scores loading on each of these factors. General function, nocturnal 
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symptoms and daytime function were all highly significantly improved with CPAP 
(p<0.0001), with 95%, 95% and 91 % of patients respectively reporting improvement 
on each of these summary scores. Nuisance, mask problems and side-effects were 
rated as present in some degree by 66%, 72% and 73% of patients respectively. 






Component 1 Component 2 Component 3 
Frequent awakenings 0.62 0.74 -0.11 0.19 
Noise 0.59 0.68 0.10 0.11 
Redisore eyes 0.62 0.68 0.13 0.07 
Leaking mask 0.55 0.19 0.84 -0.06 Mask rubbing 0.37 -0.11 0.81 0.11 
Dry throat 0.53 0.17 0.14 0.85 
Nasal stuffiness 0.36 0.14 -0.13 0.82 
Component name 'Nuisance' `Mask `Side-effects' 
problems' 
11.2.9 Rank correlation 
Putative predictive associations between domains of illness severity, sleepiness, road 
traffic incident rates, change in symptoms and function and problems with CPAP use 
were assessed with rank correlation (Table 11.8). Subjective CPAP use was not 
significantly correlated with any objective index of severity of SAHS, but was 
positively correlated with pre-treatment Epworth sleepiness score and negatively 
correlated with the degree of nuisance of CPAP therapy reported. CPAP nuisance was 
negatively correlated with SAHS severity. Improvements in daytime function and 
nocturnal symptoms correlated with baseline Epworth sleepiness score and reported 
CPAP use, and negatively with Epworth sleepiness score on CPAP. The frequency of 
driving incidents before treatment was correlated with Epworth sleepiness score, the 
frequency of microarousals and the extent of nocturnal hypoxemia. 
Most of these significant correlations were modest in size, with r-values 
approximating 0.2, but stronger correlations were seen between pre-treatment 
sleepiness and the rates of sleep-related near-miss driving incidents (r=0.54), and 
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11.3 Discussion 
This study documents experience and perceptions of CPAP in a large sample of 
unselected CPAP-users with a wide range of illness severity. Although necessarily 
limited by its use of mainly self-reported and retrospective information, the study 
provides evidence of patient-perceived, CPAP-induced improvement across a wide 
range of function, including sleepiness, driving competence, cognitive function, work 
efficiency, well-being and nocturnal symptoms. Furthermore, coherent correlations 
linked pre-CPAP driving competence, use of CPAP and benefit from CPAP to 
predictive variables. 
PC AP Use 
Mean objective CPAP compliance demonstrated in this study (5.1 hours/night) was 
closely in agreement with that of others in cross-sectional CPAP clinic series 
(Rauscher et al 1993b, Krieger 1992, Pepin et al 1995) which included both new and 
long-term users. As in other studies employing objective CPAP compliance ratings 
and subjective reports of CPAP use (Rauscher et al 1993b, Kribbs et al 1993a), 
patients were seen to overestimate CPAP by approximately one hour. This is 
illustrated by the tendency for datapoints in the scattergram of objective versus 
subjective CPAP use (Figure 11.1) to lie below the line of identity. 
Self-reported CPAP use was significantly associated with outcome measures 
assessing post-treatment sleepiness and improvement in function and symptoms, 
confirming and extending findings of others showing correlations between compliance 
and subjective change in sleepiness with treatment (Meurice et a11994, Rauscher et al 
1993b). 
The observed triangular association between pre-CPAP sleepiness, subsequent 
compliance and post-treatment sleepiness (Table 11.8) is suggestive of a positively 
reinforcing loop. Poorer compliance was associated with greater rates of sleep-related 
collisions after treatment, providing additional corroboration of the benefits of CPAP. 
Degree of CPAP compliance was linked only to prior sleepiness and not illness 
severity, confirming the hypothesis that sleepiness is the primary determinant of 
CPAP acceptance (Waldhorn et al 1990, Rauscher et al 1991). Apart from the 
nuisance problem factor (see below), problems with CPAP use were not associated 
with reduced compliance- 
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S1_gpiiness 
Subjective sleepiness, assessed by the Epworth sleepiness scale, was significantly 
improved with CPAP, with average scores after treatment falling within the normal 
range (Johns 1992). The Epworth sleepiness scale, although subjective and completed 
retrospectively, may be a relatively robust measure of sleepiness, dealing with 
memorable real-life situations rather than transient mood states. In addition, the use of 
retrospective Epworth scores may avoid the unawareness of sleepiness observed in 
some SAHS patients prior to treatment (Dement et al 1978) and the minimisation of 
sleepiness by patients keen to continue driving. Sleep onset latency on the MSLT was 
improved but not normalised by CPAP, as previously reported in the parallel-group 
pilot study (Engleman et al 1993; Chapter 5), the placebo-controlled crossover study 
(Engleman et al 1994b; Chapter 6) and by others (Sangal et al 1992b, Bedard et al 
1993, Kribbs et al 1993b), with only one study showing normalisation of sleep onset 
latency with CPAP (Lamphere et al 1989). 
Road Traffic Incidents 
The survey documents a high prevalence of sleep-related road traffic incidents in 
untreated patients, with 39% of all driving patients being aware of sleep-related near- 
miss incidents before treatment (see Figure 11.2). These results are compatible with 
others' findings of increased accident rates in SAHS patients (Findley et al 1988, 
George et a! 1987). Self-reported mileage-adjusted rates of near-miss incidents were 
significantly improved after CPAP. Thus the study shows for the first time significant 
improvement in actual driving competence with CPAP, in keeping with research 
suggesting that treatment (Findley et al 1989a, Haraldsson et al 1991) may improve 
driving skills on simulators. Although no significant difference in sleep-related 
collision rate after CPAP was observed, the low frequency of such events before 
CPAP in a small population (see Figure 11.2) may contribute to this finding. Road 
traffic incidents before treatment were significantly correlated with sleepiness as well 
as polysomnographic measures of sleep fragmentation and hypoxaemia. These 
findings of putative predictors for driving competence in both sleepiness and illness 
severity in SAHS extend those of Findley et al (1989b). 
Function and Symptoms 
CPAP-treated patients reported highly significant improvements in all symptom and 
function items, except sex drive. These findings are consistent with the objective and 
subjective improvements in daytime function with CPAP shown by the crossover 
studies (Engleman et al 1994b; Chapters 6 and 7). Patients in this survey indicated that 
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daytime impairments were ̀ better or `much better, while the crossover studies 
indicated rather subtle improvements. 
The high frequency of reported improvements in daytime function items, especially 
those relating to concentration, work efficiency, absence from work and ability to drive 
distances safely, suggests that these areas of function are compromised in a significant 
proportion of SAHS patients (see Table 11.5). Together with the data on road traffic 
incidents, the above findings suggest a high cost to community and industry from 
SAHS and a substantial preventative value for CPAP. The magnitude of reported 
improvement in daytime function and nocturnal symptoms was related to severity of 
initial illness. Greater reported improvements in daytime function and in nocturnal 
symptoms was associated with greater reported CPAP use, greater sleepiness before 
treatment and lesser sleepiness after treatment. 
Problems with CPAP Use 
Reported problems with CPAP use, which the majority of patients classified as 
`minor' in nature, were remarkably frequent, despite intervention during patient 
follow-up. Problems with CPAP use have previously been associated with reduced 
compliance by ourselves (Engleman et al 1993) and by others (Rauscher et a! 1993b), 
but significant relationships between problems and reported CPAP use were limited to 
the nuisance problem complex. In contrast to nuisance problems, mask problem and 
side-effect scores were not associated with lower SAHS severity, reported CPAP use 
or satisfaction with treatment. 
Nuisance Problems 
The nuisance complex, describing complaints relating to noise, frequent awakenings 
and sore eyes with CPAP treatment, exhibited a interesting pattern of association with 
putative determinants and effects (Table 11.8). This problem complex was weakly 
correlated with milder polysomnographic illness, lower subsequent CPAP use and 
lesser perceived benefit. One of the nuisance complex items, noise from CPAP units, 
has been associated with lower SAHS severity (Pepin et al 1995), but not previously 
with lesser CPAP compliance. 
Although high-scorers for nuisance problems had milder initial illness and poorer 
subsequent CPAP compliance, the evidence from the mild patients participating in the 
crossover study (Chapter 7) suggests that patients with low indices of illness severity 
receive objective benefits for cognitive function from CPAP. Thus patients' 
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unawareness of the benefits of CPAP may be insufficient justification for withholding 
treatment, although some patients may decline to use it. The lack of correlation 
between polysomnographic indices of illness severity and CPAP use may well 
confirm the value of CPAP therapy in `heavy snorers disease' (Lugaresi et al 1989) or 
`upper airway resistance syndrome' (Guilleminault et al 1993) as well as SAHS. It 
may be that patient education can aid insight into illness-induced impairment and thus 
promote improved compliance with and benefit from CPAP. 
In summary, this questionnaire-based study documents high rates of road traffic 
incident rates before CPAP, which were significantly reduced by treatment. The high 
frequency of positive responses to items rating change in function since CPAP 
suggests that untreated SAHS carries substantial costs to community and industry. 
These positive ratings however substantiate accepted wisdom that CPAP therapy 
improves a wide range of function and symptoms, and corroborate the findings of 
improved daytime function following CPAP demonstrated in the crossover study 
(Chapter 6). Reported CPAP use was influenced by sleepiness before treatment but 
not by prior illness severity or CPAP-related side-effects and mask problems. Greater 
reported CPAP use was associated with better resolution of sleepiness and greater 
improvement in daytime function and nocturnal symptoms. 
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Chapter 12: 
CONCLUSIONS AND PROSPECTS FOR FUTURE RESEARCH 
The research studies presented within this thesis provide a contribution to the 
knowledge of the effects of CPAP therapy on daytime function on two levels. These 
studies suggest that objective and subjective improvements in symptoms, daytime 
sleepiness, cognitive performance and psychological well-being are experienced by 
patients with SAHS after CPAP therapy. Thus, although CPAP is a relatively 
obtrusive and expensive treatment, the clinical usefulness of CPAP therapy is 
corroborated by these studies. On a secondary level, the studies in this thesis provide 
an organic record of the refinement of methodological techniques and measures useful 
in this particular area of study, and of issues requiring further investigation. 
The pilot parallel-group study (Chapter 5) improved on previous studies by employing 
a control for repeated testing. This trial showed improvements in excessive daytime 
sleepiness and psychological well-being with CPAP, but failed to show an 
improvement in cognitive performance. This led to the adoption of a rigorous study 
design to control for inter-individual variability, learning effects and expectation of 
benefit from treatment, and to the inclusion of sleep-loss sensitive performance 
measures. The randomised, placebo-controlled crossover study (Chapter 6) in turn 
showed improved symptoms, excessive daytime sleepiness, cognitive performance 
and psychological well-being with CPAP. These findings of CPAP-related benefits 
for all areas of daytime function were corroborated by reports from a cross-section of 
CPAP users (Chapter 11). These two studies, one using objective measures and the 
other focusing on perceived benefits, provided cross-validation of the benefits of 
CPAP. Each suggested, whether with a driving-based vigilance task or through self- 
reports of road traffic incidents, that driving impairment might be improved by CPAP. 
These and the findings of improved work efficiency and work absenteeism in the 
CPAP users' survey (Chapter 11) provide support for the contention that CPAP 
reduces costs to state and industry from SAHS. 
The clinical applications of CPAP therapy were examined by the crossover study of 
patients with mild SAHS (Chapter 7), which indicated objective and subjective 
benefits for symptoms, cognitive performance and well-being from CPAP in 
symptomatic patients with AHI 5 to 15 per hour slept This may indicate that 
therapeutic trials of CPAP are merited in such patients. The higher levels of sleep 
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fragmentation in the better CPAP users within this range of SAHS severity may also 
support the role of sleep fragmentation in inducing daytime deficits in SAHS. 
The CPAP compliance rates, objectively measured in these prospective studies of new 
CPAP users (Chapters 6 and 7), were disappointingly low, although synchronous 
studies showed similar findings (Kribbs et a! 1993a, Reeves-Hoche et al 1994). Self- 
reported CPAP compliance rates in the survey of CPAP users (Chapter 11) were not 
related the commonly-experienced problems of mask discomfort, but did show a 
weak association with the degree of nuisance-type complaints from users, 
emphasising the inconvenient nature of the therapy. Nevertheless, the surprisingly low 
objective compliance rates of CPAP users in the randomised crossover studies of 
daytime function still resulted in demonstrable improvements in daytime function. The 
precise relationship between CPAP use and benefit is still ill-understood, and requires 
further examination. Further work is also required to identify the determinants of 
CPAP compliance, so that use of therapy can be optimised. 
Both parallel-group and crossover studies showed a relatively small improvement in 
objective daytime sleepiness, as measured by the MSLT, with CPAP. Sleep onset 
latencies remained in the range associated with moderate sleepiness following therapy. 
This observation finds agreement in studies conducted before (Fry et al 1990, Gaddy 
and Doghramji 1991) and synchronously (Sangal et al 1992b, Bedard et al 1993, 
Kribbs et al 1994b) with those reported in this thesis. It remains to be seen whether 
this lack of normalisation is due to insensitivity in the MSLT instrument, or to 
persistent but lessened sleepiness after CPAP. The use of alternative tests of 
sleepiness, such as the maintenance of wakefulness test, may help clarify this issue. 
Although cognitive improvements with CPAP were demonstrated in the crossover 
study (Chapters 6 and 7), the study design did not elucidate whether these 
improvements were complete or partial, and if other cognitive abilities remained 
impaired. Further investigation is required to identify the type and scale of 
improvements in cognitive performance following CPAP. 
Further prospective and quantitative investigations of the effects of CPAP on driving 
ability are also required. Driving impairment was self-reported in the crossover study 
(Chapter 6) and patient survey (Chapter 11) studies, and retrospective in the survey, 
compromising the quality of these data. Prospective and quantitative studies would 
help evaluate the scale of benefit from CPAP. 
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The study of auditory evoked potentials indicated trends towards improvement in 
neurophysiological function following CPAP, while the ambulatory blood pressure 
study suggested that selective benefits from CPAP in lowering blood pressure might 
be gained by SAHS patients at risk of cardiovascular accidents. In the auditory evoked 
potential study, limited sample size might well have contributed to a Type 2 statistical 
error. Larger samples may yet show that evoked potential measures, linked through 
other research to both sleepiness and cognitive function, cross-validate the 
improvements in these domains of function with CPAP therapy. Another fruitful area 
of research, raised during the course of these thesis studies, might be to examine 
whether patients with mild SAHS may also gain protection from cardiovascular 
morbidity and mortality from CPAP. 
The study of correlates of daytime function (Chapter 10) indicated that severity of the 
nocturnal events of SAHS was modestly related to daytime sleepiness and to cognitive 
impairment, but did not identify whether daytime impairment is more closely related 
to sleep fragmentation or hypoxaemia. The best overall correlates of daytime 
impairment were AHI and a factor score representing overall severity of nocturnal 
measures, supporting the contention (Gould et al 1988) that the primary breathing 
pauses which lead in turn to oxygen desaturations and to microarousals are the best 
currently available measure of severity of SAHS. 
The reversibility of impairments observed in the studies of daytime function (Chapter 
5,6 and 7) might support the view that these are most closely related to the sleep 
fragmentation of SAHS. However, no relationships between microarousal frequency 
and daytime function were observed in the correlational study of nocturnal 
determinants (Chapter 10). The lack of correlations between microarousal index and 
the daytime deficits of SAHS may lead to queries of the suitability of current 
techniques used to measure sleep fragmentation. The commonly-used 
electroencephalogr3phic measure of microarousal index varies in definition between 
centres, and objective research is required to validate optimal criteria. Recent interest 
has focused on the autonomic arousals accompanying apnoea termination (Davies et al 
1993,1994b, Rees et al 1993,1995, Rees and Calverley 1995), which may or may not 
lead to electroencephalographic arousals. Such `sub-cortical' arousals may prove a 
future useful index of nocturnal physiological events in SAHS, and possibly also to 
daytime impairment (Sahloul et al 1995). 
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The studies of this thesis confirm the clinical efficacy of CPAP in improving the 
daytime impairments associated with SAHS. Although inconvenient, CPAP results in 
objective and subjective benefits to users. Until therapeutic advances supersede this 
valuable treatment, it is necessary for scientists and clinicians to further describe the 
effects of this treatment, and to work towards maximising its use and its benefits in 
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Name: 
CPAP PATIENT QUESTIONNAIRE 
Date of Birth: Date questionnaire completed: 
Roughly how many nights per week do you use CPAP? nightshveek 
On the nights that you use CPAP, how many hours do you 
manage to use the CPAP therapy? hours/night 
The following symptoms may be associated with the sleep apnoea syndrome. Please tick a single column 
for each symptom to indicate if CPAP therapy has made any difference to these. 
MUCH WORSE NO BETTER MUCH 










Have any of the following factors been affected by CPAP therapy (please tick one column for each factor)? 
MUCH WORSE NO BETTER MUCH 






Are you in employment at the moment (please circle appropriate answer)'? YES NO 
If you answered yes above, please tick one column below to tell us whether your ability to attend for work 
has changed since starting CPAP. 
MUCH MORE NO FEWER MUCH FEWER 





Has your sex drive changed since starting CPAP (please tick a single column)? 
GREATLY SLIGHTLY NO SLIGHTLY GREATLY 
REDUCED REDUCED CHANGE INCREASED INCREASED 
SEX DRIVE 
Has your weight changed since starting CPAP (Please circle one answer and fill in weight change if 
appropriate)? 
WEIGHT DECREASED WEIGHT IS THE SAME WEIGHT INCREASED 
BY kg BY kg 
How likely are you to doze off or fall asleep in the following situations, in contrast to just feeling tired? 
This question refers to your usual way of life both before and since starting CPAP. Even if you have not 
done some of these things recently, try to work out how they might affect you now and in the past. Use the 
following scale to choose the most appropriate number for each situation. 
0 would NEVER doze 
1 SLIGHT chance of dozing 
2 MODERATE chance of dozing 









Sitting and reading 
Watching TV 
Sitting inactive in a public place (e. g. a theatre or meeting) 
As a passenger in a car for an hour without a break 
Lying down to rest in the afternoon when circumstances 
permit 
Sitting and talking to someone 
Sitting quietly after a lunch without alcohol 
In a car while stopped for a few minutes in traffic 
ZZ( 
Occasionally CPAP therapy may be associated with side effects. Please tick a single column for each side 
effect to inform us if you are suffering these problems and if they affect your ability to benefit from CPAP. 
SIGNIFICANT PROBLEM 
PROBLEM 
BUT ABLE PRESENT 
TO UNABLE TO EVEN 
CONTINUE CONTINUE BEFORE 
NOT A MINOR USING USING STARTING 




MASK LEAK N/A 
COLD AIRSTREAM N/A 
NOSEBLEEDS 
MASK RUBBING N/A 
DIFFICULTY N/A 
EXHALING 
MORE FREQUENT N/A 
AWAKENINGS 
EXCESSIVE NOISE N/A 
FROM CPAP UNIT 
BLOATING 




Do you drive (please circle appropriate answer)? YES NO 
We would like to know more about your experience of driving both before and since starting CPAP. This 
information is entirely confidential and will not be passed to insurers, police or other authorities. Please 
complete all of this section you are a driver, but leave blank if you do not drive. 
Approximately how many miles per year do you drive? miles 
Is driving involved in your occupation (please circle appropriate answer)? YES NO 
Has your ability to drive longer distances safely changed since starting CPAP? Please tick a single 
column. 
MUCH WORSE NO BETTER MUCH NEVER A 





We would like to investigate whether CPAP is reducing road accidents caused by sleepiness. The 
definition of accident types is presented below: 
Near Miss Accident- Almost had a collision but avoided at last moment 
Minor Accident- Collided with property or person, but no people were injured 
Major Accident- Collided with property or person, and people were injured 
In the 5 years before you started CPAP, how many of each of the following events happened to you? 
NEAR MISS 
ACCIDENT MINOR ACCIDENT MAJOR ACCIDENT 
Number of events in all 
Number of these caused 
by sleepiness 
Since you started CPAP, how many accidents or near-! Hisses have you been involved in? 
NEAR MISS 
ACCIDENT MINOR ACCIDENT MAJOR ACCIDENT 
Number of events in all 
Number of these caused 
by sleepiness 
PLEASE CHECK THAT ALL APPROPRIATE SECTIONS OF THIS FORM ARE FILLED IN 
THANK YOU FOR YOUR-HELP 
22-3 
PLEASE ASK YOUR SPOUSE OR PARTNER TO FILL IN THIS FORM 
CPAP PARTNER'S QUESTIONNAIRE 
Your Name: Date questionnaire completed: 
Your partner's name: Partner's date of birth: 
The following symptoms may be associated with the sleep apnoea syndrome. Please tick a single column 
for each symptom to indicate if CPAP therapy has made any difference to your partner's health. 









How likely is/was your partner to doze off or fall asleep in the following situations, in contrast to just 
feeling tired? This question refers to your partner's usual way of life before and since starting CPAP. Even 
if your partner has not done some of these things recently, try to work out how they might affect him/her 
now and in the past. Use the following scale to choose the most appropriate number for each situation. 
0 would NEVER doze 
1 SLIGHT chance of dozing 
2 MODERATE chance of dozing 








Sitting and reading 
Watching TV 
Sitting inactive in a public place (e. g. a theatre or meeting) 
As a passenger in a car for an hour without a break 
Lying down to rest in the afternoon when circumstances 
permit 
Sitting and talking to someone 
Sitting quietly after a lunch without alcohol 
In a car while stopped fot a few minutes in traffic 
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Abstract 
Background-Patients with the sleep 
apnoea/hypopnoea syndrome often 
receive continuous positive airway pres- 
sure to improve their symptoms and 
daytime performance, yet objective evi- 
dence of the effect of this treatmtnt on 
cognitive performance is lacking. 
Methods"-A prospective parallel group 
study was performed comparing the 
change in objective daytime sleepiness as 
assessed by multiple sleep latency, cogni- 
tive function, and mood in 21 patients 
(mean (SE) number of apnoeas and 
hypopnoeas/hour 57 (6)) who received 
continuous positive airway pressure for 
three months and 16 patients (49(6) 
apnoeas and hypopnoeaslhour) who 
received conservative treatment for a 
similar period. 
Results-Both groups showed significant 
within group changes in cognitive func- 
tion between baseline and three months, 
but when comparisons were made 
between groups the only significant dif- 
ference was a greater improvement in 
multiple sleep latency with continuous 
positive airway pressure. However, the 
improvement in sleep latency with con- 
tinuous positive airway pressure was rel- 
atively small (3.5 (0.5) to 5.6 (0.7) min). 
The group treated with continuous posi- 
tive airway pressure was divided into 
those who complied well with treatment 
(>4.5 hoursinight) and those who did 
not. Those who complied well (n = 14) 
showed significant improvement in mean 
sleep latency and also in depression score 
compared with the controls but no 
greater improvement in cognitive func- 
tion. 
Conclusion-Tipis study confirms signifi- 
cant improvements in objective sleepi- 
ness and mood with continuous positive 
airway pressure, but shows no evidence 
of major improvements in cognitive 
function. 
(Thorax 1993; 48: 911-914) 
Daytime sleepiness, impaired daytime perfor- 
mance and lowered mood are common 
symptoms of the sleep apnoea/hypopnoea 
syndrome, and there is objective evidence of 
911 
daytime sleepiness and impaired cognitive 
performance in these patients. '" Treatment 
with continuous positive airway pressure has 
been shown to improve nocturnal breathing 
pattern, ' nocturnal sleep quality, ' objective 
daytime sleepiness, ' and also mood. 7 
Although patients with the sleep apnoea/ 
hypopnoea syndrome frequently report 
improvements in subjective daytime function 
with continuous positive airway pressure, 
objective confirmation of its effect on cogni- 
tive function is lacking. We therefore con- 
ducted a controlled trial to assess changes in 
cognitive performance, mood and daytime 
sleepiness in such patients after treatment. 
Methods 
A prospective parallel group study was per- 
formed comparing the change in cognitive 
function, mood and objective daytime sleepi- 
ness after at least three months (mean (SE) 
6 (1) months) of treatment with either con- 
tinuous positive airway pressure or conserva- 
tive treatment only. Each patient gave written 
informed consent to the study, which had the 
approval of the local ethical advisory commit- 
tee. 
All patients underwent an overnight sleep 
study to confirm the diagnosis of the sleep 
apnoea/hypopnoea syndrome, defined as hav- 
ing more than 15 apnoeas and hypopnoeas 
per hour of sleep' Polysomnography was 
performed using our standard techniques° 
with monitoring of electroencephalography 
(EEG), electro-oculography and electromyo- 
graphy, thoracic and abdominal movement 
by inductance plethysmography, oronasal 
flow with a thermocouple, and oxygen satura- 
tion by ear oximetry (Ohmeda Biox 3700). 
An apnoea was defined as a cessation of air- 
flow for 10 seconds or more, and a hypo- 
pnoea as a reduction in thoracoabdominal 
movement of 50% or more for 10 seconds or 
longer. ' Sleep was scored by conventional cri- 
teria1° and arousals were scored when there 
was a rise in electromyographic activity dur- 
ing sleep coincident with return of a or 9 
EEG activity for at least 1.5 seconds. " 
Patients receiving continuous positive airway 
pressure underwent a further overnight sleep 
study in which the pressure was titrated to a 
level where respiratory abnormalities and 
arousals were minimised. Patients given con- 
tinuous positive airway pressure used Sleep 
912 Engleman, Chtshirs, Deary, Douglas 
Table l Mean (SE) clinical feawres of aeaanenc group: ar basstine assessment patient had slept the night in their own bed. 
Patients had only non-caffeinated drinks on CPAP C = 21) Connrl (n = 16) p the days of testing. 
Age (years) 53(3) 53(3) 1.00 
Because patients with the sleep apnoea/ 
Body mass index (kg/mz) 34(2) 32(2) 0.31 hypopnoea syndrome tend to have arousals 
No of apnoeas and hypopnoeas/h slept 57(6) 49(6) 0.38 associated with apnoeas and hypopnoeas 
No of arousals/h slept 






0.27 after sleep onset, the 
definition of sleep soon pp 
onset used in the multiple sleep latency test 
CPAP--continuous positive airway pressure. was modified to one 20 second etloch of any 
Easy II or Sleep Easy III units, which were 
fitted with hidden time clocks. 
Allocation to treatment groups was not 
randomised but was partially based on 
patients' preference. _Half. of the control group had declined to start continuous positive 
airway pressure while the other half were 
directly assigned to conservative treatment. 
All patients were given advice on weight loss 
and avoidance of evening alcohol. The clini- 
cal. features of the two groups were similar 
(table 1). 
ASSESSMENT 
At each time of testing all patients underwent 
a multiple sleep latency test'2 and on a non- 
consecutive day a3 hour battery of psycho- 
metric tests, including assessment of cognitive 
performance and mood, as detailed in table 2. 
Both sessions were performed after the 
Table 2 PsychQme c baurry 
Tests of general function WAIS subtests--information, 
and of memory arithmetic, block design, 
digit symbol substitution 
TtailMaking tasks A and B 
Auditory verbal learning test 
Premorbid level of function National adult reading test 
Processing time Inspection time test 
Simple unprepared reaction 
time 
Concentration Paced auditory serial 
addition test (presentation 
raves 2a and 4 a) 
Driving simulator 
Mood Hospital anxiety and 
depression scale 
WAIS-Wechaier adult intelligence scale. 



















Mean sleep ! aunty in patients with the sleep apnocaryndrvme at baseline and after 
treatment with continuous positive airway pressure (CPAP) or after having been given 
advice alone (control). 
sleep stage. This definition of sleep onset in 
such patients has since been accepted by the 
American Sleep Disorders Association. " The 
psychometric battery was designed to incor- 
porate tests of a wide range of neuropsycho- 
logicalfunction, including general level of 
function, visuomotor stall, concentration abil- 
ity, vigilance, memory, and mood. A stan- 
dardised alternative to the word list in the 
auditory verbal learning test was used in the 
repeat testing session to obviate learning 
related improvements in score. " The admin- 
istration of the national adult reading test 
rendered an estimate of premorbid perfor- 
mance IQ. This estimate was subtracted from 
the performance IQ score obtained from the 
Wechsler adult intelligence scale performance 
subtests to calculate an "IQ decrement" score 
for each patient. Overall change in cognitive 
function score for each individual was 
assessed by using a summed Z score" of each 
patient's performance in all cognitive tests in 
the battery. 
STATISTICS 
Data from the multiple sleep latency test and 
the psychometric tests were analysed by the 
BMDP package. " Baseline values between 
the two groups were compared by Student's 
unpaired c tests. Non-normally distributed 
data were examined using the Mann-Whitney 
U test. Two way analysis of variance was used 
to assess the interaction of the treatment and 
repeated test factors when examining the 
change in cognitive function from baseline to 
the second assessment in the two groups. 
Results 
ALL PATIENTS 
Comparison of treatment groups at baseline 
There were no differences in psychometric 
function at baseline in the two groups. 
However, the mean sleep latency on the 
multiple sleep latency test was longer in the 
conservatively treated group (fig; p=0.01). 
Within group changes in scores from first to 
second assessment 
Both groups showed significant improve- 
ments in scores in a wide range of psycho- 
metric function tests (table 3). There was also 
significant lengthening of sleep latency in the 
multiple sleep latency test on the group 
treated with continuous positive airway pres- 
sure. 
Comparison of change in scores from first to 
second assessment between the two groups 
There was no significant difference between 
the two groups in changes in any of the 
Bawina TrS$UT I Baseline Treatment 
CPAP Control 
-Effect of continuous positive airway Pressurs on sleep apnoea 
Table 3 Mean (SE) significant within group changes*jrom first to second assessment 
CPAPgroup Conrsm/87ouP 
Test Champ P Champ P 
Information (no correct) 1.4(0.4) <0.01 0-9(0-4) 0-05 
Digit symbol substitution 
(no correct) 3-6(0-9) <0.01 
IQ: 
Verbal 4.0(1.8) <0.05 
Performance 5.6(2.1) <0.05 
Full 2.1(1.0) 0.05 4.6(1.4) <0.01 
TrailMaking task B (s) -27.3(2-7) <0.01 
PASAT (no correct): 
4s 4-3(1-5) 0-01 
2s 5.3(1.7) 0.01 4.7(1.6) 0.01 
Driving response time (s) -6.2(2.4) <0.05 
Sleep latency (min): 
Mean 2.1(0.8) 0-01 
anum 1.3(0.5) <0.05 
CPAP-continuous positive airway pressure; PASAT-paced auditory serial addition 
test. *All significant changes were in the direction of improvement in the tests concerned. 
psychometric function tests (p > 0.2). Mean 
sleep latency lengthened significantly in the 
treated group compared with the control 
group (p < 0.02; fig). Similarly, the treated 
group had a trend to greater improvement 
in the shortest of the five sleep latencies 
during the multiple sleep latency test 
(p > 0.05). 
GOOD COMPLIERS 
The hidden time clocks in the continuous 
positive airway pressure units allowed an 
average nightly usage to be calculated for 
each patient. The mean (SE) usage for the 
group was 5-9 (1.4) hours per night. We 
divided the group treated with continuous 
positive airway pressure into those who com- 
plied well with treatment and used their units 
for more than 4.5 hours per night (n = 14) 
and those who used it for less than 4.5 hours 
per night. The results for the good compliers 
were compared with those for the controls. 
The good compliers again showed signifi- 
cantly greater improvements in mean sleep 
latency compared with the conservatively 
treated patients (visit 1: 3.4 (0-5) minutes, 
visit 2: 5.5 (0-4) minutes; p<0.05) and 
shortest sleep latency (visit 1: 1-3 (0.3) min- 
utes, visit 2: 2.4 (0-3) minutes; p<0.05). 
The good compliers also showed a signifi- 
cantly greater improvement in depression 
score (p = 0.05) but no significant improve- 
ments in any cognitive function assessment 
compared with the control group. 
There was no difference between the 
treated and control group in the change in 
weight during the study period (treated gained 
1-4 (0.6) kg, control gained 1.6 (1-3) kg). 
Discussion 
This study shows that treatment with contin- 
uous positive airway pressure results in 
improvements in objective sleepiness and 
may improve mood in good compliers, but 
we were unable to show any improvement in 
cognitive performance. We thus confirm the 
findings of Lamphere et al of an improvement 
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in objective daytime sleepiness with continu- 
ous positive airway pressure, although our 
changes are much less dramatic than those of 
Lamphere er a!. b In part, this may reflect dif- 
ferences in criteria of defining sleep onset 
during the daytime naps, which we defined as 
a first 20 second epoch of any sleep stage 
rather than the first minute of any sleep stage 
to detect short sleep episodes rapidly dis- 
rupted by apnoeic arousals. Our data showing 
a moderate improvement in sleep latency 
with continuous positive airway pressure 
come midway between the dramatic improve- 
ments reported by Lamphere er alb and the 
lack of improvement with continuous positive 
airway pressure or uvulopalatopharyngo- 
plasty, or both, recently reported by Sangal er 
al. " Although our different criteria for sleep 
onset might change the absolute value of 
multiple sleep latency in comparison with 
earlier studies, ' it is difficult to see how this 
could adversely affect our ability to dete_: t 
improvement with continuous positive airway 
pressure. We have confirmed the results of 
Derderian er al that the treatment may 
improve mood. ' 
There has been a relative paucity of data 
on the effects of continuous positive airway 
pressure on cognitive performance. In a pro- 
visional report Bearpark er al found improve- 
ments in scores in visual memory, verbal 
fluency, and mental set flexibility on retesting 
after 4-5 months of continuous positive air- 
way pressure, but their study had no control 
group to evaluate the effects of learning on 
performance. 18 Similarly, Charbonneau er al 
have reported improved cognitive function 
with the treatment in an uncontrolled study. 19 
Our finding of within group improvements in 
cognitive performance on retesting in both 
groups shows that a learning curve exists for 
cognitive function tests. It also indicates the 
need for control groups in such studies and 
shows that the conclusions of Bearpark er alle 
and Charbonneau er a! '9 that continuous 
positive airway pressure improves psycho- 
metric function cannot be drawn from their 
studies. Our studies are consistent with the 
observation of Walsieben er al, who found no 
improvement in cognitive function after two 
nights of continuous positive airway pressure 
treatment in a small study (n = 7), 3 
The lack of demonstrable improvement in 
cognitive function in our study could be due 
to our choice of psychometric performance 
tests, to the wide interindividual variability, to 
poor compliance with treatment, or to the 
fact that there genuinely is no improvement 
in cognitive function which might be perma- 
nently impaired in patients with the sleep 
apnoea/hypnoea syndrome. We chose the 
psychometric function tests to reflect the 
abnormalities that we have previously 
detected in patients with the syndrome' ` and 
to cover a wide range of cognitive functions. 
Our patients were well within the operating 
range for all the cognitive function tests and 
thus the lack of an improvement was not due 
to there being no room for improvement in 
their results. We believe that the battery of 
914 
tests used is fairly comprehensive. Never- 
theless, Findley a at have shown improve- 
ment in a long and repetitive task designed to 
simulate driving, m although it remains to be 
seen whether this reflects improved cognitive 
function, a decrease in daytime microsleeps, 
or improved performance with greater famil- 
iarity with the task. We believe that the large 
interindividual variability in cognitive func- 
tion may have resulted in our failure to find 
differences in a parallel group design such as 
we used. We are thus initiating a crossover 
study of the effect of continuous positive air- 
way pressure or placebo on objective daytime 
sleepiness, cognitive function and mood. 
Compliance with - treatment was somewhat 
disappointing in our study, with a mean use 
of continuous positive airway pressure of 5.9 
hours/night. We suggest, however, that this 
probably reflects use in the community and is 
certainly in keeping with other recent studies 
which have objectively examined compliance 
in patients with the sleep apnoea/hypnoea 
syndrome? ' 22 
This study shows that there are significant 
improvements in both objective daytime 
sleepiness and mood with continuous positive 
airway pressure in patients with the sleep 
apnoea/hypopnoea syndrome, but we found 
no evidence of major improvements in cogni- 
tive function with such treatment. 
We thank Sisters C Hoy and M Vennelle and Ms K Stedul 
and H Biernacka for technical and nursing help and Mn E 
Dolan for preparing the manuscript. 
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Compliance with CPAP therapy in patients with 
the sleep apnoea/hypopnoea syndrome 
Heather 1\I Engleman, Sascha E Martin, Neil J Douglas 
Abstract 
Background - Continuous positive air- 
way pressure (CPAP) therapy is the 
treatment of choice for the sleep apnoea/ 
hypopnoea syndrome. Compliance with 
this relatively obtrusive therapy has not 
been well studied. 
Methods - Usage of CPAP was investi- 
gated in 54 patients with sleep apnöea] 
hypopnoea syndrome (median 36 (range 
7-129) apnoeas+hypopnoeas/hour slept) 
over the first 1-3 months after starting 
CPAP therapy. In all cases CPAP usage 
was monitored by hidden time clocks 
that indicated for how long the machines 
were switched on - that is, the CPAP run 
time. In 32 patients the time at which the 
CPAP mask pressure was at the thera- 
peutic level of CPAP pressure set for that 
patient - that is, the mask time - was also 
monitored. In all patients objective day- 
time sleepiness was assessed by multiple 
sleep latency before and after CPAP 
therapy. 
Results - The mean (SE) nightly CPAP 
run time was 4.7 (0.3) hours. There was no 
correlation between run time and sever- 
ity of the sleep apnoea/hypopnoea syn- 
drome as assessed by apnoea-hypo- 
pnoea frequency or multiple sleep latency, ' 
and no correlation between CPAP usage 
and improvement in multiple sleep 
latency. Thirty two patients in whom 
mask time was recorded had therapeutic 
CPAP pressures for 89% (3%) of their 
CPAP run times. Patients who exper- 
ienced side effects from CPAP used their 
CPAP machines significantly less than 
those who did not. 
Conclusions- Patients with sleep apnoea/ 
hypopnoea syndrome used CPAP for less 
than five hours/night on average with no 
correlation between severity of sleep 
apnoea/hypopnoea syndrome and CPAP 
usage. Patients who complained of side 
effects used their CPAP therapy less. It is 
recommended that, as a minimum, 
CPAP run time should be regularly 
recorded in all patients receiving CPAP 
therapy. 
(Thorax 1994; 49: 263-266) 
Recent evidence indicates that the sleep 
apnoea hypopnoea syndrome has a prevalence 
in middle age of 2% in women and 4°'o in 
men, ' approaching the approximately 6% pre- 
valence of asthma in the middle aged popula- 
tion. " The treatment of choice for the sleep 
apnoea hypopnoea syndrome is continuous 
positive airway pressure , CPAP) therapy via 
the nose. 
Compliance with therapy in patients with 
airflow obstruction is relatively poor. ' De- 
spite the fact that CPAP therapy is more 
obtrusive than the use of bronchodilator 
inhalers, and that CPAP therapy carries a 
relatively high initial capital cost, there have 
been few studies of compliance with CP AP 
therapy in patients with the sleep apnoea 
hypopnoea syndrome and no studies in a Brit- 
ish population. We have therefore studied 
CPAP use in such patients, and have also 
examined whether there were correlations 
between indices of severity of the sleep apnoea 
hypopnoea syndrome and objective measures 
of compliance. 
Methods 
Usage of CPAP was studied in 54 patients 
during the first 1-3 months after initiation of 
CPAP therapy. 
PATIENTS 
Of the 54 patients studied, 48 were men. The 
mean (SE) age was 51 (1. "3) years and body 
mass index was 33 (1.1) kg, m=. Each had at 
least two major symptoms of the sleep apnoea 
hypopnoea syndrome, plus at least five 
apnoeas+hypopnoeas hour of sleep' recorded 
by overnight polysomnographic monitoring 
performed with our usual equipment and scor- 
ing techniques. ' These patients were deliber- 
ately selected to provide a wide range of fre- 
quencies of apnoeas - hypopnoeas (median 36 
(range 7-129), hour slept). 
All patients had multiple sleep latency tests 
perfortned1° in the baseline state and again, 
off CPAP, after the last night of CPAP ther- 
apy. Sleep onset was defined by the first 20 
second epoch of any sleep stage" 
CPAP THERAPY 
Following an initial positive clinical sleep 
study, all patients had the rationale for CP AP 
therapy explained to them and the CPAP 
equipment demonstrated. They then had an 
overnight CPAP titration sleep study in which 
the CPAP pressure was adjusted to the mini- 
mum pressure that normalised breathing pat- 
tern and minimised electroencephalographic 
arousals, defined as an episode of alpha or theta 
rhythm for at least 1.5 seconds associated with 
a transient increase in electromyographic tone, 
however brief. " In the morning the patients' 
further queries about CPAP therapy were 
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answered and they were allowed home with an 
appropriately set CPAP unit and a correctly 
'fitting mask or intranasal system The import- 
ance of all night use of the CPAP machines was 
stressed. The patients were given a telephone 
number to contact if they experienced any 
problems with their CPAP machines or side 
effects, and were phoned after two weeks on 
CPAP to check their progress. 
PROTOCOLS 
The first 22 patients studied received Respiro- 
nics Sleep Easy II or Sleep Easy III CPAP 
units with hidden time clocks which indicated 
for how long the machines were switched on - 
the "CPAP run time. " These time clocks were 
read when the machines were issued and re- 
read after three- months. These patients were 
taking part in a parallel group study of the 
effect of CPAP on daytime function. " 
The 32 subsequent patients were issued 
with ResCare Sullivan APD 1 CPAP units 
which had been modified by building in two 
time clocks. T'he first, -as- in the Sleep 
Easy II 
and III machines, indicated the CPAP run 
time. The second was linked to a pressure 
sensitive switch connected via a polythene 
tube to the CPAP mask, this tube passing 
along the CPAP hosing. " The pressure sensi- 
tive switch was set so that it was activated 
when the pressure in the mask was more than 
2 cm H, O below the therapeutic level of CPAP 
pressure set for that patient, thus monitoring 
the time spent at an effective CP AP pressure - 
"the mask time. " These patients were taking 
part in a crossover trial of CPAP therapy; their 
time clocks were read when the CPAP units 
were dispensed and again one month thereafter. 
STATISTICAL ANALYSIS - 
Correlation analysis to determine significant 
associations and multiple regression analysis 
with forward stepwise entry of variables to 
assess the relative contributions of different 
factors were conducted using the SPSS-X 
Package"`s 
Results 
The mean (SE) nightly CPAP run time for the 
54 patients was 4.7 (0.4) hours. There was no 
correlation between CPAP run time and fre- 
quency of apnoeas + hypopnoeas (fig 1), base- 
line multiple sleep latency time (. \ASLT; fig 2), 
or body mass index, nor was there any correla- 
tion between change in MSLT following 
therapy and CPAP run time (fig 3). Separate 
anal ses of the data from the two component 
studies showed that none of these correlations 
were significant. 
The 32 patients in whom mask time was 
recorded had therapeutic CPAP pressures for 
89% (3%ö) of their CPAP run times (fig 4). The 
patient in whom appropriate CPAP pressure 
was only achieved for 2416 of the night was 
subsequently found to have displaced the cap 
from one of the sensing ports on his CPAP 
mask. 
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Figure 4 Relation between CPAP-run thus aid-CPAP 
mask time, the time at therapeutic CPAP pressure. 
A total of 13 of these 32 patients (41%) 
contacted our staff to report problems associ- 
ated with the use of their CPAP units. Nine 
complained of nasal congestion and were pre- 
scribed steroid nasal spray to relieve this side 
effect, two experienced dryness of the upper 
airway which was treated by humidification of 
the CPAP airstream, and five patients disliked 
the pressure effects of the CPAP system. Aver- 
age CPAP mask time was higher in the patients 
reporting no problems with CPAP than in 
those reporting problems (4.1 (0.6) v 2.4 (0.4) 
hoursnight; p=0.02), with a trend (p<0.1) 
towards higher CPAP run times in those 
patients reporting no problems (4.3 -'0.6) v 2.8 
(0-6) hours: night). 
The therapeutic CPAP pressure assessed for 
each patient during the CPAP titration run 
and given to these patients during the studies 
correlated significantly with the frequency of 
apnoeas +hvpopnoeas (p<0.001), collar size 
(p <0.001), the male sex (p < 0.02), and body 
mass index (P<0-05). Multiple regression 
showed that the most important variables in 
determining CPAP pressure were collar size 
(p < 0.005) and apnoea + hypopnoea frequency 
(p<0.02), which together explain 33% of the 
variance in prescribed CPAP pressure. 
Discussion 
The average duration of CPAP use (4.7 hours; 
night) seems disappointing. However, these 
results have to be compared with those 
obtained by similar objective methods in other 
chronic conditions. For example, asthmatic 
patients have been shown by electronic moni- 
toring devices to use their chronic treatment as 
instructed on only 37% of days; and anti- 
epileptic treatment was taken as prescribed on 
39% of days in another study. 16 
The results in our study are very similar to 
those in a contemporaneous study performed 
in two centres in North America for which the 
average duration of CPAP used by 35 patients 
with sleep apnoea hypopnoea syndrome was 
4.9 (2.0) hours, hight, and the CPAP was 
received at the appropriate pressure for 911,16 of 
the CPAP run time. ' 7 The subjects in that 
study only used their CPAP units for 66% of 
the nights, however, and we therefore deduce 
that their average CPAP use was 3.2 hours, 
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night. Similar results have been reported by 
another North American group. " CPAP run 
times averaging 5.1 hours night were obtained 
in a French sample of 45 patients. '" Our results 
extend these observations by examining corre- 
lates between CPAP usage and severity of the 
sleep apnoea hypopnoea syndrome, and indic- 
ate that there was no correlation between any 
measure of severity of the sleep apnoea hypo- 
pnoea syndrome and objective CPAP use. This 
somewhat surprising result means, not only 
that patients with severe sleep apnoea hypo- 
pnoea syndrome cannot be relied upon to com- 
ply with their therapy, but also that some 
patients with mild sleep apnoea hypopnoea 
. -syndrome 
in terms of apnoea+hypopnoea 
frequency or objective daytime sleepiness 
(MSLT) use their CPAP therapy regularly. 
Our results also extend these previous obser- 
vations by reporting results in British patients 
in whom CP AP units were provided free of 
charge. Theoretically this might reduce moti- 
vation to use CPAP in comparison with 
patients who had to pay for their own units, 
but our CPAP usage is similar to that in North 
America. " 
CPAP therapy is obtrusive, and it is not 
surprising that patients do not use it all night 
every night. However, the results in this study 
indicate that CPAP usage is extremely variable 
between patients and that, on average, CPAP 
use is less than five hours night. Even with this 
level of compliance, however, these patients 
have reported improvements in symptoms and 
we have identified statistically significant im- 
provements in objective daytime sleepiness 
which, in the first sample of 22i patients, rose to 
5.5 (0.4) minutes from a preCPAP level of 3.5 
-(0-7) minutes. " It thus seems likely that the 
patients titrate their own CP AP use to provide 
an acceptable balance between the incon- 
venience of CPAP and the benefits of therapy. 
The patients in whom mask time was moni- 
tored achieved satisfactory mask pressures for 
an average of 89% of the run time. These APD 
1 CPAP units had built-in delay timers which 
allowed the patients to ramp up their CP AP 
pressure, achieving therapeutic CPAP pres- 
sure within 20 minutes of the machine being 
switched on. One would therefore anticipate 
that optimal CPAP pressure would only be 
achieved for 93% of the night in patients using 
a 20 minute delay on one occasion if the 
machine was switched on for the average 4.7 
hours, -night. It thus seems that these patients 
are achieving satisfactory CPAP pressures for 
most of the time during which the CPAP 
machines are switched on, with the one notice- 
able exception of the patient whose pressure 
monitor port cap was displaced. Thus, while 
monitoring the time at the appropriate CP AP 
pressure is the ideal method of monitoring 
compliance and manufacturers should work 
towards this end, recording the time for which 
the machine is switched on appears to give a 
' good measure of CPAP use. We would recom- 
mend that, as a minimum, the machine run 
time should be regularly recorded in all 
patients receiving CPAP therapy. 
Our study documents a relatively high inci- 
OL 
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Effect of continuous positive airway pressure treatment on 
daytime function in sleep apnoea/hypopnoea syndrome 
Heather M Engleman, Sascha E Martin, Ian J Deary, Neil J Douglas 
summary 
Continuous positive airway pressure (CPAP) is the treatment of 
choice for the sleep apnoea/hypopnoea syndrome (SAHS); it 
is usually given with the aim of improving daytime cognitive 
function, mood, and sleepiness. However, its efficacy has not 
been validated by controlled trials. We have carried out a 
randomised, placebo-controlled, crossover study of objective 
daytime sleepiness, symptoms, cognitive function, and mood 
in a consecutive series of 32 SAHS patients with a median 
apnoea plus hypopnoea frequency of 28 (range 7-129) per 
hour slept. 
Patients were treated with 4 weeks each of CPAP and an 
oral placebo, which they were told might improve upper airway 
muscle function during sleep. Assessments on the last day of 
each treatment included a multiple sleep latency test and 
tests of symptom scores, mood profiles, and cognitive 
performance. The patients had significantly less daytime 
sleepiness on CPAP than during the placebo period (mean 
sleep latency 7.2 [SE 0.7 ] vs 6.1 (0-71 min, p=0.03). There 
were also improvements with CPAP in symptom ratings (2.1 
[0.2] vs 4.3 [0.3], p<0.001), mood (p<0.05 for several 
measures), and cognitive performance, which showed 
improved vigilance (obstacles hit In Steer Clear "driving" test 
76 [5] vs 81 [6], p<0.01), mental flexibility (trail- 
making B time 66 [5] vs 75 (5] s, p<0.05), and attention 
(p<0.05). 
Objectively monitored CPAP use averaged only 3.4 (0.4) 
hours per night, but this study provides evidence of improved 
cognitive performance even at this low level of CPAP 
compliance. 
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Introduction 
The sleep apnoea/hypopnoea syndrome (SAHS) affects 
2-4% of men and 1-2% of women in middle age. 12 The 
main clinical features are disordered respiration during 
sleep, daytime sleepiness, ' impaired daytime cognitive 
performance, " and dysphoric mood; -' patients have 
increased mortality and morbidity from cardiovascular 
events° and road traffic accidents. ' The treatment of choice 
for SAHS is continuous positive airway pressure (CPAP), 
given in an attempt to improve daytime sleepiness, 
cognitive function, and- mood, but there have been few 
adequate studies of the efficacy of this expensive and 
obtrusive therapy. Findings on the effect of CPAP on 
sleepiness have differed; one uncontrolled study reported 
striking improvements, ° whereas a parallel-group study 
found only minor changes. ' We have examined the effect of 
CPAP therapy on cognitive function, sleepiness, and mood 
in SAHS patients in a placebo-controlled crossover study. 
Patl"nb and methods 
Design 
CPAP therapy (Sullivan APD-1 units, ResCare, Abingdon, UK), 
used throughout sleep, was given for 4 weeks, and oral placebo 
(ranitidine 300 mg homologue [inactive], Glaxo, Greenford, UK; 
two tablets at bedtime) for 4 weeks. The treatment order was 
randomly allocated and there was no intervening washout period. 
Subjects were told about the mechanisms of action of CPAP 
therapy and that the placebo tablets might improve upper airway 
muscle function in sleep. Sham CPAP therapy is not possible, 
because a nasal mask without effective CPAP would worsen both 
sleep and gas exchange. The study was approved by the Lothian 
Health Board Ethics Subcommittee. 
Subjects were recruited from consecutive outpatients referred 
for investigation of SAHS, who had at least two symptoms of the 
syndrome. 1° All patients in the consecutive series underwent a 
clinical sleep study by our standard procedure" with monitoring of 
the electroencephalogram, electro-oculogram, electromyogram, 
thoracic and abdominal respiratory effort, oronasal flow, and 
oximetry to establish a minimum frequency of apnoeas and 
hypopnoeas of 5 or more per hour of sleep. We approached 
consecutive patients who satisfied this criterion, who had no 
coexisting disorder causing excessive sleepiness, and who lived 
within 50 miles of the laboratory. Of the 43 patients invited to join 
the study, 35 accepted (3 could not afford the required time off 
work, 3 were reluctant to use CPAP and 1 to take tablets, and 1 had 
an attack of facial angio-oedema after using the CPAP mask on the 
CPAP titration night). 
Subjects underwent a night of CPAP titration with 
polysomnography to establish the therapeutic CPAP pressure at 
which breathing irregularities and arousals from sleep were lowest. 
Subjects were instructed to use the CPAP unit all night, every 
night, and especially on the nights before assessments. They were 
encouraged to report any problems with CPAP use immediately by 
telephone so that we could resolve difficulties to optimise CPAP 
compliance. 
3 patients withdrew after treatment started (pressure at work, 
relocation, and reluctance to use CPAP in I each). Their 
assessment results were excluded from analysis. Of the 32 
remaining subjects, 15 had been assigned placebo as the first 
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treatment, and 17 CPAP first. The 26 men and 6 women had a 
median apnoea plus hypopnoea frequency of 28 (range 7-129) per 
hour of sleep, a mean age of 49 (SE 1.5) years, and a mean 
body-mass index of 33 (1.6) kg per m2. 
Assessments 
The last day of each treatment period was spent in the laboratory. 
Objective daytime sleepiness was measured with the multiple sleep 
latency test (MSLT), " in which the subject is given five 20 min 
daytime nap opportunities, the first at 1000 hours and the others 
every 2 hours until 1800 hours. Electroencephalographic 
monitoring detects sleep, and the time from lights-out to the first 
20 s period of any sleep stage is the sleep onset latency. " 
Between MSLT naps, cognitive function, symptoms, and mood 
were assessed. General cognitive function was assessed by the 
national adult reading test (NART) and the Wechsler adult 
intelligence scale (WAIS-R; digit symbol substitution and block 
design)" and trailmaking tests A and B. Vigilance and attention 
were tested with a 30 min driving-based task (SteerClear, 
Healthdyne International, Brussels), " the rapid visual information 
processing test (RVIPT), 1' the paced auditory serial addition test 
(PASAT, 13 with 2s and 4s presentation rates), and eight-choice 
reaction time. Verbal fluency was assessed with the Borkowski 
test" and memory with the Benton revised visual retention test. " 
Each test was done at the same time of day during the two study 
periods to avoid circadian influences. The cognitive tests cover a 
wide range of function known to be affected by SAHS. '"ls The 
administration of the NART" at the familiarisation session 
allowed us to make an estimate of premorbid function and the 
WAIS-R subtests allowed measurement of current function 
(performance intelligence quotient [IQ)). By subtracting the 
WAIS-R performance IQ on each treatment from the NART 
estimate of premorbid performance IQ, an "IQ decrement score" 
was obtained. Alternative forms of the Borkowski test and the 
Benton visual retention test were used in succeeding assessment 
sessions to reduce practice effects further. 
An in-house symptom questionnaire asked patients to rate the 
presence or absence and frequency of symptoms of SAHS- 
choking during the night, morning headaches, morning confusion, 
frequent waking during the night, daytime sleepiness, sleepiness in 
the evenings, snoring, and sleepiness while driving. 
Mood questionnaires were selected to assess the impact of illness 
in terms of psychological distress (hospital anxiety and depression 
scale" and general health questionnaire-28"), the quality of 
specific areas of life, excluding sleep quality (Nottingham health 
profile part 2"), and the mood dimensions of energetic arousal, 
tense arousal, and hedonic tone (UWIST mood adjective 
checklist"). Mood and symptom questionnaires were administered 
in the early part of the day, when endogenous mood symptoms tend 
to be most severe. 
Before the study, subjects attended a5h session of 
familiarisation with the psychometric battery, to introduce the 
mood and psychiatric questionnaires and to reduce subsequent 
test-retest improvements in cognitive test scores. At this session 
patients were educated in CPAP use and masks were fitted. 
Compliance with CPAP therapy was monitored by reading 
hidden timedocks in the CPAP units. " The timedocks counted 
both the total number of hours that machines were switched on 
("runtime") and the total hours that the CPAP pressure was within 
2 cm water of that prescribed ("masktime") u 
Subjects were asked to avoid caffeine-containing drinks before 
attending for assessments, and were offered only decaffeinated 
drinks during the assessment day. At the final assessment, subjects 
were asked to state which treatment they preferred. 
Analysis 
All statistical analyses were done with SPSS-PC+(SPSS Inc, 
Chicago, USA). McNemar's test for repeated measures was used to 
assess the significance of frequencies of individual symptoms on 
the symptom questionnaire and psychiatric cases identified by 
mood questionnaires. The binomial test was used to test the 
significance of patients' treatment preference. The distributions of 
outcome variables were examined and non-normal distributions 
pllaM CMp p 
Trailm*nt8dme(s) 75(5) 66(5) 002 
Digit WW st )MUOOM 51(2) 52(2) 0 05 
Steerperf 81(6) 76(5) 0 01 
IQdeawmtscore 72(20) 40(2 1) 0 04 
RADS rudery acoae 57(08) 45(06) 0 02 
HAGS Ampres$4on acae 5-2(07) 33(05) 0-002 
GHQ-28 5,2(0-9) 18(0.7) 0 003 
NHP 79(09) 49(09) 0002 
EnergM c arwsa score 19-5(1-0) 241(10) 0001 
Data Oren as mean (SE). *No Correct; tno of obstacles hit. 
W{DS-hosphal am Iety and depression scale: GHQ- general health questionnaire (total 
am); NHP-Nottingham health profile part 2 (total score). 
Table: Comparison of psychometric function scores on placebo 
and on CPAP 
found in-5 cases-floor effects for the number of RVIPT misses, 
tense arousal, and general health questionnaire-28 score, and 
ceiling effects for scores for hedonic tone and the 4s PASAT. 
Placebo and CPAP scores for these variables were compared by the 
paired Wilcoxon's test. All other dependent variables were 
normally distributed and were examined with two-way analysis of 
variance (ANOVA), comparing assessment scores on the two 
treatments, with treatment order as a between-subjects factor and 
treatment as a within-subject factor; variables judged likely to 
affect treatment response were entered as covariates. 
R. salts 
The mean number of symptom complaints was 
significantly lower on CPAP therapy than on placebo (2.1 
[SE 0.2] vs 4.3 [0.3], p <0.001). There were also significant 
differences between the CPAP and placebo periods in 
daytime sleepiness (13 vs 26 patients reported daytime 
napping, p=0.001) and snoring (3 vs 30, p<0.0001). 20 
(63%) of the 32 patients decided after weighing benefit of 
treatment and ease of use that their preferred form of 
treatment was CPAP, and 12 preferred tablets. This bias 
towards CPAP was not significant (p=0.22). 
Mean CPAP runtime for patients in the study was 3.7 
(0.4) h per night and an effective CPAP pressure was 
delivered to the mask for 3.4 (0.4) h, a mean 89 (3)% of the 
time that units were run. 
CPAP had a significant effect on objective daytime 
sleepiness. The mean and minimum sleep onset latencies in 
the MSLT were significantly longer on CPAP than on 
placebo (mean 7.2 [0.7] vs 6.1 [0.7] min, p=0.03; minimum 
3.5 [0.4] vs 2.9 [0.4] min, p=0.05). 
CPAP improved cognitive function (table) as assessed by 
tests of mental flexibility (trailmaking B), coding efficiency 
(digit symbol substitution), and vigilance (SteerClear). In 
addition, CPAP reduced IQ decrement in comparison with 
placebo. There was an improvement in PASAT 2s 
presentation rate performance on CPAP (p<0-001 on 
ANOVA) but there was also an order effect (p<0.02), 
indicating a potential carry-over effect of treatment. We 
therefore compared PASAT 2s data from the first 
assessment only, with a resulting loss of statistical power, 
and found no significant difference between CPAP and 
placebo (p = 0.11). 
Despite the familiarisation session, several of the 
cognitive test scores showed learning effect interactions 
(SteerClear task, p<0.001); trailmaking B, p=0.019; 
correct responses on the RVIPT, p<0.01; digit symbol 
substitution subtest, p=0.034; 2s PASAT, p=0.003). 
However, the treatment-order randomisation meant that 
these learning effects did not influence the analysis of 
effects of treatment type. 
CPAP produced significant improvements in all mood 
questionnaires (table). In the Nottingham health profile 
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significantly improved the self-rated levels of energetic 
arousal (p <0.001), but there was no significant change it 
tension or hedonic tone (an index of pleasant/unpleasant 
mood). 
Using the hospital anxiety and depression scale as a 
screening device to identify psychiatric "cases", " we identified 10 patients with anxiety and 8 with depression 
while taking placebo. Only 4 patients were found to have 
anxiety and 4 depression during the CPAP period, but the 
differences were not significant (p=0,11 and 0.22, 
respectively). The number of patients identified as 
Psychiatric cases with the general _healthquestonnaire1B was 11 during placebo treatment and 5 on CPAP (p - 0" 
I8). 
Apnoea plus hypopnoea frequency, an index of SAHS 
severity, and CPAP masktime, an index of CPAP 
compliance, were entered as putative covariares in the 
analyses of variance. They were significant covariates for 
only a very few outcome variables, and their inclusion did 
not lead to treatment effects becoming nonsignificant in 
any case. Increased CPAP use was correlated with greater improvements in symptom scores (p < 0.03), quality of life 
(Nottingham health profile, p<0-03), and concentration 
(PASAT 2 s, p <0.02), 
Discussion 
This study showed, for the first time within a controlled 
investigation, objective and subjective improvements in daytime function after the introduction of CPAP therapy 
for SANS. The total number of reported symptoms, including both daytime and night-time symptoms, was 
lower on CPAP. The reported improvements in daytime 
sleepiness on the symptom questionnaire were objectively 
corroborated by the increase in MSLT sleep onset latencies 
during the day. 
The lengthening of MSLT sleep onset latency on CPAP 
was small compared with increments found by others, 'A" 
and even the improved sleep latencies were below the 
normal range for healthy adults. '' However, the 
improvement is similar to that in other open or parallel 
group studies of the effects of CPAP on MSLT. ' 3' It is 
possible that patients with SANS become accustomed to 
falling asleep rapidly and that this ability, which is 
measured by the MSLT, is retained after treatment. However, the persistence of low sleep latencies after CPAP 
treatment is a cause for concern and further work is needed 
to clarify whether better compliance with CPAP treatment 
might result in greater improvements in sleep latencies. 
Another feature supporting the improvement in sleepiness 
measures was the increase in energetic arousal scores from 
the UWIST mood adjective checklist, a well-validated 
instrument measuring the dimensions of mood. "' Energetic 
arousal level is related to activation in the reticular 
activating system of the brainstern, which modulates 
wakefulness-drowsiness. 2° Our measures of objective 
sleepiness and subjective energy levels may therefore have a 
common biological basis. 
The results of the cognitive assessments suggest reliably for the first time that CPAP treatment improves vigilance, 
mental flexibility, and coding speed, all areas of function known to be compromised in SANS, "' and significantly 
reduces the degree of cognitive deficit (IQ decrement). 
Although CPAP did not significantly change verbal fluency 
or memory, the cognitive tasks showing CPAP-related 
T LANCET 4 
I unpruvemcnw in ycrcormance wert uiose trat require 
t simultaneously rapid and co-ordinated responses. Langan 
et al, - found, similarly, that scores on complex, timed 
cognitive tasks were sensitive to the effects of diabetic 
i hypoglycaemia, whereas memory and verbal performance 
were not affected. The processes precipitating cognitive 
impairment in diabetes and SAHS may not be identical, but 
the modest deficits found in both disorders may be best 
measured with complex, timed tasks. 
Mood assessments showed striking improvements in 
psychological distress and quality of life on CPAP. Since 
both the questionnaires we used include anxiety subscales, 
they cross-validate each other. With both questionnaires 
the number of patients identified as psychiatric cases was 
smaller during the CPAP period; however, no differences 
achieved significance. Patients' mean score for the general 
health questionnaire fell in the pathological range on 
placebo but was well within the normal range on CPAP. 
Previous research on mood after CPAP in SA}fS has 
shown improved scores - for psychological distress. 
Derderian et al, 26 in a small parallel-group study of 
untreated and CPAP-treated SANS patients, found 
significantly improved depression and fatigue factors. A 
larger uncontrolled study of depression questionnaire 
responses from SAHS patients also found significantly 
improved scores after CPAP, " but neither study took 
account of the effect of expectations of post-treatment 
improvement. Our study, by using a placebo period, 
controls for such expectations. 
pur findings of widespread learning effects on repeated 
cognitive testing, despite efforts to familiarise subjects and 
boost performance to the top of the learning curve, cast 
doubt on the reliability of preliminary results from 
uncontrolled studies of improved cognitive performance 
after CPAP. ' Our study controlled for the effects of 
learning through the use of a randomised, crossover design. 
Use of an oral tablet placebo for CPAP is not ideal, but we 
believe that this is the best available placebo. The potential 
value of the tablet treatment was emphasised to patients, 
with the approval of the local ethics committee. At 
recruitment, many patients expressed the hope that the 
tablet treatment would prove more beneficial, and after the 
study 12 stated that they preferred tablets. This finding 
indicates the level of belief in the placebo therapy. 
However, most of the patients, some of whom had mild 
SAHS, preferred the more obtrusive option ofCPAP. 
Objectively monitored CPAP compliance rates are 
disappointingly low in the light of instructions to use the 
units every night, but the monitored usage is very similar to 
that found in North American patients. '0 The minimum 
therapeutic usage of CPA? is as yet unknown, but it seems 
likely that patients may adjust their CPAP use to a level that 
produces subjective benefits in daytime function. Our 
results imply that full-night use may not be necessary to 
reduce daytime cognitive performance deficits. The low 
compliance and the lack of significant preference for CPAP 
indicate, however, that improvements in therapy for SAHS 
are needed. Further study will identify the severity of 
SAHS at which CPAP is a beneficial and acceptable 
therapeutic option. Because of the strong evidence linking 
SANS with reduced road safety, ' these objective data lend 
weight to the argument for aggressive treatment of SAHS. 
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